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Ce manuscrit est divisé en trois chapitres.  
Le premier chapitre présente l’intérêt du fluor en chimie médicinale. Son influence sur les propriétés 
chimiques et physico-chimiques des molécules sera discutée. 
Le deuxième chapitre présente la réaction de contraction de cycle de (trifluorométhyl)pipéridines 
ainsi que de (trifluorométhyl)azépanes via un intermédiaire aziridinium, afin d’obtenir des 
2-(trifluorométhyl)pyrrolidines (Schéma 1, éq 1) et des 2-(trifluorométhyl)pipéridines 
fonctionnalisées (Schéma 1, éq 2).  
 
Schéma 1 
Le troisième chapitre présente une séquence de cycloadditions [2+1]/[3+2] impliquant un alcyne 
terminal, un difluorocarbène et le (trifluorométhyl)diazométhane, afin d’obtenir des 
4-fluoro-6-(trifluorométhyl)pyridazines substituées en position C3 (Schéma 2).  
 
Schéma 2 
Ces pyridazines ont ensuite été fonctionnalisées en position C4 par une substitution nucléophile 
aromatique (SNAr) pour conduire aux pyridazines 3,4,6-substituées (Schéma 3). 
 
Schéma 3 
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Chapitre 1 : Le fluor en chimie médicinale 
L’atome de fluor est un atome petit possédant un rayon de Van der Waals de 1.47 Å, intermédiaire 
entre celui de l’hydrogène et celui de l’oxygène, tout en étant proche de celui de l’oxygène. Le fluor 
étant l’élément le plus électronégatif de la classification périodique, induit la polarisation de la liaison 
C–F avec une charge négative partielle sur l’atome de fluor et une charge positive partielle sur l’atome 
de carbone, ce qui confère à la liaison C–F un caractère ionique significatif. Ainsi, la liaison   C–F est 
courte (1.40 Å) et forte (l’énergie de liaison est de 105 kcal/mol) (Tableau 1).  
Atome (A) H F O N C Cl Br 
Rayon Van der Waals (Å) 1.20 1.47 1.52 1.55 1.70 1.75 1.85 
Electronégativité de Pauling 2.1 4.0 3.5 3.0 2.5 3.2 2.8 
Longueur de la liaison CA (Å) 1.09 1.40 1.43 1.47 1.54 1.77 1.97 
Force de la liaison CA (kcal/mol) 98 105 84 70 83 77 66 
Tableau 1 
Une autre propriété qui dérive de l’électronégativité élevée du fluor, est que ses trois paires 
d’électrons libres sont fortement attirées par le noyau ce qui rend cet atome relativement inerte. 
D’autre part, une orbitale antiliante σ* de faible énergie, orientée dans le plan de la liaison C–F, peut 
accepter les électrons d’un groupement donneur proche, tel qu’une paire d’électrons libres ou les 
électrons d’une liaison σ. 
Le remplacement d’une liaison C–H par une liaison C–F est très utilisé en chimie médicinale, car si 
l’introduction d’un atome de fluor, ne modifie pas la taille de la molécule, en revanche, 
électroniquement parlant, ce remplacement n’est pas négligeable et peut avoir une influence sur la 
stabilité métabolique, sur les interactions protéine-ligand et sur les propriétés physico-chimiques 
telles que le pKa ou la lipophilie des molécules.  
Chapitre 2 : Contraction de cycle : synthèse de 2-(trifluorométhyl)pyrrolidines et de 
2-(trifluorométhyl)pipéridines fonctionnalisées 
Les pyrrolidines et les pipéridines sont des cycles azotés à cinq et six chaînons respectivement, qui 
appartiennent à la famille des amines cycliques secondaires. Les motifs pyrrolidine et pipéridine sont 
présents dans de nombreux alcaloïdes possédant des activités biologiques intéressantes. De plus, ils 
représentent des motifs que nous pouvons retrouver dans certains médicaments présents sur le 
marché. 
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Du fait des propriétés intéressantes du fluor, nous nous sommes intéressés à la synthèse des 
α-(trifluorométhyl)pyrrolidines et α-(trifluorométhyl)pipéridines A par contraction de cycle, à partir 
de (trifluorométhyl)pipéridines et de (trifluorométhyl)azépanes C respectivement via des 
intermédiaires aziridiniums B. Nous supposons que dû à la présence du groupement CF3, l’attaque 
d’un nucléophile devrait se faire de manière régioséléctive sur la position C2’ de l’aziridinium B pour 
conduire au produit de contraction de cycle A (Schéma 4).  
 
Schéma 4 
A) Synthèse de 2-(trifluorométhyl)pyrrolidines, 2-substituées 
Dans un premier temps, nous avons étudié la réaction de contraction de cycle de 
3-hydroxy-3-(trifluorométhyl)pipéridine C1 pour obtenir des α-(trifluorométhyl)pyrrolidines A1 
(Schéma 5). 
 
Schéma 5 
La pipéridine 3 a été facilement obtenue à partir de la N-Boc-pipéridin-3-one 1. Lorsque la 
pipéridinone 1 a été soumise à une réaction de trifluorométhylation en présence du réactif de 
Ruppert-Prakash (TMSCF3), la (trifluorométhyl)pipéridine 2 a été obtenue avec 77% de rendement. 
La déprotection de l’amine de 2 en présence d’acide triflluoroacétique (TFA), suivie de la protection 
par un groupement benzyle (BnBr, K2CO3, TBAI) a permis la formation de la 
N-benzyl-3-hydroxy-3-(trifluorométhyl)pipéridine 3 avec un rendement quantitatif pour les 2 étapes 
(Schéma 6). Signalons que le remplacement du groupement Boc par un groupement benzyle est 
nécessaire pour permettre, grâce à l’assistance anchimérique de l’azote, la formation de l’aziridinium 
intermédiaire B1 après activation de l’alcool tertiaire.  
21 
 
 
Schéma 6 
Afin d’étudier si la formation de l’aziridinium ainsi que la contraction de la pipéridine 3 était possible, 
la réactivité de la pipéridine 3 a d’abord été examinée avec du chlorure de thionyle (SOCl2) dans du 
CH2Cl2 en présence d’un excès de triéthylamine (Et3N). Cependant, dans ces conditions, le produit 
désiré 4a n’a pas été obtenu (Tableau 2, entrée 1). La pipéridine 3 a ensuite été mise en réaction avec 
de la Et3N (4.0 équiv) et du chlorure de méthane sulfonyle (MsCl) (3.1 équiv), et dans ces nouvelles 
conditions, la pyrrolidine chlorée 4a a été isolée avec néanmoins un rendement faible de 7% et une 
conversion de 10% de 3 (Tableau 2, entrée 2). Etant donné la faible réactivité de l’alcool tertiaire du 
composé 3, cet alcool a été activé par un mélange de triphénylphosphine et de diiode en présence 
d’imidazole. Le composé souhaité 4b a été isolé avec un rendement de 25% pour une conversion 
totale de 3 (Tableau 2, entrée 3). Suite à ce résultat, le composé 3 a été traité par un réactif 
électrophile plus puissant, à savoir le trifluorure de diéthylaminosuflure (DAST). Le produit fluoré de 
contraction de cycle 4c a été obtenu avec un rendement de 71% (Tableau 2, entrée 4). Après avoir 
vérifié que la contraction de cycle de la (trifluorométhyl)pipéridine 3 était possible, il nous restait à 
trouver un mode d’activation de 3 compatible avec l’utilisation d’autres nucléophiles comme des 
amines, des alcools et dérivés, ainsi que des nucléophiles carbonés. Pour cela, la pipéridine 3 a été 
traitée par de l’anhydride triflique (Tf2O) en présence de l’éponge à proton D au reflux de CH2Cl2. 
Après 5 h de réaction, de la benzylamine a été ajoutée au milieu réactionnel et dans ces conditions, 
la pyrrolidine désirée 4d a été isolée avec un rendement de 75% (Tableau 2, entrée 5). 
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Entrée Conditions Nucléophile Conversion de 3 (%) Rdt 4 (%) 
1 SOCl2 (1.3 équiv), Et3N (4.0 équiv) CH2Cl2 
Cl  4a (0%) 
2 MsCl (3.1 équiv), Et3N (4.0 équiv) CH2Cl2 
Cl 10 4a (7%) 
3 PPh3 (1.5 équiv), Imidazole (2.0 équiv) I2 (1.5 équiv), THF 
I 100 4b (25%) 
4 DAST (1.4 équiv)  THF F
 100 4c (71%) 
5 
Tf2O (1.5 équiv) 
Eponge à proton D (2.0 équiv)  
BnNH2 (2.5 équiv), CH2Cl2 
BnNH2 100 4d (75%) 
Tableau 2 
L’obtention de la pyrrolidine 4d en fin de réaction, peut s’expliquer par la formation successive des 
intermédiaires 5 et 6. Lorsque la pipéridine 3 est traitée par le Tf2O, le triflate 5 formé est déplacé par 
l’atome d’azote de la pipéridine 5, grâce à une assistance anchimérique et provoque la formation de 
l’aziridinium intermédiaire 6. Le nucléophile ajouté dans le milieu peut alors attaquer 
régiosélectivement cet aziridinium 6 en position C2’ pour conduire à la pyrrolidine 4e (Schéma 7). 
Signalons que le rôle de l’éponge à proton D est de piéger les protons présents dans le milieu 
réactionnel, afin que le doublet de l’azote reste disponible pour réaliser une attaque nucléophile 
intramoléculaire et transformer l’intermédiaire 5 en aziridinium 6.  
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Schéma 7 
Après avoir établi les conditions optimales pour la contraction de cycle de la pipéridine 3, d’autres 
nucléophiles ont été impliqués dans la réaction afin d’établir le champ d’application de cette réaction 
de contraction de cycle. Lorsque l’aniline a été utilisée comme nucléophile, la pyrrolidine 7 a été 
obtenue avec 71% de rendement. L’utilisation des amines secondaires telles que la N-méthylaniline, 
la diéthylamine, la diallylamine, la dibenzylamine et la morpholine, ont permis d’isoler les pyrrolidines 
correspondantes 812 avec des rendements compris entre 60% et 83% (Schéma 8). 
 
Schéma 8 
Suite à ces résultats, l’utilisation de nucléophiles oxygénés a été envisagée. Lorsque des alcools et des 
alcoolates ont été utilisés, les produits de contraction de cycle 1319 ont été isolés avec des 
rendements moyens à bons (51%77%). Soulignons que l’eau peut être également utilisée comme 
nucléophile, pour conduire à la pyrrolidine 17 avec 61% de rendement. De plus, le phénolate de 
sodium ainsi que l’acétate de tétrabutylammonium permettent aussi la formation des produits de 
contraction de cycle 18 (75%) et 19 (72%) (Schéma 9). 
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Schéma 9 
Des nucléophiles soufrés, sous forme de thiols ou de thiolates, peuvent également être engagés dans 
cette réaction de contraction et les pyrrolidines 2022 ont été obtenues avec des bons rendements. 
De plus, lorsque la pipéridine 3 a été traitée par de l’anhydride triflique, en présence de l’éponge à 
proton D, suivi par l’addition du fluorure ou chlorure de tétrabutylammonium, les pyrrolidines 23 et 
24 ont été isolées avec des rendements de 30% et 49% respectivement. Enfin, l’addition des 
nucléophiles carbonés est possible. Lorsqu’un cyanure ou l’anion du malonate de méthyle ont été 
utilisés comme nucléophiles, les pyrrolidines 25 et 26 ont été isolées avec des bons rendements 
(Schéma 10). 
 
Schéma 10 
Après avoir étudié le champ d’application de la contraction de cycle de la pipéridine 3 avec divers 
nucléophiles, nous avons voulu déterminer si au cours de cette réaction, un transfert de chiralité était 
possible. Pour cela, les deux énantiomères de 3 ont été séparés par SFC (Supercritical Fluid 
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Chromatography) et ils ont ensuite été traités par de l’anhydride triflique en présence de l’éponge à 
proton D. Après 5 h au reflux du CH2Cl2, du méthanol a été ajouté au milieu réactionnel. Les composés 
(+)-13 et ()-13 ont été obtenus avec des pouvoirs rotatoires opposés, indiquant un transfert de 
chiralité pendant la contraction de cycle. Cependant, la détermination des excès énantiomériques de 
(+)-13 et ()-13 n’a pas été possible, une autre méthode a donc dû être mise au point pour vérifier ce 
transfert de chiralité. 
 
Schéma 11 
Ainsi, dans un premier temps, la pipéridine 3 a été traitée par de l’anhydride triflique, en présence de 
l’éponge à proton D, suivi par l’addition d’une amine chirale comme nucléophile, la 
(S)-α-méthylbenzylamine. Dans ce cas, la pyrrolidine 27 a été obtenue sous la forme d’un mélange de 
diastéréoisomères dans un rapport 1:1 (Schéma 12).  
 
Schéma 12 
Chacun des deux énantiomères de 3 a été traité dans les mêmes conditions (Tf2O/éponge à proton 
D/(S)-α-méthylbenzylamine) pour conduire cette fois-ci aux pyrrolidines 27a et 27b avec une 
diastéréosélectivité supérieure à 95>5 pour chaque composé (Schéma 13). Ce résultat, confirme que 
la contraction de cycle de pipéridines en pyrrolidines procède via un transfert total de chiralité. 
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Schéma 13 
Afin de connaitre l’influence du groupement CF3 sur le processus de contraction de cycle, la pipéridine 
28, substituée en position C3 par un groupement méthyle à la place du groupement trifluorométhyle, 
a été traitée par Tf2O/éponge à proton D, suivi de l’ajout du fluorure de tétrabutylammonium. Le 
composé 30 a été obtenu avec un rendement de 36% tandis que le produit attendu de contraction 
29 n’a pas été observé. Cela confirme donc l’hypothèse selon laquelle, le groupement CF3 agit comme 
un groupement directeur qui oriente le réarrangement de l’aziridinium intermédiaire vers le produit 
de contraction de cycle (Schéma 14). 
 
Schéma 14 
B) Synthèse de 2-(trifluorométhyl)pipéridines, 2-substituées 
Suite à ces travaux, nous avons voulu appliquer les conditions précédemment développées 
(Tf2O/éponge à proton D/nucléophile) au 3,3-hydroxy-(trifluorométhyl)azépane C2 afin d’accéder à 
des α-(trifluorométhyl)pipéridines A2 (Schéma 15). 
 
Schéma 15 
Le N-benzylazépane 39 a été synthétisé à partir du chloroacétaldehyde 31 en 9 étapes. Le 
chloroacétaldehyde 31 a été mis en réaction avec de la poudre d’indium et du bromure d’allyle dans 
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l’eau pour donner, après 3 h, le composé 32 avec 80% de rendement. Le composé 32, a ensuite été 
mis en réaction avec de l’allylamine pour former l’amino-alcool 33 avec un rendement de 96%, puis 
cet amino-alcool a été protégé par un groupement Boc pour conduire au composé 34 avec un 
rendement de 93%. Après la métathèse cyclisante de 34 en présence du catalyseur de Grubbs de 
première génération (Grubbs-I), l’azépane 35 a été obtenu avec 69% de rendement. Cet azépane a 
ensuite été hydrogéné en présence d’une quantité catalytique de PtO2 dans l’éthanol, pour donner 
le produit réduit 36 avec un rendement quantitatif. L’oxydation du composé 36 en présence du réactif 
de Dess-Martin, a permis la formation de l’azépanone 37 (86% de rendement). Après 
trifluorométhylation de 37 pendant 5 jours, à l’aide du TMSCF3, le (trifluorométhyl)azépane 38 a été 
isolé avec 93% de rendement. Les deux dernières étapes de la synthèse de 39 consistent en la 
déprotection de la fonction amine de 38 suivie de sa protection par un groupement benzyle, pour 
conduire au 3,3-hydroxy-(trifluorométhyl)azépane 39 (85%, 2 étapes) (Schéma 16). 
 
Schéma 16 
Ayant synthétisé le substrat de départ 39, ce dernier a été traité par de l’anhydride triflique, en 
présence de l’éponge à proton D au reflux du CH2Cl2 et après 5 h, différents nucléophiles ont été 
ajoutés au milieu réactionnel. Lorsque des amines primaires comme la benzylamine ou l’aniline ont 
été utilisées, les pipéridines 40 et 41 ont été isolées respectivement avec un rendement de 62% et 
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un rendement quantitatif. De plus, les α-(trifluorométhyl)pipéridines 4245 ont été obtenues avec 
de très bons rendements, lorsque des amines secondaires, telles que la diéthylamine, la diallylamine, 
la benzylamine et la morpholine, ont été utilisées comme nucléophiles (Schéma 17). 
 
Schéma 17 
Après avoir étudié la réactivité de l’aziridinium B2 vis-à-vis de nucléophiles azotés, des nucléophiles 
oxygénés, sous forme d’alcools ou d’alcoolates, ont été examinés. Ainsi, les pipéridines 4652 ont été 
synthétisées avec de très bons rendements (82%quant). Soulignons que les meilleurs résultats ont 
été obtenus lorsque le nucléophile est sous la forme d’alcoolate (PhO) et d’acétate (AcO) puisque 
les pipéridines 51 et 52 ont été isolées avec des rendements quantitatifs (Schéma 18). 
 
Schéma 18 
Deux nucléophiles soufrés sous la forme de thiolates ont été utilisés pour réaliser la contraction de 
cycle. Les α-(trifluorométhyl)pipéridines désirées 53 et 54 ont été isolées avec des bons rendements. 
Les sels d’halogénures tels que le fluorure, le chlorure, le bromure et l’iodure de tétrabutylammonium 
ont aussi été utilisés, afin d’obtenir les pipéridines halogénées 5558 avec des rendements allant de 
69% à 89%. De plus, les pipéridines 59 et 60 ont été isolées avec des rendements excellents, lorsque 
le cyanure ou l’anion du malonate de méthyle ont été impliqués dans le processus de contraction de 
cycle. Signalons que le traitement de l’azépane 39, par l’anhydride triflique, suivi de l’addition du 
borohydrure de sodium, a permis l’obtention du composé 61 avec 73% de rendement (Schéma 19). 
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Schéma 19 
Il est intéressant de noter que la fluorométhyl-pipéridine 55 a été obtenue avec un rendement 
amélioré de 71% versus 61% lorsque l’azépane 39 a été traité par du DAST dans le THF (Schéma 20 
versus Schéma 18). 
 
Schéma 20 
La synthèse d’α-(trifluorométhyl)pipéridines substituées par un groupement alkyle a ensuite été 
envisagée. Pour cela, le (trifluorométhyl)azépane 39 a été traité par Tf2O/éponge à proton D, suivi de 
l’addition d’un organocupromagnésien. Le composé désiré 62 a été obtenu avec 50% de rendement. 
Parallèlement à la formation de 62, la formation du composé 56 a été observée par analyse GC/MS, 
indiquant une réaction entre l’ion chlorure de l’organocupromagnésien et l’aziridinium intermédiaire 
(Schéma 21). 
 
Schéma 21 
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Afin d’étudier l’influence du groupement CF3 sur la régiosélectivité de la réaction, nous avons 
remplacé le groupement CF3 de l’azépane 39, par un groupement CH3, comme nous l’avons fait pour 
la contraction de la pipéridine 3. Lors du traitement de l’azépane 63 par Tf2O/éponge à proton D suivi 
par l’addition de fluorure de tétrabutylammonium, la pipéridine 64 n’a pas été observée. Le seul 
produit isolé a été l’azépane 65 (31%), confirmant encore une fois le rôle important du CF3 comme 
groupement directeur pendant la contraction de cycle (Schéma 22). 
 
Schéma 22 
Pour résumer, la synthèse  d’α-(trifluorométhyl)pyrrolidines et d’α-(trifluorométhyl)pipéridines, 
possédant un centre quaternaire en position C2, a été réalisée par contraction de cycle de pipéridines 
et d’azépanes trifluorométhylées. La réaction est compatible avec une variété de nucléophiles tels 
que des amines, des alcools, des halogènes ou mêmes des nucléophiles soufrés et carbonés. De plus, 
il a été démontré que les contractions de cycle s’effectuaient via un transfert de chiralité. Enfin, notre 
hypothèse selon laquelle le pôle d’attaque du nucléophile sur l’intermédiaire bicyclique aziridinium 
était dirigé par le groupement trifluorométhyle a été validée. 
Chapitre 3 : Synthèse d’ α-(trifluorométhyl)pyridazines par une séquence de cycloadditions 
[2+1]/[3+2] 
Les pyridazines sont des hétérocycles aromatiques à six chaînons comportant deux atomes d’azote 
adjacents. Depuis leur découverte dans certains produits naturels ainsi qu’à la lumière des activités 
biologiques variées que ces produits possèdent, un grand intérêt synthétique pour le motif pyridazine 
est apparu ces dernières années. Au vu de l’importance pour le noyau pyridazine ainsi que les 
bénéfices apportés par le fluor en chimie médicinale, la mise au point d’une méthode de synthèse 
d’α-(trifluorométhyl)pyridazines est donc intéressante.  
En se basant sur des travaux précédemment effectués au laboratoire, nous avons envisagé d’accéder 
aux 6-(trifluorométhyl)pyridazines I par une séquence de cycloadditions [2+1]/[3+2] impliquant un 
alcyne terminal, un difluorocarbène et un composé diazo. En effet, le difluorocyclopropène F pourrait 
être formé lorsque l’alcyne E serait mis en réaction avec le difluorocarbène. Ce difluorocyclopropène, 
pourrait ensuite réagir avec le (trifluorométhyl)diazométhane pour conduire à une 
cyclopropanopyrazoline G. Suite au réarrangement de G suivie d’une aromatisation de H, les 
(trifluorométhyl)pyridazines I pourraient être obtenues (Schéma 23). 
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Schéma 23 
Le (trifluorométhyl)diazométhane 67, peut être formé à partir du chlorure de la trifluoroéthylamine 
66, en présence du nitrite de sodium dans un mélange CH2Cl2/H2O à 0 °C. De l’acide nitreux (HNO2), 
généré in situ, réagit avec la trifluoroéthylamine 66 pour former l’intermédiaire nitroso qui, après une 
déshydratation, conduit au (trifluorométhyl)diazométhane 67 (Schéma 24). 
 
Schéma 24 
Afin de vérifier si la réaction de cycloaddition entre un alcyne, un difluorocarbène et le 
(trifluorométhyl)diazométhane serait possible, le phénylacétylène a été mis en réaction avec le 
réactif de Ruppert-Prakash (TMSCF3) et d’iodure de sodium (NaI) dans le THF à 110 °C pendant 2 h. 
Dans ces conditions, l’ion iodure attaque le silicium du TMSCF3 pour former l’anion CF3, qui grâce à la 
haute température, peut se décomposer en ion F et en difluorocarbène. Une fois le difluorocarbène 
formé, celui-ci peut subir une cycloaddition [2+1] en présence de phénylacétylène, afin de former un 
difluorocyclopropène. En présence du (trifluorométhyl)diazométhane (0.6 M dans le CH2Cl2), ce 
difluorocyclopropène peut subir une deuxième cycloaddition [3+2] pour mener à la pyridazine 
désirée 68 avec 87% de rendement (Schéma 25). 
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Schéma 25 
L’étude du champ d’application de la séquence de cycloadditions [2+1]/[3+2] a été ensuite réalisée 
sur des alcynes terminaux, substitués par des groupements aryles possédant des groupements riches 
en électrons. Lorsque le noyau aromatique porte un substituant électro-donneur en position ortho 
ou para, les pyridazines correspondantes 6971 ont été isolées avec de très bons rendements 
(73%83%). La pyridazine 72, fonctionnalisée par un noyau benzénique tri-substitué, a été isolée avec 
un bon rendement de 76%. Cependant, la pyridazine 73, dont le noyau aromatique est substitué par 
un groupement N,N-diméthylaniline, n’a pas été obtenue, probablement à cause d’une 
incompatibilité entre le caractère nucléophile de l’azote de l’aniline et le caractère électrophile du 
difluorocarbène. Signalons qu’un alcyne terminal substitué par un groupement naphtyle peut aussi 
être engagé dans la séquence de cycloadditions pour donner la (trifluorométhyl)pyridazine 74 avec 
79% de rendement. (Schéma 26).  
 
Schéma 26 
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Nous nous sommes par la suite intéressés à des alcynes terminaux portant des aryles qui possèdent 
des groupements électro-attracteurs. Lorsque le groupement aryle est substitué par un groupement 
CF3 en position ortho, ou un groupement ester en position méta et para, les pyridazines 75, 76 et 77 
ont été isolées avec des bons rendements de 66% à 76%. Cependant, la présence d’un groupement 
phosphonate, ainsi qu’un groupement nitro sur le noyau aromatique a conduit aux pyridazines 78 et 
79 avec des rendements plus faibles de 27% et 34% respectivement. Des aryles substitués par des 
halogènes peuvent aussi être engagés dans la séquence de cycloadditions [2+1]/[3+2], puisque les 
pyridazines 80, 81 et 82 ont été formées avec des rendements qui varient de moyens à bons (Schéma 
27). 
 
Schéma 27 
Devant les faibles rendements des pyridazines 78 et 79, un autre protocole a été mis en place afin 
d’accéder à ces composés avec des meilleurs rendements. Ainsi, le difluorocarbène peut être généré 
par réaction du fluorosulfonyldifluoroacétate de triméthylsilyle (TFDA) avec du fluorure de sodium 
(NaF) dans le diglyme à 120 °C. En effet, le TFDA est décomposé en difluorocarbène à 120 °C par une 
quantité catalytique de NaF, générant un équivalent de TMSF, du CO2, du SO2 ainsi qu’un ion F. Il 
s’agit donc d’un procédé qui ne génère pas de nucléophiles tels que CF3 ou l’ion I dans le milieu 
réactionnel (Schéma 28). 
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Schéma 28 
Après traitement des alcynes possédant des groupements aryles appauvris en électrons, avec du 
TFDA en présence de NaF dans le diglyme, les pyridazines correspondantes ont toutefois été 
obtenues avec des rendements similaires à ceux obtenus avec le protocole TMSCF3/NaI. Seule la 
pyridazine 79, possédant un aryle avec un groupement nitro en position para, a été isolée avec un 
rendement supérieur de 56% versus 34% obtenu avec TMSCF3/NaI. De plus, la pyridazine 83, 
possédant un aryle substitué par un cyanure en position méta a été obtenue avec 60% de rendement 
(Schéma 29).  
 
Schéma 29 
Après avoir étudié la réactivité de divers alcynes terminaux substitués par des aryles dans la séquence 
de cycloadditions [2+1]/[3+2], la réactivité d’alcynes terminaux substitués par des hétérocycles 
aromatiques a été examinée. Plus précisément, des alcynes substitués par une pyridine, un thiophène 
ainsi qu’un groupement benzoxazole ont été traités dans les deux conditions réactionnelles 
(TMSCF3/NaI ou/et TFDA/NaF), et les pyridazines 8488 ont été isolées avec des rendements qui 
varient de faibles à très bons. Signalons que dans le cas des pyridazines 84 et 86, l’utilisation du 
protocole TFDA/NaF a mené à la dégradation du produit (Schéma 30). 
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Schéma 30 
La réactivité des alcynes terminaux substitués par des groupements alkyles a été également étudiée. 
Les pyridazines 8991, possédant des groupements alkyles en position C3, ont été obtenues avec des 
rendements plus modestes de 20%39% comparés à ceux obtenus avec des alcynes substitués par 
des groupements aryles (Schéma 31). 
 
Schéma 31 
Des alcynes terminaux substitués par des chaînes alkyles portant une fonction amine protégée ont 
ensuite été engagés dans la séquence de cycloadditions [2+1]/[3+2]. Ainsi, les pyridazines 92 et 93, 
possédant des groupements phtalimides, ont été obtenues avec des rendements modestes en 
appliquant les deux protocoles. Enfin, la pyridazine 94 a aussi été isolée avec un rendement de 64% 
(TMSCF3/NaI) et 36% (TFDA/NaF) (Schéma 32). 
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Schéma 32 
Afin d’élargir cette séquence de cycloadditions à la synthèse de pyridazines substituées en position 
C6 par différents groupements fluorés, d’autres composés diazo ont été préparés et utilisés. Le 
(pentafluoroéthyl)diazométhane a été préparé dans le laboratoire de façon similaire au 
(trifluorométhyl)diazométhane, et il a pu être engagé dans la réaction de cycloaddition [3+2], pour 
conduire à la pyridazine 95 avec 71% de rendement (Schéma 33). 
 
Schéma 33 
De la même manière, lorsque le (difluorométhyl)diazométhane, préparé à partir de la 
difluoroéthylamine et du nitrite de tert-butyle, a été mis en réaction avec le difluorocyclopropène 
obtenu par cycloaddition [2+1] du difluorocarbène sur le phénylacétylène, la fluoropyridazine 96 a 
été isolée avec un rendement modeste de 44% (Schéma 34).  
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Schéma 34 
La séquence de cycloadditions [2+1]/[3+2] est donc une méthode générale et efficace, qui permet de 
synthétiser des pyridazines J possédant différents substituants en positions C3 et C6. Toutefois, la 
substitution en position C4 reste limitée au fluor. Comme les halogénopyridazines peuvent être 
impliquées dans des substitutions nucléophiles aromatiques (SNAr), le déplacement de l’atome de 
fluor en cette position par différents nucléophiles a été envisagé, afin d’obtenir une diversité de 
pyridazines 3,4,6-fonctionnalisées K (Schéma 35). 
 
Schéma 35 
Ainsi, lorsque la pyridazine 68 a été traitée par la benzylamine dans l’acétonitrile, la pyridazine désirée 
97 a été isolée avec 83% de rendement. D’autres nucléophiles ont été utilisés et il est apparu que les 
amines, les alcools et les composés soufrés sont des nucléophiles capables de substituer l’atome de 
fluor, pour accéder aux pyridazines 98102 avec de très bons rendements. L’anion du malonate de 
méthyle a aussi permis de déplacer sélectivement l’atome de fluor, et la pyridazine 103 a été isolée 
avec 92% de rendement. Enfin les pyridazines 104 et 105, substituées respectivement par un 
groupement nitrométhane et un groupement méthyle en position C4, ont été obtenues avec des 
rendements plus faibles de 52% et 12% (Schéma 36). 
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Schéma 36 
Après avoir examiné la réactivité de la pyridazine 68 vis-à-vis de différents nucléophiles, l’influence 
du substituant en position C3 sur la SNAr a été examinée. Pour cela, la réactivité des pyridazines 
possédant des aryles électro-appauvris ainsi que des aryles électro-enrichis a été étudiée en utilisant 
comme nucléophile la morpholine. Lorsque la pyridazine 81 substituée par un aryle possédant un 
atome de fluor en position para a été testée, le composé attendu 106 a été obtenu avec un 
rendement quantitatif. La pyridazine 77 substituée par un aryle en C3 portant un groupement 
mésomère-attracteur en para (ester de méthyle) en C3 a conduit au produit 107 avec 82% de 
rendement. Enfin, lorsque le substituant en C3 est un aryle possédant un groupement méthoxy en 
position para ou ortho, les pyridazines 108 et 109 ont été obtenues avec des rendements bons à 
excellents (Schéma 37). Il semble donc que les propriétés électroniques du substituant en position C3 
de la pyridazine n’influencent que légèrement la réaction SNAr.  
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Schéma 37 
L’influence du substituant en position C6 vis-à-vis de la SNAr a également été examinée. Ainsi, lorsque 
la pyridazine 95, substituée par un groupement pentafluoroéthyle en position C6, a été traitée par 
l’allylamine ainsi que par l’éthanethiolate de sodium, les pyridazines 110 et 111 ont été isolées avec 
des rendements respectifs de 90% et 84% (Schéma 38).  
 
Schéma 38 
De façon similaire, le traitement de la pyridazine 96, possédant un groupement difluorométhyle en 
position C6, par l’allylamine et l’éthanethiolate de sodium, a conduit respectivement aux pyridazines 
112 et 113 avec des rendements de 92% et 87% (Schéma 39). 
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Schéma 39 
Pour conclure, nous avons montré que des alcynes terminaux peuvent être engagés dans une 
séquence de cycloadditions [2+1]/[3+2] avec un difluorocarbène et par la suite avec un composé 
diazo, afin d’accéder à des pyridazines possédant un atome de fluor en position C4. Grâce à une 
substitution nucléophile aromatique, ces pyridazines peuvent être ensuite fonctionnalisées en 
position C4, ce qui permet d’accéder à une diversité de 3,4,6-pyridazines tri-substituées. 
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Our quality of life is closely linked to the discovery of new drugs and biologically active molecules. 
Among others, heterocycles represent an important family for the pharmaceutical and agrochemical 
industry, with 70% of pharmaceuticals and agrochemicals containing a heterocyclic motif.1 Indeed, 
the insertion of such motif in a drug candidate can not only influence its physico-chemical properties 
but can also act as a bioisoster of other heterocycles. 
However, the development of such bioactive molecules, which have no secondary effects for humans 
is often complicated. In order to modulate the physico-chemical and pharmacokinetical properties of 
a compound, medicinal chemists have turned their attention to the introduction of one or more 
fluorine atoms. This modification allows the improvement of a variety of properties such as a 
molecules lipophilicity, selectivity or bioavailability. 
Consequently, the research for novel synthetic methods, which would allow access to fluorinated 
heterocycles, is imperative. Our work is focused on this purpose. 
This manuscript is divided in three chapters.  
The first chapter deals with fluorine in medicinal chemistry. The influence of fluorine on molecules 
chemical and physico-chemical properties will be discussed. 
The second chapter is devoted to the ring contraction of (trifluoromethyl)piperidines and 
(trifluoromethyl)azepanes via an aziridinium intermediate to obtain 2-substituted, 
2-(trifluoromethyl)pyrrolidines (eq 1) and 2-substituted, 2-(trifluoromethyl)piperidines (eq 2) 
respectively. Bibliographic data concerning the chemistry of 2-substituted, 
2-(trifluoromethyl)pyrrolidines and 2-substituted, 2-(trifluoromethyl)piperidines will be presented. 
 
 
                                                          
1  Bioactive Heterocyclic Compound Classes : Pharmaceuticals and Agrochemicals; Lamberth, C.; Dinges, J., Eds.; 
Wiley-VCH : Weinheim, 2012. 
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The third chapter deals with the synthesis of α-(trifluoromethyl)pyridazines by a 
[2+1]/[3+2]-cycloaddition sequence between a terminal alkyne, a difluorocarbene and 
(trifluoromethyl)diazomethane.  
  
These (trifluoromethyl)pyridazines could be further functionalized at the C4 position to lead to a 
diversity of 3,4,6-substituted pyridazines.  
 
Bibliographic data concerning the chemistry of α-(trifluoromethyl)pyridazines will be presented.  
The molecules, figures, schemes and tables will be numbered according to their order of apparition 
in the manuscript. For the presentation of bibliographic data, the number of each molecule will be 
proceeded by L2 (for chapter 2) and L3 (for chapter 3). For the presentation of our results, the 
molecules will be numbered starting from 1 for each chapter.
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1. Introduction 
Since the isolation of fluorine in 1886 by Henri Moissan, who was awarded the Nobel Prize in 1906, 
fluorinated compounds have opened new opportunities due to their interesting properties. Indeed, 
before 1950, the idea that the incorporation of a fluorine atom in a natural compound could have a 
beneficial effect on its biological properties was inconceivable, especially given that the first 
fluorinated natural product was toxic (Figure 1).2  
 
Figure 1 
However, since 1955 and after the approval of the first fluorine-containing drug, around 150 
fluorinated molecules have reached the market. Indeed, to date around 25% of all marketed drugs 
contain a fluorine atom.3 
2. Fluorine properties and its influence on the chemical and 
physico-chemical properties of molecules 
2.1. CF bond generalities 
Fluorine is a small atom with a Van der Waals radius close to the Van der Waals radius of oxygen 
(Table 1).4 It is the most electronegative element in the periodic table, and as a result, the CF bond 
is highly polarized, with the fluorine atom bearing the partial negative charge and the carbon atom 
bearing the partial positive charge.4,5 Due to the attraction between these two charges, the CF bond 
has a less covalent and a more significant ionic character, it is very short and very strong (105 
kcal/mol).  
 
 
 
 
                                                          
2 a) Marais, J. S. C. Onderstepoort J. Vet. Sci. Anim. Ind. 1943, 18, 203206; b) Marais, J. S. C. Onderstepoort J. 
Vet. Sci. Anim. Ind. 1944, 20, 6773. 
3 Fried, J.; Sabo, E. F. J. Am. Chem. Soc. 1954, 76, 14551456. 
4 Hunter, L. Beilstein J. Org. Chem. 2010, 6, doi : 10.3762/bjoc.6.38. 
5 O’Hagan, D. Chem. Soc. Rev. 2008, 37, 308319. 
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Atom (A) H F O N C Cl Br 
Van der Waals radius (Å) 1.20 1.47 1.52 1.55 1.70 1.75 1.85 
Pauling electronegativity 2.1 4.0 3.5 3.0 2.5 3.2 2.8 
Length of the CA bond (Å) 1.09 1.40 1.43 1.47 1.54 1.77 1.97 
Strength of the CA bond (kcal/mol) 98 105 84 70 83 77 66 
Table 1 
Another consequence of the high electronegativity of the fluorine atom, is that its three lone pairs 
are strongly attracted by the nucleus, making this atom inert and unreactive. The high polarization of 
the CF bond, can also result in a low-energy σ* antibonding orbital, located behind the carbon atom 
in the plane of the CF bond (Figure 2). This orbital, can accept the electrons of a nearby 
electron-donating group such as a σ bond or a lone pair.4,5 The importance of these orbitals will be 
discussed in Section 2.5.  
 
Figure 2 
Even if the replacement of a CH or a COH by a CF bond does not influence the size of the molecule, 
it can surely induce modifications in properties such as the pKa, the lipophilicity or the conformation 
of a molecule. 
2.2. Influence of a fluorine atom on the pKa 
Due to the high electronegativity of the fluorine atom, the modulation of the pKa of proximal 
functional groups can be achieved, depending on the number of fluorine atoms, as well as their 
position in the molecule. For example, the replacement of a hydrogen atom by one fluorine atom in 
acetic acid, can lead to a decrease of the pKa by 2.2 units, while the replacement of three hydrogens 
by three fluorine atoms, can induce a decrease of 4.6 units (Figure 3).6  
 
Figure 3 
                                                          
6 Böhm, H. -J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. ChemBioChem 
2004, 5, 637643. 
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Similarly, the basicity of ethylamine decreases linearly due to the presence of one, two and three 
fluorine atoms (Figure 4).7 
 
Figure 4 
2.3. Influence of a fluorine atom on the lipophilicity of molecules 
For a drug candidate to cross the membrane, it has to be sufficiently lipophilic. At the same time, high 
lipophilicity can often result in reduced solubility, which can then lead to several undesired properties 
for the compound, such as incomplete absorption after administration. To find a balance between 
lipophilicity and minimal polarity, fluorine is often used as a modulator.  
The lipophilicity of the drugs is normally measured as the logarithmic partition coefficient (log P) 
between n-octanol and water, the higher the log P is, the higher is the lipophilicity of the compound.8 
When a fluorine atom is proximal to an amino group, the amine is less protonated and exists mostly 
in its neutral form, due to the decreased basicity of the amino group, caused by the presence of 
fluorine. This implies that the concentration of the compound is increased in octanol. Therefore by 
increasing the log P, the lipophilicity of the fluorinated compound is also increased compared to the 
non-fluorinated one.9  
2.4. Influence of a fluorine atom on the metabolic stability and 
bioavailability of molecules 
A recurring problem in medicinal chemistry, is the oxidation and the metabolism of a drug prior to its 
elimination, by enzymes such as cytochrome P450 monooxygenases. In order to prevent this 
oxidation, the metabolically labile sites can be blocked with a fluorine substituent.8 Due to the 
strength of the CF bond and its oxidative stability, this bond is highly stable towards chemical and 
metabolic transformations. 
An example of the influence of fluorine on drugs metabolic stability, is illustrated in Figure 5. Blockage 
of the metabolically labile sites of SCH-48461 by the incorporation of a fluorine atom, can prevent 
the oxidation of the phenyl ring and the dealkylation of the methoxy group, leading to the discovery 
of the cholesterol-absorption inhibitor ezetimibe, which is 400 times more potent than SCH-48461. 
                                                          
7 Gillis, E. P.; Eastman, K. J.; Hill, M. D.; Donnelly, D. J.; Meanwell, N. A. J. Med. Chem. 2015, 58, 83158359. 
8 Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Chem. Soc. Rev. 2008, 37, 320330. 
9 Reddy, V. P. in Organofluorine Compounds in Biology and Medicine, Elsevier: Oxford, UK, 2015. 
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Figure 5 
In addition, by modulating the lipophilicity and the metabolic stability of a drug, one can influence its 
absorption as well as its distribution. Indeed, due to the fact that the enzymes active site has a low 
polarity, the more lipophilic the drug candidate is, the higher its effective concentration is in the active 
site. As a result, smaller doses are required for an optimal efficacy.9 
2.5. Influence of a fluorine atom on molecular conformation 
Due to its small size and high electronegativity, a fluorine atom plays an important role on the 
conformation of a molecule. Indeed, the CF bond can not only interact with its environment through 
electrostatic (dipole-dipole and charge-dipole) interactions, but due to its low-energy CF σ* 
antibonding orbital, it can also participate in a hyperconjugation effect. However, given its high 
electronegativity, which holds strongly its three lone pairs, fluorine is only a poor donor and hydrogen 
bonding acceptor unlike oxygen or nitrogen. The participation of fluorine in such interactions (dipole-
dipole, charge-dipole, hyperconjugation) might contribute to an enhanced affinity of fluorine-
containing compounds with an enzyme active site. 
A) Dipole-dipole interactions 
The ionic nature of the CF bond, confers to this bond a high dipolar moment, which is responsible 
for any electrostatic interactions. For example, Müller et al. studied the spatial conformation of 
fluorine containing drugs in their protein targets, and proved the existence of an interaction between 
the fluorine atom and the amide carbon of the protein receptor as it is shown in Figure 6a.6,10  
Another example indicating the influence of fluorine on the conformation of a molecule is illustrated 
in Figure 6b, where in α-fluorocarbonyls, the CF bond is aligned antiparallel to the C=O bond, with 
                                                          
10 Müller, K.; Faeh, C.; Diederich, F. Science 2007, 317, 18811886. 
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the CF dipole opposed to the carbonyl dipole. It is worth mentioning, that this effect decreases with 
the decrease of the dipole moment of the carbonyl group.5 
 
Figure 6 
B) Charge-dipole interactions 
Electrostatic interactions, associated with the CF bond, become stronger when a neighboring group 
bears a formal charge. In 2005, Snyder et al. studied the family of 3-fluoropiperidines, and observed 
the preferential axial disposition of the fluorine in each compound, due to a charge-dipole interaction 
(Figure 7).11 
 
Figure 7 
Furthermore, these interactions were also observed in the case of the 2-fluoroethylammonium and 
the protonated 2-fluoroethanol, where the gauche conformation is privileged (Figure 8). This 
enhanced gauche effect, can be attributed to the increased polarization of the CN+ or the CO+ bond 
due to the nitrogen or the oxygen positive charge, and to an interaction between the partially 
negative fluorine atom and the formally positively-charged nitrogen or oxygen atom.12 It is worth 
mentioning, that intramolecular F-H interactions probably contribute to this stability, although the 
magnitude of this contribution is not clear. The gauche conformation is also preferred when X is a 
pyridine, even though the system cannot accommodate hydrogen bonding.13 The fact that the gauche 
conformation is favored even when hydrogen bonding is not possible, proves that charge-dipole 
interaction is more important than any hydrogen bonding. 
                                                          
11 Sun, A.; Lankin, D. C.; Hardcastle, K.; Snyder, J. P. Chem. Eur. J. 2005, 11, 15791591. 
12 Briggs, C. R. S.; Allen, M. J.; O’Hagan, D.; Tozer, D. J.; Slawin, A. M. Z.; Goeta, A. E.; Howard, J. A. K. Org. Biomol. 
Chem. 2004, 2, 732740. 
13 Gooseman, N. E. J.; O’Hagan, D.; Peach, M. J. G.; Slawin, A. M. Z.; Tozer, D. J.; Young, R. J. Angew. Chem. Int. 
Ed. 2007, 46, 59045908. 
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Figure 8 
C) Hyperconjugation effect 
The hyperconjugation effect, which is observed in the case of fluorine-containing molecules, is closely 
related to its low-energy σ* antibonding orbital. For example, for 1,2-difluoroethane there are two 
possible conformers (gauche and anti) (Figure 9).4,5 Although one might predict that the anti 
conformation is privileged due to the repulsion of the two fluorine atoms, surprisingly, it is the gauche 
conformation that is favored. Indeed, in the gauche conformer, the two σ*CF orbitals receive 
electrons in the form of electron rich bonds (CH bond), thus stabilizing the conformation, whereas 
in the anti conformation, each σ*CF orbital is aligned with an adjacent electron-deficient CF bond. 
As a result in the case of the anti conformation, the hyperconjugation cannot occur. 
 
Figure 9 
3. Biologically active CF3-containing molecules 
Among a variety of fluorinated groups, the trifluoromethyl group has received much attention over 
the last decades.7,14 In 1928, Lehmann was the first to report that compounds containing a 
trifluoromethyl group, have interesting biological activities. More specifically, he found that 
m-nitrobenzotrifluoride and m-trifluoromethylbenzoic acid, were potent stimulants and that 
m-aminobenzotrifluoride had a narcotic effect, the three of them affecting the central nervous 
system of frogs (Figure 10).15 
                                                          
14 a) Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, D.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; 
Liu, H. Chem. Rev. 2014, 114, 24322506; b) Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J. L.; 
Soloshonok, V. A.; Izawa, K.; Liu, H. Chem. Rev. 2016, 116, 422518. 
15 Lehmann, F. Arch. Exp. Path. Pharmakol. 1928, 130, 250255. 
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Figure 10 
It was not until the 1950’s that the trifluoromethyl group was widely recognized as a substituent of 
distinctive properties.16 In 1987, the antidepressant fluoxetine, more commonly known as Prozac®, 
was approved by the Food and Drug Administration (FDA) and became the most prescribed 
antidepressant drug worldwide (Figure 11).8 
 
Figure 11 
Since then, a large number of trifluoromethylated drugs were approved by the FDA, some of them 
being in the top 200 of the most successful drugs on the market and each of them treating a different 
type of disease. For example efavirenz, sold under the name Sustiva® and Stocrin®, is used to treat 
and prevent HIV/AIDS and sitagliptin, marketed under the trade name Januvia® is an 
antihyperglycemic drug. Other examples include celecoxib, an anti-inflammatory drug, nilotinib used 
for the treatment of chronic myelogenous leukemia, and siponimod which is an investigational drug 
used to treat multiple sclerosis (Figure 12).17 
                                                          
16 a) Heidelberger, C.; Chaudhuri, N. K.; Danneberg, P.; Mooren, D.; Griesbach, L.; Duschinsky, R.; Schnitzer, R. 
J. Nature 1957, 179, 663666 ; b) Yale, H. L. J. Med. Pharm. Chem. 1959, 1, 121133. 
17 Zhu, W.; Wang, J.; Wang, S.; Gu, Z.; Aceña, J. L.; Izawa, K.; Liu, H.; Soloshonok, V. A. J. Fluorine Chem. 2014, 
167, 3754. 
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Figure 12 
Therefore, the introduction of fluorine-containing groups into bioactive molecules, resulted in a 
positive effect for the compounds, such as rendering them more selective or potent. Indeed, the 
trifluoromethyl group can be used as a bioisoster for an ethyl group, an isopropyl group or even a 
carbonyl.10,18 
For instance, in an inhibitor of cathepsin K I, a trifluoroethylamino group was introduced as an amide 
isoster (Figure 13).19 It is worth mentioning, that cathepsin K (CTSK) is a lysosomal cysteine protease 
which might be the enzyme responsible for the degradation of type I collagen. Therefore, CTSK 
inhibitor I might be effective for the treatment of osteoporosis. Replacement, of the C=O bond by a 
CCF3 bond, led to a more potent and more selective inhibitor II towards cathepsin K, without 
influencing the basicity of the amide.  
 
                                                          
18 Hangmann, W. K. J. Med. Chem. 2008, 51, 43594369. 
19 Black, W. C.; Bayly, C. I.; Davis, D. E.; Desmarais, S.; Falgueyret, J.-P.; Léger, S.; Li, C. S.; Massé, F.; McKay, D. 
J.; Palmer, J. T.; Percival, M. D.; Robichaud, J.; Tsou, N.; Zamboni, R. Bioorg. Med. Chem. Lett. 2005, 15, 
47414744. 
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Figure 13 
Another example demonstrating the importance of the trifluoromethyl group, is illustrated in Figure 
14. Piperidine III is an antagonist of the gonadotropin releasing hormone (GnRH), which is a peptide 
released by the hypothalamus. GnRH can activate its own receptor, that causes the release of 
luteinizing hormone, therefore regulating gonadal steroid hormone production. As a result, GnRH is 
implicated in several hormone diseases such as prostate cancer, and its suppression by an inhibitor 
is the key for the treatment of these disorders. By introducing a CF3 group at the α position of the 
piperidine and in spite of a small reduction of the inhibition, piperidine IV showed an increased oral 
bioavailability in dogs.20 
 
Figure 14 
Thus, the introduction of a CF3 group into biologically active molecules, can have a significant impact 
on drug development due to the fluorine impact on chemical and physico-chemical properties. Given 
that for a large number of biologically active molecules, a CF3 group is present on saturated or 
unsaturated heterocycles, we have focused on the development of synthetic methods to obtain 
trifluoromethylated heterocycles.  
                                                          
20 Jiang, J.; DeVita, R. J.; Goulet, M. T.; Wyvratt, M. J.; Lo, J. -L.; Ren, N.; Yudkovitz, J. B.; Cui, J.; Yang, Y. T.; Cheng, 
K.; Rohrer, S. P. Bioorg. Med. Chem. Lett. 2004, 14, 17951798. 
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1. Generalities, Biological activity and synthesis of 
pyrrolidines and piperidines 
1.1. Generalities 
Pyrrolidines and piperidines belong to the family of cyclic secondary amines and can also be classified 
as saturated heterocycles. Pyrrolidines are 5-membered rings containing one nitrogen atom, and 
piperidines are 6-membered rings also containing one nitrogen atom (Figure 15).  
 
Figure 15 
Both heterocycles can be found in numerous natural and non-natural compounds, presenting a 
diversity of biological activities, with both of them being in the top 10 of the most frequently used 
ring systems in FDA approved small molecule drugs.21 As an evidence of their importance it may be 
noted that by the end of the year 2000, there were over 12.000 compounds possessing a piperidine 
or a pyrrolidine core, mentioned in clinical or preclinical studies.22 Due to the interesting properties 
induced by a fluorine atom or by a CF3 group, we became interested in the synthesis of pyrrolidines 
and piperidines containing a CF3 group at the C2 position. 
1.2.  Biological activity of 2-substituted, 2-(trifluoromethyl) 
pyrrolidines 
As already mentioned, pyrrolidine alkaloids are enormously ubiquitous in a variety of natural and 
non-natural compounds. There are around 80 pyrrolidine alkaloids known, which are mainly 
extracted from plants belonging to the Colanaceae, Convolvulaceae and Erythroxylaceae families.  
In 1889, Carl Liebermann was one of the first to isolate one of the most simple pyrrolidine alkaloids, 
hygrine, along with a related compound called cuscohygrine, both found in coca leaves (Figure 16).23 
                                                          
21 Taylor, R. D.; MacCoss, M.; Lawson, A. D. G. J. Med. Chem. 2014, 57, 58455859.  
22 Watson, P. S.; Jiang, B.; Scott, B. Org. Lett. 2000, 2, 36793681. 
23 Pictet, A. in The vegetable alkaloids. With particular to their chemical constitution, New York : J. Wiley & sons 
1904. 
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Figure 16 
Other simple and well-known pyrrolidine alkaloids, are the amino acids proline and hydroxyproline, 
both isolated in 1901 by Hermann Emil Louis Fischer from casein (Figure 17).24 One of the simplest 
alkaloids, proline, can be used as a precursor for the synthesis of more complex alkaloids.25 
 
Figure 17 
Since then, a large number of natural products and drugs containing a pyrrolidine ring has been 
discovered, all of them endowed with a variety of biological activities and pharmacological behaviors 
and some of them are illustrated in Figure 18.26 For example, kaitocephalin27 is a glutamate receptor 
antagonist, that may be useful for the treatment of neurological disorders such as Alzheimer’s 
disease. Radicamine A,28 which was isolated from a plant mainly found in China, Korea and Japan, 
presents a potential inhibitory activity against α-glucosidases, closely linked to diabetes. In addition, 
spirotryptostatin A,29 isolated from the Aspergillus fumigatus fungus, is a potent anti-cancer drug due 
to its anti-mitotic properties. Other examples, include marketed drugs such as captopril 
(hypertension treatment), which was later replaced by enalapril due to its undesired side-effects, and 
ramipril which is used for the treatment of high blood pressure and congestive heart failure. 
                                                          
24 Plimmer R. H. A. In Monographs on biochemistry; The chemical constitution of the proteins, Part I. Analysis 
(2nd ed.), R.H.A. Plimmer & F.G. Hopkins, Eds.; London: Longmans, Green and Co. 1908. 
25 Bhat, C.; Tilve, S. G. RSC Adv. 2014, 4, 54055452. 
26 Kumar, A.; Gupta, G.; Srivastava, S. J. Comb. Chem. 2010, 12, 458462. 
27 Shin-ya, K.; Kim, J.-S.; Furihata, K.; Hayakawa, Y.; Seto, H. Tetrahedron Lett. 1997, 38, 70797082. 
28 a) Shibano, M.; Tsukamoto, D.; Masuda, A.; Tanaka, Y.; Kusano, G. Chem. Pharm. Bull. 2001, 49, 13621365; 
b) Shibano, M.; Tsukamoto, D.; Kusano, G. Heterocycles 2002, 57, 15391553. 
29 Edmondson, S.; Danishefsky, S. J.; Sepp-Lorenzino, L.; Rosen, N. J. Am. Chem. Soc. 1999, 121, 21472155. 
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Figure 18 
Given the great abundance of pyrrolidines in natural alkaloids as well as pharmaceuticals, their 
trifluoromethylated analogues represent potential biologically interesting compounds.  
Fluoroquinolones have been used as antibacterial agents in antiinfective chemotherapy. However, 
their frequent clinical use has rendered them ineffective towards the quinolone and 
methicillin-resistant Staphylococcus aureus. It has been reported that the introduction of a CF3 group 
onto the pyrrolidine A, increases their potency towards Staphylococcus aureus, while maintaining low 
side effects (Figure 19).30  
 
Figure 19 
Another example that demonstrates the influence of the CF3 group on the biological profile of a 
pyrrolidinic compound, is illustrated in Figure 20. MIF-1, a melanocyte-stimulating hormone release 
                                                          
30 Fukui, H.; Shibata, T.; Naito, T.; Nakano, J.; Maejima, T.; Senda, H.; Iwatani, W.; Tatsumi, Y.; Suda, M.; Arika, 
T. Bioorg. Med. Chem. Lett. 1998, 8, 28332838. 
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inhibiting factor, is an endogenous brain peptide, that is able to modulate dopaminergic 
neurotransmission in vitro and in vivo. It is therefore considered to be an encouraging agent for the 
treatment of several brain disorders such as Parkinson’s disease or depression. In a series of in vivo 
acute pain experiments on rat model, Brigaud et al. showed that, while MIF-1 had no effect, its 
α-(trifluoromethyl) analogue CF3-(MIF-1) improved the compounds biological activity, exhibiting a 
significant analgesic effect.31 
 
Figure 20 
1.3. Biological activity of 2-substituted, 2-(trifluoromethyl) 
piperidines 
The piperidine ring is an important structural feature, present in many natural products and 
pharmaceuticals. Their structure can vary from very simple alkaloids to more complicated ones. One 
of the simplest piperidine-containing natural products, is the poisonous alkaloid coniine isolated from 
the poison Hemlock (Conium maculatum), along with ()--conhydrine. They both cause muscular 
paralysis leading to death (Figure 21).32 
 
Figure 21 
Other piperidine alkaloids, include (−)-allosedamine and lobeline, both isolated from Lobelia inflata 
(also known as Indian tobacco). The first one is used for the treatment of respiratory illnesses such 
asthma, bronchitis and pneumonia,33 and the second one has been used as a substitution therapy for 
tobacco smoking cessation and is reported to have many nicotine-like effects, including 
                                                          
31 Jlalia, I.; Lensen, N.; Chaume, G.; Dzhambazova, E.; Astasidi, L.; Hadjiolova, R.; Bocheva, A.; Brigaud, T. Eur. J. 
Med. Chem. 2013, 62, 122129. 
32 Felpin, F. -X. ; Lebreton, J. Eur. J. Org. Chem. 2003, 36933712. 
33 Wieland, H.; Koschara, W.; Dane, E.; Renz, J.; Schwarze, W.; Linde, W. Liebigs Ann. Chem. 1939, 540, 
103156. 
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cardiovascular and central nervous effects.34 A third example includes micropine,35 isolated from 
Microcos philippinensis, a plant whose ethanol extracts show antimicrobial activity (Figure 22).  
As far as pharmaceutically active piperidine-containing molecules are concerned, among others we 
can cite naratriptan, which is a triptan drug marketed by GlaxoSmithKline and is used for the 
treatment of migraine headaches. Ritalin, also called methylphenidate, is a drug owned by Novartis 
and used for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. We can 
also cite miglitol, an oral anti-diabetic drug, that inhibits the ability of the patient to break down 
complex carbohydrates into glucose (Figure 22).36 
 
Figure 22 
Taking into account the importance of the presence of a piperidine ring in biologically active 
compounds, whether it is natural alkaloids or pharmaceutical drugs, it is logical, that their 
trifluoromethylated analogues were also studied. 
Indeed, some examples of biologically active piperidines containing a CF3 group have been reported. 
For instance, mTORC1 is a protein complex that controls protein synthesis and therefore the mTORC1 
inhibitor, containing a α-(trifluoromethyl)piperidine, can modulate the cellular proliferation (Figure 
23).37  
                                                          
34 Wieland, H. Ber. Dtsch. Chem. Ges. 1921, 54, 17841788.  
35 Aguinaldo, A. M.; Read, R. W. Phytochemistry 1990, 29, 23092313. 
36 a) Dragutan, I.; Dragutan, V.; Demonceau, A. RSC Adv. 2012, 2, 719736; b) Zhang, S.; Cha, L.; Li, L.; Hu, Y.; Li, 
Y.; Zha, Z.; Wang, Z. J. Org. Chem. 2016, 81, 31773187. 
37 Aay, N.; Blazey, C. M.; Bowles, O. J.; Bussenius, J.; Curtis, J. K.; Defina, S. C.; Dubenko, L.; Harris, J. R.; Jackson- 
Ugueto, E. E.; Kim, A. I.; Manalo, J. -C. L.; Pack, M.; Peto, C. J.; Rice, K. D.; Tsang, T. H.; Wang, L. 2010 (WO 
2010138490). 
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Figure 23 
α-Trifluoromethylated piperidines can also have an inhibitory effect towards Janus kinases 1 (JAK 1) 
and 2 (JAK 2), which are implicated in the proliferation and survival of the cells. As a result, these 
inhibitors, could eventually be used for the treatment of asthma, cancer or even rheumatoid arthritis 
(Figure 24).38 
 
Figure 24
                                                          
38 a) Childers, M. L.; Fuller, P.; Guerin, D.; Katz, J. D.; Pu, Q.; Scott, M. E.; Thompson, C. F.; Martinez, M.; Falcone, 
D.; Torres, L.; Deng, Y.; Kuruklasuriya, R.; Zeng, H.; Bai, Y.; Kong, N.; Liu, Y.; Zheng, Z. 2014 (WO 2014146491); 
b) Dinsmore, C.; Fuller, P.; Guerin, D.; Katz, J. D.; Thompson, C. F.; Falcone, D.; Deng, W.; Torres, L.; Zeng, H.; 
Bai, Y.; Fu, J.; Kong, N.; Liu, Y.; Zheng, Z. 2014 (WO 2014146493). 
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1.4. Main synthetic methods to access 2-substituted, 
2-(trifluoromethyl)pyrrolidines and 2-substituted, 
2-(trifluoromethyl)piperidines 
Several synthetic methods have been reported in the literature, to obtain 
α-(trifluoromethyl)pyrrolidines and α-(trifluoromethyl)piperidines. As our goal is to synthesize 
2-(trifluoromethyl)pyrrolidines and 2-(trifluoromethyl)piperidines possessing a quaternary center at 
the C2 position, we will only focus on methods developed to obtain 2-substituted, 
2-(trifluoromethyl)pyrrolidines and 2-substituted, 2-(trifluoromethyl)piperidines (Figure 25). 
 
Figure 25 
Recently, a review was published by our laboratory, presenting the synthetic methods used to access 
substituted α-(trifluoromethyl)piperidines.39 These methods were also applied to the synthesis of 
substituted α-(trifluoromethyl)pyrrolidines. Therefore, we will first summarize these methods which 
can be found in the recently-published review and we will then present in detail the synthetic 
methods reported to access only 2-substituted, 2-(trifluoromethyl)pyrrolidines. 
1.4.1. Synthetic methods to access 2-substituted, 
2-(trifluoromethyl)piperidines 
The most common method to access 2-substituted, 2-(trifluoromethyl)piperidines B is from 
(trifluoromethyl)imines C. Nenajdenko et al. showed that these imines, which could be formed from 
the corresponding lactams, reacted with a variety of nucleophiles to afford the desired 
(trifluoromethyl)piperidines B.40 Alternatively, piperidines B, could be accessed from imines D. 
Indeed, imines D, which were obtained from the corresponding lactams, could react with the 
                                                          
39 Rioton, S.; Gomez Pardo, D.; Cossy, J. Molecules 2017, 22, 483505.  
40 a) Gulevich, A. V.; Shevchenko, N. E.; Balenkova, E. S.; Röschenthaler, G. -V.; Nenajdenko, V. G. Synlett 2009, 
403406; b) Odinets, I. L.; Artyushin, O. I.; Lyssenko, K. A.; Shevchenko, N. E.; Nenajdenko, V. G.; Röschenthaler, 
G. -V. J. Fluorine Chem. 2009, 130, 662666; c) Shevchenko, N. E.; Balenkova, E. S.; Röschenthaler, G. -V.; 
Nenajdenko, V. G. Synthesis 2010, 120126; d) Shmatova, O. I.; Nenajdenko, V. G. Eur. J. Org. Chem. 2013, 
63976403; e) Shmatova, O. I.; Shevchenko, N. E.; Balenkova, E. S.; Röschenthaler, G. -V.; Nenajdenko, V. G. 
Eur. J. Org. Chem. 2013, 30493058; f) Shmatova, O. I.; Shevchenko, N. E.; Balenkova, E. S.; Röschenthaler, 
G. -V.; Nenajdenko, V. G. Mendeleev Commun. 2013, 23, 9293; g) Shevchenko, N. E.; Shmatova, O. I.; 
Balenkova, E. S.; Röschenthaler, G. -V.; Nenajdenko, V. G. Eur. J. Org. Chem. 2013, 22372245; h) Shmatova, O. 
I.; Khrustalev, V. N.; Nenajdenko, V. G. Org. Lett. 2016, 18, 44944497. 
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Ruppert-Prakash reagent (TMSCF3), to form α-(trifluoromethyl)piperidines B.41 Access to 
2-substituted, 2-(trifluoromethyl)piperidines B, has also been achieved by the electrophilic-induced 
cyclization of aminoalkynes E. In 2011, Hammond et al. reported that the reaction of aminoalkynes E 
with TMSCF3 in the presence of a silver salt, could lead to the cyclized products B.42 
(Trifluoromethyl)piperidines B, were also obtained by ring-expansion of aziridines F. De Kimpe et al., 
showed that when the aziridine F was activated by a tosyl group (R=tosyl), a nucleophile could attack 
this aziridine at the less substituted position, inducing the ring-opening of F, followed by a ring-closure 
leading to the 6-membered ring B.43 In addition, ring-closing metathesis (RCM) is a very common and 
effective method to obtain α-(trifluoromethyl)piperidines B and it was a method mainly developed 
by the groups of Osipov and Dixneuf. The most common starting materials are dienes G, which in the 
presence of a variety of catalysts such as Grubbs-I, Grubbs-II, Hoveyda-II or even other 
ruthenium-allenylidene catalysts were able to afford the desired unsaturated piperidines B.44 
Furthermore, the ring-closing metathesis of 1,6-enynes H and 1,7-enynes I, in the presence of 
ruthenium catalysts, led to a variety of substituted piperidines B.45 Polyfunctionalized 
(trifluoromethyl)piperidine derivatives B could also be synthesized from highly electrophilic imines K 
and 1,3-dienes J by an aza-Diels Alder reaction.46,36b In order for the cycloaddition reaction to occur, 
the imines used as dienophiles must be activated either by an electron-withdrawing group or by a 
Lewis acid (Scheme 1). 
                                                          
41 a) Shevchenko, N. E.; Vlasov, K.; Nenajdenko, V. G.; Röschenthaler, G. -V. Tetrahedron 2011, 67, 6974; b) 
Levin, V. V.; Dilman, A. D.; Belyakov, P. A.; Struchkova, M. I.; Tartakovsky, V. A. Eur. J. Org. Chem. 2008, 
52265230. 
42 Han, J.; Xu, B.; Hammond, G. B. Org. Lett. 2011, 13, 34503453. 
43 Dolfen, J.; Kenis, S.; Van Hecke, K.; De Kimpe, N.; D’hooghe, M. Chem. Eur. J. 2014, 20, 1065010653. 
44 a) Osipov, S. N.; Bruneau, C.; Picquet, M.; Kolomiets, A. F.; Dixneuf, P. H. Chem. Commun. 1998, 20532054; 
b) Osipov, S. N.; Artyushin, O. I.; Kolomiets, A. F.; Bruneau, C.; Picquet, M.; Dixneuf, P. H. Eur. J. Org. Chem. 
2001, 38913897; c) Osipov, S. N.; Artyushin, O. I.; Kolomiets, A. F.; Bruneau, C.; Dixneuf, P. H. Synlett 2000, 
10311033; d) Osipov, S. N.; Kobelikova, N. M.; Shchetnikov, G. T.; Kolomiets, A. F.; Bruneau, C.; Dixneuf, P. H. 
Synlett 2001, 621622; e) Vorobyeva, D. V.; Mailyan, A. K.; Peregudov, A. S.; Karimova, N. M.; Vasilyeva, T. P.; 
Bushmarinov, I. S.; Bruneau, C.; Dixneuf, P. H.; Osipov, S. N. Tetrahedron 2011, 67, 35243532. 
45 a) Mailyan, A. K.; Krylov, I. M.; Bruneau, C.; Dixneuf, P. H.; Osipov, S. N. Eur. J. Org. Chem. 2013, 53535363; 
b) Eckert, M.; Monnier, F.; Shchetnikov, G. T.; Titanyuk, I. D.; Osipov, S. N.; Toupet, L.; Dérien, S.; Dixneuf, P. H. 
Org. Lett. 2005, 7, 37413743. 
46 Kobel’kova, N. M.; Osipov, S. N.; Kolomiets, A. F. Russ. Chem. Bull., Int. Ed. 2002, 51, 12981302. 
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Scheme 1 
In addition to the above methods, two more particular synthetic routes exist, allowing the formation 
of 2-substituted, 2-(trifluoromethyl)piperidines of type B. In 2012, Fustero et al. reported the one-pot 
iodocyclization of oxazinone L2.2, followed by a [1,2]-shift of the CF3 group of the intermediate L2.3 
to afford (trifluoromethyl)lactone L2.4, which could then be transformed to a variety of 
α-(trifluoromethyl)pipecolic acid derivatives L2.5 (Scheme 2).47  
 
Scheme 2 
                                                          
47 a) Fustero, S.; Albert, L.; Aceña, J. L.; Sanz-Cervera, J. F.; Asensio, A. Org. Lett. 2008, 10, 605608; b) Fustero, 
S.; Albert, L.; Mateu, N.; Chiva, G.; Miró, J.; González, J.; Aceña, J. L. Chem. Eur. J. 2012, 18, 37533764. 
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In 2016, multi-substituted α-(trifluoromethyl)piperidines L2.11 were obtained via a one-pot, 
multicomponent reaction between isoxazole L2.6, ketoester L2.7, ammonium acetate and aryl 
aldehydes L2.8. According to the proposed mechanism, isoxazole L2.6 could undergo a Michael 
addition in the presence of the enolized ketoester L2.7, to form intermediate L2.9. Then, the product 
obtained from the condensation of aldehyde L2.8 with ammonium acetate, could react with L2.9 to 
obtain compound L2.10, which after an intramolecular cyclization led to the desired spiropiperidines 
L2.11 (Scheme 3).48 
 
Scheme 3 
1.4.2. Synthetic methods to access 2-substituted, 
2-(trifluoromethyl)pyrrolidines 
The majority of the synthetic routes mentioned above, have been used to access 2-substituted, 
2-(trifluoromethyl)pyrrolidines L. Therefore treatment of (trifluoromethyl)imines M with different 
nucleophiles,40 or treatment of imines N with TMSCF3,41a,49 led to a variety of functionalized 
pyrrolidines L. Moreover, the electrophilic-induced cyclization of aminoalkynes O was successfully 
applied to the synthesis of (trifluoromethyl)pyrrolidines L in the presence of a silver salt.42 The 
regioselective ring-opening of aziridines P, followed by a ring-closure, also allowed the formation of 
pyrrolidines L.43 Similarly, the optically pure aziridine Q, could be opened in the presence of the 
dimethyl malonate anion, to afford a ring-opening product which after an intramolecular nucleophilic 
                                                          
48 Shi, W.; Wang, Y.; Zhu, Y.; Zhang, M.; Song, L.; Deng, H. Synthesis 2016, 48, 35273536. 
49 a) Levin, V. V.; Kozlov, M. A.; Dilman, A. D.; Belyakov, P. A.; Struchkova, M. I.; Tartakovsky, V. A. Russ. Chem. 
Bull., Int. Ed. 2009, 58, 484486; b) Huang, W.; Ni, C.; Zhao, Y.; Zhang, W.; Dilman, A. D.; Hu, J. Tetrahedron 
2012, 68, 51375144. 
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substitution, led to the optically active pyrrolidine derivative L.50 In addition, 
(trifluoromethyl)pyrrolidines L were also obtained by the ring-closing metathesis of dienes R,44a,b as 
well as enynes S51 and T45b in the presence of Grubbs-I catalyst or other ruthenium allenylidene 
complexes (Scheme 4). 
 
Scheme 4 
In addition to the methods reported above, some other methods exist, to access 2-substituted, 
2-(trifluoromethyl)pyrrolidine derivatives L, mostly by cyclization.  
In 1996, the α-(trifluoromethyl)pyroglutamic acid L2.17 was synthesized from the 
(trifluoromethyl)imine L2.12. The addition of an organomagnesium reagent on L2.12, followed by the 
oxidation of the double bond, afforded compound L2.14. After saponification of L2.14, followed by a 
deprotection and a cyclization, the α-(trifluoromethyl)pyroglutamic acid L2.17 was isolated (Scheme 
5).52 
                                                          
50 Katagiri, T.; Katayama, Y.; Taeda, M.; Ohshima, T.; Iguchi, N.; Uneyama, K. J. Org. Chem. 2011, 76, 93059311. 
51 Sémeril, D.; Le Notre, J.; Bruneau, C.; Dixneuf, P. H.; Kolomiets, A. F.; Osipov, S. N. New J. Chem. 2001, 25, 
1618. 
52 Koksch, B.; Ullmann, D.; Jakubke, H. -D.; Burger, K. J. Fluorine Chem. 1996, 80, 5357. 
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Scheme 5 
In 2006, Brigaud et al. were the first authors to report the synthesis of optically pure 
α-(trifluoromethyl)prolines L2.21 as well as the synthesis of α-(trifluoromethyl)prolinol L2.22.53 A 
mixture of morpholinones L2.18a and L2.18b, underwent a 9-BBN hydroboration to form a mixture 
of alcohols L2.19a and L2.19b, which after cyclization by an intramolecular nucleophilic attack of the 
amines nitrogen to the iodine or the mesylate group, gave the bicyclic compounds (R,S)-L2.20 and 
(R,R)-L2.20, easily separated by silica gel chromatography (Scheme 6).  
 
Scheme 6 
The removal of the chiral auxiliary of (R,S)-L2.20 and (R,R)-L2.20 after hydrogenolysis, afforded the 
(trifluoromethyl)prolines (S)-L2.21 and (R)-L2.21. After treatment of (S)-L2.21 with LAH, 
α-(trifluoromethyl)prolinol (S)-L2.22 was isolated in 84% yield (Scheme 7).53 
                                                          
53 Chaume, G.; Van Severen M. -C.; Marinkovic, S.; Brigaud, T. Org. Lett. 2006, 8, 61236126. 
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Scheme 7 
Alternatively, when the diastereomeric mixture of L2.19a and L2.19b was oxidized by the Jones 
reagent, a cyclization took place to afford the bicyclic lactams (R,S)-L2.23 and (R,R)-L2.23 in 61% and 
20% yield respectively, conveniently separated by silica gel chromatography. After saponification of 
the lactone of (R,S)-L2.23 and (R,R)-L2.23 with LiOH and cleavage of the benzylic bond using Li/NH3, 
α-(trifluoromethyl)pyroglutamic acids (S)-L2.24 and (R)-L2.24 were isolated in 49% and 69% yield 
respectively (Scheme 8).54 
 
Scheme 8 
Brigaud et al. reported an alternative pathway to access α-(trifluoromethyl)proline derivatives by an 
iodocyclization of the morpholinone mixture L2.18 induced by I2. After the dehydroiodination of 
L2.25, compounds (R,S)-L2.26 and (R,R)-L2.26 were obtained. At this stage (R,S)-L2.26 and (R,R)-L2.26 
were easily separated by silica gel chromatography (Scheme 9).55  
                                                          
54 Chaume, G.; Van Severen M. -C.; Ricard, L.; Brigaud, T. J. Fluorine Chem. 2008, 129, 11041109. 
55 Caupène, C.; Chaume, G.; Ricard, L.; Brigaud, T. Org. Lett. 2009, 11, 209212. 
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Scheme 9 
Dihydroxylation of (R,S)-L2.26 and (R,R)-L2.26 followed by cleavage of the chiral auxiliary, led to 
α-(trifluoromethyl)dihydroxyprolines (S)-L2.27 and (R)-L2.27 in 68% and 73% yield respectively 
(Scheme 10). The dihydroxylation afforded the two compounds with complete diastereoselectivity in 
favour of the compounds possessing the two hydroxyl groups in a trans relationship with the CF3 
group, indicating that the CF3 moiety directs the dihydroxylation and not the chiral auxiliary.55 
 
Scheme 10 
In 2013, Zhang et al. reported an alternative synthetic route to access (trifluoromethyl)proline 
(R)-L2.21 by the enantioselective alkynylation of imine L2.28 catalyzed by the complex zinc/ligand L*. 
The obtained acetylenic compound L2.29 was hydrogenated (H2, Pd/C), and the TBS group was then 
cleaved, to afford L2.30. This compound was cyclized after treatment with mesyl chloride, to give the 
protected (R)-proline L2.31. Deprotection of the amine led to the (trifluoromethyl)proline (R)-L2.21 
in 66% yield (Scheme 11).56 
                                                          
56 Huang, G.; Yin, Z.; Zhang, X. Chem. Eur. J. 2013, 19, 1199211998. 
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Scheme 11 
In 2013 Osipov et al. reported the intramolecular cyclization of homopropargylamines L2.32a and 
L2.32b, to access the α-CF3-dehydroproline derivatives L2.34a and L2.34b.57 When the 
N-Boc-protected homopropargylamines L2.32a were treated with TFA, a mixture of the deprotected 
compound L2.33a and the cyclized product L2.34a was obtained, which after treatment with the 
silver salt Ag(OTf), gave the dehydroprolines L2.34a, possessing a quaternary center at the C2 
substituted by an ester and a CF3 group (Scheme 12, eq 1). However, when the N-Cbz-protected 
propargylamino-phosphonates L2.32b, were treated with a mixture of TFA/TsOH, the deprotected 
amines L2.33b were not observed. In this case, a spontaneous cyclization took place, to afford 
dehydroprolines L2.34b, while the addition of a silver salt was not necessary. This reaction therefore 
represents the first example of an intramolecular cyclization of amines containing a propargyl group 
without the use of a metal as an activator (Scheme 12, eq 2).  
 
Scheme 12
                                                          
57 Zotova, M. A.; Vasil’eva, T. P.; Osipov, S. N. Russ. Chem. Bull., Int. Ed. 2013, 62, 792796. 
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2. Context of the study and objective 
Over the past few years, due to the increasing interest in (trifluoromethyl)pyrrolidines and 
(trifluoromethyl)piperidines in medicinal chemistry, we became interested in developing synthetic 
methods to obtain functionalized α-(trifluoromethyl)pyrrolidines and α-(trifluoromethyl)piperidines. 
In our laboratory, the ring expansion of prolinols L2.35 to piperidines L2.37, via a bicyclic aziridinium 
intermediate L2.36, was reported.58 Although the reaction is stereoselective, in some cases a mixture 
of 6-membered rings L2.37 and 5-membered rings L2.38 was obtained (Scheme 13). 
 
Scheme 13 
More recently, it has been shown that the presence of a CF3 group on the proline derivative L2.39, 
allowed the exclusive formation of the α-(trifluoromethyl)piperidines L2.41 via the aziridinium 
intermediate L2.40 (Scheme 14).59  
 
Scheme 14 
Based on the reactivity of L2.39, it seems that the CF3 group is responsible for the regioselective attack 
of the nucleophile on the aziridinium intermediate (see Section 3). Thus, we envisioned to access 
2-substituted-2-(trifluoromethyl)pyrrolidines (n=1) and 2-substituted-2-(trifluoromethyl)piperidines 
(n=2) I by the ring contraction of hydroxypiperidines (n=1) and hydroxyazepanes (n=2) III respectively, 
as the presence of CF3 group could eventually direct the attack of the nucleophile only at the C2’ of 
the aziridinium intermediate II (Scheme 15). 
                                                          
58 a) Cossy, J.; Gomez Pardo, D. Chemtracts 2002, 15, 579605; b) Cossy, J.; Gomez Pardo, D.; Dumas, C.; 
Mirguet, O.; Déchamps, I.; Métro, T. -X.; Burger, B.; Roudeau, R.; Appenzeller, J.; Cochi, A. Chirality 2009, 21, 
850856; c) Gomez Pardo, D.; Cossy, J. Chem. Eur. J. 2014, 20, 45164525 and references therein. 
59 Rioton, S.; Orliac, A.; Antoun, Z.; Bidault, R.; Gomez Pardo, D.; Cossy, J. Org. Lett. 2015, 17, 29162919. 
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Scheme 15 
It is worth mentioning that examples of ring contractions are scarce in the literature.60 Nevertheless, 
one example of ring contraction via an aziridinium intermediate was reported in 2000 by the group 
of De Kimpe. When piperidines L2.42, were treated with boron tribromide (BBr3), intermediate L2.43 
possessing a good leaving group at the C3 position, was formed. Due to the nitrogen anchimeric 
assistance, the aziridinium intermediate L2.44 was formed, to afford after the attack of a bromide 
anion, pyrrolidines L2.45 in moderate to good yields. However, along with the ring contracted 
products L2.45, piperidines L2.46 were formed, probably after the demethylation of the methoxy 
group of L2.42 by BBr3, or by sodium hydroxide-induced rearrangement of pyrrolidines L2.45 via the 
intermediate aziridinium L2.44 (Scheme 16).61 
 
Scheme 16 
                                                          
60 a) Duhamel, L.; Poirier, J. M. Tetrahedron Lett. 1976, 24372440; b) Duhamel, P.; Kotera, M. J. Org. Chem. 
1982, 47, 16881691; c) Donati, D.; Fusi, S.; Macripo, M. A.; Ponticelli, F. J. Heterocycl. Chem. 1987, 24, 481483; 
d) Plaquevent, J. -C.; Chichaoui, I. Bull. Soc. Chim. Fr. 1996, 133, 369379. 
61 Abbaspour Tehrani, K.; Van Syngel, K.; Boelens, M.; Contreras, J.; De Kimpe, N.; Knight, D. W. Tetrahedron 
Lett. 2000, 41, 25072510. 
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Before we start discussing our results, we will briefly present the regioselective ring-opening of the 
2-(trifluoromethyl)aziridirines via the formation of an aziridinium intermediate. This regioselective 
attack can be induced due to the presence of the CF3 group on the aziridinium. 
3. Regioselective ring-opening of 2-(trifluoromethyl) 
aziridinium intermediates 
The regioselective ring-opening of 2-(trifluoromethyl)aziridines IV, has been the subject of many 
publications. However, (trifluoromethyl)aziridines whose nitrogen is substituted by an alkyl group, 
are unreactive towards nucleophilic attack, therefore their prior activation is necessary. Here, we will 
report the aziridines ring-opening via an aziridinium intermediate which can be formed either by 
activation under acidic conditions (R’=H) or by activation by N-alkylation (R’=alkyl). The nucleophilic 
attack is regioselective at the C3 position of V, possibly due to a steric effect as well as an electrostatic 
repulsion between the nucleophile and the CF3 group at the C2 position (Scheme 17). 
 
Scheme 17 
3.1.1. Formation of an aziridinium under acidic conditions 
In 1997, Karimova et al. reported the activation of aziridine L2.47, by a variety of strong acids (NuH), 
to afford the aziridinium intermediate L2.48 which, after attack of the counter-ion (Nu) at the C3 
position, led to a regioselective ring-cleavage and the formation of α-(trifluoromethyl)amines L2.49 
(Scheme 18).62 It is worth mentioning, that treatment of aziridines L2.47 with a strong acid is 
necessary, otherwise these aziridines remain unreactive towards nucleophiles. This lack of reactivity 
is probably due to the presence of the CF3 group, which decreases the aziridines basicity (by two 
units) compared to the non-fluorinated aziridines, rendering the protonation more difficult. 
                                                          
62 Karimova, N. M.; Teplenicheva, Y. L.; Kolomiets, A. F.; Folkin, A. V. Russ. Chem. Bull. 1997, 46, 11361139.  
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Scheme 18 
Two years later, Katagiri et al. reported the acid-promoted ring-opening of N-benzyl-aziridine L2.50, 
with a variety of nucleophiles. Indeed, the optically active aziridine L2.50 was activated in the 
presence of sulfuric or trifluoromethanesulfonic acid, to form the corresponding aziridiniums L2.51a 
and L2.51b respectively, which in the presence of different nucleophiles, gave the 
α-(trifluoromethyl)amines L2.52, in good yields and with good enantiomeric excess (Scheme 19).63 
Interestingly, when aziridine L2.50 was treated with PhSH, without the presence of a strong acid, the 
ring-opening product L2.52 was isolated in a lower yield of 40%, along with 50% recovery of L2.50. 
Another interesting point, is that nitrogen-containing nucleophiles, could not promote the 
ring-opening of aziridines, due to the nitrogen protonation under these acidic conditions. 
 
Scheme 19 
The regioselective ring-opening of other enantiopure aziridines was studied. For example, when the 
optically pure trans-aziridine L2.53 was activated by trifluoroacetic acid, the aziridinium intermediate 
L2.54 was formed. The regioselective and stereoselective attack of the counter-ion on the aziridinium 
L2.54 at the C3 position, allowed the ring-opening and therefore the access to the 
anti-(trifluoromethyl)amine L2.55 (Scheme 20).64  
                                                          
63 Katagiri, T.; Takahashi, M.; Fujiwara, Y.; Ihara, H.; Uneyama, K. J. Org. Chem. 1999, 64, 73237329. 
64 Davoli, P.; Forni, A.; Franciosi, C.; Moretti, I.; Prati, F. Tetrahedron: Assymetry 1999, 10, 23612371. 
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Scheme 20 
Furthermore, (trifluoromethyl)aziridines L2.56 can be either activated by a strong acid (HCl or 
CF3CO2H) to form the aziridinium salt L2.57a, where the resulting counter-ion can then serve as a 
nucleophile, or activated by CF3SO2H to form the aziridinium L2.57b which can then be attacked by 
an external nucleophile. In both cases, the corresponding amines L2.58 were obtained in moderate 
to excellent yields. The authors highlighted that the attack took place at the C3 position, indicating 
that the presence of the CF3 group and not the presence of the ester group, is responsible for the 
regioselective and diastereoselective ring-opening of the aziridinium (Scheme 21).65  
 
Scheme 21 
In 2014, De Kimpe and D’hooghe reported the acid-promoted regio- and stereoselective ring-opening 
of cis- and trans-(trifluoromethyl)aziridines L2.59a and L2.59b, to afford a range of 
α-(trifluoromethyl)amines L2.61a and L2.61b via the corresponding aziridinium intermediates L2.60a 
and L2.60b. After the activation of the aziridines L2.59a and L2.59b with sulfuric acid, and after 
treatment with water and methanol, the regioselective ring-opening of the aziridiniums L2.60a and 
L3.60b took place (Scheme 22).66 The syn- and anti-products were obtained in good to excellent yields 
from the cis- and trans-aziridines respectively. 
                                                          
65 Crousse, B.; Narizuka, S.; Bonnet-Delpon, D.; Bégué, J. -P. Synlett 2001, 679681. 
66 Moens, M.; De Kimpe, N.; D’hooghe, M. J. Org. Chem. 2014, 79, 55585568. 
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Scheme 22 
It is worth mentioning that when bromic acid was utilized, the activation of aziridines L2.59a and 
L2.59b occurred by HBr itself, and the ring-opened products L2.63a and L2.63b, were obtained in 
good yields without the addition of sulfuric acid, after the attack of the bromine anion to the C3 
position of the aziridinium L2.62a and L2.62b (Scheme 23).  
 
Scheme 23 
Interestingly, when the enantiopure aziridine L2.64, substituted by a phenyl and a CF3 group at the 
C2 position, was treated with a mixture of perchloric acid and water, two products were formed. The 
first one L2.66, obtained in 78% yield, is the result of the attack of the nucleophile to the aziridinium 
L2.65 at C3 and the second one L2.67, obtained in 3% yield, corresponds to the attack of the 
nucleophile at the benzylic C2 position of the aziridinium intermediate L2.65 (Scheme 24).67 It is worth 
                                                          
67 Grellepois, F.; Nonnenmacher, J.; Lachaud, F.; Portella, C. Org. Biomol. Chem. 2011, 9, 11601168. 
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noting, that when the N-benzyl group was replaced by a N-tosyl group, the amino alcohol L2.67 was 
the only isolated product.  
 
Scheme 24 
3.1.2. Formation of an aziridinium by N-alkylation 
An alternative method to activate an aziridine is by alkylation of the nitrogen, to form an aziridinium 
intermediate. Katagiri et al. reported in 1999 the successful N-methylation of 
(trifluoromethyl)aziridine L2.50 using the Meerwein’s reagent (Me3OBF4), to obtain the aziridinium 
L2.68. In order for an external nucleophile to attack the aziridinium L2.68, the presence of a 
non-reactive counter-ion (BF4) is necessary. In the presence of different nucleophiles, the aziridinium 
L2.68 underwent a regioselective attack of the nucleophile at C3, to afford a variety of 
α-(trifluoromethyl)amines L2.69 (Scheme 25).63 It should be noted that under these conditions, the 
ring-opening of aziridines by carbanions as well as amines, is possible. This ring-opening, was not 
possible by the acid-promoted ring-opening of aziridines (see Section 3.1.1.).  
 
Scheme 25 
Due to the difficulty to cleave the N-methyl group, the authors have also examined the N-allylation 
of aziridine L2.50. Treatment of the aziridine L2.50 with allyl iodide in the presence of AgBF4, led to 
the formation of the activated aziridinium L2.70, which after the addition of n-butylamine, afforded 
the ring-opened product L2.71 in a regioselective manner (Scheme 26).63 
 
Scheme 26 
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Furthermore, primary -iodoamines L2.74 were obtained in very good yields, from aziridines L2.72. 
Treatment of aziridines L2.72 with methyl iodide or benzyl iodide, afforded the aziridiniums L2.73, 
which, in the presence of iodide as a counter-ion, resulted in the regioselective attack of the anion at 
the C3 position and the formation of 2-iodo-1-(trifluoromethyl)amines L2.74 (Scheme 27).68 It is 
worth mentioning that when alkyl iodides were used for the ring-opening of non-activated 
alkylaziridines, the attack of the nucleophile, took place at the substituted aziridine carbon C2, under 
thermodynamic conditions.69 This indicates that due to the electron-withdrawing nature of the CF3 
group, the recyclization of L2.74 towards the aziridinium L2.73 was not possible, pointing out that the 
reaction proceeds under kinetic control. 
 
Scheme 27 
The group of De Kimpe and D’hooghe reported the regioselective and stereoselective ring-opening 
of cis- and trans-aziridines L2.59a and L2.59b by N-methylation of the aziridines in the presence of 
Me3OBF4. When the aziridiniums L2.75a and L2.75b were treated with thiophenol or benzylamine, 
the corresponding ring-opened products L2.76a and L2.76b, were obtained in poor to moderate 
yields. When thiophenol was used, one unexpected side-product was also isolated, the corresponding 
non-methylated amines L2.77a and L2.77b (Scheme 28).66 The authors do not propose any 
explanation for the formation of L2.77a and L2.77b. 
                                                          
68 Kenis, S.; D’hooghe, M.; Verniest, G.; Nguyen, V. D.; Thi, T. A.; Van Nguyen, T.; De Kimpe, N. J. Org. Biomol. 
Chem. 2011, 9, 72177223. 
69 D’hooghe, M.; Catak, S.; Stankovic, S.; Waroquier, M.; Kim, Y.; Ha, H. -J.; Van Speybroeck, V.; De Kimpe, N. 
Eur. J. Org. Chem. 2010, 49204931. 
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Scheme 28 
In summary, the presence of a CF3 group can influence the regioselectivity of the ring-opening of an 
aziridinium intermediate, by directing the attack of the nucleophile, to the carbon which does not 
possess the trifluoromethyl group.
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4. Results and discussion 
As previously mentioned, our goal is to access 2-substituted, 2-(trifluoromethyl)pyrrolidines (n=1) 
and 2-substituted, 2-(trifluoromethyl)piperidines (n=2) I by inducing a ring contraction of 
3-hydroxy-3-(trifluoromethyl)piperidine (n=1) and 3-hydroxy-3-(trifluoromethyl)azepane (n=2) III via 
a bicyclic aziridinium intermediate II. This goal is based on the hypothesis that a CF3 group at the C2 
position of intermediate II, would be responsible for the regioselective attack of the nucleophile at 
the C2’ position of the aziridinium II (Scheme 29). 
 
Scheme 29 
At first, we started by studying the ring contraction of 3-hydroxy-piperidine III to 
α-(trifluoromethyl)pyrrolidines I (n=1), and we then expanded our study to the synthesis of 
α-(trifluoromethyl)piperidines I (n=2). 
4.1.1. Synthesis of 2-substituted, 2-(trifluoromethyl)pyrrolidines 
4.1.1.1. Synthesis of the starting material 
The synthesis of N-benzyl-3-hydroxy-3-(trifluoromethyl)piperidine 1, was envisioned from the 
commercially available N-Boc-piperidin-3-one 3. After the trifluoromethylation of piperidone 3, 
(trifluoromethyl)piperidine 2 should be obtained, and the replacement of a N-Boc by a N-benzyl 
group, would lead to the desired N-benzyl-3-hydroxy-3-(trifluoromethyl)piperidine 1 (Scheme 30). It 
is worth noting that the replacement of the Boc group by a benzyl group is necessary, as the nitrogen 
has to be nucleophilic enough to form an aziridinium intermediate II. 
 
Scheme 30 
The trifluoromethylation of N-Boc-piperidone 3 was carried out with the Ruppert-Prakash reagent, 
trimethyl(trifluoromethyl)silane (TMSCF3), in the presence of a stoichiometric amount of 
tetrabutylammonium fluoride (TBAF) as a fluorine source (THF, rt, 19 h), to afford 
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3-hydroxy-piperidine 2 in 77% yield. The next step consists of the deprotection of the N-Boc group 
with an excess of trifluoroacetic acid (TFA, 7.0 equiv) and treatment of the resulting ammonium salt 
with benzyl bromide under basic conditions (K2CO3, TBAI) to access the desired 
N-benzyl-3-hydroxy-3-(trifluoromethyl)piperidine 1 in a quantitative yield for the 2 steps (Scheme 
31). 
 
Scheme 31 
4.1.1.2. Optimization of the conditions for the ring contraction  
Having the (trifluoromethyl)piperidine 1 in hand, this latter was treated with thionyl chloride in the 
presence of triethylamine (Et3N) in dichloromethane (CH2Cl2), however under these conditions, the 
desired pyrrolidine 4 was not observed (Scheme 32). 
 
Scheme 32 
On the contrary, when piperidine 1 was treated with mesyl chloride and Et3N, the conversion of 1 
was low (10%), but the ring contraction product 4 was isolated in a 7% yield. The formation of 4 can 
be explained by the formation of intermediate 5 which led to aziridinium 6, due to the anchimeric 
assistance of the nitrogen. The chlorine anion present in the reaction mixture, can attack the 
aziridinium 6 at the C2’ position to afford (trifluoromethyl)pyrrolidine 4 (Scheme 33). 
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Scheme 33 
Due to the low yield and the poor reactivity of the tertiary alcohol of 1 towards mesyl chloride, the 
activation of the alcohol was achieved with a mixture of triphenylphosphine and iodine in the 
presence of imidazole. After the formation of intermediate 7 and due to the anchimeric assistance of 
the nitrogen, the aziridinium intermediate 8 was formed, which after the attack of the iodine anion 
to the C2’ position, led to the desired iodomethyl-pyrrolidine 9 in 25% yield and a total conversion of 
1 (Scheme 34). 
 
Scheme 34 
A more powerful electrophilic activator, such as diethylaminosulfur trifluoride (DAST) was then 
utilized to activate the tertiary alcohol of 1. By using DAST, the fluorinated pyrrolidine 12, 
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corresponding to the ring contracted product, was selectively obtained in a good yield of 71%. The 
formation of pyrrolidine 12 is the result of the attack of a fluorine anion coming from DAST, to the 
aziridinium intermediate 11 (Scheme 35). 
 
Scheme 35 
The DAST reagent, allowed us to verify that the ring contraction of 
N-benzyl-3-hydroxy-3-(trifluoromethyl)piperidine 1 is an efficient process when the appropriate 
activator of the hydroxy group is used. In addition, the reaction proved to be regioselecive given that 
the attack takes place only at the C2’ position. However, the inconvenience of the DAST reagent is 
that other external nucleophiles cannot be used and in consequence the access to a diversity of 
substituted (trifluoromethyl)pyrrolidines is impossible. As a result, alternative reaction conditions 
allowing the activation of the hydroxy group by other electrophilic reagents must be found, in order 
to introduce nucleophiles different from a fluorine atom on the (trifluoromethyl)pyrrolidines. 
In 2011, Charette et al. reported the formation of a bicyclic aziridinium intermediate L2.80, starting 
from prolinol L2.78, when this latter was treated with triflic anhydride (Tf2O), in the presence of 
proton sponge (1,8-bis(dimethylamino)naphthalene) VII in CH2Cl2. After the addition of different 
nucleophiles, piperidines L2.81 were obtained in good to excellent yields (Scheme 36).70  
                                                          
70 Jarvis, S. B. D.; Charette, A. B. Org. Lett. 2011, 13, 38303833. 
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Scheme 36 
Thus, when 3-hydroxy-piperidine 1 was treated with triflic anhydride (1.5 equiv), in the presence of 
the proton sponge VII (2.0 equiv) in CH2Cl2 at reflux, and after 5 h, benzylamine (2.5 equiv) was added 
to the reaction mixture, the ring contraction product, pyrrolidine 15 was isolated in 75% yield. This 
product is the result of the regioselective nucleophilic attack of the benzylamine to the aziridinium 
intermediate 14 (Scheme 37). 
 
Scheme 37 
As these conditions, successfully led to the desired pyrrolidine 15 and as they may allow the use of 
different nucleophiles, the scope of this reaction was then studied. 
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4.1.1.3. Scope of the reaction 
Utilizing the conditions previously developed (Tf2O/Proton sponge VII/nucleophile), different primary 
and secondary amines were examined as nucleophiles. By adding aniline to the reaction mixture, the 
desired compound 16 was isolated in 71% yield (Table 2, entry 2). Five secondary amines were also 
tested, such as methylphenylamine, diethylamine, diallylamine, dibenzylamine and morpholine. In 
each case, the ring contraction products 1721 were obtained in good yields (Table 2, entries 37). 
The best results were obtained with dibenzylamine and morpholine, where the 
2-(trifluoromethyl)pyrrolidines 20 and 21 were isolated in 83% and 80% yield respectively (Table 2, 
entries 6 and 7). It is worth mentioning that when ammonia was involved in the ring contraction 
process, compound 23 was formed instead of the desired pyrrolidine 22 (Table 2, entry 8).71 This 
product is the result of the addition of the amine to the aziridinium 14, which is followed by a second 
nucleophilic attack of the formed amino-pyrrolidine 22 on a second aziridinium intermediate 14. 
 
 
 
 
 
 
 
 
 
 
 
                                                          
71  
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Entry NuH Product Yield (%) 
1 BnNH2 
 
75 
2 PhNH2 
 
71 
3 NHMePh 
 
78 
4 HNEt2 
 
66 
5 
 
 
60 
6 Bn2NH 
 
83 
7 
 
 
80 
8 NH3 
 
0 
Table 2 
Furthermore, pyrrolidines 2430 were obtained in good yields when oxygenated nucleophiles were 
used. By using methanol and ethanol, the desired products 24 and 25 were isolated in 51% and 77% 
yield respectively (Table 3, entries 1 and 2). When allyl and benzyl alcohol were utilized, piperidine 1 
was transformed to the corresponding pyrrolidines 26 and 27, in 57% and 65% yield respectively 
(Table 3, entries 3 and 4). Even water can be used as a nucleophile, leading to prolinol 28 in 61% yield, 
91 
 
although 14.0 equiv of H2O were required (Table 3, entry 5). In addition, when piperidine 1 was 
treated with an oxygenated anion such as sodium phenolate and tetrabutylammonium acetate, the 
desired pyrrolidines 29 and 30 were isolated in 75% and 72% yield respectively (Table 3, entries 6 and 
7). 
 
Entry NuH Product Yield (%) 
1 MeOH 
 
51 
2 EtOH 
 
77 
3  
 
57 
4 BnOH 
 
65 
5a H2O 
 
61 
6 PhONa 
 
75 
7 TBAOAc 
 
72 
a) 14.0 equiv of water were used. 
Table 3 
Other nucleophiles, such as sulfur-containing nucleophiles can undergo the ring contraction, either 
in the form of thiols or thiolates. Even if sodium ethanethiolate was able to induce the ring-opening 
of the aziridinium to produce 31 in 60% yield, thiols, which are soft nucleophiles were also able to 
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produce the ring contraction products, given that pyrrolidine 31 was obtained in 54% yield when 
ethanethiol was used as a nucleophile. (Table 4, entry 1). Pyrrolidines 32 and 33, were isolated in 89% 
and 61% yield when benzyl thiol and thiophenol were utilized respectively (Table 4, entries 2 and 3).  
 
Entry NuH Product Yield (%) 
1 EtSNa EtSH 
 
60 
54 
2 BnSH 
 
89 
3 PhSH 
 
61 
Table 4 
Piperidine 1 was also transformed to the corresponding fluoromethyl- and chloromethyl-pyrrolidines 
12 and 4 in moderate yields (3049%), after the addition of tetrabutylammonium fluoride and 
tetrabutylammonium chloride respectively (Scheme 38). It is worth noting that 
fluoromethyl-pyrrolidine 12 was obtained in a better yield of 71% when piperidine 1 was treated with 
DAST (see Scheme 35). 
 
Scheme 38 
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Carbanions can also induce successfully the ring contraction. When piperidine 1 was treated with 
tetrabutylammonium cyanide and sodium dimethylmalonate, (trifluoromethyl)pyrrolidines 34 and 35 
were isolated in 75% and 70% yield respectively (Scheme 39). 
 
Scheme 39 
4.1.1.4. Use of a chiral nucleophile: Chirality transfer 
Our next objective was to define whether a chirality transfer was induced or not, during the ring 
contraction process. Consequently, the two enantiomers of 1 were separated by Supercritical Fluid 
Chromatography (SFC). The two enantio-enriched piperidines (+)-1 and ()-1, were treated with triflic 
anhydride, in the presence of the proton sponge VII and methanol. Compounds (+)-24 and ()-24, 
were obtained in moderate yields and with opposite optical rotations, which could mean that the 
chirality was transferred during the reaction. However, the determination of the enantiomeric excess 
of (+)-24 and ()-24 by SFC was not possible, implying that another way had to be found, to prove the 
chirality transfer (Scheme 40).  
 
Scheme 40 
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Therefore the racemic piperidine ()-1 was treated with triflic anhydride and the proton sponge VII, 
using a chiral amine, (S)-()-α-methylbenzylamine as a nucleophile. The desired pyrrolidine 36 was 
obtained in 75% yield as a mixture of two diastereoisomers (dr=50:50) (Scheme 41). 
 
Scheme 41 
The two enantio-enriched piperidines (+)-1 and ()-1 were then treated with the conditions 
developed above (Tf2O/proton sponge VII/(S)-()-α-methylbenzylamine), to afford the ring 
contraction products 36a and 36b in good yields and with diastereoselectivities superior to 95:5 in 
both cases (Scheme 42). This latter experiment, indicates that the ring contraction of piperidine (+)-1 
and ()-1 proceeds with a chirality transfer. 
 
Scheme 42 
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4.1.1.1. Comparison of the reactivity of 3-hydroxy-3-(trifluoromethyl)piperidine with 
3-hydroxy-3-methylpiperidine 
To study the influence of the CF3 group on the ring contraction process, the 
N-benzyl-3-hydroxy-3-methylpiperidine 37 was prepared and its reactivity under the conditions 
developed previously (Tf2O/proton sponge VII/nucleophile) was studied. The attack of the 
nucleophile on the aziridinium 38, can either take place at the C2 position to produce the 
ring-expansion product 39 (route a), or at the C2’ position to produce the ring contraction product 40 
(route b) (Scheme 43).  
 
Scheme 43 
Piperidine 37 was synthesized by addition of methylmagnesium bromide to piperidone 1 (THF, rt, 16 
h). The N-Boc-3-hydroxy-3-methylpiperidine 41 was isolated in 50% yield, which after a 
deprotection/protection sequence (TFA/CH2Cl2 then BnBr/K2CO3/TBAI/MeCN) led to the desired 
3-hydroxy-piperidine 37 in 78% yield (for the two steps) (Scheme 44). 
 
Scheme 44 
Piperidine 37, was then treated with triflic anhydride in the presence of the proton sponge VII and 
after 5 h at reflux, TBAF was added to the reaction mixture. Under these conditions, only the 
6-membered ring 43 was observed (Scheme 45), indicating that without the CF3 group, the attack 
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takes place at the C2 position of the aziridinium 38.72 Therefore, this last experiment confirms the 
role of the CF3 group as a directing group for the regioselective attack of the nucleophile at the C2’ 
position of the aziridinium, allowing a ring contraction process versus a ring-expansion.  
 
Scheme 45 
4.1.2. Synthesis of 2-substituted, 2-(trifluoromethyl)piperidines 
Having demonstrated that the ring contraction of piperidine 1 was possible and that the 
corresponding α-(trifluoromethyl)pyrrolidines can be obtained, our next goal was to apply the 
previously developed conditions (Tf2O/proton sponge VII/nucleophile) to (trifluoromethyl)azepane 
III, in order to access α-(trifluoromethyl)piperidines I via a similar aziridinium intermediate II (Scheme 
46). 
 
Scheme 46 
4.1.2.1. Synthesis of the starting material 
The synthesis of N-benzyl-3-hydroxy-3-(trifluoromethyl)azepane 44 was envisioned from the 
hydroxy-azepane 45, which would be formed after a ring-closing metathesis applied to the 
unsaturated aminoalcohol 46. Compound 46 would be obtained from the commercially available 
                                                          
72 Anxionnat, B.; Robert, B.; George, P.; Ricci, G.; Perrin, M. -A.; Gomez Pardo, D.; Cossy, J. J. Org. Chem. 2012, 
77, 60876099. 
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chloroacetaldehyde 47, by addition of an allyl metal, followed by treatment with allylamine (Scheme 
47).73 
 
Scheme 47 
After treatment of chloroacetaldehyde 47 with allyl bromide, in the presence of indium in H2O, 
compound 48 was formed in 80% yield and was then reacted with allylamine, to give after 5 days at 
86 °C, the unsaturated aminoalcohol 46 in 96% yield. Compound 46 was then protected with a Boc 
group to give the N-Boc-protected aminoalcohol 49, which after a ring-closing metathesis in the 
presence of 15 mol % of Grubbs-I catalyst, afforded azepane 45 in 69% yield. Hydrogenation of the 
double bond (H2/platinum oxide (PtO2)), followed by oxidation with the Dess-Martin periodinane, led 
to azepanone 51 in an overall yield of 86%. Trifluoromethylation of 51 with TMSCF3 and TBAF and 
finally replacement of the N-Boc by a N-benzyl group, afforded the desired (trifluoromethyl)azepane 
44 (Scheme 48).  
                                                          
73 Prokopiou, P. A.; Browning, C.; Buckley, J. M.; Clark, K. L.; Fechner, L.; Gore, P. M.; Hancock, A. P.; Hodgson, 
S. T.; Holmes, D. S.; Kranz, M.; Looker, B. E.; Morriss, K. M. L.; Parton, D. L.; Russell, L. J.; Slack, R. J.; Sollis, S. L.; 
Vile, S.; Watts, C. J. J. Med. Chem. 2011, 54, 21832195. 
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Scheme 48 
 
4.1.2.2. Scope of the ring contraction process 
Having the 3-hydroxy-3-(trifluoromethyl)azepane 44 in hand, the ring contraction conditions 
previously developed (Tf2O/proton sponge VII/nucleophile) were applied to this azepane, in order to 
access the corresponding α-(trifluoromethyl)piperidines. The reaction was successful and no further 
optimization was needed, as the corresponding piperidines were obtained in very good to excellent 
yields. 
Primary amines such as benzylamine and aniline, produced the corresponding piperidines 54 and 55 
in very good to excellent yields from azepane 44 (Table 5, entries 1 and 2). When secondary amines 
such as diethylamine and diallylamine were used, even better yields in the piperidines were obtained 
as the desired compounds 56 and 57 were isolated in 92% and 85% yield respectively (Table 5, entries 
3 and 4). By utilizing dibenzylamine and morpholine, piperidines 58 and 59 were afforded in 
quantitative yields (Table 5, entries 5 and 6). 
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Entry NuH Product Yield (%) 
1 BnNH2 
 
62 
2 PhNH2 
 
quant 
3 HNEt2 
 
92 
4 
  
85 
5 Bn2NH 
 
quant 
6 
 
 
quant 
Table 5 
Several oxygenated nucleophiles were also tested. When methanol and ethanol were used, the 
corresponding substituted piperidines 60 and 61, were isolated in 93% and 95% yield respectively 
(Table 6, entries 1 and 2), while allyl alcohol and benzyl alcohol led to piperidines 62 and 63 in 93% 
and 82% yield respectively (Table 6, entries 3 and 4). Treatment of 44 with H2O, led to compound 64 
in 93% yield (Table 6, entry 5). Moreover, piperidines 65 and 66 were obtained in quantitative yields, 
when charged nucleophiles such as phenolate and acetate were added to the reaction media (Table 
6, entries 6 and 7). 
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Entry NuH Product Yield (%) 
1 MeOH 
 
93 
2 EtOH 
 
95 
3  
 
93 
4 BnOH 
 
82 
5 H2O 
 
93 
6 PhONa 
 
quant 
7 TBAOAc 
 
quant 
Table 6 
Furthermore, treatment of azepane 44 with Tf2O in the presence of the proton sponge VII, followed 
by the addition of reagents such as sodium ethanethiolate and sodium thiophenolate, led to 
piperidines 67 (92%) and 68 (85%) (Scheme 49). 
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Scheme 49 
2-Methylhalogen piperidines were also obtained when tetrabutylammonium fluoride, chloride, 
bromide and iodide were added to the reaction media. The corresponding 2-substituted, 
2-(trifluoromethyl)piperidines 6972 were afforded in good to very good yields from 61%89% 
(Scheme 50). 
 
Scheme 50 
It is interesting to mention, that when azepane 44 was treated with DAST in THF, the 
fluoromethyl-piperidine 69 was obtained in a better yield than by using Tf2O/proton sponge VII/TBAF 
(71% versus 61%) (Scheme 50 and Scheme 51). 
 
Scheme 51 
102 
 
In addition, azepane 44 was transformed to (trifluoromethyl)piperidines 73 and 74 in excellent yields, 
by using a cyanide (94%) and a malonate anion (quantitative yield) (Scheme 52).  
 
Scheme 52 
The addition of a methyl group to the aziridinium 53 to produce 75 (Scheme 53) was then considered. 
Therefore, azepane 44 was treated with triflic anhydride, in the presence of the proton sponge VII 
and then methyllithium was added to the reaction media. Under these conditions, only traces of the 
desired product 75 were detected by GC/MS analysis of the crude mixture, as well as the chlorinated 
piperidine 70 as the major product (Scheme 53). This result indicates that a reaction between 
methyllithium and dichloromethane takes place, by releasing a chlorine anion, which attacks the 
aziridinium. To avoid this secondary reaction, methylcyanocuprate was prepared from methyllithium 
and copper cyanide in THF, and then added to the reaction mixture. Here again, only traces of 
piperidine 75 were detected by GC/MS analysis, while piperidine 70 was still detected as the major 
product. Finally, the replacement of the organocuprolithium complex by organocupromagnesium 
chloride, afforded the desired piperidine 75 in 50% yield. It is worth noting that the presence of the 
undesired compound 70 was detected, although this latter was not isolated (Scheme 53). 
 
Scheme 53 
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Interestingly, when sodium borohydride was utilized as a hydride source, the ring contraction product 
76 was successfully obtained in 73% yield (Scheme 54). 
 
Scheme 54 
4.1.2.3. Comparison of the reactivity of 3-hydroxy-3-(trifluoromethyl)azepane with 
3-hydroxy-3-methylazepane 
As for the transformation of (trifluoromethyl)piperidines to (trifluoromethyl)pyrrolidines, the 
replacement of the CF3 group of azepane 44 by a methyl group, was achieved to verify the 
regioselectivity of the attack of a nucleophile on the aziridinium intermediate. Therefore, the 
synthesis of 3-hydroxy-3-methylazepane 77 was envisaged, to establish whether the attack of the 
nucleophile would take place at the C2 or the C2’ position of the aziridinium intermediate 78 (route 
a versus route b) (Scheme 55).  
 
Scheme 55 
Azepane 77 was obtained from azepanone 51, previously synthesized (see Scheme 48). Treatment of 
51 with methylmagnesium bromide in THF, afforded the N-Boc-azepane 81 in 72% yield. Treatment 
of azepane 81 with trifluoroacetic acid, led to the deprotected ammonium salt, which was then 
treated with benzyl bromide, in the presence of potassium carbonate and tetrabutylammonium 
iodide. The desired azepane 77 was isolated with a quantitative yield (Scheme 56).  
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Scheme 56 
After treatment of azepane 77 with triflic anhydride, proton sponge VII and tetrabutylammonium 
fluoride, the ring contraction product 82 was not isolated, but compound 83 was obtained instead. 
This latter, results from the attack of the nucleophile at the C2 position of the aziridinium 
intermediate 78 (Scheme 57).72 As before, we can deduce that the presence of the CF3 group on the 
azepane, is important and necessary for the regioselective attack of the nucleophile on the 
aziridinium at the C2’ position, to afford only the ring contraction products. 
 
Scheme 57
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5. Conclusion 
The ring contraction of 3-hydroxy-3-(trifluoromethyl)piperidine 1 and 
3-hydroxy-3-(trifluoromethyl)azepane 44 was accomplished, to afford the corresponding 
pyrrolidines74 1536 and piperidines 5476 respectively, possessing a quaternary center at the C2 
position. A variety of nucleophiles such as amines, alcohols, thiols, carbanions and halides, can be 
used to obtain a diversity of 2-substituted, 2-(trifluoromethyl)pyrrolidines and 2-substituted, 
2-(trifluoromethyl)piperidines in good to excellent yields (Scheme 58).  
 
Scheme 58 
It was also demonstrated that the role of the CF3 group was crucial for the regioselectivity of the 
reaction. Our hypothesis according to which, the CF3 acts as a directing group to afford uniquely the 
ring contraction products, is therefore validated. 
Finally, it is important to mention that the chirality transfer during the ring contraction was 
confirmed, proving that enantio-enriched pyrrolidines and piperidines can be obtained. 
 
 
 
 
 
 
                                                          
74 Feraldi-Xypolia, A.; Gomez Pardo, D.; Cossy, J. Chem. Eur. J. 2015, 21, 1287612880. 
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1. General experimental methods 
All reactions were carried out under an argon atmosphere unless otherwise specified. Flasks were 
oven-dried at 120 °C and cooled down under argon prior to use. Without any specification, all 
commercially available products were used directly without any purification. THF and Et2O were 
distilled over sodium/benzophenone and Et3N and CH2Cl2 were distilled over CaH2 before their use. 
MeCN and DMSO were bought dry from Aldrich and used as received. All others reagents were used 
as obtained from Aldrich, without further purification unless otherwise specified. 
Purification by flash column chromatography was carried out by using silica gel (pore size 60 Å, 230 
mesh). TLC were performed on silica gel plate (Merck 60F254) and visualized either with a UV lamp 
(254 nm) or by treatment with an aqueous potassium permanganate solution (KMnO4/K2CO3/AcOH) 
and subsequent heating. 
Melting points (Mp) were recorded using a Wagner & Munz Kofler bench and a Büchi Melting Point 
M-560 apparatus with open capillaries. 
1H NMR spectra were recorded on a Bruker AVANCE 400 at 400 MHz and data are reported as follows: 
chemical shift in ppm, with the solvent as internal standard (CDCl3, δ 7.26 ppm, DMSO-d6, δ 2.50 
ppm). The multiplicity and shape of signals are designated by the following abbreviations: s = singlet, 
d = doublet, t = triplet, q = quadruplet, m = multiplet, br = broad, app = apparent. Coupling constants 
J were measured in Hertz. 
13C NMR spectra were recorded on a Bruker AVANCE 400 at 100 MHz and data are reported as 
follows: chemical shift in ppm, with the solvent as internal standard (CDCl3, δ 77.16 ppm, DMSO-d6, 
δ 39.52 ppm). The multiplicity and shape of signals are designated by the following abbreviations: s = 
singlet, d = doublet, t = triplet, q = quadruplet, br = broad, m = multiplet. Coupling constants J were 
measured in Hertz.  
Infrared (IR) were recorded with a Bruker TENSORTM 27 (IRFT), wave-numbers are indicated in cm–1. 
Mass spectra with electronic impact (MS-EI) were recorded from a Shimadzu GCMS-QP 2010S. 
High Resolution Mass Spectra (HRMS) were performed by the Centre Regional de Microanalyse 
(Université Pierre et Marie Curie, Paris VI, France). 
Optical rotations were measured with a Perkin Elmer 343 polarimeter in a 10-cm cell. The 
concentrations indicated are in g/100 mL. 
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2. Synthesis and spectroscopic data of N-benzyl-3-hydroxy-
3-(trifluoromethyl)piperidine (1) 
tert-Butyl 3-trifluoromethyl-3-hydroxypiperidin-1-carboxylate (2)75 
 
To a stirred solution of N-Boc-3-piperidone 3 (2.0 g, 9.74 mmol, 1.0 equiv) in THF (40 mL) at 0 °C was 
added TMSCF3 (2.94 mL, 19.47 mmol, 2.0 equiv). A solution of TBAF (1.0 M in THF, 19.5 mL, 19.47 
mmol, 2.0 equiv) was added dropwise and the resulting mixture was stirred at rt for 19 h. The solution 
was quenched with an aqueous and saturated solution of NH4Cl (40 mL) and stirred for another 20 
min. The solution was then concentrated under reduced pressure and diluted in CH2Cl2. The organic 
layer was separated and washed with H2O (twice), dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure. The crude mixture was purified by flash chromatography 
(EtOAc/PE=10:90 to 20:80) to afford 2 (2.03 g, 7.52 mmol, 77%) as a white solid. 
IR (neat): 3407, 2978, 1740, 1672, 1432, 1368, 1278, 1247, 1145, 1045, 1010 cm–1. 
1H NMR (DMSO-d6, 400 MHz at 122 oC): δ 5.48 (br s, OH), 3.69 (d, J = 13.2 Hz, 1H, H6), 3.68 (m, 1H, 
H2), 3.27 (d, J = 13.5 Hz, 1H, H6), 3.03 (m, 1H, H2), 1.801.73 (m, 3H, H3 and H4), 1.55 (m, 1H, H4), 1.44 
(s, 9H, H10). 
13C NMR (DMSO-d6, 400 MHz at 122 oC): δ 153.7 (C, C8), 125.8 (C, q, J = 286.5 Hz, C7), 78.3 (CH2, C6), 
69.3 (C, q, J = 26.6 Hz, C5), 46.6 (C, C9), 42.3 (CH2, C2), 28.3 (CH2, C4), 27.5 (3xCH3, C10), 18.8 (CH2, C3).  
MS m/z (relative intensity): 269 (M+•, 0.7), 210 (2), 196 (10), 85 (8), 57 (100).   
 
 
 
 
                                                          
75 Ryu, J. H.; Kim, S. A.; Ryu, K. H.; Kim, J. S.; Kim, N. H.; Han, H. Y.; Kim, Y. H.; Youn, W. -N.; Lee, Y. -J.; Son, H. J.; 
Lee, B. -Y.; Park, S. H.; Lee, J. -Y.; Lee, H. J.; Jung, H. C.; Shin, Y. A.; Lee, J. A.; Lee, B. R.; Sa, J. H. 2011 (WO 
2011/139107). 
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N-Benzyl-3-hydroxy-3-(trifluoromethyl)piperidine (1) 
 
To a stirred solution of tert-butyl 3-trifluoromethyl-3-hydroxypiperidin-1-carboxylate 2 (2.03 g, 7.52 
mmol, 1.0 equiv) in CH2Cl2 (42 mL) at rt was added TFA (3.91 mL, 52.64 mmol, 7.0 equiv). The reaction 
mixture was stirred at rt for 15 h and then concentrated under reduced pressure. 
To a stirred solution of the crude material previously obtained in MeCN (77 mL) at rt were added 
successively BnBr (0.90 mL, 7.52 mmol, 1.0 equiv), K2CO3 (5.2 g, 37.6 mmol, 5.0 equiv) and TBAI (1.39 
g, 3.76 mmol, 0.5 equiv). The reaction mixture was heated at 75 °C for 4 h and then allowed to cool 
to rt. The reaction mixture was quenched with H2O and extracted with CH2Cl2 (twice). The organic 
layer was dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude 
mixture was purified by flash chromatography (EtOAc/PE=10:90) to afford 1 (1.93 g, 7.44 mmol, 
quant) as a colorless oil. 
IR (neat): 3458, 3030, 2953, 2817, 1496, 1454, 1368, 1284, 1181, 1149, 1103, 1029, 1009, 943 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.357.23 (m, 5Η, H10, H11 and H12), 3.55 (s, 2H, H8), 3.47 (br s, OH), 
2.862.83 (m, 2H, H2 and H6), 2.20 (d, J = 11.2 Hz, 1H, H6), 1.97 (m, 1H, H2), 1.861.79 (m, 2H, H3 and 
H4), 1.62 (m, 1H, H3), 1.48 (m, 1H, H4). 
13C NMR (CDCl3, 100 MHz): δ 137.3 (C, C9), 129.1 (2xCH, C10 or C11), 128.6 (2xCH, C10 or C11), 127.6 (CH, 
C12), 125.5 (C, q, J = 282.4 Hz, C7), 71.3 (C, q, J = 28.6 Hz, C5), 62.7 (CH2, C8), 57.1 (CH2, dapp, J = 2.0 Hz, 
C6), 52.9 (CH2, C2), 28.2 (CH2, C4), 20.3 (CH2, C3). 
MS m/z (relative intensity): 259 (M+•, 20), 182 (14), 168 (23), 146 (17), 134 (12), 91 (100), 65 (12). 
HRMS: calcd for C13H17F3NO (M+H+): 260.1257. Found 260.1260. 
Separation of the two enantiomers by SFC: RegisPack 4.4*250 mm, 5µm, Pressure=137 bar, 
CO2/MeOH=95:5, Flow rate=40 mL/min, UV=210 nm, tR=1.8 min and tR=2.8 min.
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3. Synthesis and spectroscopic data of 2-substituted, 
2-(trifluoromethyl) pyrrolidines  
General Protocol for the synthesis of 2-(trifluoromethyl)pyrrolidines  
To a stirred solution of N-benzyl-3-hydroxy-3-(trifluoromethyl)piperidine 1 (1.0 equiv) and proton 
sponge VII (2.0 equiv) in CH2Cl2 (0.047 M) at 15°C was added triflic anhydride (1.5 equiv). After 5 h 
of stirring at reflux, the solution was cooled to rt, the nucleophile (2.5 equiv) was added and the 
reaction mixture was stirred at rt for 16 h. The reaction mixture was diluted with H2O, extracted with 
CH2Cl2 and the combined extracts were dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure. The crude mixture was purified by flash chromatography. 
N-Benzyl-2-chloromethyl-2-(trifluoromethyl)pyrrolidine (4) 
 
1) Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = tetrabutylammonium 
chloride (268 mg, 0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography 
(PE=100%) to afford 4 (53 mg, 0.19 mmol, 49%) as colorless oil. 
2) To a stirred solution of N-benzyl-3-hydroxy-3-(trifluoromethyl)piperidine 1 (250 mg, 0.96 mmol, 
1.0 equiv) in CH2Cl2 (6 mL) at 0 °C were added Et3N (0.54 mL, 3.9 mmol, 4.0 equiv) and MsCl (0.23 mL, 
2.9 mmol, 3.1 equiv). The resulting mixture was stirred at reflux for 48 h. The reaction mixture was 
quenched with a H2O, extracted with CH2Cl2 and the combined organic phases were dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude mixture was 
purified by flash chromatography (PE=100%) to afford 4 (20 mg, 0.07 mmol, 7%) as a colorless oil. 
IR (neat): 2922, 2852, 1719, 1457, 1409, 1375, 1261, 1097, 1042, 1018 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.357.21 (m, 5Η, H10, H11 and H12), 4.02 (d, J = 16.8 Hz, 1H, H8), 3.98 (d, 
J = 14.4 Hz, 1H, H8), 3.92 (d, J = 11.9 Hz, 1H, H6), 3.75 (d, J = 11.9 Hz, 1H, H6), 2.82 (tapp, J = 6.5 Hz, 2H, 
H2), 2.30 (m, 1H, H4), 2.19 (m, 1H, H4), 1.841.77 (m, 2H, H3). 
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13C NMR (CDCl3, 100 MHz): δ 140.0 (C, C9), 128.5 (2xCH, C10 or C11), 128.1 (2xCH, C10 or C11), 127.5 (C, 
q, J = 289.8 Hz, C7), 127.1 (CH, C12), 68.6 (C, q, J = 24.5 Hz, C5), 52.4 (CH2, C2), 52.2 (CH2, C8), 45.1 (CH2, 
C6), 31.4 (CH2, C4), 22.6 (CH2, C3). 
MS m/z (relative intensity): 279 (M+•, 0.5), 277 (M+•, 2), 228 (12), 208 (7), 91 (100), 65 (9). 
HRMS: calcd for C13H16ClF3N (M+H+): 278.0918, and 280.0888. Found 278.0920 and 280.0889. 
N-Benzyl-2-iodomethyl-2-(trifluoromethyl)pyrrolidine (9) 
 
To a stirred solution of N-benzyl-3-hydroxy-3-(trifluoromethyl)piperidine 1 (141 mg, 0.54 mmol, 1.0 
equiv) in THF (3 mL) at rt, were added PPh3 (214 mg, 0.82 mmol, 1.5 equiv), imidazole (74 mg, 1.09 
mmol, 2.0 equiv) and I2 (207 mg, 0.82 mmol, 1.5 equiv). The resulting mixture was stirred at rt for 48 
h. The reaction mixture was diluted in CHCl3, and the organic phase was washed with H2O and brine, 
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude mixture 
was purified by flash chromatography (PE=100%) to afford 9 (51 mg, 0.14 mmol, 25%) as a colorless 
oil. 
IR (neat): 3029, 2924, 2852, 1495, 1455, 1372, 1277, 1141, 1101, 1029 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.377.20 (m, 5Η, Η10, Η11 and Η12), 4.05 (d, 1H, J = 13.9 Hz, H8), 3.78 (d, 
1H, J = 13.8 Hz, H8), 3.59 (dm, 1H, J = 11.2 Hz, H6), 3.46 (dm, 1H, J = 11.2 Hz, H6), 2.89 (m, 1H, H2), 2.75 
(m, 1H, H2), 2.222.09 (m, 2H, H4), 1.781.76 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 139.5 (C, C9), 128.3 (2xCH, C10 or C11), 128.2 (2xCH, C10 or C11), 126.9 (CH, 
C12), 128.4 (C, q, J = 292.1 Hz, C7), 67.1 (C, q, J = 24.2 Hz, C5), 51.6 (CH2, C8), 51.3 (CH2, C2), 34.5 (CH2, 
C4), 22.0 (CH2, C3) 8.5 (CH2, C6). 
MS m/z (relative intensity): 369 (M+•, 3), 300 (18), 228 (15), 173 (10), 91 (100), 65 (11). 
N-Benzyl-2-fluoromethyl-2-(trifluoromethyl)pyrrolidine (12) 
 
1) Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = tetrabutylammonium 
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fluoride (1.0 M in THF, 261 mg, 0.96 mmol, 2.5 equiv). The crude mixture was purified by flash 
chromatography (Pentane=100%) to afford 12 (30 mg, 0.11 mmol, 30%) as colorless oil. 
2) To a stirred solution of N-benzyl-3-hydroxy-3-(trifluoromethyl)piperidine 1 (100 mg, 0.39 mmol, 
1.0 equiv) in THF (4 mL) at 0 °C was added DAST (66 L, 0.54 mmol, 1.4 equiv). The resulting mixture 
was stirred at 0 °C for 1 h and at rt for 3 h. The reaction mixture was quenched with a saturated 
aqueous solution of Na2CO3, extracted with EtOAc and the combined organic phases were dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude mixture was 
purified by flash chromatography (PE=100% to EtOAc/PE=5:95) to afford 12 (71 mg, 0.27 mmol, 71%) 
as a colorless oil. 
IR (neat): 2956, 2923, 2853, 1727, 1456, 1187, 1145, 1030, 944 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.347.24 (m, 5Η, H10, H11 and H12), 4.69 (dd, J = 43.4 and 9.9 Hz, 1H, H6), 
4.58 (dd, J = 41.9 and 9.9 Hz, 1H, H6), 4.15 (d, J = 13.5 Hz, 1H, H8), 3.84 (d, J = 13.5Hz, 1H, H8), 2.84 (m, 
1H, H2), 2.64 (dd, J = 15.3 and 7.9 Hz, 1H, H2), 2.20 (m, 1H, H4), 2.01 (m, 1H, H4), 1.831.73 (m, 2H, 
H3). 
13C NMR (CDCl3, 100 MHz): δ 140.1 (C, C9), 128.4 (2xCH, C10 or C11), 128.2 (2xCH, C10 or C11), 127.2 (C, 
dq, J = 287.4 and 7.5 Hz, C7), 127.1 (CH, C12), 82.5 (CH2, d, J = 178.6 Hz, C6), 67.3 (C, dq, J = 25.1 and 
18.6 Hz, C5), 53.3 (CH2, C8), 52.7 (CH2, C2), 30.7 (CH2, C4), 22.8 (CH2, C3). 
MS m/z (relative intensity): 261 (M+•, 3), 228 (6), 192 (8), 170 (3), 91 (100), 65 (10). 
HRMS: calcd for C13H16F4N (M+H+): 262.1213. Found 262.1215. 
N-Benzyl-2-{[(N-benzyl)amino]methyl}-2-(trifluoromethyl)pyrrolidine (15) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = benzylamine (105 L, 
0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (PE=100% to 
EtOAc/PE=1:99) to afford 15 (101 mg, 0.29 mmol, 75%) as a yellow oil. 
IR (neat): 3028, 2922, 2822, 1495, 1453, 1371, 1286, 1142, 1101, 1028, 922 cm–1. 
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1H NMR (CDCl3, 400 MHz): δ 7.327.22 (m, 10Η, Har), 3.94 (d, J = 13.7 Hz, 1H, H13), 3.84 (s, 2H, H7), 
3.72 (d, J = 13.7 Hz, 1H, H13), 2.95 (dapp, J = 11.9 Hz, 1H, H6), 2.812.69 (m, 3H, H2 and H6), 2.38 (m, 1H, 
H4), 2.06 (m, 1H, H4), 1.88 (br s, NH), 1.761.73 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 140.3 (C, C8 or C14), 140.1 (C, C8 or C14), 128.5 (2xCH, Car), 128.5 (C, q, J 
= 291.1 Hz, C12), 128.4 (2xCH, Car), 128.1 (2xCH, Car), 128.1 (2xCH, Car), 127.1 (CH, C11 or C17), 126.9 (CH, 
C11 or C17), 68.3 (C, q, J = 23.0 Hz, C5), 54.2 (CH2, C7), 52.0 (CH2, C2 or C13), 52.0 (CH2, C2 or C13), 48.3 
(CH2, C6), 30.6 (CH2, C4), 22.4 (CH2, C3).  
HRMS: calcd for C20H24F3N2 (M+H+): 349.1886. Found 349.1885. 
N-Benzyl-2-{[(N-phenyl)amino]methyl}-2-(trifluoromethyl)pyrrolidine (16) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = aniline (88 L, 0.96 
mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=2:98) to afford 
16 (92 mg, 0.27 mmol, 71%) as a yellow oil. 
IR (neat): 3029, 2923, 2821, 1599, 1506, 1453, 1380, 1269, 1230, 1133, 1097, 1030, 990, 950 cm–1.  
1H NMR (CDCl3, 400 MHz): δ 7.337.18 (m, 7Η, Har), 6.766.65 (m, 3Η, H8 and H10), 4.25 (br s, NH), 
4.06 (d, J = 13.4 Hz, 1H, H12), 3.62 (ddapp, J = 13.4 and 1.9 Hz, 1H, H12), 3.36 (tapp, J = 13.1 Hz, 2H, H6), 
2.96 (m, 1H, H2), 2.76 (m, 1H, H2), 2.232.12 (m, 2H, H4), 1.831.72 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 148.3 (C, C7 or C13), 139.4 (C, C7 or C13), 129.5 (2xCH, Car), 128.6 (2xCH, 
Car), 128.5 (C, q, J = 292.9 Hz, C11), 128.5 (2xCH, Car), 127.3 (CH, C16), 117.9 (CH, C10), 113.2 (2xCH, C8), 
68.4 (C, q, J = 22.9 Hz, C5), 51.9 (CH2, C12), 51.4 (CH2, C2), 42.4 (CH2, C6), 30.5 (CH2, C4), 21.8 (CH2, C3).  
MS m/z (relative intensity): 334 (M+•, 0.9), 228 (13), 209 (6), 105 (13), 91 (100), 77 (17), 65 (12), 50 
(3). 
HRMS: calcd for C19H22F3N2 (M+H+): 335.1730. Found 335.1729. 
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N-Benzyl-2-{[(N-benzyl-N-methyl)amino]methyl}-2-(trifluoromethyl)pyrrolidine (17) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = methylaniline (107 L, 
0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (Et2O/PE=1:99) to 
afford 17 (105 mg, 0.30 mmol, 78%) as a yellow oil. 
IR (neat): 3028, 2924, 2821, 1599, 1506, 1453, 1380, 1268, 1230, 1133, 1097, 1030, 990, 950 cm–1.  
1H NMR (CDCl3, 400 MHz): δ 7.337.22 (m, 7Η, Har), 6.776.72 (m, 3Η, H9 and H11), 4.29 (d, J = 13.6 
Hz, 1H, H13), 3.71 (dapp, J = 15.9 Hz, 2H, H6 and H13), 3.56 (d, J = 15.9 Hz, 1H, H6), 3.09 (s, 3H, H7), 2.91 
(m, 1H, H2), 2.60 (qapp, J = 8.2 Hz, 1H, H2), 2.121.97 (m, 2H, H4), 1.731.60 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 150.5 (C, C8 or C14), 139.5 (C, C8 or C14), 129.3 (2xCH, Car), 128.9 (C, q, J 
= 295.4 Hz, C12), 128.5 (2xCH, Car), 128.3 (2xCH, Car), 127.1 (CH, C17), 116.8 (CH, C11), 112.1 (2xCH, C9), 
70.2 (C, q, J = 21.1 Hz, C5), 52.6 (CH2, C6), 52.3 (CH2, C13), 51.1 (CH2, C2), 40.5 (CH3, C7), 29.6 (CH2, C4), 
22.1 (CH2, C3).  
MS m/z (relative intensity): 348 (M+•, 0.7), 228 (8), 227 (9), 120 (63), 91 (100), 77 (8), 65 (15). 
HRMS: calcd for C20H24F3N2 (M+H+): 349.1886. Found 349.1888. 
N-Benzyl-2-{[(N,N-diethyl)amino]methyl}-2-(trifluoromethyl)pyrrolidine (18) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = diethylamine (100 L, 
0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=2:98) to 
afford 18 (80 mg, 0.25 mmol, 66%) as a colorless oil. 
IR (neat): 2968, 2811, 1496, 1455, 1373, 1278, 1135, 1102, 1067, 1029, 958 cm–1.  
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1H NMR (CDCl3, 400 MHz): δ 7.307.22 (m, 5Η, H12, H13 and H14), 4.16 (d, J = 13.8 Hz, 1H, H10), 3.70 
(dq, J = 13.9 and 1.9 Hz, 1H, H10), 2.83 (m, 1H, H2), 2.782.70 (m, 3H, H6 and H7), 2.632.57 (m, 4H, 
H2, H6 and H7), 2.37 (m, 1H, H4), 1.97 (m, 1H, H4), 1.761.72 (m, 2H, H3), 1.00 (t, J = 7.1 Hz, 6H, H8). 
13C NMR (CDCl3, 100 MHz): δ 140.3 (C, C11), 129.1 (C, q, J = 295.0 Hz, C9), 128.4 (2xCH, C12 or C13), 
128.2 (2xCH, C12 or C13), 126.8 (CH, C14), 69.4 (C, q, J = 20.7 Hz, C5), 53.6 (CH2, C6), 52.4 (CH2, C10), 51.5 
(CH2, C2), 48.5 (2xCH2, C7), 30.3 (CH2, C4), 22.2 (CH2, C3), 11.9 (2xCH3, C8).  
MS m/z (relative intensity): 314 (M+•, 0.1), 227 (10), 91 (76), 86 (100), 65 (12), 58 (7). 
HRMS: calcd for C17H26F3N2 (M+H+): 315.2043. Found 315.2043. 
N-Benzyl-2-{[(N,N-diallyl)amino]methyl}-2-(trifluoromethyl)pyrrolidine (19) 
 
Following the general protocol: 1 (71 mg, 0.27 mmol, 1.0 equiv), proton sponge (117.4 mg, 0.55 mmol, 
2.0 equiv), triflic anhydride (68 L, 0.41 mmol, 1.5 equiv). Nucleophile = diallylamine (84 L, 0.68 
mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=1:99) to afford 
19 (56 mg, 0.17 mmol, 60%) as a colorless oil. 
IR (neat): 3077, 2977, 2814, 1643, 1496, 1454, 1376, 1282, 1137, 1100, 995, 919 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.297.21 (m, 5H, H13, H14 and H15), 5.905.80 (m, 2H, H8), 5.175.11 (m, 
4H, H9), 4.15 (d, J = 13.8 Hz, 1H, H11), 3.68 (d, J = 13.8 Hz, 1H, H11), 3.43 (dd, J = 14.3 and 4.7 Hz, 2H, 
H7), 3.09 (dd, J = 12.0 and 4.0 Hz, 2H, H7), 2.82 (m, 1H, H2), 2.77 (d, J = 16.0 Hz, 1H, H6), 2.72 (d, J = 
16.0 Hz, 1H, H6), 2.60 (qapp, J = 7.9 Hz, 1H, H2), 2.39 (m, 1H, H4), 2.00 (m, 1H, H4), 1.751.71 (m, 2H, 
H3). 
13C NMR (CDCl3, 100 MHz): δ 140.0 (C, C12), 135.9 (2xCH, C8), 128.9 (C, q, J = 294.2 Hz, C10), 128.4 
(2xCH, C13 or C14), 128.2 (2xCH, C13 or C14), 126.9 (CH, C15), 117.4 (2xCH2, C9), 69.4 (C, q, J = 21.0 Hz, 
C5), 58.5 (2xCH2, C7), 52.8 (CH2, C6), 52.3 (CH2, C11), 51.4 (CH2, C2), 30.4 (CH2, C4), 22.2 (CH2, C3). 
MS m/z (relative intensity): 338 (M+•, 0.04), 225 (8), 110 (100), 91 (97), 81 (3), 65 (15). 
HRMS: calcd for C19H26F3N2 (M+H+): 339.2043. Found 339.2041. 
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N-Benzyl-2-{[(N,N-dibenzyl)amino]methyl}-2-(trifluoromethyl)pyrrolidine (20) 
 
Following the general protocol: 1 (79 mg, 0.31 mmol, 1.0 equiv), proton sponge (131.1 mg, 0.6 mmol, 
2.0 equiv), triflic anhydride (76 L, 0.46 mmol, 1.5 equiv). Nucleophile = dibenzylamine (0.15 mL, 0.16 
mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=2:98 to 10:90) 
to afford 20 (111 mg, 0.25 mmol, 83%) as a white solid. 
Mp: 6871 °C 
IR (neat): 3031, 2922, 2848, 2361, 1159, 1119, 1099, 752 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.387.19 (m, 15H, Har), 4.11 (d, J = 12.0 Hz, 1H, H6), 4.10 (d, J = 12.0 Hz, 
2H, H7), 3.64 (d, J = 13.7 Hz, 1H, H6), 3.43 (d, J = 13.7 Hz, 2H, H7), 2.862.77 (m, 3H, H2 and H13), 2.57 
(m, 1H, H2), 2.47 (m, 1H, H4), 1.88 (m, 1H, H4), 1.741.69 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 139.8 (C, C14), 139.5 (2xC, C8), 129.1 (4xCH, Car), 128.8 (C, q, J = 294.8 Hz, 
C12), 128.4 (4xCH, Car), 128.4 (2xCH, Car), 128.3 (2xCH, Car), 127.1 (2xCH, Car), 126.9 (CH, Car), 69.4 (C, 
q, J = 21.3 Hz, C5), 60.2 (2xCH2, C7), 52.6 (CH2, C13), 52.3 (CH2, C6), 51.3 (CH2, C2), 29.9 (CH2, C4), 22.2 
(CH2, C3). 
MS m/z (relative intensity): 347 (M+•–Bn•, 0.3), 210 (59), 181 (4), 91 (100), 65 (7). 
HRMS: calcd for C27H30F3N2 (M+H+): 439.2356. Found 439.2359. 
N-Benzyl-2-[(morpholino)methyl]-2-(trifluoromethyl)pyrrolidine (21) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = morpholine (85 L, 
0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=5:95 to 
10:90) to afford 21 (101 mg, 0.31 mmol, 80%) as a brown oil. 
IR (neat): 2957, 2851, 2808, 1496, 1455, 1397, 1371, 1287, 1135, 1118, 1036, 967 cm–1.  
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1H NMR (CDCl3, 400 MHz): δ 7.377.21 (m, 5Η, H12, H13 and H14), 4.14 (d, J = 13.8 Hz, 1H, H10), 3.74 
(dq, J = 13.8 and 1.8 Hz, 1H, H10), 3.68 (tapp, J = 4.6 Hz, 4H, H8), 2.802.69 (m, 4H, H2, H6 and H7), 
2.662.50 (m, 4H, H2, H6 and H7), 2.27 (m, 1H, H4), 2.07 (m, 1H, H4), 1.791.72 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 140.1 (C, C11), 128.7 (C, q, J = 293.6 Hz, C9), 128.4 (2xCH, C12 or C13), 
128.2 (2xCH, C12 or C13), 126.9 (CH, C14), 68.8 (C, q, J = 21.6 Hz, C5), 67.4 (2xCH2, C8), 58.7 (CH2, C6), 
55.9 (2xCH2, C7), 52.5 (CH2, C10), 51.6 (CH2, C2), 30.9 (CH2, C4), 22.3 (CH2, C3).  
MS m/z (relative intensity): 328 (M+•, 0.2), 228 (8), 100 (100), 91 (54), 65 (5). 
HRMS: calcd for C17H24F3N2O (M+H+): 329.1835. Found 329.1837. 
N-Benzyl-2-methoxymethyl-2-(trifluoromethyl)pyrrolidine (24) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = methanol (39 L, 0.96 
mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=2:98) to afford 
24 (53.6 mg, 0.20 mmol, 51%) as a colorless oil. 
IR (neat): 2893, 2816, 1495, 1453, 1366, 1331, 1139, 1102, 1030 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.307.16 (m, 5H, H11, H12 and H13), 4.11 (d, J = 13.7 Hz, 1H, H9), 3.74 (d, 
J = 13.7 Hz, 1H, H9), 3.67 (d, J = 9.8 Hz, 1H, H6), 3.52 (d, J = 9.8 Hz, 1H, H6), 3.38 (s, 3H, H7), 2.77 (tdapp, 
J = 7.4 and 2.9 Hz, 1H, H2), 2.58 (dd, J = 15.5 and 8.0 Hz, 1H, H2), 2.102.07 (m, 2H, H4), 1.741.67 (m, 
2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 140.8 (C, C10), 128.3 (2xCH, C11 or C12), 128.2 (2xCH, C11 or C12), 127.8 (C, 
q, J = 287.1 Hz, C8), 126.8 (CH, C13), 72.5 (CH2, C6), 67.7 (C, q, J = 24.5 Hz, C5), 59.6 (CH3, C7), 53.3 (CH2, 
C9), 53.1 (CH2, C2), 31.0 (CH2, C4), 23.0 (CH2, C3). 
MS m/z (relative intensity): 273 (M+•, 1), 228 (24), 91 (100), 65 (9). 
HRMS: calcd for C14H19F3NO (M+H+): 274.1413. Found 274.1416. 
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N-Benzyl-2-ethoxymethyl-2-(trifluoromethyl)pyrrolidine (25) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = ethanol (56 L, 0.96 
mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=2:98) to afford 
25 (85.6 mg, 0.30 mmol, 77%) as a colorless oil. 
IR (neat): 2976, 2875, 1495, 1454, 1379, 1360, 1139, 1122, 1103, 1030, 949 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.347.21 (m, 5Η, H12, H13 and H14), 4.16 (d, J = 13.6 Hz, 1H, H10), 3.77 (d, 
J = 13.9 Hz, 1H, H10), 3.74 (d, J = 9.6 Hz, 1H, H6), 3.593.51 (m, 3H, H6 and H7), 2.81 (tdapp, J = 7.4 and 
2.9 Hz, 1H, H2), 2.63 (dd, J = 15.1 and 8.2 Hz, 1H, H2), 2.152.11 (m, 2H, H4), 1.771.70 (m, 2H, H3), 
1.24 (t, J = 7.0 Hz, 3H, H8). 
13C NMR (CDCl3, 100 MHz): δ 141.0 (C, C11), 128.3 (2xCH, C12 or C13), 128.2 (2xCH, C12 or C13), 127.8 (C, 
q, J = 286.9 Hz, C9), 126.8 (CH, C14), 70.0 (CH2, C6), 67.8 (C, q, J = 24.4 Hz, C5), 67.2 (CH2, C7), 53.3 (CH2, 
C10), 53.2 (CH2, C2), 31.1 (CH2, C4), 23.0 (CH2, C3), 15.4 (CH3, C8). 
MS m/z (relative intensity): 287 (M+•, 0.5), 228 (17), 91 (100), 65 (7). 
HRMS: calcd for C15H21F3NO (M+H+): 288.1570. Found 288.1572. 
N-Benzyl-2-[(prop-2-en-1-yloxy)methyl]-2-(trifluoromethyl)pyrrolidine (26) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = allyl alcohol (66 L, 
0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (PE=100% to 
EtOAc/PE=1:99) to afford 26 (66 mg, 0.22 mmol, 57%) as a colorless oil. 
IR (neat): 2833, 1495, 1454, 1366, 1330, 1139, 1090, 1020, 989, 926 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.347.19 (m, 5H, H13, H14 and H15), 5.92 (m, 1H, H8), 5.32 (dqapp, J = 17.2 
and 1.7 Hz, 1H, H9), 5.21 (dqapp, J = 10.5 and 1.5 Hz, 1H, H9), 4.15 (d, J = 13.7 Hz, 1H, H11), 4.064.04 
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(m, 2H, H7), 3.78 (d, J = 12.4 Hz, 1H, H11), 3.75 (d, J= 9.6 Hz, 1H, H6), 3.60 (d, J = 9.8 Hz, 1H, H6), 2.82 
(m, 1H, H2), 2.63 (dd, J = 15.3 and 8.4 Hz, 1H, H2), 2.142.12 (m, 2H, H4), 1.781.71 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 140.8 (C, C12), 134.6 (CH, C8), 128.3 (2xCH, C13 or C14), 128.2 (2xCH, C13 
or C14), 127.8 (C, q, J = 287.5 Hz, C10), 126.8 (CH, C15), 117.2 (CH2, C9), 72.6 (CH2, C7), 69.8 (CH2, C6), 
67.8 (C, q, J = 24.6 Hz, C5), 53.4 (CH2, C11), 53.1 (CH2, C2), 31.2 (CH2, C4), 23.0 (CH2, C3). 
MS m/z (relative intensity): 299 (M+•, 0.6), 228 (21), 91 (100), 65 (8). 
HRMS: calcd for C16H21F3NO (M+H+): 300.1570. Found 300.1570. 
N-Benzyl-2-[(benzyloxy)methyl]-2-(trifluoromethyl)pyrrolidine (27) 
 
Following the general protocol: 1 (79 mg, 0.30 mmol, 1.0 equiv), proton sponge (130.6 mg, 0.61 mmol, 
2.0 equiv), triflic anhydride (76 L, 0.46 mmol, 1.5 equiv). Nucleophile = benzyl alcohol (79 L, 0.76 
mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=1:99) to afford 
27 (69 mg, 0.20 mmol, 65%) as a colorless oil. 
IR (neat): 3030, 2874, 1496, 1454, 1366, 1330, 1139, 1096, 1028, 926 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.387.21 (m, 10Η, Har), 4.62 (d, J = 11.8 Hz, 1H, H7), 4.57 (d, J = 12.1 Hz, 
1H, H7), 4.15 (d, J = 13.6 Hz, 1H, H13), 3.79 (d, J = 9.9 Hz, 1H, H6), 3.78 (d, J = 13.1 Hz, 1H, H13), 3.64 (d, 
J = 9.9 Hz, 1H, H6), 2.83 (tdapp, J = 7.4 and 3.0 Hz, 1H, H2), 2.65 (qapp, J = 8.0 Hz, 1H, H2), 2.162.13 (m, 
2H, H4), 1.781.72 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 140.8 (C, C8 or C14), 138.1 (C, C8 or C14), 128.6 (2xCH, Car), 128.3 (2xCH, 
Car), 128.2 (2xCH, Car), 127.9 (CH, C11 or C17), 127.7 (C, q, J = 286.8 Hz, C12), 127.6 (2xCH, Car), 126.8 (CH, 
C11 or C17), 73.7 (CH2, C7), 69.9 (CH2, C6), 67.9 (C, q, J = 24.6 Hz, C5), 53.4 (CH2, C13), 53.2 (CH2, C2), 31.2 
(CH2, C4), 23.0 (CH2, C3). 
MS m/z (relative intensity): 349 (M+•, 0.1), 243 (3), 228 (20), 91 (100), 77 (5), 65 (9). 
HRMS: calcd for C20H23F3NO (M+H+): 350.1726. Found 350.1727. 
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N-Benzyl-2-[(hydroxy)methyl]-2-(trifluoromethyl)pyrrolidine (28) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = H2O (0.1 mL, 5.55 
mmol, 14.0 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=5:95 to 
10:90) to afford 28 (62 mg, 0.24 mmol, 61%) as a brown oil. 
IR (neat): 3445, 3030, 2927, 2852, 1496, 1454, 1366, 1287, 1138, 1109, 1058, 943 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.357.25 (m, 5Η, H10, H11 and H12), 4.09 (d, J = 13.3 Hz, 1H, H8), 3.84 (d, 
J = 10.9 Hz, 1H, H6), 3.68 (dq, J = 13.3 and 1.8 Hz, 1H, H8), 3.61 (m, 1H, H6), 2.90 (m, 1H, H2), 2.75 (qapp, 
J = 17.3 Hz, 1H, H2), 2.53 (br s, OH), 2.192.15 (m, 2H, H4), 1.80 (m, 1H, H3), 1.71 (m, 1H, H3). 
13C NMR (CDCl3, 100 MHz): δ 139.3 (C, C9), 128.7 (2xCH, C10 or C11), 128.5 (2xCH, C10 or C11), 128.0 (C, 
q, J = 291.6 Hz, C7), 127.4 (CH, C12), 69.2 (C, q, J = 23.3 Hz, C5), 59.5 (CH2, C6), 52.2 (CH2, C8), 51.9 (CH2, 
C2), 30.1 (CH2, C4), 22.1 (CH2, C3). 
MS m/z (relative intensity): 259 (M+•, 0.6), 228 (17), 91 (100), 65 (8). 
HRMS: calcd for C13H17F3NO (M+H+): 260.1257. Found 260.1260. 
N-Benzyl-2-phenoxymethyl-2-(trifluoromethyl)pyrrolidine (29) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = sodium phenoxy 
trihydrate (164.1 mg, 0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography 
(EtOAc/PE=2:98) to afford 29 (98 mg, 0.29 mmol, 75%) as a colorless oil. 
IR (neat): 3030, 2955, 2814, 1600, 1589, 1497, 1474, 1455, 1367, 1331, 1288, 1238, 1139, 1077, 1055, 
947 cm–1. 
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1H NMR (CDCl3, 400 MHz): δ 7.347.19 (m, 7Η, Har), 7,01–6.94 (m, 3Η, H8 and H10), 4.29 (d, J = 9.6 Hz, 
1H, H6), 4.18 (d, J = 13.7 Hz, 1H H12), 4.13 (d, J = 9.8 Hz, 1H, H6), 3.80 (d, J = 13.6 Hz, 1H, H12), 2.89 (m, 
1H, H2), 2.78 (qapp, J = 7.8 Hz, 1H, H2), 2.252.23 (m, 2H, H4), 1.871.81 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 158.5 (C, C13), 140.5 (C, C7), 129.7 (2xCH, Car), 128.4 (2xCH, Car), 128.1 
(2xCH, Car), 127.6 (C, q, J = 286.8 Hz, C11), 126.9 (CH, C16), 121.5 (CH, C10), 114.7 (2xCH, C8), 67.7 (C, q, 
J = 25.0Hz, C5), 67.5 (CH2, C6), 53.3 (CH2, C2 or C12), 53.3 (CH2, C2 or C12), 31.3 (CH2, C4), 23.1 (CH2, C3). 
MS m/z (relative intensity): 335 (M+•, 0.3), 228 (22), 91 (100), 77 (5), 65 (8). 
HRMS: calcd for C19H21F3NO (M+H+): 336.1570. Found 336.1569. 
N-Benzyl-2[(acetyl)methyl]-2-(trifluoromethyl)pyrrolidine (30) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = tetrabutylammonium 
acetate (290.7 mg, 0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography 
(EtOAc/PE=5:95 to 10:90) to afford 30 (84 mg, 0.28 mmol, 72%) as a yellow oil. 
IR (neat): 3030, 2973, 2813, 1749, 1496, 1454, 1367, 1226, 1141, 1050, 955, 907 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.317.22 (m, 5H, H12, H13 and H14), 4.39 (d, J = 11.8 Hz, 1H, H6), 4.32 (d, 
J = 11.8 Hz, 1H, H6), 4.06 (d, J = 13.6 Hz, 1H, H10), 3.81 (d, J = 13.6 Hz, 1H, H10), 2.82 (m, 1H, H2), 2.67 
(qapp, J = 7.5 Hz, 1H, H2), 2.21 (m, 1H, H3), 2.13 (s, 3H, H8), 1.99 (m, 1H, H3), 1.821.74 (m, 2H, H4). 
13C NMR (CDCl3, 100 MHz): δ 170.7 (C, C7), 140.0 (C, C11), 128.4 (2xCH, C12 or C13), 128.1 (2xCH, C12 or 
C13), 127.5 (C, q, J = 288.3 Hz, C9), 127.0 (CH, C14), 67.0 (C, q, J = 24.9 Hz, C5), 63.4 (CH2, C6), 53.0 (CH2, 
C10), 52.5 (CH2, C2), 31.4 (CH2, C4), 22.7 (CH2, C3), 21.0 (CH3, C8).  
MS m/z (relative intensity): 301 (M+•, 1), 228 (25), 91 (100), 65 (8). 
HRMS: calcd for C15H19F3NO2 (M+H+): 302.1362. Found 302.1364. 
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N-Benzyl-2-[(ethylsulfanyl)methyl]-2-(trifluoromethyl)pyrrolidine (31) 
 
1) Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = sodium ethanethiolate 
(81.1 mg, 0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography 
(EtOAc/PE=1:99) to afford 31 (70 mg, 0.23 mmol, 60%) as a colorless oil. 
2) Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = ethyl mercaptan (72 
L, 0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=1:99) 
to afford 31 (64 mg, 0.21 mmol, 54%) as a colorless oil. 
IR (neat): 2968, 2928, 2831, 1495, 1454, 1373, 1330, 1315, 1266, 1137, 1100, 1075, 1029, 943 cm–1.  
1H NMR (CDCl3, 400 MHz): δ 7.387.36 (m, 2Η, Har), 7.327.28 (m, 2Η, Har), 7.257.20 (m, 1Η, Har), 
4.00 (d, J = 13.6 Hz, 1H, H10), 3.84 (d, J = 13.6 Hz, 1H, H10), 3.27 (d, J = 12.9 Hz, 1H, H6), 2.772.71 (m, 
2H, H2), 2.73 (d, J = 12.6 Hz, 1H, H6), 2.59 (q, J = 8.0 Hz, 2H, H7), 2.33 (m, 1H, H4), 2.15 (m, 1H, H4), 
1.821.75 (m, 2H, H3), 1.30 (t, J = 7.4 Hz, 3H, H8). 
13C NMR (CDCl3, 100 MHz): δ 140.2 (C, C11), 128.3 (2xCH, C12 or C13), 128.3 (C, q, J = 291.6 Hz, C9), 
128.2 (2xCH, C12 or C13), 126.9 (CH, C14), 68.0 (q, J = 23.8 Hz, C5), 52.3 (CH2, C10), 51.9 (CH2, C2), 35.2 
(CH2, C6), 31.7 (CH2, C4), 27.9 (CH2, C7), 22.4 (CH2, C3), 15.1 (CH3, C8).  
MS m/z (relative intensity): 303 (M+•, 0.1), 228 (22), 91 (100), 65 (7). 
HRMS: calcd for C15H21F3NS (M+H+): 304.1341. Found 304.1342. 
N-Benzyl-2-[(benzylsulfanyl)methyl]-2-(trifluoromethyl)pyrrolidine (32) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = benzyl mercaptan 
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(113 L, 0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (PE=100%) 
to afford 32 (126 mg, 0.34 mmol, 89%) as a colorless oil. 
IR (neat): 3063, 3028, 2954, 2821, 1602, 1494, 1454, 1369, 1315, 1257, 1145, 1100, 1073, 1029, 997, 
944 cm–1.  
1H NMR (CDCl3, 400 MHz): δ 7.367.22 (m, 10Η, Har), 3.94 (d, J = 13.7 Hz, 1H, H13), 3.74 (s, 2H, H7), 
3.73 (d, J = 16.0 Hz, 1H, H13), 3.15 (d, J = 12.7 Hz, 1H, H6), 2.762.65 (m, 3H, H2 and H6) 2.16 (m, 1H, 
H4), 2.05 (m, 1H, H4), 1.771.70 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 140.1 (C, C8 or C14), 138.2 (C, C8 or C14), 129.0 (2xCH, Car), 128.7 (2xCH, 
Car), 128.3 (2xCH, Car), 128.3 (2xCH, Car), 128.2 (C, q, J = 291.8 Hz, C12), 127.3 (CH, C11 or C17), 126.9 (CH, 
C11 or C17), 67.9 (C, q, J = 23.9 Hz, C5), 52.2 (CH2, C13), 51.8 (CH2, C2), 37.9 (CH2, C7), 34.6 (CH2, C6), 31.7 
(CH2, C4), 22.3 (CH2, C3).  
MS m/z (relative intensity): 365 (M+•, 0.5), 228 (42), 91 (100), 65 (10). 
HRMS: calcd for C20H23F3NS (M+H+): 366.1498. Found 366.1499. 
N-Benzyl-2-[(phenylsulfanyl)methyl]-2-(trifluoromethyl)pyrrolidine (33) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleopile = sodium thiophenolate 
(127 mg, 0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (PE=100%) 
to afford 33 (83 mg, 0.24 mmol, 61%) as a colorless oil. 
IR (neat): 3062, 3028, 2955, 2834, 1584, 1495, 1480, 1454, 1438, 1372, 1314, 1252, 1137, 1100, 1026, 
997, 943 cm–1.  
1H NMR (CDCl3, 400 MHz): δ 7.407.18 (m, 10Η, Har), 4.07 (d, J = 13.6 Hz, 1H, H12), 3.80 (ddapp, J = 13.6 
and 1.4 Hz, 1H, H12), 3.67 (d, J = 12.6 Hz, 1H, H6), 3.21 (d, J = 12.6 Hz, 1H, H6), 2.85 (m, 1H, H2), 2.75 
(qapp, J = 7.2 Hz, 1H, H2), 2.38 (m, 1H, H4), 2.19 (m, 1H, H4), 1.851.78 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 139.9 (C, C7 or C13), 137.2 (C, C7 or C13), 129.5 (2xCH, Car), 129.2 (2xCH, 
Car), 128.4 (2xCH, Car), 128.3 (2xCH, Car), 128.2 (C, q, J = 292.4 Hz, 1C, C11), 127.0 (CH, C10 or C16), 126.4 
(CH, C10 or C16), 68.1 (C, q, J = 23.8 Hz, C5), 52.3 (CH2, C12), 51.7 (CH2, C2), 37.5 (CH2, C6), 31.8 (CH2, C4), 
22.4 (CH2, C3).  
MS m/z (relative intensity): 351 (M+•, 0.3), 228 (43), 123 (2), 91 (100), 77 (3), 65 (9). 
125 
 
HRMS: calcd for C19H21F3NS (M+H+): 352.1341. Found 352.1341. 
N-Benzyl-2-cyanomethyl-2-(trifluoromethyl)pyrrolidine (34)  
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = tetrabutylammonium 
cyanide (273 mg, 0.96 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography 
(EtOAc/PE=4:96) to afford 34 (78 mg, 0.29 mmol, 75%) as a yellow oil. 
IR (neat): 3031, 2962, 2839, 2359, 2252, 1454, 1373, 1349, 1278, 1141, 1105, 1076, 1029, 979, 914 
cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.377.23 (m, 5Η, H11, H12 and H13), 4.03 (d, J = 13.5 Hz, 1H, H9), 3.86 (d, 
J = 13.5 Hz, 1H, H9), 2.89 (m, 1H, H2), 2.89 (d, J = 16.0 Hz, 1H, H6), 2.76 (m, 1H, H2), 2.74 (d, J = 16.0 Hz, 
1H, H6), 2.36 (m, 1H, H4), 2.20 (m, 1H, H4), 1.931.84 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 138.8 (C, C10), 128.5 (2xCH, C11 or C12), 128.0 (2xCH, C11 or C12), 127.3 
(CH, C13), 127.1 (C, q, J = 290.6 Hz, C8), 116.4 (C, C7), 66.2 (C, q, J = 25.6 Hz, C5), 52.0 (CH2, C9), 51.6 
(CH2, C2), 33.4 (CH2, C4), 22.2 (CH2, C6), 22.0 (CH2, C3). 
MS m/z (relative intensity): 268 (M+•, 1), 228 (8), 199 (3), 91 (100), 65 (11), 54 (5). 
HRMS: calcd for C14H16F3N2 (M+H+): 269.1260. Found 269.1259. 
N-Benzyl-2-[(1,3-dimethyl-propanedioate)methyl]-2-(trifluoromethyl)pyrrolidine (35) 
 
Following the general protocol: 1 (100 mg, 0.39 mmol, 1.0 equiv), proton sponge (165.3 mg, 0.77 
mmol, 2.0 equiv), triflic anhydride (96 L, 0.58 mmol, 1.5 equiv). Nucleophile = sodium 
dimethylmalonate. The crude mixture was purified by flash chromatography (EtOAc/PE=10:90) to 
afford 35 (101 mg, 0.27 mmol, 70%) as a yellow oil. 
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For the sodium dimethylmalonate: To a stirred suspension of NaH (60% wt oil dispersion, 40 mg, 1.00 
mg, 2.6 equiv) in THF (3 mL) at 15°C was added dropwise dimethylmalonate (0.35 mL, 1.35 mmol, 
3.5 equiv) and the solution was stirred at rt for 30 min.  
IR (neat): 2956, 2845, 1736, 1455, 1436, 1366, 1268, 1137 1104, 1038 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.327.22 (m, 5H, H13, H14 and H15), 4.10 (d, J = 13.5 Hz, 1H, H11), 3.78 (s, 
3H, H9 or H9’), 3.77 (m, 1H, H7), 3.68 (s, 3H, H9 or H9’), 3.57 (dq, J = 13.5 and 2.3 Hz, 1H, H11), 2.86 (m, 
1H, H2), 2.64–2.59 (m, 2H, H2 and H6), 2.38 (dd, J = 15.0 Hz and 6.1 Hz, 1H, H6), 2.13 (m, 1H, H4), 
1.821.66 (m, 3H, H3 and H4). 
13C NMR (CDCl3, 100 MHz): δ 170.6 (C, C8 or C8’), 170.2 (C, C8 or C8’), 139.4 (C, C12), 128.6 (C, q, J = 
294.3 Hz, C10), 128.4 (2xCH, C13 or C14), 128.3 (2xCH, C13 or C14), 127.0 (CH, C15), 67.6 (C, q, J = 23.2 Hz, 
C5), 53.1 (CH3, C9 or C9’), 53.0 (CH3, C9 or C9’), 51.9 (CH2, C11), 51.1 (CH2, C2), 46.7 (CH, C7), 31.2 (CH2, 
C4), 29.2 (CH2, C6), 21.9 (CH2, C3). 
MS m/z (relative intensity): 373 (M+•, 1), 304 (24), 242 (7), 228 (10), 91 (100), 65 (7). 
HRMS: calcd for C18H23F3NO4 (M+H+): 374.1574. Found 374.1581. 
(+)-N-Benzyl-2-{[(S)-N-(1-methylbenzyl)amino]methyl}-2-(trifluoromethyl)pyrrolidine (+)-(36a) 
 
Following the general protocol: (+)-1 (28 mg, 0.11 mmol, 1.0 equiv), proton sponge (46.3 mg, 0.22 
mmol, 2.0 equiv), triflic anhydride (27 L, 0.16 mmol, 1.5 equiv). Nucleophile = 
(S)-()-α-methybenzylamine (34 L, 0.27 mmol, 2.5 equiv). The crude mixture was purified by flash 
chromatography (EtOAc/Pentane=2:98) to afford 36a (30 mg, 0.08 mmol, 77%) as a yellow oil. 
IR (neat): 3028, 2966, 2925, 2835, 1494, 1453, 1370, 1285, 1131, 1103, 1076, 1028 cm–1. 
[]D20 +26 (c 0.8, CHCl3) 
1H NMR (CDCl3, 400 MHz): δ 7.287.19 (m, 10Η, Har), 3.85 (d, J = 13.9 Hz, 1H, H14), 3.743.66 (m, 2H, 
H7 and H14), 2.782.68 (m, 4H, H2 and H6), 2.39 (m, 1H, H4), 2.08 (m, 1H, H4), 1.781.69 (m, 2H, H3), 
1.63 (br s, NH), 1.37 (d, J = 6.6 Hz, 3H, H8). 
13C NMR (CDCl3, 100 MHz): δ 146.0 (C, C9 or C15), 140.2 (C, C9 or C15), 128.7 (C, q, J = 291.6 Hz, C13), 
128.6 (2xCH, Car), 128.4 (2xCH, Car), 128.0 (2xCH, Car), 127.1 (CH, C12 or C18), 126.9 (CH, C12 or C18), 126.6 
(2xCH, Car), 68.3 (C, q, J = 23.0 Hz, C5), 59.0 (CH, C7), 52.0 (CH2, C2 or C14), 51.9 (CH2, C2 or C14), 47.1 
(CH2, C6), 30.6 (CH2, C4), 24.1 (CH3, C8), 22.4 (CH2, C3). 
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MS m/z (relative intensity): 362 (M+•, 0.05), 228 (6), 209 (38), 208 (24), 134 (10), 105 (62), 91 (100), 
79 (7), 77 (7), 65 (10), 51 (3). 
HRMS: calcd for C21H26F3N2 (M+H+): 363.2043. Found: 363.2044. 
 ()-N-Benzyl-2-{[(S)-N-(1-methylbenzyl)amino]methyl}-2-(trifluoromethyl)pyrrolidine ()-(36b) 
 
Following the general protocol: ()-1 (56 mg, 0.22 mmol, 1.0 equiv), proton sponge (91.8 mg, 0.43 
mmol, 2.0 equiv), triflic anhydride (53 L, 0.32 mmol, 1.5 equiv). Nucleophile = 
(S)-()-α-methybenzylamine (68 L, 0.54 mmol, 2.5 equiv). The crude mixture was purified by flash 
chromatography (EtOAc/Pentane=2:98) to afford 36b (68 mg, 0.19 mmol, 86%) as a yellow oil. 
IR (neat): 3028, 2960, 2924, 2833, 1494, 1453, 1370, 1285, 1148, 1131, 1104, 1075, 1028, 964 cm–1. 
[]D20 38 (c 1.0, CHCl3) 
1H NMR (CDCl3, 400 MHz): δ 7.367.21 (m, 10Η, Har), 4.06 (d, J = 13.8 Hz, 1H, H14), 3.763.71 (m, 2H, 
H7 and H14), 2.90 (m, 1H, H2), 2.80 (d, J = 11.7 Hz, 1H, H6), 2.73 (m, 1H, H2), 2.54 (d, J = 11.7 Hz, 1H, 
H6), 2.40 (m, 1H, H4), 2.01 (m, 1H, H4), 1.791.76 (m, 2H, H3), 1.62 (br s, NH), 1.36 (d, J = 6.6 Hz, 3H, 
H8). 
13C NMR (CDCl3, 100 MHz): δ 145.8 (C, C9 or C15), 140.3 (C, C9 or C15), 128.6 (4xCH, Car), 128.6 (C, q, J = 
292.8 Hz, C13), 128.1 (2xCH, Car), 127.1 (CH, C12 or C18), 127.0 (CH, C12 or C18), 126.7 (2xCH, Car), 68.4 (C, 
q, J = 23.0 Hz, C5), 59.0 (CH, C7), 52.0 (2xCH2, C2 and C14), 47.0 (CH2, C6), 30.5 (CH2, C4), 25.6 (CH3, C8), 
22.3 (CH2, C3). 
MS m/z (relative intensity): 362 (M+•, 0.04), 228 (8), 209 (49), 208 (29), 134 (12), 105 (69), 91 (100), 
79 (8), 77 (8), 65 (10), 51 (3). 
HRMS: calcd for C21H26F3N2 (M+H+): 363.2043. Found: 363.2045. 
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4. Synthesis and spectroscopic data of N-benzyl-3-hydroxy-
3-methylpiperidine (37) 
tert-Butyl 3-methyl-3-hydroxypiperidin-1-carboxylate (41)76 
 
To a stirred solution of N-Boc-3-piperidone 3 (1.48 g, 7.43 mmol, 1.0 equiv) in THF (37 mL) at 0 °C was 
added MeMgBr (3.0 M in Et2O, 9.9 mL, 29.7 mmol, 4.0 equiv) and the resulting mixture was stirred at 
rt for 16 h. The solution was quenched with an aqueous and saturated solution of NH4Cl and extracted 
with EtOAc (twice). The organic layer was then dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure. The crude mixture was purified by flash chromatography 
(Et2O/PE=30:70) to afford 41 (800 mg, 3.72 mmol, 50%) as a colorless oil. 
IR (neat): 3393, 2930, 1684, 1422, 1365, 1274, 1247, 1158, 1049, 1025, 1001 cm–1. 
 1H NMR (DMSO-d6, 400 MHz at 122 oC): δ 3.81 (br s, OH), 3.323.22 (m, 2H, H2), 3.19 (d, J = 12.8 Hz, 
1H, H6), 3.13 (d, J = 12.9 Hz, 1H, H6), 1.67 (m, 1H, H3), 1.541.50 (m, 2H, H4), 1.38 (m, 1H, H3), 1.42 (s, 
9H, H10), 1.11 (s, 3H, H7). 
13C NMR (DMSO-d6, 400 MHz at 122 oC): δ 153.8 (C, C8), 77.6 (C, C9), 66.2 (C, C5), 54.2 (CH2, C6), 42.9 
(CH2, C2), 37.2 (CH2, C4), 27.6 (3xCH3, C10), 25.4 (CH3, C7), 21.1 (CH2, C3).  
MS m/z (relative intensity): 215 (M+•, 2), 159 (9), 142 (7), 101 (9), 85 (8), 58 (8), 57 (100), 56 (5).  
N-Benzyl-3-hydroxy-3-methylpiperidine (37) 
 
To a stirred solution of tert-butyl 3-methyl-3-hydroxypiperidin-1-carboxylate 41 (607 mg, 2.82 mmol, 
1.0 equiv) in CH2Cl2 (16 mL) at rt, was added TFA (1.47 mL, 19.74 mmol, 7.0 equiv). The reaction 
mixture was stirred at rt for 15 h and then concentrated under reduced pressure. 
                                                          
76 Wenthur, C. J.; Morrison, R.; Felts, A. S.; Smith, K. A.; Engers, J. L.; Byers, F. W.; Daniels, J. S.; Emmitte, K. A.; 
Conn, P. J.; Lindsley, C. W. J. Med. Chem. 2013, 56, 52085212. 
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To a stirred solution of the crude material previously obtained in MeCN (29 mL) at rt were added 
successively BnBr (0.34 mL, 2.82 mmol, 1.0 equiv), K2CO3 (1.9 g, 14.1 mmol, 5.0 equiv) and TBAI (0.52 
mg, 1.41 mmol, 0.5 equiv). The reaction mixture was heated at 75 °C for 4 h and then allowed to cool 
to rt. The reaction mixture was quenched with H2O and extracted with CH2Cl2 (twice). The organic 
layer was dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude 
mixture was purified by flash chromatography (EtOAc/PE=50:50) to afford 37 (452 mg, 2.02 mmol, 
78%) as a colorless oil. 
IR (neat): 3447, 2931, 2798, 1495, 1452, 1366, 1289, 1206, 1135, 1076, 1040, 968 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.347.25 (m, 5Η, H10, H11 and H12), 3.52 (s, 2H, H8), 3.33 (br s, OH), 2.79 
(d, J = 10.7 Hz, 1H, H2), 2.59 (d, J = 10.9 Hz, 1H, H6), 1.95 (d, J = 11.0 Hz, 1H, H6), 1.89 (dd, J = 11.3 and 
2.4 Hz, 1H, H2), 1.77 (m, 1H, H3), 1.62 (dd, J = 13.1 and 2.2 Hz, 1H, H4), 1.52 (m, 1H, H3), 1.24 (m, 1H, 
H4), 1.14 (s, 3H, H7). 
13C NMR (CDCl3, 100 MHz): δ 138.3 (C, C9), 129.1 (2xCH, C10 or C11), 128.4 (2xCH, C10 or C11), 127.3 (CH, 
C12), 67.9 (C, C5), 65.1 (CH2, C6), 62.9 (CH2, C8), 53.2 (CH2, C2), 36.6 (CH2, C4), 26.5 (CH3, C7), 22.0 (CH2, 
C3). 
MS m/z (relative intensity): 205 (M+•, 10), 147 (5), 146 (6), 134 (65), 114 (11), 92 (9), 91 (100), 85 
(14), 65 (10). 
HRMS: calcd for C13H20NO (M+H+): 206.1539. Found 206.1542.  
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5. Synthesis and spectroscopic data of N-benzyl-3-fluoro-3-
methyl piperidine (43) 
N-Benzyl-3-fluoro-3-methylpiperidine (43) 
 
Following the general protocol: N-benzyl-3-hydroxy-3-methylpiperidine 37 (50 mg, 0.24 mmol, 1.0 
equiv), proton sponge (104 mg, 0.49 mmol, 2.0 equiv), triflic anhydride (61 L, 0.37 mmol, 1.5 equiv). 
Nucleophile = tetrabutylammonium fluoride (1.0 M in THF, 0.61 mL, 0.61 mmol, 2.5 equiv). The crude 
mixture was purified by flash chromatography (EtOAc/PE=5:95 and 10:90) to afford 43 (18 mg, 0.09 
mmol, 36%) as a yellow oil. 
IR (neat): 2935, 2859, 2801, 1732, 1679, 1604, 1495, 1453, 1376, 1304, 1284, 1204, 1166, 1130, 1028, 
920, 881 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.337.23 (m, 5Η, H10, H11 and H12), 3.55 (s, 2H, H8), 2.652.53 (m, 2H, 
H2 and H6), 2.272.17 (m, 2H, H2 and H6), 1.851.76 (m, 2H, H3 and H4), 1.571.45 (m, 2H, H3 and H4), 
1.34 (d, J = 21.7 Hz, 3H, H7). 
13C NMR (CDCl3, 100 MHz): δ 138.1 (C, C9), 129.2 (2xCH, C10 or C11), 128.3 (2xCH, C10 or C11), 127.1 (CH, 
C12), 92.7 (C, d, J = 169.7 Hz, C5), 62.9 (CH2, C8), 62.0 (CH2, d, J = 22.9 Hz, C6), 53.0 (CH2, C2), 35.4 (CH2, 
d, J = 22.4 Hz, C4), 25.2 (CH3, d, J = 24.1 Hz, C7), 22.3 (CH2, d, J = 4.7 Hz, C3). 
MS m/z (relative intensity): 207 (M+•, 24), 206 (17), 146 (8), 134 (9), 130 (34), 116 (39), 92 (15), 91 
(100), 65 (14). 
HRMS: calcd for C13H19FN (M+H+): 208.1496. Found 208.1497. 
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6. Synthesis and spectroscopic data of 
N-benzyl-3-hydroxy-3-(trifluoromethyl)azepane (44) 
1-Chloropent-4-en-2-ol (48)77 
 
A solution of allyl bromide (5.48 mL, 63 mmol, 1.6 equiv) and In (5.88 g, 51.2 mmol, 1.3 equiv) in H2O 
(99 mL) was stirred for 15 min and then 2-chloroacetaldehyde 47 (5 mL, 39.4 mmol, 1.0 equiv) was 
added to the gray heterogeneous mixture. After 3 h at rt, the reaction mixture was extracted with 
Et2O and the combined extracts were washed with brine, dried over anhydrous Na2SO4, filtered and 
concentrated under reduced presssure to afford 48 (3.7 g, 30.9 mmol, 80%) as a colorless oil. 
IR (neat): 3382, 3079, 2956, 2917, 1642, 1432, 1047, 996, 919 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 5.81 (ddt, J = 17.3, 10.2 and 7.1 Hz, 1H, H4), 5.185.11 (m, 2H, H5), 3.88 
(m, 1H, H2), 3.61 (dd, J = 11.2 and 4.0 Hz, 1H, H1), 3.51 (d, J = 11.2 and 6.3 Hz, 1H, H1), 3.29 (br s, OH), 
2.392.31 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 133.3 (CH, C4), 118.2 (CH2, C5), 70.5 (CH, C2), 49.0 (CH2, C1), 38.5 (CH2, 
C3). 
N-(Allylamino)pent-7-en-5-ol (46)73 
 
1-chloropent-4-en-2-ol 48 (3.73 g, 30.9 mmol, 1.0 equiv) was treated with allylamine (11.6 mL, 154 
mmol, 5.0 equiv) and the reaction mixture was stirred at 86 °C for 5 days. The solution was 
concentrated under reduced pressure to remove the excess of allylamine. The crude mixture was 
purified by flash chromatography (MeOH/CH2Cl2=2:98 and 10:90) to afford 46 (4.2 g, 29.4 mmol, 96%) 
as an orange oil. 
IR (neat): 3301, 3076, 2978, 2911, 2825, 1642, 1441, 1341, 1078, 993, 913 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 5.975.79 (m, 2H, H2 and H7), 5.285.07 (m, 4H, H1 and H8), 4.38 (s, 2H, 
OH and NH), 3.85 (m, 1H, H4), 3.373.35 (m, 2H, H6), 2.78 (dd, J = 12.2 and 3.0 Hz, 1H, H5), 2.59 (dd, J 
= 12.2 and 9.5 Hz, 1H, H5), 2.272.23 (m, 2H, H3). 
                                                          
77 Jaber, J. J.; Mitsui, K.; Rychnovsky, S. D. J. Org. Chem. 2001, 66, 46794686. 
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13C NMR (CDCl3, 100 MHz): δ 134.4 (CH, C2 or C7), 134.3 (CH, C2 or C7), 118.2 (CH2, C1 or C8), 117.6 (CH2, 
C1 or C8), 68.3 (CH, C4), 53.5 (CH2, C5), 51.6 (CH2, C6), 39.8 (CH2, C3). 
tert-Butyl allyl(2-hydroxypent-4-en-1-yl)carbamate (49)73 
 
To a stirred solution of N-(allylamino)pent-7-en-5-ol 46 (1.2 g, 8.5 mmol, 1.0 equiv) in CH2Cl2 (16.3 
mL) was added Et3N (1.77 mL, 12.7 mmol, 1.5 equiv) and Boc2O (2.09 mL, 9.77 mmol, 1.15 equiv) and 
the reaction mixture was stirred at rt for 16 h. The reaction mixture was evaporated under reduced 
pressure, diluted in EtOAc and treated with HCl 1M and extracted with EtOAc. The combined extracts 
were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude mixture was 
purified by flash chromatography (EtOAc/PE=15:85 and 20:80) to afford 49 (1.9 g, 7.9 mmol, 93%) as 
a colorless oil. 
IR (neat): 3433, 3079, 2978, 2931, 2248, 1669, 1461, 1409, 1366, 1247, 1168, 1097, 993, 913 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 5.895.75 (m, 2H, H2 and H7), 5.145.09 (m, 4H, H1 and H8), 3.85 (m 3H, 
H4 and H6), 3.55 (s, 1H, OH), 3.25 (m, 2H, H5), 2.242.22 (m, 2H, H3), 1.46 (s, 9H, H11). 
13C NMR (CDCl3, 100 MHz): δ 157.4 (C, C9), 134.4 (CH, C2 or C7), 133.9 (CH, C2 or C7), 117.8 (CH2, C1 or 
C8), 116.4 (CH2, C1 or C8), 80.3 (C, C10), 70.9 (CH, C4), 53.0 (CH2, C5), 51.6 (CH2, C6), 39.8 (CH2, C3), 28.4 
(3xCH3, C11). 
tert-Butyl 3-hydroxy-2,3,4,7-tetrahydro-1H-azepine-1-carboxylate (45)73  
 
To a stirred solution of tert-butyl allyl(2-hydroxypent-4-en-1-yl)carbamate 49 (4.7 g, 19.5 mmol, 1.0 
equiv) in CH2Cl2 (106 mL) was added Grubbs-I catalyst (2.48 g, 2.92 mmol, 15 mol %) and the reaction 
mixture was stirred for 48 h at rt and concentrated under reduced pressure. The crude mixture was 
purified by flash chromatography (EtOAc/PE=25:75) to afford 45 (2.86 g, 13.4 mmol, 69%) as a brown 
oil. 
IR (neat): 3428, 2976, 2930, 1668, 1415, 1366, 1246, 1161, 1057, 880 cm–1. 
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1H NMR (CDCl3, 400 MHz) mixture of rotamers: δ 5.745.64 (m, 2H, H3 and H4), 4.14 (dapp, J = 17.5 
Hz, 1H, H2), 4.01 (m, 1H, H6), 3.77 (dapp, J = 16.7 Hz, 2H, H2 and H7), 3.60 (m, 1H, H7), 2.38 (m, 2H, H5), 
1.47 (s, 9H, H10). 
13C NMR (CDCl3, 100 MHz) mixture of rotamers: δ 156.8 (C, C8), 155.3 (C, C8’), 130.0 (CH, C3’ or C4’), 
129.4 (CH, C3 or C4), 126.3 (CH, C3 or C4), 125.9 (CH, C3’ or C4’), 80.3 (C, C9), 70.0 (CH, C6), 69.4 (CH, C6’), 
54.3 (CH2, C7), 54.1 (CH2, C7’), 48.2 (CH2, C2), 47.2 (CH2, C2’), 34.4 (CH2, C5), 33.8 (CH2, C5’), 28.4 (3xCH3, 
C10). 
MS m/z (relative intensity): 213 (M+•, 0.05), 157 (6), 139 (11), 11 (5), 94 (11), 83 (5), 68 (10), 57 (100), 
55 (18). 
tert-Butyl 3-(hydroxy)azepane-1-carboxylate (50)73  
 
To a stirred solution of tert-Butyl 3-hydroxy-2,3,4,7-tetrahydro-1H-azepine-1-carboxylate 45 (2.86 g, 
13.4 mmol, 1.4 equiv) in EtOH (224 mL) was added PtO2 (305 mg, 1.34 mmol, 10 mol %) and the 
reaction mixture was stirred under H2 atmosphere for 16 h. The solution was then filtered over Celite, 
washed with EtOAc and concentrated under reduced pressure to afford 50 (2.84 g, 13.2 mmol, quant) 
as a brown oil. 
IR (neat): 3425, 2975, 2929, 2863, 1692, 1666, 1478, 1415, 1365, 1250, 1160, 1053 cm–1. 
 1H NMR (CDCl3, 400 MHz) mixture of rotamers: δ 3.94 (m, 1H, H6), 3.683.56 (m, 2H, H2 and H7), 3.37 
(dd, J = 14.8 and 4.2 Hz, 1H, H7), 3.10 (m, 1H, H2), 1.88 (m, 1H, H5), 1.781.64 (m, 3H, H3 and H4), 1.50 
(m, 1H, H5), 1.47 (s, 9H, H10), 1.35 (m, 1H, H4). 
13C NMR (DMSO-d6, 400 MHz) mixture of rotamers: δ 154.7 (C, C8), 154.4 (C, C8’), 78.3 (C, C9), 78.2 
(C, C9’), 68.8 (CH, C6), 53.3 (CH2, C7), 53.0 (CH2, C7’), 47.1 (CH2, C2), 46.8 (CH2, C2’), 36.2 (CH2, C5), 35.6 
(CH2, C5’), 28.1 (3xCH3, C10), 27.3 (CH2, C3), 27.3 (CH2, C3’), 20.8 (CH2, C4), 20.6 (CH2, C4’).  
MS m/z (relative intensity): 215 (M+•, 0.49), 159 (5), 141 (16), 114 (6), 84 (7), 70 (22), 57 (100). 
 
 
 
134 
 
tert-Butyl 3-oxoazepane-1-carboxylate (51)78 
 
To a solution of tert-butyl 3-(hydroxy)azepane-1-carboxylate 50 (2.24 g, 10.4 mmol, 1.0 equiv) in 
CH2Cl2 (52 mL) was added Dess-Martin periodinane (4.85 g, 3.56 mL, 11.4 mmol, 1.1 equiv) and the 
reaction mixture was stirred at rt for 2.5 h. The mixture was then quenched with a saturated aqueous 
solution of Na2S2O3, followed by an aqueous solution of NaOH 1M. The resulting mixture was 
extracted with CH2Cl2, dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (Et2O/PE=20:80 to 30:70) to give 51 (1.9 g, 8.91 
mmol, 86%) as a colorless oil. 
IR (neat): 2975, 2933, 2864, 1700, 1458, 1415, 1366, 1251, 1158, 1094, 889 cm–1. 
 1H NMR (CDCl3, 400 MHz) mixture of rotamers: δ 4.03 (m, 2H, H7), 3.96 (m, 2H, H7’), 3.45 (m, 2H, H2), 
3.38 (m, 2H, H2’), 2.53 (dd, J = 7.6 and 4.1 Hz, 2H, H5), 1.851.72 (m, 4H, H3 and H4), 1.51 (s, 9H, H10), 
1.46 (s, 9H, H10’). 
13C NMR (CDCl3, 400 MHz) mixture of rotamers: δ 212.2 (C, C6), 155.2 (C, C8), 154.3 (C, C8’), 80.5 (C, 
C9), 80.3 (C, C9’), 58.5 (CH2, C7), 57.7 (CH2, C7’), 49.9 (CH2, C2), 49.7 (CH2, C2’), 42.8 (CH2, C5), 42.5 (CH2, 
C5’), 29.2 (CH2, C3), 28.3 (CH2, C3’), 28.4 (3xCH3, C10), 28.3 (3xCH3, C10’), 23.9 (CH2, C4), 23.7 (CH2, C4’).  
MS m/z (relative intensity): 213 (M+•, 2.7), 157 (9), 140 (7), 113 (5), 84 (32), 70 (4), 57 (100). 
tert-Butyl 3-hydroxy-3-(trifluoromethyl)azepane-1-carboxylate (52) 
 
To a stirred solution of tert-butyl 3-oxoazepane-1-carboxylate 51 (1.54 g, 7.22 mmol, 1.0 equiv) in 
THF (30 mL) at 0 °C was added TMSCF3 (2.16 mL, 14.44 mmol, 2.0 equiv). A solution of TBAF (1.0 M in 
THF, 14.44 mL, 14.44 mmol, 2.0 equiv) was added dropwise and the resulting mixture was stirred at 
rt for 5 days. The solution was quenched with an aqueous and saturated solution of NH4Cl and stirred 
for another 20 min. The solution was then concentrated under reduced pressure and diluted in 
CH2Cl2. The organic layer was separated and washed with H2O (twice), dried over anhydrous MgSO4, 
                                                          
 78 Mangion, I. K.; Nwamba, I. K.; Shevlin, M.; Huffman, M. A. Org. Lett. 2009, 11, 35663569. 
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filtered and concentrated under reduced pressure. The crude mixture was purified by flash 
chromatography (EtOAc/PE=5:95) to afford 52 (1.90 g, 6.71 mmol, 93%) as a colorless oil. 
IR (neat): 3392, 2935, 1659, 1423, 1368, 1287, 1152, 1119, 868 cm–1. 
 1H NMR (CDCl3, 400 MHz): δ 4.91 (br s, OH), 4.21 (d, J = 15.0 Hz, 1H, H7), 3.84 (m, 1H, H2), 3.07 (d, J = 
15.0 Hz, 1H, H7), 2.99 (d, J = 13.5 and 5.9 Hz, 1H, H2), 1.941.53 (m, 6H, H3, H4 and H5), 1.48 (s, 9H, 
H11). 
13C NMR (CDCl3, 400 MHz): δ 159.0 (C, C9), 126.1 (C, q, J = 286.4 Hz, C8), 81.4 (C, C10), 76.7 (C, q, J = 
26.3 Hz, C6), 49.5 (CH2, C7), 47.7 (CH2, C2), 34.1 (CH2, C3 or C4 or C5), 28.4 (3xCH3, C11), 28.3 (CH2, C3 or 
C4 or C5), 20.1 (CH2, C3 or C4 or C5).  
MS m/z (relative intensity): 283 (M+•, 0.19), 228 (4), 210 (5), 182 (5), 70 (19), 57 (100). 
HRMS: calcd for C12H20F3NO3Na (M+Na+): 306.1288. Found 306.1288.  
N-Benzyl-3-hydroxy-3-(trifluoromethyl)azepane (44) 
 
To a stirred solution of tert-butyl 3-hydroxy-3-(trifluoromethyl)azepane-1-carboxylate 52 (1.9 g, 6.71 
mmol, 1.0 equiv) in CH2Cl2 (37 mL) at rt, was added TFA (3.49 mL, 46.95 mmol, 7.0 equiv). The reaction 
mixture was stirred at rt for 18 h and then concentrated under reduced pressure. 
To a stirred solution of the crude material previously obtained in MeCN (68 mL) at rt were added 
successively BnBr (0.80 mL, 6.71 mmol, 1.0 equiv), K2CO3 (4.6 g, 33.5 mmol, 5.0 equiv) and TBAI (1.24 
g, 3.35 mmol, 0.5 equiv). The reaction mixture was heated at 75 °C for 4 h and then allowed to cool 
to rt. The reaction mixture was quenched with H2O and extracted with CH2Cl2 (twice). The organic 
layer was dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude 
mixture was purified by flash chromatography (EtOAc/PE=5:95) to afford 44 (1.56 g, 5.71 mmol, 85%) 
as a colorless oil. 
IR (neat): 3296, 3030, 2935, 2867, 1453, 1258, 1185, 1151, 1117, 1092, 982 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.367.24 (m, 5Η, H11, H12 and H13), 3.79 (br s, OH), 3.78 (d, J = 13.0 Hz, 
1H, H9), 3.73 (d, J = 13.0 Hz, 1H, H9), 2.84 (s, 2H, H7), 2.80 (m, 1H, H2), 2.49 (m, 1H, H2), 1.921.81 (m, 
2H, H3 and H5), 1.711.47 (m, 4H, H3, H4 and H5). 
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13C NMR (CDCl3, 100 MHz): δ 137.9 (C, C10), 129.2 (2xCH, C11 or C12), 128.7 (2xCH, C11 or C12), 127.8 
(CH, C13), 126.4 (C, q, J = 283.7 Hz, C8), 72.9 (C, q, J = 26.8 Hz, C6), 63.9 (CH2, C9), 54.7 (CH2, C2), 54.2 
(CH2, dapp, J = 2.1 Hz, C7), 34.7 (CH2, C5), 27.3 (CH2, C3), 20.7 (CH2, C4). 
MS m/z (relative intensity): 273 (M+•, 18), 182 (6), 160 (20), 146 (5), 134 (6), 91 (100), 84 (16), 70 
(12), 65 (18). 
HRMS: calcd for C14H19F3NO (M+H+): 274.1413. Found 274.1415.  
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7. Synthesis and spectroscopic data of 2-substituted, 
2-(trifluoromethyl)piperidines 
General Protocol for the synthesis of 2-(trifluoromethyl)piperidines  
To a stirred solution of N-benzyl-3-hydroxy-3-(trifluoromethyl)azepane 44 (1.0 equiv) and proton 
sponge VII (2.0 equiv) in CH2Cl2 (0.047 M) at 15 °C, was added triflic anhydride (1.5 equiv). After 5 h 
of stirring at reflux, the solution was cooled to rt, the nucleophile (2.5 equiv) was added and the 
reaction mixture was stirred at rt for 16 h. The reaction mixture was diluted with H2O, extracted with 
CH2Cl2 and the combined extracts were dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure. The crude mixture was purified by flash chromatography. 
N-Benzyl-2-{[(N-benzyl)amino]methyl}-2-(trifluoromethyl)piperidine (54) 
 
Following the general protocol: 44 (150 mg, 0.55 mmol, 1.0 equiv), proton sponge (235.2 mg, 1.10 
mmol, 2.0 equiv) and triflic anhydride (0.14 mL, 0.82 mmol, 1.5 equiv). Nucleophile = benzylamine 
(151 L, 1.37 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography 
(Et2O/PE=10:90) to afford 54 (123 mg, 0.34 mmol, 62%) as a yellow oil. 
IR (neat): 3028, 2935, 2851, 1453, 1240, 1116 cm–1.  
1H NMR (CDCl3, 400 MHz): δ 7.337.12 (m, 10Η, Har), 4.13 (d, J = 15.4 Hz, 1H, H14), 3.76 (d, J = 13.4 
Hz, 1H, H8), 3.70 (d, J = 13.4 Hz, 1H, H8), 3.46 (ddapp, J = 15.5 and 2.2 Hz, 1H, H14), 2.95 (d, J = 11.9 Hz, 
1H, H7), 2.692.65 (m, 2H, H2), 2.57 (d, J = 12.0 Hz, 1H, H7), 2.32 (m, 1H, H5), 1.89 (m, 1H, H5), 1.721.51 
(m, 4H, H3 and H4). 
13C NMR (CDCl3, 100 MHz): δ 140.2 (CH, C9 or C15), 140.1 (C, C9 or C15), 129.4 (C, q, J = 299.3 Hz, C13), 
128.7 (2xCH, Car), 128.4 (2xCH, Car), 128.1 (2xCH, Car), 127.3 (2xCH, Car), 127.0 (CH, C12 or C18), 126.9 
(CH, C12 or C18), 62.4 (C, q, J = 20.5 Hz, C6), 54.2 (CH2, C8), 53.3 (CH2, C14), 49.9 (CH2, C7), 46.7 (CH2, C2), 
28.7 (CH2, C5), 25.3 (CH2, C3), 20.4 (CH2, C4).  
MS m/z (relative intensity): 362 (M+•, 0.03), 242 (10), 223 (21), 222 (17), 120 (9), 91 (100), 65 (9). 
HRMS: calcd for C21H26F3N2 (M+H+): 363.2043. Found 363.2042. 
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N-Benzyl-2-{[(N-phenyl)amino]methyl}-2-(trifluoromethyl)piperidine (55) 
 
Following the general protocol: 44 (81.6 mg, 0.30 mmol, 1.0 equiv), proton sponge (128 mg, 0.60 
mmol, 2.0 equiv) and triflic anhydride (74 L, 0.45 mmol, 1.5 equiv). Nucleophile = aniline (68 L, 0.75 
mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=1:99) to afford 
55 (103 mg, 0.30 mmol, quant) as a colorless oil. 
IR (neat): 3395, 3026, 2947, 2851, 1604, 1504, 1120, 1072 cm–1.  
1H NMR (CDCl3, 400 MHz): δ 7.357.13 (m, 7Η, Har), 6.706.56 (m, 3Η, H9 and H11), 4.43 (br s, NH), 
4.20 (d, J = 14.8 Hz, 1H, H13), 3.47 (dapp, J = 13.3 Hz, 2H, H7 and H13), 3.13 (m, 1H, H7), 2.81 (m, 1H, H2), 
2.71 (m, 1H, H2), 2.11 (m, 1H, H5), 1.96 (dapp, J = 14.5 Hz, 1H, H5), 1.711.49 (m, 4H, H3 and H4). 
13C NMR (CDCl3, 100 MHz): δ 148.1 (C, C8), 139.4 (C, C14), 129.4 (2xCH, Car), 129.1 (C, q, J = 299.8 Hz, 
C12), 128.7 (2xCH, Car), 127.8 (2xCH, Car), 127.1 (CH, C17), 117.6 (CH, C11), 112.8 (2xCH, C9), 62.4 (C, q, J 
= 21.1 Hz, C6), 53.6 (CH2, C13), 46.2 (CH2, C2), 44.7 (CH2, C7), 29.0 (CH2, C5), 25.2 (CH2, C3), 20.4 (CH2, 
C4).  
MS m/z (relative intensity): 348 (M+•, 1), 242 (25), 222 (4), 106 (17), 91 (100), 77 (11), 65 (8), 51 (4). 
HRMS: calcd for C20H24F3N2 (M+H+): 349.1886. Found 349.1886. 
N-Benzyl-2-{[(N,N-diethyl)amino]methyl}-2-(trifluoromethyl)piperidine (56) 
 
Following the general protocol: 44 (72 mg, 0.26 mmol, 1.0 equiv), proton sponge (112.9 mg, 0.53 
mmol, 2.0 equiv) and triflic anhydride (66 L, 0.40 mmol, 1.5 equiv). Nucleophile = diethylamine (68 
L, 0.66 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=2:98) 
to afford 56 (80 mg, 0.24 mmol, 92%) as a colorless oil. 
IR (neat): 2967, 2875, 1453, 1239, 1135, 1114, 1066 cm–1.  
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1H NMR (CDCl3, 400 MHz): δ 7.347.20 (m, 5Η, H13, H14 and H15), 4.29 (d, J = 15.1 Hz, 1H, H11), 3.51 
(ddapp, J = 15.1 and 1.8 Hz, 1H, H11), 2.83–2.55 (m, 8H, H2, H7 and H8), 1.991.97 (m, 2H, H5), 1.601.52 
(m, 4H, H3 and H4), 0.96 (t, J = 7.1 Hz, 6H, H9). 
13C NMR (CDCl3, 100 MHz): δ 140.7 (C, C12), 129.8 (C, q, J = 299.4 Hz, C10), 128.3 (2xCH, C13 or C14), 
127.7 (2xCH, C13 or C14), 126.7 (CH, C15), 63.4 (C, q, J = 18.9 Hz, C6), 56.3 (CH2, C7), 54.3 (CH2, C11), 48.0 
(2xCH2, C8), 47.4 (CH2, C2), 29.3 (CH2, C5), 25.5 (CH2, C3), 20.2 (CH2, C4), 11.5 (2xCH3, C9).  
MS m/z (relative intensity): 328 (M+•, 0.01), 242 (1), 91 (27), 86 (100), 65 (12), 58 (7). 
HRMS: calcd for C18H28F3N2 (M+H+): 329.2199. Found 329.2198. 
N-Benzyl-2-{[(N,N-diallyl)amino]methyl}-2-(trifluoromethyl)piperidine (57) 
 
Following the general protocol: 44 (90 mg, 0.33 mmol, 1.0 equiv), proton sponge (141.1 mg, 0.66 
mmol, 2.0 equiv) and triflic anhydride (82 L, 0.49 mmol, 1.5 equiv). Nucleophile = diallylamine (101 
L, 0.82 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=1:99) 
to afford 57 (99 mg, 0.28 mmol, 85%) as a colorless oil. 
IR (neat): 2931, 2854, 1453, 1236, 1156, 1135, 1115, 918 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.327.18 (m, 5H, H14, H15 and H16), 5.895.79 (m, 2H, H9), 5.135.09 (m, 
4H, H10), 4.26 (d, J = 15.1 Hz, 1H, H12), 3.52 (d, J = 15.1 Hz, 1H, H12), 3.29 (dd, J = 14.5 and 6.0 Hz, 2H, 
H8), 3.12 (dd, J = 14.5 and 6.7 Hz, 2H, H8), 2.87 (d, J = 16.1 Hz, 1H, H7), 2.84 (d, J = 15.6 Hz, 1H, H7), 
2.622.59 (m, 2H, H2), 2.011.98 (m, 2H, H5), 1.601.43 (m, 4H, H3 and H4). 
13C NMR (CDCl3, 100 MHz): δ 140.4 (C, C13), 135.7 (2xCH, C9), 129.6 (C, q, J = 299.1 Hz, C11), 128.4 
(2xCH, C14 or C15), 127.7 (2xCH, C14 or C15), 126.7 (CH, C16), 117.4 (2xCH2, C10), 63.5 (C, q, J = 19.1 Hz, 
C6), 58.2 (2xCH2, C8), 55.3 (CH2, C7), 54.3 (CH2, C12), 47.3 (CH2, C2), 29.4 (CH2, C5),25.5 (CH2, C3), 20.2 
(CH2, C4). 
MS m/z (relative intensity): 352 (M+•, 0.01), 242 (2), 110 (100), 91 (49), 81 (3), 65 (6). 
HRMS: calcd for C20H28F3N2 (M+H+): 353.2199. Found 353.2199. 
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N-Benzyl-2-{[(N,N-dibenzyl)amino]methyl}-2-(trifluoromethyl)piperidine (58) 
 
Following the general protocol: 44 (85 mg, 0.31 mmol, 1.0 equiv), proton sponge (133.3 mg, 0.62 
mmol, 2.0 equiv) and triflic anhydride (77 L, 0.47 mmol, 1.5 equiv). Nucleophile = dibenzylamine 
(0.15 mL, 0.78 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (PE=100%) 
to afford 58 (141 mg, 0.31 mmol, quant) as a yellow oil. 
IR (neat): 3028, 2935, 2852,1452, 1388, 1133, 1107, 1099 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.367.15 (m, 15H, Har), 4.31 (d, J = 15.0 Hz, 1H, H14), 3.92 (d, J = 13.9 
Hz, 2H, H8), 3.52 (d , J = 15.7 Hz, 1H, H14), 3.48 (d, J = 13.9 Hz, 2H, H8), 2.97 (d, J = 14.7 Hz, 1H, H7), 2.88 
(d, J = 14.7 Hz, 1H, H7), 2.642.56 (m, 2H, H2), 2.12 (m, 1H, H5), 1.79 (m, 1H, H5), 1.541.42 (m, 4H, H3 
and H4). 
13C NMR (CDCl3, 100 MHz): δ 140.1 (C, C15), 139.3 (2xC, C9), 129.2 (4xCH, Car), 129.5 (C, q, J = 299.4 Hz, 
C13), 128.4 (2xCH, Car), 128.4 (4xCH, Car), 127.7 (2xCH, Car), 127.1 (2xCH, Car), 126.7 (CH, Car), 63.7 (C, 
q, J = 19.3 Hz, C6), 59.7 (2xCH2, C8), 54.5 (CH2, C7 or C14), 54.3 (CH2, C7 or C14), 47.5 (CH2, C2), 29.1 (CH2, 
C5), 25.5 (CH2, C3), 20.1 (CH2, C4). 
MS m/z (relative intensity): 451 (M+•–H•, 0.01), 210 (60), 181 (4), 91 (100), 65 (6). 
HRMS: calcd for C28H32F3N2 (M+H+): 453.2512. Found 453.2514. 
N-Benzyl-2-[(morpholino)methyl]-2-(trifluoromethyl)piperidine (59) 
 
Following the general protocol: 44 (102 mg, 0.37 mmol, 1.0 equiv), proton sponge (160.0 mg, 0.75 
mmol, 2.0 equiv) and triflic anhydride (93 L, 0.56 mmol, 1.5 equiv). Nucleophile = morpholine (82 
L, 0.93 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=5:95) 
to afford 59 (128 mg, 0.37 mmol, quant) as a yellow oil. 
IR (neat): 2953, 2852, 2807, 1454, 1290, 1135, 1109, 1070 cm–1.  
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1H NMR (CDCl3, 400 MHz): δ 7.327.17 (m, 5Η, H13, H14 and H15), 4.24 (d, J = 15.1 Hz, 1H, H11), 
3.673.60 (m, 4H, H9), 3.53 (d, J = 15.1 Hz, 1H, H11), 2.71 (d, J = 14.8 Hz, 1H, H7), 2.66 (d, J = 14.7 Hz, 
1H, H7), 2.61–2.50 (m, 6H, H2 and H8), 2.04 (m, 1H, H5), 1.89 (m, 1H, H5), 1.591.42 (m, 4H, H3 and H4). 
13C NMR (CDCl3, 100 MHz): δ 140.4 (C, C12), 129.4 (C, q, J = 298.7 Hz, C10), 128.3 (2xCH, C13 or C14), 
127.5 (2xCH, C13 or C14), 126.7 (CH, C15), 67.3 (2xCH2, C9), 63.0 (C, q, J = 19.5 Hz, C6), 60.5 (CH2, C7), 
55.9 (2xCH2, C8), 54.2 (CH2, C11), 47.1 (CH2, C2), 29.5 (CH2, C5), 25.3 (CH2, C3), 20.1 (CH2, C4).  
MS m/z (relative intensity): 342 (M+•, 0.02), 242 (12), 100 (100), 91 (78), 65 (8), 56 (8). 
HRMS: calcd for C18H26F3N2O (M+H+): 343.1992. Found 343.1988. 
N-Benzyl-2-methoxymethyl-2-(trifluoromethyl)piperidine (60) 
 
Following the general protocol: 44 (78 mg, 0.29 mmol, 1.0 equiv), proton sponge (122.3 mg, 0.57 
mmol, 2.0 equiv) and triflic anhydride (71 L, 0.43 mmol, 1.5 equiv). Nucleophile = methanol (29 L, 
0.71 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=2:98) to 
afford 60 (76 mg, 0.26 mmol, 93%) as a colorless oil. 
IR (neat): 2929, 2853, 1453, 1243, 1163, 1120, 1082, 1028, 955 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.297.15 (m, 5H, H12, H13 and H14), 4.12 (d, J = 14.7 Hz, 1H, H10), 3.59 (d, 
J = 9.8 Hz, 1H, H7), 3.48 (d, J = 9.9 Hz, 1H, H7), 3.48 (d, J = 14.4 Hz, 1H, H10), 3.29 (s, 3H, H8), 2.60 (m, 
1H, H2), 2.50 (m, 1H, H2), 2.91 (dtdapp, J = 14.1, 4.3 and 1.1 Hz, 1H, H5), 1.77 (m, 1H, H5), 1.571.35 (m, 
4H, H3 and H4). 
13C NMR (CDCl3, 100 MHz): δ 141.0 (C, C11), 129.0 (C, q, J = 298.1 Hz, C9), 128.3 (2xCH, C12 or C13), 
128.1 (2xCH, C12 or C13), 126.8 (CH, C14), 74.0 (CH2, C7), 62.3 (C, q, J = 21.0 Hz, C6), 59.7 (CH3, C8), 54.7 
(CH2, C10), 46.7 (CH2, C2), 28.8 (CH2, C5), 25.2 (CH2, C4), 20.0 (CH2, C3). 
MS m/z (relative intensity): 287 (M+•, 0.17), 252 (18), 91 (100), 65 (9). 
HRMS: calcd for C15H21F3NO (M+H+): 288.1570. Found 288.1572. 
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N -Benzyl-2-ethoxymethyl-2-(trifluoromethyl)piperidine (61) 
 
Following the general protocol: 44 (102 mg, 0.37 mmol, 1.0 equiv), proton sponge (160.0 mg, 0.75 
mmol, 2.0 equiv) and triflic anhydride (93 L, 0.56 mmol, 1.5 equiv). Nucleophile = ethanol (54 L, 
0.93 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=2:98) to 
afford 61 (107 mg, 0.36 mmol, 95%) as a yellow oil. 
IR (neat): 2936, 2876, 1453, 1370, 1165, 1121, 1029 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.387.20 (m, 5Η, H13, H14 and H15), 4.20 (d, J = 14.8 Hz, 1H, H11), 3.69 (d, 
J = 9.9 Hz, 1H, H7), 3.57 (d, J = 9.8 Hz, 1H, H7), 3.583.45 (m, 3H, H8 and H11), 2.67 (m, 1H, H2), 2.57 (m, 
1H, H2), 1.98 (dt, J = 14.1 and 4.3 Hz, 1H, H5), 1.86 (m, 1H, H5), 1.631.59 (m, 2H, H4), 1.521.42 (m, 
2H, H3), 1.19 (t , J = 7.0 Hz, 3H, H9). 
13C NMR (CDCl3, 100 MHz): δ 141.1 (C, C12), 129.1 (C, q, J = 298.2 Hz, C10), 128.3 (2xCH, C13 or C14), 
128.1 (2xCH, C13 or C14), 126.7 (CH, C15), 71.6 (CH2, C7), 67.3 (CH2, C8), 62.3 (C, q, J = 20.8 Hz, C6), 54.6 
(CH2, C11), 46.7 (CH2, C2), 28.9 (CH2, C5), 25.3 (CH2, C3), 20.1 (CH2, C4), 15.1 (CH3, C9). 
MS m/z (relative intensity): 301 (M+•, 0.24), 242 (23), 91 (100), 65 (8). 
HRMS: calcd for C16H23F3NO (M+H+): 302.1726. Found 302.1726. 
N -Benzyl-2-[(prop-2-en-1-yloxy)methyl]-2-(trifluoromethyl)piperidine (62) 
 
Following the general protocol: 44 (91.6 mg, 0.34 mmol, 1.0 equiv), proton sponge (143.7 mg, 0.67 
mmol, 2.0 equiv) and triflic anhydride (83 L, 0.50 mmol, 1.5 equiv). Nucleophile = allylic alcohol (57 
L, 0.84 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=1:99) 
to afford 62 (98 mg, 0.31 mmol, 93%) as a yellow oil. 
IR (neat): 2939, 2853, 1452, 1165, 1122, 1092, 993, 926 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.377.20 (m, 5H, H14, H15 and H16), 5.86 (m, 1H, H9), 5.28 (dd, J = 17.2 
and 1.6 Hz, 1H, H10), 5.17 (dd, J = 10.4 and 1.2 Hz, 1H, H10), 4.18 (d, J = 14.8 Hz, 1H, H12), 3.98 (dd, J = 
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5.5 and 1.2 Hz, 2H, H8), 3.69 (d, J = 9.9 Hz, 1H, H7), 3.60 (d, J= 10.0 Hz, 1H, H7), 3.56 (d, J = 15.0 Hz, 1H, 
H12), 2.67 (m, 1H, H2), 2.57 (m, 1H, H2), 2.00 (dt, J = 14.0 and 4.2 Hz, 1H, H5), 1.87 (m, 1H, H5), 1.631.59 
(m, 2H, H4), 1.541.42 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 141.0 (C, C13), 134.5 (CH, C9), 129.0 (C, q, J = 298.0 Hz, C11), 128.3 (2xCH, 
C14 or C15), 128.1 (2xCH, C14 or C15), 127.5 (CH, C16), 117.3 (CH2, C10), 72.7 (CH2, C8), 71.2 (CH2, C7), 62.4 
(C, q, J = 20.9 Hz, C6), 54.7 (CH2, C12), 46.7 (CH2, C2), 28.9 (CH2, C5), 25.2 (CH2, C3), 20.0 (CH2, C4). 
MS m/z (relative intensity): 313 (M+•, 0.6), 242 (28), 91 (100), 65 (7). 
HRMS: calcd for C17H23F3NO (M+H+): 314.1726. Found 314.1725. 
N -Benzyl-2-[(benzyloxy)methyl]-2-(trifluoromethyl)piperidine (63) 
 
Following the general protocol: 44 (89.7 mg, 0.33 mmol, 1.0 equiv), proton sponge (140.7 mg, 0.66 
mmol, 2.0 equiv) and triflic anhydride (82 L, 0.49 mmol, 1.5 equiv). Nucleophile = benzyl alcohol (85 
L, 0.82 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=1:99) 
to afford 63 (98 mg, 0.27 mmol, 82%) as a colorless oil. 
IR (neat): 2938, 2854, 1453, 1366, 1121, 1094, 1028 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.357.18 (m, 10Η, Har), 4.52 (s, 2H, H8), 4.17 (d, J = 14.8 Hz, 1H, H14), 
3.71 (d, J = 9.7 Hz, 1H, H7), 3.63 (d, J = 9.8 Hz, 1H, H7), 3.57 (d, J = 14.8 Hz, 1H, H14), 2.67 (m, 1H, H2), 
2.56 (m, 1H, H2), 2.01 (dt, J = 13.4 and 4.1 Hz, 1H, H5), 1.90 (m, 1H, H5), 1.621.58 (m, 2H, H4), 
1.531.42 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 140.9 (C, C9 or C15), 138.0 (C, C9 or C15), 129.0 (C, q, J = 298.3 Hz, C13), 
128.5 (2xCH, Car), 128.3 (2xCH, Car), 128.1 (2xCH, Car), 127.7 (CH, C12 or C18), 127.6 (2xCH, Car), 126.8 
(CH, C12 or C18), 73.8 (CH2, C8), 71.4 (CH2, C7), 62.4 (C, q, J = 21.0 Hz, C6), 54.7 (CH2, C14), 46.7 (CH2, C2), 
28.9 (CH2, C5), 25.2 (CH2, C3), 20.0 (CH2, C4). 
MS m/z (relative intensity): 363 (M+•, 0.3), 242 (35), 91 (100), 65 (9). 
HRMS: calcd for C21H25F3NO (M+H+): 364.1883. Found 364.1881. 
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N-Benzyl-2-[(hydroxy)methyl]-2-(trifluoromethyl)piperidine (64) 
 
Following the general protocol: 44 (68.7 mg, 0.25 mmol, 1.0 equiv), proton sponge (107.7 mg, 0.50 
mmol, 2.0 equiv) and triflic anhydride (63 L, 0.38 mmol, 1.5 equiv). Nucleophile = H2O (11 L, 0.63 
mmol, 2.5 equiv). The crude mixture was purified by flash chromatography (EtOAc/PE=5:95) to afford 
64 (64 mg, 0.23 mmol, 93%) as a yellow oil. 
IR (neat): 3448, 3030, 2948, 2853, 1453, 1138, 1116, 1082 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.357.24 (m, 5Η, H11, H12 and H13), 4.27 (d, J = 14.5 Hz, 1H, H9), 3.98 (d, 
J = 10.9 Hz, 1H, H7), 3.453.37 (m, 2H, H7 and H9), 2.79 (m, 1H, H2), 2.68 ( m, 2H, H2 and OH), 2.011.96 
(m, 2H, H5), 1.641.59 (m, 3H, H3 and H4), 1.42 (m, 1H, H3). 
13C NMR (CDCl3, 100 MHz): δ 139.2 (C, C10), 128.8 (2xCH, C11 or C12), 128.7 (C, q, J = 297.0 Hz, C8), 
128.1 (2xCH, C11 or C12), 127.3 (CH, C13), 63.2 (C, q, J = 21.2 Hz, C6), 60.9 (CH2, C7), 53.9 (CH2, C9), 46.5 
(CH2, C2), 28.1 (CH2, C5), 25.2 (CH2, C3), 20.2 (CH2, C4). 
MS m/z (relative intensity): 273 (M+•, 0.1), 242 (19), 91 (100), 65 (6). 
HRMS: calcd for C14H19F3NO (M+H+): 274.1413. Found 274.1416. 
N -Benzyl-2-(phenoxymethyl)-2-(trifluoromethyl)piperidine (65) 
 
Following the general protocol: 44 (68.1 mg, 0.25 mmol, 1.0 equiv), proton sponge (107 mg, 0.50 
mmol, 2.0 equiv) and triflic anhydride (62 L, 0.37 mmol, 1.5 equiv). Nucleophile = sodium phenoxy 
trihydrate (106 mg, 0.62 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography 
(EtO2/PE=1:99) to afford 65 (87 mg, 0.25 mmol, quant) as a colorless oil. 
IR (neat): 3030, 2943, 2852, 1601, 1497, 1236, 1122 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.397.20 (m, 7Η, Har), 6.976.91 (m, 3Η, H9 and H11), 4.21 (d, J = 9.3 Hz, 
1H, H7), 4.18 (d, J = 13.3 Hz, 1H, H13), 4.12 (d, J = 9.7 Hz, 1H, H7), 3.64 (ddapp, J = 14.7 and 1.2 Hz, 1H, 
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H13), 2.73 (m, 1H, H2), 2.64 (m, 1H, H2), 2.11 (dt, J = 14.1 and 4.0 Hz, 1H, H5), 2.00 (m, 1H, H5), 1.691.65 
(m, 2H, H4), 1.581.47 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 158.7 (C, C8), 140.6 (C, C14), 129.6 (2xCH, Car), 128.8 (C, q, J = 297.9 Hz, 
C12), 128.4 (2xCH, Car), 128.1 (2xCH, Car), 126.9 (CH, C17), 121.4 (CH, C11), 114.9 (2xCH, C9), 68.6 (CH2, 
C7), 62.4 (C, q, J = 21.3 Hz, C6), 54.7 (CH2, C13), 46.7 (CH2, C2), 28.9 (CH2, C5), 25.2 (CH2, C3), 20.0 (CH2, 
C4). 
MS m/z (relative intensity): 349 (M+•, 0.16), 242 (29), 91 (100), 77 (5), 65 (6). 
HRMS: calcd for C20H23F3NO (M+H+): 350.1726. Found 350.1723. 
N-Benzyl-2[(acetyl)methyl]-2-(trifluoromethyl)piperidine (66) 
 
Following the general protocol: 46 (84.8 mg, 0.31 mmol, 1.0 equiv), proton sponge (133 mg, 0.62 
mmol, 2.0 equiv) and triflic anhydride (77 L, 0.47 mmol, 1.5 equiv). Nucleophile = 
tetrabutylammonium acetate (234 mg, 0.78 mmol, 2.5 equiv). The crude mixture was purified by flash 
chromatography (EtOAc/PE=2:98) to afford 66 (98 mg, 0.31 mmol, quant) as a colorless oil. 
IR (neat): 2944, 2853, 1748, 1453, 1337, 1225, 1122, 1046 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.337.21 (m, 5H, H13, H14 and H15), 4.41 (d, J = 11.8 Hz, 1H, H7), 4.30 (d, 
J = 11.8 Hz, 1H, H7), 4.11 (d, J = 14.9 Hz, 1H, H11), 3.62 (d, J = 14.9 Hz, 1H, H11), 2.69 (m, 1H, H2), 2.60 
(m, 1H, H2), 2.07 (s, 3H, H9), 2.02 (dt, J = 13.8 and 4.4 Hz, 1H, H5), 1.80 (m, 1H, H5), 1.641.48 (m, 4H, 
H3 and H4). 
13C NMR (CDCl3, 100 MHz): δ 170.6 (C, C8), 140.2 (C, C12), 128.3 (2xCH, C13 or C14), 127.7 (2xCH, C13 or 
C14), 128.5 (C, q, J = 297.7 Hz, C10), 126.9 (CH, C15), 63.8 (CH2, C7), 61.7 (C, q, J = 21.6 Hz, C6), 54.4 (CH2, 
C11), 46.6 (CH2, C2), 28.7 (CH2, C5), 25.1 (CH2, C3), 20.9 (CH3, C9), 19.8 (CH2, C4).  
MS m/z (relative intensity): 315 (M+•, 0.5), 242 (20), 91 (100), 65 (7). 
HRMS: calcd for C16H21F3NO2 (M+H+): 316.1519. Found 316.1515. 
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N-Benzyl-2-[(ethylsulfanyl)methyl]-2-(trifluoromethyl)piperidine (67) 
 
 
Following the general protocol: 44 (88 mg, 0.32 mmol, 1.0 equiv), proton sponge (138. mg, 0.64 mmol, 
2.0 equiv) and triflic anhydride (80 L, 0.48 mmol, 1.5 equiv). Nucleophile = sodium ethanethiolate 
(75.2 mg, 0.81 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography 
(EtOAc/PE=1:99 and 2:98) to afford 67 (94 mg, 0.30 mmol, 92%) as a colorless oil. 
IR (neat): 2932, 2852, 1453, 1233, 1140, 1114 cm–1.  
1H NMR (CDCl3, 400 MHz): δ 7.387.12 (m, 5Η, H13, H14 and H15), 4.15 (d, J = 14.2 Hz, 1H, H11), 3.36 
(ddapp, J = 14.1 and 2.6 Hz, 1H, H11), 3.30 (d, J = 12.7 Hz, 1H, H7), 2.492.39 (m, 5H, H2, H7 and H8), 2.20 
(m, 1H, H5), 1.80 (dt, J = 14.2 and 4.0 Hz, 1H, H5), 1.581.54 (m, 2H, H4), 1.45–1.34 (m, 2H, H3), 1.16 
(tdapp, J = 7.3 and 0.7 Hz, 3H, H9). 
13C NMR (CDCl3, 100 MHz): δ 140.1 (C, C12), 129.2 (C, q, J = 300.2 Hz, C10), 128.4 (2xCH, C13 or C14), 
128.3 (2xCH, C13 or C14), 126.8 (CH, C15), 62.3 (C, q, J = 20.6 Hz, C6), 54.2 (CH2, C11), 45.9 (CH2, C2), 36.8 
(CH2, C7), 29.6 (CH2, C5), 27.4 (CH2, C8), 25.1 (CH2, C3), 20.4 (CH2, C4), 14.9 (CH3, C9).  
MS m/z (relative intensity): 317 (M+•, 0.02), 242 (19), 91 (100), 65 (7). 
HRMS: calcd for C16H23F3NS (M+H+): 318.1498. Found 318.1496. 
N-Benzyl-2-[(phenylsulfanyl)methyl]-2-(trifluoromethyl)piperidine (68) 
 
Following the general protocol: 44 (79.5 mg, 0.29 mmol, 1.0 equiv), proton sponge (125 mg, 0.58 
mmol, 2.0 equiv) and triflic anhydride (72 L, 0.44 mmol, 1.5 equiv). Nucleophile = sodium 
thiophenolate (127 mg, 0.73 mmol, 2.5 equiv). The crude mixture was purified by flash 
chromatography (PE=100%) to afford 68 (90 mg, 0.25 mmol, 85%) as a colorless oil. 
IR (neat): 3061, 2945, 2851, 1584, 1453, 1139, 1114 cm–1.  
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1H NMR (CDCl3, 400 MHz): δ 7.507.14 (m, 10Η, Har), 4.31 (d, J = 14.2 Hz, 1H, H13), 3.79 (ddapp, J = 12.3 
and 2.3 Hz, 1H, H7), 3.49 (ddapp, J = 14.2 and 2.5 Hz, 1H, H13), 2.94 (d, J = 12.3 Hz, 1H, H7), 2.672.53 
(m, 2H, H2), 2.38 (m, 1H, H5), 1.95 (dapp, J = 14.2 Hz, 1H, H5), 1.651.48 (m, 4H, H3 and H4). 
13C NMR (CDCl3, 100 MHz): δ 139.8 (C, C8 or C14), 137.3 (C, C8 or C14), 129.6 (2xCH, Car), 129.1 (2xCH, 
Car), 129.1 (C, q, J = 300.2 Hz, C12), 128.5 (2xCH, Car), 128.3 (2xCH, Car), 126.9 (CH, C11 or C17), 126.3 (CH, 
C11 or C17), 62.4 (C, q, J = 20.9 Hz, C6), 54.3 (CH2, C13), 46.0 (CH2, C2), 39.2 (CH2, C7), 29.8 (CH2, C5), 25.1 
(CH2, C3), 20.5 (CH2, C4).  
MS m/z (relative intensity): 365 (M+•, 0.04), 242 (31), 123 (2), 91 (100), 65 (7). 
HRMS: calcd for C20H23F3N2S (M+H+): 366.1498. Found 366.1497. 
N-Benzyl-2-fluoromethyl-2-(trifluoromethyl)piperidine (69) 
 
1) Following the general protocol: 44 (80.1 mg, 0.29 mmol, 1.0 equiv), proton sponge (126 mg, 0.59 
mmol, 2.0 equiv) and triflic anhydride (73 L, 0.44 mmol, 1.5 equiv). Nucleophile = 
tetrabutylammonum fluoride (1.0 M in THF, 0.73 mL , 0.73 mmol, 2.5 equiv). The crude mixture was 
purified by flash chromatography (Pentane=100%) to afford 69 (49 mg, 0.18 mmol, 61%) as colorless 
oil. 
2) To a stirred solution of N-benzyl-3-hydroxy-3-(trifluoromethyl)azepane 44 (152 mg, 0.55 mmol, 1.0 
equiv) in THF (6 mL) at 0 °C was added DAST (95 L, 0.78 mmol, 1.4 equiv). The resulting mixture was 
stirred at 0 °C for 1 h and at rt for 3 h. The reaction mixture was quenched with a saturated aqueous 
solution of Na2CO3, extracted with EtOAc and the combined extracts were dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure. The crude mixture was purified by flash 
chromatography (PE=100%) to afford 69 (109 mg, 0.40 mmol, 71%) as a colorless oil. 
IR (neat): 2949, 2854, 1453, 1166, 1145, 1223 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.347.23 (m, 5Η, H11, H12 and H13), 4.60 (d, J = 47.2 Hz, 2H, H7), 4.16 (d, 
J = 14.9 Hz, 1H, H9), 3.63 (dapp, J = 14.9 and 1.5 Hz, 1H, H9), 2.672.57 (m, 2H, H2), 2.04 (m, 1H, H5), 
1.751.43 (m, 5H, H3, H4 and H5). 
13C NMR (CDCl3, 100 MHz): δ 140.3 (C, C10), 128.5 (2xCH, C11 or C12), 128.4 (C, qd, J = 297.6 and 1.7 
Hz, C8), 127.9 (2xCH, C11 or C12), 127.0 (CH, C13), 84.3 (CH2, dq, J = 181.4 and 2.2 Hz, C7), 61.9 (C, dq, J 
= 21.7 and 17.0 Hz, C6), 55.0 (CH2, C9), 46.7 (CH2, C2), 28.0 (CH2, C5), 25.1 (CH2, C3), 19.7 (CH2, C4). 
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MS m/z (relative intensity): 275 (M+•, 3.7), 242 (9), 206 (15), 91 (100), 65 (8), 55 (3). 
HRMS: calcd for C14H18F4N (M+H+): 276.1370. Found 276.1371. 
N-Benzyl-2-chloromethyl-2-(trifluoromethyl)piperidine (70) 
 
Following the general protocol: 44 (80.5 mg, 0.29 mmol, 1.0 equiv), proton sponge (129 mg, 0.59 
mmol, 2.0 equiv) and triflic anhydride (73 L, 0.44 mmol, 1.5 equiv). Nucleophile = 
tetrabutylammonium chloride (215.4 mg, 0.74 mmol, 2.5 equiv). The crude mixture was purified by 
flash chromatography (PE=100%) to afford 70 (59 mg, 0.20 mmol, 69%) as colorless oil. 
IR (neat): 2947, 2853, 1453, 1142, 1117 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.427.22 (m, 5Η, H11, H12 and H13), 4.09 (d, J = 14.4 Hz, 1H, H9), 3.95 (d, 
J = 12.1 Hz, 1H, H7), 3.61 (d, J = 12.1 Hz, 1H, H7), 3.52 (dq, J = 14.5 and 2.2 Hz, 1H, H9), 2.662.61 (m, 
2H, H2), 2.07 (m, 1H, H5), 1.93 (dtdapp, J = 14.2, 4.1 and 1.4 Hz, 1H, H5), 1.691.61 (m, 2H, H4), 1.581.45 
(m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 139.8 (C, C10), 128.6 (C, q, J = 299.5 Hz, C8), 128.4 (2xCH, C11 or C12), 128.3 
(2xCH, C11 or C12), 127.0 (CH, C13), 62.9 (C, q, J = 21.2 Hz, C6), 54.0 (CH2, C9), 46.2 (CH2, C2), 45.0 (CH2, 
C7), 28.6 (CH2, C5), 25.0 (CH2, C3), 20.0 (CH2, C4). 
MS m/z (relative intensity): 293 (M+•, 0.4), 291(M+•, 1.3), 242 (19), 222 (10), 208 (7), 91 (100), 65 
(10). 
HRMS: calcd for C14H18ClF3N (M+H+): 292.1074 and 294.1043. Found 292.1076 and 294.1045. 
N-Benzyl-2-bromomethyl-2-(trifluoromethyl)piperidine (71) 
 
Following the general protocol: 44 (251 mg, 0.92 mmol, 1.0 equiv), proton sponge (393.6 mg, 1.84 
mmol, 2.0 equiv) and triflic anhydride (229 L, 1.38 mmol, 1.5 equiv). Nucleophile = 
tetrabutylammonium bromide (740.2 mg, 2.30 mmol, 2.5 equiv). The crude mixture was purified by 
flash chromatography (PE=100%) to afford 71 (250 mg, 0.74 mmol, 81%) as colorless oil. 
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IR (neat): 2946, 2853, 1453, 1141, 1070 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.457.23 (m, 5Η, H11, H12 and H13), 4.07 (d, J = 14.4 Hz, 1H, H9), 3.85 (d, 
J = 11.5 Hz, 1H, H7), 3.52 (m, 1H, H9), 3.48 (d, J = 11.5 Hz, 1H, H7), 2.652.62 (m, 2H, H2), 2.09 (m, 1H, 
H5), 1.92 (dtdapp, J = 14.1, 4.1 and 1.3 Hz, 1H, H5), 1.691.62 (m, 2H, H4), 1.581.47 (m, 2H, H3). 
13C NMR (CDCl3, 100 MHz): δ 139.6 (C, C10), 128.4 (2xCH, C11 or C12), 128.3 (2xCH, C11 or C12), 127.8 (C, 
q, J = 299.8 Hz, C8), 127.0 (CH, C13), 62.2 (C, q, J = 21.1 Hz, C6), 54.0 (CH2, C9), 46.1 (CH2, C2), 34.2 (CH2, 
C7), 29.7 (CH2, C5), 25.0 (CH2, C3), 20.0 (CH2, C4). 
MS m/z (relative intensity): 337 (M+•, 0.7), 335 (M+•, 0.7), 268 (8), 266 (8), 242 (12), 91 (100), 65 (8). 
HRMS: calcd for C14H18BrF3N (M+H+): 336.0569 and 338.0549. Found 336.0572 and 338.0546. 
N-Benzyl-2-iodomethyl-2-(trifluoromethyl)piperidine (72) 
 
Following the general protocol: 44 (107.6 mg, 0.39 mmol, 1.0 equiv), proton sponge (168.8 mg, 0.79 
mmol, 2.0 equiv) and triflic anhydride (98 L, 0.59 mmol, 1.5 equiv). Nucleophile = 
tetrabutylammonium iodide (363.6 mg, 0.98 mmol, 2.5 equiv). The crude mixture was purified by 
flash chromatography (PE=100%) to afford 72 (135 mg, 0.35 mmol, 89%) as colorless oil. 
IR (neat): 2944, 2853, 1450, 1139, 1112, 1064 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.497.20 (m, 5Η, H11, H12 and H13), 4.02 (d, J = 14.3 Hz, 1H, H9), 3.72 (d, 
J = 11.4 Hz, 1H, H7), 3.47 (dq, J = 14.3 and 2.5 Hz, 1H, H9), 3.33 (d, J = 11.4 Hz, 1H, H7), 2.632.58 (m, 
2H, H2), 2.00 (m, 1H, H5), 1.89 (dtdapp, J = 14.2, 3.8 and 0.9 Hz, 1H, H5), 1.701.46 (m, 4H, H3 and H4). 
13C NMR (CDCl3, 100 MHz): δ 139.2 (C, C10), 128.5 (2xCH, C11 or C12), 128.3 (2xCH, C11 or C12), 127.0 
(CH, C13), 125.7 (C, q, J = 300.6 Hz, C8), 61.1 (C, q, J = 20.9 Hz, C6), 53.9 (CH2, C9), 46.0 (CH2, C2), 31.9 
(CH2, C5), 25.0 (CH2, C3), 20.1 (CH2, C4), 10.3 (CH2, C7). 
MS m/z (relative intensity): 383(M+•, 1.9), 314 (28), 256 (3), 242 (19), 187 (10), 186 (11), 91 (100), 65 
(14). 
HRMS: calcd for C14H18F3IN (M+H+): 384.0431. Found 384.0439.  
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N-Benzyl-2-cyanomethyl-2-(trifluoromethyl)piperidine (73) 
 
Following the general protocol: 44 (94 mg, 0.34 mmol, 1.0 equiv), proton sponge (147.4 mg, 0.69 
mmol, 2.0 equiv) and triflic anhydride (86 L, 0.52 mmol, 1.5 equiv). Nucleophile = 
tetrabutylammonium cyanide (231 mg, 0.86 mmol, 2.5 equiv). The crude mixture was purified by 
flash chromatography (EtOAc/PE=5:95) to afford 73 (92 mg, 0.32 mmol, 94%) as a yellow oil. 
IR (neat): 2951, 2853, 1453, 1240, 1142, 1117 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.447.22 (m, 5Η, H12, H13 and H14), 4.12 (d, J = 14.4 Hz, 1H, H10), 3.50 
(dq, J = 14.4 and 2.2 Hz, 1H, H10), 3.06 (d, J = 17.2 Hz, 1H, H7), 2.64 (d, J = 17.2 Hz, 1H, H7), 2.672.56 
(m, 2H, H2), 2.11 (dtdapp, J = 14.1, 3.8 and 1.4 Hz, 1H, H5), 2.00 (m, 1H, H5), 1.691.51 (m, 4H, H3 and 
H4). 
13C NMR (CDCl3, 100 MHz): δ 138.9 (C, C11), 128.6 (2xCH, C12 or C13), 128.2 (2xCH, C12 or C13), 128.0 (C, 
q, J = 298.7 Hz, C9), 127.3 (CH, C14), 116.0 (C, C8), 60.9 (C, q, J = 22.2 Hz, C6), 54.4 (CH2, C10), 46.3 (CH2, 
C2), 31.4 (CH2, C5), 24.8 (CH2, C7), 24.4 (CH2, C3), 20.1 (CH2, C4). 
MS m/z (relative intensity): 282 (M+•, 1.6), 242 (14), 213 (7), 91 (100), 65 (10), 54 (3). 
HRMS: calcd for C15H18F3N2 (M+H+): 283.1417. Found 283.1419. 
N-Benzyl-2-[(1,3-dimethyl-propanedioate)methyl]-2-(trifluoromethyl)piperidine (74) 
 
Following the general protocol: 44 (81.3 mg, 0.30 mmol, 1.0 equiv), proton sponge (127.5 mg, 0.60 
mmol, 2.0 equiv) and triflic anhydride (74 L, 0.45 mmol, 1.5 equiv). Nucleophile = sodium 
dimethylmalonate. The crude mixture was purified by flash chromatography (Et2O/PE=10:90) to 
afford 74 (115 mg, 0.30 mmol, quant) as a colorless oil. 
For the sodium dimethylmalonate: To a stirred suspension of NaH (60% wt oil dispersion, 31 mg, 0.77 
mmol, 2.6 equiv) in THF (3 mL) at 15 °C was added dropwise dimethylmalonate (0.12 mL, 1.04 mmol, 
3.5 equiv) and the reaction mixture was stirred at rt for 30 min. 
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IR (neat): 2954, 2852, 1736,1436, 1237, 1140, 1115 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.317.19 (m, 5H, H14, H15 and H16), 4.25 (d, J = 15.2 Hz, 1H, H12), 3.95 
(dd, J = 6.2 and 3.2 Hz, 1H, H8), 3.78 (s, 3H, H10 or H10’), 3.45 (s, 3H, H10 or H10’), 3.44 (dd, J = 15.1 and 
2.4 Hz, 1H, H12), 2.81 (dd, J = 15.5 and 3.2 Hz, 1H, H7), 2.70 (m, 1H, H2), 2.61 (m, 1H, H2), 2.20 (dd, J = 
15.6 Hz and 6.3 Hz, 1H, H7), 1.90 (dd, J = 14.1 Hz and 2.1 Hz, 1H, H5), 1.601.43 (m, 5H, H3, H4 and H5). 
13C NMR (CDCl3, 100 MHz): δ 170.8 (C, C9 or C9’), 169.9 (C, C9 or C9’), 139.6 (C, C13), 129.2 (C, q, J = 
299.6 Hz, C11), 128.4 (2xCH, C14 or C15), 127.3 (2xCH, C14 or C15), 126.6 (CH, C16), 62.1 (C, q, J = 21.0 Hz, 
C6), 53.8 (CH2, C12), 53.0 (CH3, C10 or C10’), 52.8 (CH3, C10 or C10’), 46.5 (CH2, C2), 46.0 (CH, C8), 30.9 (CH2, 
C7), 30.2 (CH2, C5), 25.1 (CH2, C3), 20.2 (CH2, C4). 
MS m/z (relative intensity): 387 (M+•, 1.8), 318 (34), 242 (11), 91 (100), 65 (6), 55 (4). 
HRMS: calcd for C19H25F3NO4 (M+H+): 388.1730. Found 388.1730. 
N-Benzyl-2-ethyl-2-(trifluoromethyl)piperidine (75) 
 
Following the general protocol: 44 (70.8 mg, 0.26 mmol, 1.0 equiv), proton sponge (111 mg, 0.52 
mmol, 2.0 equiv) and triflic anhydride (64 L, 0.39 mmol, 1.5 equiv); the organocuprate was added. 
The crude mixture was purified by flash chromatography (PE=100%) to afford 75 (35 mg, 0.13 mmol, 
50%) as a colorless oil. 
To a stirred solution of coppercarbonitrile (93.7 mg, 1.04 mmol, 4.0 equiv) in THF (9.95 mL) at 78°C 
under Ar atmosphere, was added methylmagnesium chloride (3 M, 0.43 mL, 1.3 mmol, 5.0 equiv) and 
the reaction mixture was stirred at rt for 1h.  
IR (neat): 2945, 2852, 1453,1243, 1132, 1117 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.357.20 (m, 5H, H12, H13 and H14), 4.16 (d, J = 15.2 Hz, 1H, H10), 3.48 
(ddapp, J = 15.2 and 2.4 Hz, 1H, H10), 2.642.59 (m, 2H, H2), 1.96 (dq, J = 15.0 and 7.5 Hz, 1H, H7), 
1.841.45 (m, 7H, H3, H4, H5 and H7), 0.98 (t, J = 7.5 Hz, 3H, H8). 
13C NMR (CDCl3, 100 MHz): δ 140.6 (C, C11), 130.1 (C, q, J = 299.7 Hz, C9), 128.4 (2xCH, C12 or C13), 127.7 
(2xCH, C12 or C13), 126.7 (CH, C14), 61.8 (C, q, J = 20.2 Hz, C6), 53.7 (CH2, C10), 46.3 (CH2, C2), 29.0 (CH2, 
C5), 25.5 (CH2, C3 or C7), 25.3 (CH2, C3 or C7), 20.5 (CH2, C4), 7.3 (CH3, C8). 
MS m/z (relative intensity): 272 (M+•, 1.2), 242 (6), 202 (23), 91 (100), 65 (8), 55 (3). 
HRMS: calcd for C15H21F3N (M+H+): 272.1620. Found 272.1622. 
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N-Benzyl-2-methyl-2-(trifluoromethyl)piperidine (76) 
 
Following the general protocol: 44 (153 mg, 0.56 mmol, 1.0 equiv), proton sponge (240 mg, 1.12 
mmol, 2.0 equiv) and triflic anhydride (139 L, 0.84 mmol, 1.5 equiv). Nucleophile = sodium 
borohydride (53 mg, 1.4 mmol, 2.5 equiv). The crude mixture was purified by flash chromatography 
(PE=100%) to afford 76 (105 mg, 0.41 mmol, 73%) as a colorless oil. 
IR (neat): 2942, 2852, 1454, 1382, 1310, 1251, 1160, 1136, 1121, 1088, 957 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.347.19 (m, 5H, H11, H12 and H13), 4.06 (d, J = 14.8 Hz, 1H, H9), 3.54 (dd, 
J = 14.8 and 1.5 Hz, 1H, H9), 2.65 (m, 1H, H2), 2.49 (m, 1H, H2), 1.99 (m, 1H, H5), 1.621.42 (m, 5H, H3, 
H4, and H5 ), 1.34 (d, J = 0.8 Hz, 3H, H7). 
13C NMR (CDCl3, 100 MHz): δ 141.1 (C, C10), 129.6 (C, q, J = 296.5 Hz, C8), 128.4 (2xCH, C11 or C12), 127.9 
(2xCH, C11 or C12), 126.8 (CH, C13), 59.3 (C, q, J = 21.8 Hz, C6), 54.4 (CH2, C9), 46.6 (CH2, C2), 34.0 (CH2, 
C5), 25.7 (CH2, C3), 20.9 (CH2, C4), 20.6 (CH3, C7). 
MS m/z (relative intensity): 257 (M+•, 5.9), 189 (10), 188 (70), 91 (100), 65 (14), 55 (6). 
HRMS: calcd for C14H19F3N (M+H+): 258.1464. Found 258.1462.  
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8. Synthesis and spectroscopic data of 
N-benzyl-3-hydroxy-3-methylazepane (77) 
tert-Butyl 3-hydroxy-3-methylazepane-1-carboxylate (81) 
 
To a stirred solution of tert-butyl 3-oxoazepane-1-carboxylate 51 (303 mg, 1.42 mmol, 1.0 equiv) in 
THF (7.1 mL) at 0 °C was added MeMgBr (3.0 M in Et2O, 1.89 mL, 5.68 mmol, 4.0 equiv) and the 
resulting mixture was stirred at rt for 16 h. The solution was quenched with an aqueous and saturated 
solution of NH4Cl and extracted with EtOAc. The organic layers were then dried over anhydrous 
MgSO4, filtered and concentrated under reduced pressure. The crude mixture was purified by flash 
chromatography (Et2O/PE=30:70) to afford 81 (234 mg, 1.01 mmol, 72%) as a yellow oil. 
IR (neat): 3445, 2973, 2929, 1664, 1479, 1416, 1366, 1282, 1159, 1118, 869 cm–1. 
 1H NMR (CDCl3, 400 MHz): δ 4.11 (br s, OH), 3.923.84 (m, 2H, H2 and H7), 2.872.79 (m, 2H, H2 and 
H7), 1.731.68 (m, 2H, H3 or H4), 1.641.62 (m, 2H, H5), 1.48 (s, 9H, H11), 1.431.26 (m, 2H, H3 or H4), 
1.18 (s, 3H, H8). 
13C NMR (CDCl3, 400 MHz): δ 158.2 (C, C9), 80.3 (C, C10), 74.5 (C, C6), 58.6 (CH2, C7), 49.6 (CH2, C2), 42.3 
(CH2, C5), 29.4 (CH2, C3 or C4), 28.5 (3xCH3, C11), 27.5 (CH3, C8), 21.9 (CH2, C3 or C4).  
MS m/z (relative intensity): 229 (M+•, 1.5), 173 (9), 156 (8), 114 (7), 99 (18), 88 (10), 86 (22), 70 (7), 
59 (15), 57 (100). 
HRMS: calcd for C12H23NO3Na (M+Na+): 252.1570. Found 252.1572.  
N-Benzyl-3-hydroxy-3-methylazepane (77) 
 
To a stirred solution of tert-butyl 3-hydroxy-3-methylazepane-1-carboxylate 81 (224 mg, 0.98 mmol, 
1.0 equiv) in CH2Cl2 (5.4 mL) at rt was added TFA (0.51 mL, 6.84 mmol, 7.0 equiv). The reaction mixture 
was stirred at rt for 18 h and then concentrated under reduced pressure. 
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To a stirred solution of the crude material previously obtained in MeCN (10 mL) at rt were added 
successively BnBr (0.12 mL, 0.98 mmol, 1.0 equiv), K2CO3 (675 mg, 4.88 mmol, 5.0 equiv) and TBAI 
(180 mg, 0.49 mmol, 0.5 equiv). The reaction mixture was heated at 75 °C for 4 h and then allowed 
to cool to rt. The reaction mixture was quenched with H2O and extracted with CH2Cl2 (twice). The 
organic layer was dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. 
The crude mixture was purified by flash chromatography (Et2O/PE=40:60) to afford 77 (212 mg, 0.97 
mmol, quant) as a colorless oil. 
IR (neat): 3421, 3028, 2925, 2860, 1495, 1452, 1391, 1369, 1300, 1200, 1127, 1109, 1074, 969 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.367.26 (m, 5Η, H11, H12 and H13), 3.76 (d, J = 13.0 Hz, 1H, H9), 3.69 (d, 
J = 13.0 Hz, 1H, H9), 2.752.67 (m, 2H, H2 and H7), 2.492.41 (m, 2H, H2 and H7), 1.81 (m,1H, H3), 1.70 
(m, 1H, H5), 1.49 (m, 3H, H3 and H4), 1.29 (m, 1H, H5), 1.12 (s, 3H, H8). 
13C NMR (CDCl3, 100 MHz): δ 139.1 (C, C10), 129.1 (2xCH, C11 or C12), 128.5 (2xCH, C11 or C12), 127.4 
(CH, C13), 69.9 (C, C6), 64.5 (CH2, C9), 63.2 (CH2, C7), 53.9 (CH2, C2), 43.9 (CH2, C5), 28.2 (CH2, C3), 27.7 
(CH3, C8), 21.0 (CH2, C4). 
MS m/z (relative intensity): 219 (M+•, 7), 176 (7), 160 (11), 146 (2), 134 (69), 129 (11), 120 (10), 99 
(7), 91 (100), 70 (7), 65 (12), 55 (11). 
HRMS: calcd for C14H22NO (M+H+): 220.1696. Found 220.1698.  
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9. Synthesis and spectroscopic data of N-benzyl-3-fluoro-3-
methylpiperidine (83) 
N-Benzyl-2-fluoro-2-methylazepane (83) 
 
Following the general protocol: N-benzyl-3-hydroxy-3-methylazepane 77 (85 mg, 0.39 mmol, 1.0 
equiv), proton sponge (166 mg, 0.78 mmol, 2.0 equiv) and triflic anhydride (96 L, 0.59 mmol, 1.5 
equiv). Nucleophile = tetrabutylammonium fluoride (1.0 M in THF, 0.97 mL, 0.97 mmol, 2.5 equiv). 
The crude mixture was purified by flash chromatography (EtOAc/PE=5:95 and 10:90) to afford 83 (27 
mg, 0.12 mmol, 31%) as a yellow oil. 
IR (neat): 2931, 2862, 1494, 1375, 1350, 1263, 1228, 1188, 1117, 1042, 1029, 965, 910 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.357.21 (m, 5H, H11, H12 and H13), 3.71 (d, J = 13.5 Hz, 1H, H9), 3.66 (d, 
J = 13.5 Hz, 1H, H9), 2.87 (m, 1H, H7), 2.732.59 (m, 3H, H2 and H7), 1.98 (m, 1H, H5), 1.861.64 (m, 3H, 
H3, H4, and H5 ), 1.58 (m, 1H, H3), 1.42 (m, 1H, H4), 1.25 (d, J = 21.7 Hz, 3H, H8). 
13C NMR (CDCl3, 100 MHz): δ 139.9 (C, C10), 129.0 (2xCH, C11 or C12), 128.3 (2xCH, C11 or C12), 127.1 
(CH, C13), 98.3 (C, d, J = 166.4 Hz, C6), 65.4 (CH2, d, J = 28.9 Hz, C7), 63.9 (CH2, C9), 57.5 (CH2, C2), 40.0 
(CH2, d, J = 23.4 Hz, C5), 30.8 (CH2, C3), 26.6 (CH3, d, J = 25.0 Hz, C8), 21.8 (CH2, d, J = 6.0 Hz, C4). 
MS m/z (relative intensity): 221 (M+•, 28), 220 (11), 174 (8), 160 (33), 146 (11), 144 (11), 135 (18), 
130 (25), 91 (100), 84 (15), 70 (10), 65 (16), 55 (9). 
HRMS: calcd for C14H21FN (M+H+): 222.1653. Found 222.1653. 
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1. Structure, biological activity and synthesis of pyridazines 
1.1. Structure79,80 
Pyridazines (1,2-diazines) are aromatic six-membered heterocycles, containing two sp2 hybridized 
adjacent nitrogen atoms. They belong to the family of diazines along with pyrimidines (1,3-diazines) 
and pyrazines (1,4-diazines). Pyridazines are planar molecules with a slightly distorted hexagonal 
geometry, whose bond lengths are similar to those of benzene (1.39 Å). Although pyridazines are 
aromatic compounds, their resonance energy (100 kJ/mol) is considerably lower than the resonance 
energy of benzene (150 kJ/mol) and pyridine (117 kJ/mol) and thus, their aromaticity is lower (Figure 
26).  
 
Figure 26 
Due to the nitrogen inductive effect, pyridazines are electron-deficient compounds with a partially 
positive charge on the carbon atoms and a partially negative charge on the nitrogen atoms. 
Pyridazines are also molecules of low basicity with a pKa of 2.3, which is lower than the pKa of pyridine 
(pKa=5.2) and are therefore not easily protonated. 
Two resonance structures contribute to the structure of pyridazine. According to calculations, 
structure B contributes more to the resonance hybrid than structure A, as the N-N bond has a 
significant single bond character (Figure 27).  
 
Figure 27 
1.2. Biological activity 
Until now, only nine natural compounds, containing a pyridazine ring, are reported in the literature, 
presenting a variety of biological activities (Figure 28). For example, pyridazomycin, which was the 
first pyridazine-containing natural product, was isolated from Streptomyces violaceoniger in 1988, 
                                                          
79 Cabal, M. -P. Six-Membered Heterocycles: 1,2-, 1,3-, 1,4-Diazines and Related Systems. In Modern 
Heterocyclic Chemistry, Vol. 2; Alvarez-Builla, J.; Vaquero, J. J.; Barluenga, J., Eds.; Wiley-VCH: Weinheim, 2011, 
16831776. 
80 Haider, N.; Holzer, W. In Product Class 8: Pyridazines, Science of Synthesis, 2004, 16, 125249.  
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and has shown antifungal and antibiotic properties81 while liguducimine A, isolated from the plant 
Ligularia duciformis, has antitussive properties.82 In addition, cinnoline 4849F, isolated in 2007, has 
shown some cytotoxic activity towards human breast cancer and ovarian cancer cells83 (Figure 28).  
 
Figure 28 
For a long time, pyridazines have been considered as dangerous heterocycles due to the potential 
toxicity of the hydrazine motif present on the pyridazine ring and, until 1950, only two drugs 
possessing a pyridazine moiety were on the market: hydralazine which is a vasodilator and 
sulfamethoxypyridazine which is an antibacterial agent (Figure 29).84 
 
Figure 29 
However, over the last years, pyridazines have been considered as privileged structures84 and one of 
the “most developable” heteroaromatic rings for drug design according to GlaxoSmithKline 
researchers.85 Therefore, the increasing interest in pyridazine-containing compounds, has led to the 
                                                          
81 Grote, R.; Chen, Y.; Zeeck, A.; Chen, Z.; Zaehner, H.; Mischnick-Luebbecke, P.; Koenig, W. A. J. Antiobiot. 1988, 
41, 595601. 
82 Zhang, C. -F.; Wang, Q.; Zhang, M. J. Asian Nat. Prod. Res. 2009, 11, 339344. 
83 Wang, K.; Guo, L.; Zou, Y.; Li, Y.; Wu, J. J. Antibiot. 2007, 60, 325327. 
84 Wermuth, C. G. Med. Chem. Commun. 2011, 2, 935941. 
85 Ritchie, T. J.; Macdonald, S. J. F.; Peace, S.; Pickett, S. D.; Luscombe, C. N. Med. Chem. Commun. 2012, 3, 
10621069. 
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development of minaprine which is an antidepressant drug, SR 41378, a potent candidate for the 
treatment of seizures, and pyridate which is a herbicide (Figure 30). 
 
Figure 30 
Nowadays, numerous synthetic biologically-active pyridazines, with various therapeutic properties, 
are developed. For example, compound I was found to have an inhibitory activity towards 
picornavirus, a virus that is responsible for several human diseases such as acute hepatitis, 
myocarditis and poliomyelitis.86 Compound II, seems to show an inhibitory activity towards acyl CoA: 
DiacylGlycerol AcylTransferase (DGAT1), an enzyme that catalyzes the formation of triglycerides. 
With the discovery of compound II, it seems that the formation of triglycerides could be modulated, 
offering a treatment for numerous diseases such as type II diabetes and obesity87 (Figure 31). 
 
Figure 31 
Due to the increasing interest in pyridazine derivatives over the last years, as well as an interest in 
introducing fluorine atoms in molecules as mentioned before, the development of 
trifluoromethylated pyridazines has become increasingly popular.  
A first example demonstrating the importance of (trifluoromethyl)pyridazines, is illustrated in Figure 
32. Due to the lack of efficient drugs and/or with low side-effects, a new class of agents e.g. triple 
reuptake inhibitors, has been developed to inhibit serotonin, norepinephrine, and dopamine 
transporters. This inhibition provokes an increase in the extracellular concentration of these 
                                                          
86 Hamdouchi, C.; Sanchez-Martinez, C.; Gruber, J.; Del Prado, M.; Lopez, J.; Rubio, A.; Heinz, B. A. J. Med. Chem. 
2003, 46, 43334341. 
87 Fox, B. M.; Iio K.; Li, K.; Choi, R.; Inaba, T.; Jackson, S.; Sagawa, S.; Shan, B.; Tanaka, M.; Yoshida, A.; Kayser, F. 
Bioorg. Med. Chem. Lett. 2010, 20, 60306033. 
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transporters and therefore an increase in the neurotransmission. Thus, these agents can be used for 
the treatment of depression. For example, BMS-911278, possessing a (trifluoromethyl)pyridazine 
ring, was presented as a potent triple reuptake inhibitor which could possibly treat depression.88  
 
Figure 32 
Another example indicating the importance of (trifluoromethyl)pyridazines is illustrated in Figure 33. 
In an attempt to develop new anti-HIV agents, due to the increasing resistance to already marketed 
drugs, a series of functionalized α-(trifluoromethyl)pyridazinones has been recently synthesized. The 
pyridazinone ring can act as a bioisoster of the pyrimidinone ring of raltegravir, an antiretroviral drug 
that targets integrase, an HIV-enzyme which integrates viral DNA into the host cell genome. Among 
a variety of synthesized pyridazinones, compounds III and IV exhibited high anti-HIV activity, while 
compound V and raltegravir showed a similar in-vitro and in-vivo anti-viral activity against the tobacco 
mosaic virus (TMV).89 
 
Figure 33 
                                                          
88 Molino, B. F.; Liu, S.; Sambandam, A.; Guzzo, P. R.; Hu, M.; Zha, C.; Nacro, K.; Manning, D. D.; Isherwood, M. 
L.; Fleming, K. N.; Cui, W.; Olson, R. E. 2007 (US2007/0021408 A1). 
89 Wang, Z.; Wang, M.; Yao, X.; Li, Y.; Tan, J.; Wang, L.; Qiao, W.; Geng, Y.; Liu, Y.; Wang, Q. Eur. J. Med. Chem. 
2012, 54, 3341. 
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1.3. Main synthetic methods to access pyridazines 
The first pyridazine synthesis was reported in 1886 by Emil Fischer.90 However, it is not until the 
1950’s that the synthesis and reactivity of pyridazines were studied. Nowadays, numerous methods 
exist to access the pyridazine ring. Among them, we can cite: 
 the condensation of hydrazine with 1,4-diketones (route a) 
 a Diels-Alder/retro Diels-Alder reaction between tetrazines and alkynes (route b) 
 a [1,3]-dipolar cycloaddition between a cyclopropene and a diazo compound (route c) 
 the ring-contraction of diazepines (route d) (Scheme 59). 
 
Scheme 59 
As our goal was to access pyridazines possessing a CF3 group to the α position of one of the two 
nitrogens, we will focus only on the synthetic methods developed to obtain 
α-(trifluoromethyl)pyridazines as well as their derivatives. It should be mentioned that we have 
decided to number the pyridazine atoms as indicated in Figure 34, whatever the substituents on the 
pyridazine ring. 
 
Figure 34 
                                                          
90 Fischer, E. Justus Liebigs Ann. Chem. 1886, 236, 126151. 
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1.4. Main synthetic methods to access α-(trifluoromethyl) 
pyridazines and derivatives 
One of the first synthesis of a α-(trifluoromethyl)pyridazine, was reported by Kobayashi et al. in 
1980.91 When triazoline L3.1 was activated with triphenylphosphine, intermediate L3.3 was formed. 
This intermediate could then react with cyclopropene L3.2 to afford intermediate L3.4 which, after 
the release of triphenylphosphine oxide, produced the polycyclic compound L3.5 possessing four CF3 
groups (38% yield) (Scheme 60). 
 
Scheme 60 
Treatment of L3.5 with ammonia in ether, followed by treatment with dinitrogen tetroxide (N2O4), 
led to the tetrakis-(trifluoromethyl)pyridazine L3.7 (Scheme 61). 
 
Scheme 61 
Beside the method presented above, a few synthetic methods are reported, to access specifically 
α-(trifluoromethyl)pyridazines and their derivatives. We have divided these methods according to the 
                                                          
91 Kobayashi, Y.; Nakano, T.; Shirahashi, K.; Takeda, A.; Kumadaki, I. Tetrahedron Lett. 1980, 21, 46154618. 
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number of CF3 groups present on the pyridazine ring (one or two) and then according to the reaction 
type.  
1.4.1. Pyridazines possessing one CF3 group 
Pyridazines possessing one CF3 group can be obtained either by:  
a) the condensation of hydrazine with a carbonyl compound or  
b) a Staudinger/intramolecular diaza-Wittig sequence. 
1.4.1.1. Condensation of hydrazine with carbonyl compounds 
Condensation of hydrazine with a variety of carbonyl compounds is a typical method to access 
α-(trifluoromethyl)pyridazines. Generally, the mechanism involves the reaction of hydrazine with a 
dicarbonyl compound C, to afford intermediate D by elimination of one molecule of H2O. Reaction of 
the second nitrogen of the hydrazine with the second carbonyl group and elimination of another 
molecule of H2O, leads to the desired pyridazines E (Scheme 62).  
 
Scheme 62 
In 1993, Takahashi et al. reported the synthesis of (trifluoromethyl)pyridazines L3.12a and L3.12b 
from compound L3.8 and hydrazine. Indeed, condensation of  L3.8 with hydrazine gave access to 
hydrazone L3.9 (85% yield), which after reaction with dibenzoyl L3.10 in the presence of 
p-toluenesulfonic acid, afforded azine L3.11 in 75% yield. Azine L3.11 was then converted to 
pyridazine L3.12a (15%) after treatment with LDA, and to pyridazine L3.12b (58%) when treated with 
sodium methoxide due to the release of a hydroxy anion during the condensation step (Scheme 63).92 
                                                          
92 Takahashi, M.; Kotashima, H.; Saitoh, T. Heterocycles 1993, 35, 909914. 
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Scheme 63 
Another interesting application of this method, was reported the same year by the group of Hegde.93 
Surprisingly, condensation of aryl and alkyl hydrazines with compound L3.13, synthesized according 
to the literature ( , TFAA, iPrNH2),94 did not lead to the expected product L3.14, but to the 
unexpected pyridazine carboxylate derivatives L3.15. Furthermore, treatment of pyridazinone L3.15 
(R=Ph) with HCl in H2O, produced hydroxypyridazinone L3.16. Finally, compound L3.16 was converted 
to different trifluoromethyl alkoxy-pyridazine derivatives L3.17 by alkylation of the hydroxy group 
with alkyl iodides in the presence of potassium carbonate (Scheme 64).93 
                                                          
93 Hegde, S. G.; Jones, C. R. J. Heterocycl. Chem. 1993, 30, 15011508. 
94 a) Huisgen, R.; Herbig, K.; Siegl, A.; Huber, H. Chem. Ber. 1966, 99, 25262545; b) Domschke, G. Z. Chem. 
1976, 16, 1314. 
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Scheme 64 
To explain the formation of L3.15, a mechanism was proposed by the authors, where the carbonyl 
that possesses the CF3 group in L3.13 was attacked by an alkyl or an aryl hydrazine, to form 
intermediate L3.18 which could then undergo a cyclization. Due to the elimination of methanol, 
intermediate L3.19 is formed, and two possible mechanisms can be envisioned to access L3.15. The 
first one involves the elimination of H2O from intermediate L3.19, which could then attack the 
enamino ester functionality to form compound L3.20 (Scheme 65). The second mechanism, involves 
a concerted rearrangement of the allylic alcohol to access L3.20. Elimination of isopropylamine could 
then lead to compound L3.21, which after an irreversible acido-basic reaction, led to the highly 
substituted (trifluromethyl)pyridazinone derivatives L3.15 (Scheme 65). 
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Scheme 65 
In 2012, this method was applied to the synthesis of a diversity of pyridazinones L3.22, following the 
same procedure as illustrated in Scheme 64.93 These pyridazinones could be further functionalized by 
the addition of neat 4-fluorobenzylamine, to give a diversity of 6-(trifluoromethyl)pyridazinones 
L3.23 which after treatment under acidic conditions led to pyridazinones L3.24 (Scheme 66).89  
 
Scheme 66 
The formation of (trifluoromethyl)pyridazinones L3.24, can be rationalized by the formation of 
intermediate L3.25 after treatment of pyridazinones L3.23 under acidic conditions. An allylic 
rearrangement can then take place to produce L3.26, which after elimination of benzylamine, leads 
to pyridazinones L3.24 (Scheme 67). 
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Scheme 67 
Furthermore, when R is an isopropyl group, treatment of L3.22 with neat 4-fluorobenzylamine, led to 
pyridazinone derivatives L3.27 in 39% yield, and treatment of L3.27 with HCl afforded 
(trifluoromethyl)pyridazinone L3.28 in 26% yield (Scheme 68).89  
 
Scheme 68 
Therefore, to explain the formation of L3.27 and L3.28 from L3.22, another mechanism was 
envisaged. Treatment of pyridazinone L3.22 with neat 4-fluorobenzylamine, afforded the 
decarboxylated compound L3.27, which after treatment with 10% HCl, gave intermediate L3.29. The 
allylic rearrangement of L3.29 followed by the elimination of a benzylamino group, led to 
pyridazinones L3.28 (Scheme 69). 
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Scheme 69 
In 2009, the synthesis of (trifluoromethyl)pyridazinones L3.34 was reported by the condensation of 
hydrazine derivatives with ketoester L3.31, under acidic conditions. After protonation of L3.31 with 
p-toluenesulfonic acid, intermediate L3.32 was attacked by the hydrazine derivatives to form 
intermediates L3.33. A condensation can then take place to afford compounds L3.34 in very good 
yields (80%94%) (Scheme 70). It is worth noting that the 1 to 1 ratio of ketoester L3.31 and hydrazine 
derivatives is important for the completion of the reaction. When this ratio is 1 to 2, the cyclization 
of L3.33 does not take place. The same result was obtained when the hydrazine is substituted by an 
aromatic ring possessing electron-withdrawing groups, such as two nitro groups, given that the 
reaction stops after the formation of compound L3.33 independently of the ratio of ketoester L3.31 
and hydrazine derivatives.95 
 
Scheme 70 
                                                          
95 Wan, W.; Hou, J.; Jiang, H.; Wang, Y.; Zhu, S.; Deng, H.; Hao, J. Tetrahedron 2009, 65, 42124219. 
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It is worth mentioning that oxidation of L3.34 (R=H), led to the (trifluoromethyl)pyridazinone L3.35 in 
95% yield (Scheme 71). 
 
Scheme 71 
More recently, the synthesis of (trifluoromethyl)pyridazines L3.39 and L3.40 was reported starting 
from chromones L3.36 and 2,3-diaminobenzene or 2,3-diaminopyridine L3.37a or 
2,3-diaminonaphthalene L3.37b. When the condensation of 2,3-diaminobenzene or 
2,3-diaminopyridine L3.37a or 2,3-diaminonaphthalene L3.37b with chromones L3.36 took place 
under acidic conditions, the chromone ring was opened to produce respectively quinoxalines L3.38a 
and L3.38b.96 Treatment of quinoxalines L3.38a with hydrazine led to (trifluoromethyl)pyridazines 
L3.39, while treatment of quinoxalines L3.38b with hydrazine afforded L3.40 in moderate to good 
yields (Scheme 72).97 
 
Scheme 72 
The formation of L3.39 and L3.40 can be explained by the attack of hydrazine on the carbonyl group 
of L3.38 to produce the intermediate compound L3.41. After the attack of the second amino group 
of the hydrazine on the carbon bearing the CF3 group, intermediate L3.42 is formed. The aminal of 
                                                          
96 Irgashev, R. A.; Safrygin, A. V.; Ezhikova, M. A.; Kodess, M. I. Röschenthaler, G. -V.; Sosnovskikh, V. Y. 
Tetrahedron 2015, 71, 18221830. 
97 Sosnovskikh, V. Y.; Safrygin, A. V.; Irgashev, R. A.; Ezhikova, M. A.; Kodess, M. I. RSC Adv. 2016, 6, 
3005630069. 
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L3.42 is then cleaved to afford L3.43, which after a [1,3]-hydride shift, leads to the desired 
(trifluoromethyl)pyridazines L3.39 and L3.40 (Scheme 73).  
 
Scheme 73 
Similarly, (trifluoromethyl)pyridazines L3.46 and L3.47 were produced in good yields from L3.45a and 
L3.45b respectively, after treatment of these latter with hydrazine under acidic conditions. It is worth 
noting that quinoxalines L3.45a and L3.45b were obtained from (trifluoromethyl)furanones L3.44 
when these latter reacted respectively with 2,3-diaminobenzene L3.37a or 2,3-diaminonaphthalene 
L3.37b (Scheme 74).98  
 
Scheme 74 
                                                          
98 Safrygin, A. V.; Irgashev, R. A.; Slepukhin, P. A.; Röschenthaler, G. -V.; Sosnovskikh, V. Y. Tetrahedron 2015, 
71, 85358543. 
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Alternatively, when R is a hydrogen, (trifluoromethyl)furanone L3.44 can directly react with hydrazine 
in acetic acid, to form a tautomeric mixture of pyridazinone derivative L3.48a and pyridazine L3.48b 
in favor of L3.48a (Scheme 75).98 
 
Scheme 75 
Recently, the group of Zhan99 reported the synthesis of (trifluoromethyl)dihydropyridazine L3.52 
starting from trifluoroacetaldehyde L3.49. Indeed after condensation of trifluoroacetaldehyde L3.49 
with phenylhydrazine, hydrazone L3.50 was formed which after a condensation with 
3-bromo-1-propynyl-benzene led to the propargylic hydrazone L3.51. The silver-catalyzed tandem 
sigmatropic rearrangement/[1,3]-hydride shift/6-aza electrocyclization of hydrazone L3.51, allowed 
the formation of L3.52. Dihydropyridazine L3.52 could then be transformed to 
(trifluoromethyl)pyridazinone L3.53 after treatment with selenium oxide (Scheme 76). 
 
Scheme 76 
The formation of L3.52 can be explained by the activation of the triple bond of the propargylic 
hydrazone L3.51 with silver triflate, that induces a 6-endo-dig cyclization to afford intermediate L3.55. 
Decomposition of L3.55 leads to the allenic intermediate L3.56 with regeneration of the silver 
                                                          
99 Ding, Z. -C.; Ju, L. -C.; Yang, Y.; An, X. -M.; Zhou, Y. -B.; Li, R. -H.; Tang, H. -T.; Ding, C. -K.; Zhan, Z. -P. J. Org. 
Chem. 2016, 81, 39363941. 
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catalyst. A [1,3]-hydrogen shift then takes place to allow the formation of L3.57, which after a 6-aza 
electrocyclization leads to dihydropyridazine L3.52100 (Scheme 77). 
 
Scheme 77 
1.4.1.2. Intramolecular diaza-Wittig reaction 
Another synthetic route to access α-(trifluoromethyl)pyridazines involves the intramolecular 
diaza-Wittig reaction of phosphazines. In this nitrogen version of the Wittig-reaction, a diazo 
compound F reacts with a nucleophilic phosphorus reagent (PR3) according to a Staudinger reaction, 
to form a N-P ylide intermediate G, called iminophosphorane. In the presence of a carbonyl group, 
this iminophosphorane G undergoes an intramolecular diaza-Wittig reaction to afford the pyridazine 
derivative I via the oxophosphetane intermediate H (Scheme 78).  
 
Scheme 78 
One example of the diaza-Wittig reaction is reported in the literature, for the synthesis of pyridazines 
possessing one CF3 group. In 2014, the synthesis of (trifluoromethyl)pyridazines L3.63 from 
(trifluoromethyl)diazomethane and carbonates L3.58, in a one-pot synthesis was reported. The first 
step involved a Morita-Baylis-Hillman reaction between the (trifluoromethyl)diazomethane and 
carbonate L3.58, in the presence of DABCO (1,4-diazabicyclo[2.2.2]octane) as a Lewis base, to form 
                                                          
100 The authors underline that when AgOTf was replaced by Rh(Oct)4, the [1,3]-shift could not take place and 
therefore a pyrazole derivative was obtained instead of the pyridazine derivative. 
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the allylic diazo compound L3.59. In the presence of tri-n-butylphosphine, L3.59 was transformed to 
the iminophosphorane intermediate L3.60, which then underwent a diaza-Wittig reaction and a 
subsequent aromatization, affording the highly substituted pyridazines L3.63 (Scheme 79).101 
 
Scheme 79 
1.4.2. Pyridazines possessing two CF3 groups 
Pyridazines possessing two CF3 groups can be accessed by:  
a) the condensation of hydrazine with a carbonyl compound, 
b) a Staudinger/intramolecular diaza-Wittig sequence, 
c) a Diels-Alder reaction with inverse electron demand/retro Diels-Alder reaction between a 
bis-(trifluoromethyl)tetrazine and an alkene. 
1.4.2.1. Condensation of hydrazine with carbonyl compounds 
In 1985, Tamborski et al. reported the condensation of hydrazine with diketone L3.64 in pyridine, to 
afford the bis-(trifluoromethyl)pyridazine L3.66, insisting on the fact that the expected intermediate 
L3.65 was not observed but instead product L3.66 was isolated in 73% yield (Scheme 80).102 
 
Scheme 80 
                                                          
101 Mao, H.; Lin, A.; Tang, Z.; Hu, H.; Zhu, C.; Cheng, Y. Chem. Eur. J. 2014, 20, 24542458. 
102 Tamborski, C.; Prabhu, U. D. G.; Eapen, K. C. J. Fluorine Chem. 1985, 28, 139150. 
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1.4.2.2. Intramolecular diaza-Wittig reaction 
In 2011, the synthesis of bis-(trifluoromethyl)pyridazines L3.72 was reported by using a diaza-Wittig 
reaction. When diazo-oxo-trifluorobutanoates L3.67 reacted with the dicarbonyl compound L3.68, in 
the presence of tris(dimethylamino)phosphine, the desired tetrasubstituted 
bis-(trifluoromethyl)pyridazines L3.72 were isolated. In this process, diazoketoesters L3.67 
underwent a Staudinger reaction in the presence of tris(dimethylamino)phosphine, to form 
phosphazines L3.69 in excellent yields (up to 97%). A diaza-Wittig reaction then took place when 
L3.69 was treated with ketoester L3.68, to produce intermediate L3.70, which released 
tris(dimethylamino)phosphine oxide to afford compound L3.71. An intramolecular condensation of 
L3.71 led to the desired bis-(trifluoromethyl)pyridazines L3.72 in 44% (R=Me) and 50% (R=Et) yield 
(Scheme 81).103 It is worth mentioning that when the reaction was carried out in the presence of 
triphenylphosphine instead of tris(dimethylamino)phosphine, the pyridazines were obtained in 
moderate yields. These moderate yields can be explained by the presence of H2O released during the 
intramolecular condensation, which can hydrolyze the diazoketoesters L3.67 and phosphazines L3.69 
(Ph instead of NMe2). In addition, these moderate yields can also come from the dissociation of 
phosphazines L3.69 into the initial diazoketoesters L3.67 and triphenylphosphine. 
 
Scheme 81 
1.4.2.3. Diels-Alder reaction with inverse electron demand involving tetrazines 
The inverse electron demand Diels-Alder reaction of a tetrazine with a dienophile, followed by a retro 
Diels-Alder reaction, releasing N2, represents one of the most common methods to obtain 
                                                          
103 Supurgibekov, M. B.; Yanyuk, N . S.; Nikolaev, V. A. Russ. J. Org. Chem. 2011, 47, 12521255. 
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bis-(trifluoromethyl)pyridazines as well as their derivatives. This reaction, under orbital control 
(LUMOdiene/HOMOdienophile), is favored by the presence of electron-withdrawing groups on the 
tetrazine and electron-donating groups on the dienophile. Therefore, an extremely electron-poor 
diene such as bis-(trifluoromethyl)tetrazine L3.73 is an excellent substrate for this reaction. Generally, 
after a [4+2]-cycloaddition between tetrazine L3.73 and an alkene, intermediate J is formed which 
after the release of N2 by a retro-Diels Alder reaction can lead to compound K. After oxidation of K, 
the desired bis-(trifluoromethyl)pyridazines L are obtained (Scheme 82).  
 
Scheme 82 
At this point, it is important to mention that this reaction was mostly used for the synthesis of 
pyridazines polycyclic derivatives and it was not until recently, that it was applied to the synthesis of 
monocyclic bis-(trifluoromethyl)pyridazines. 
In 1987, a Diels-Alder reaction with inverse electron demand was reported by the group of Seitz. 
When tetrazine L3.73 reacted with benzene derivatives L3.74 under high temperature, the 
Diels-Alder adducts L3.75 were formed. The elimination of N2, along with an oxidation by air, led to 
the bicyclic bis-(trifluoromethyl)pyridazine derivatives L3.77 in moderate to good yields (Scheme 
83).104  
 
Scheme 83 
The same group applied this method to access a diversity of bis-(trifluoromethyl)pyridazine 
derivatives.105 For example, an inverse electron demand Diels-Alder reaction using -system 
                                                          
104 Seitz, G.; Hoferichter, R.; Mohr, R. Angew. Chem. Int. Ed. Engl. 1987, 26, 332334.  
105 a) Seitz, G.; Mohr, R. Chem.-Ztg. 1987, 111, 8182; b) Hoferichter, R.; Seitz, G.; Wassmuth, H. Chem. Ber. 
1989, 122, 711714; c) Seitz, G.; Hoferichter, R.; Mohr, R. Arch. Pharm. 1989, 322, 415417; d) Seitz, G.; 
Wassmuth, H. Arch. Pharm. 1990, 323, 8991; e) Baumann, L.; Kampchen, T.; Seitz, G. Chem. Ber. 1992, 125, 
171176; f) Hoferichter, R.; Seitz, G. Liebigs Ann. Chem. 1992, 11531158; g) Reimers, U.; Seitz, G. J. Prakt. 
Chem. 1993, 335, 152156; h) Richter, M.; Seitz, G. Arch. Pharm. 1993, 326, 427428; i) Hoferichter, R.; Reimers, 
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dienophiles displaying valence tautomerism was reported in 1995.105k More specifically, when 
tetrazine L3.73 reacted with the tautomeric system cylclooctatetraene L3.78/bicyclo[4.2.0]octatriene 
L3.79, the non-isolable cycloadduct L3.80 was formed. Elimination of N2, afforded L3.81 which rapidly 
tautomerized to the more stable compound L3.82 (Scheme 84). The authors pointed out that the 
equilibrium cylclooctatetraene L3.78/bicyclo[4.2.0]octatriene L3.79 is constant in refluxing 
dichloromethane (b.p.=39.6 °C), therefore it is the cyclooctatetraene L3.78 that acts as the dienophile 
rather than the bicyclo[4.2.0]octatriene L3.79. They also specified that even if the formation of the 
tautomers L3.83 and L3.84 can be envisaged, chromatographic and spectroscopic analysis did not 
reveal the presence of such intermediates.  
However, during the Diels-Alder reaction, the side product L3.85 was isolated in 5% yield, indicating 
that a small amount of L3.83 can react with another molecule of tetrazine L3.73 to form the 
cycloadduct L3.85. Oxidation with silver oxide, promotes a [2+2]-cycloreversion to afford pyridazines 
L3.86 (61%) and L3.87 (64%) (Scheme 84).  
 
Scheme 84 
                                                          
U.; Seitz, G. Arch. Pharm. 1993, 326, 2932; j) Frenzen, G.; Massa, W.; Reimers, U.; Seitz, G. Chem. Ber. 1993, 
126, 441445; k) Baumann, L.; Folkerts, A.; Imming, P.; Klindert, T.; Massa, W.; Seitz, G.; Wocadlo, S. Liebigs 
Ann. 1995, 661666; l) Klindert, T.; Seitz, G. Synth. Comm. 1996, 26, 25872596; m) Klindert, T.; Stroetmann, I.; 
Seitz, G.; Hofner, G.; Wanner, K. T.; Frenzen, G.; Eckhoff, B. Arch. Pharm. Pharm. Med. Chem. 1997, 330, 
163168; n) Klindert, T.; Von Hagel, P.; Baumann, L.; Seitz, G. J. Prakt. Chem. 1997, 339, 623632. 
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Another example of a Diels-Alder reaction with inverse electron demand was reported, using the 
valence tautomeric dienophile e.g. cycloheptatriene L3.88/norcaradiene L3.89 (Scheme 85). 
Although cycloheptatriene L3.88 is the thermodynamically more stable system, when the molecule 
is substituted by an electron-withdrawing group the equilibrium is shifted towards norcaradiene 
L3.89. 
 
Scheme 85 
Therefore, when R is an electron-withdrawing group such as a cyano group or an ester group, the 
equilibrium is shifted towards the bicyclic tautomer L3.89. When tetrazine L3.73 reacted with 
norcaradiene L3.89, and after the release of N2, compounds L3.91 were formed via intermediate 
L3.90. The tricyclic compound L3.91 was quickly tautomerized to the more stable L3.92 which, after 
oxidation, led to the desired pyridazines L3.93 (Scheme 86).105e 
 
Scheme 86 
However, when R is an electron-donating group, both cycloheptatriene L3.88 and norcaradiene L3.89 
reacted with tetrazine L3.73 to form the corresponding pyridazines L3.96 as the major product 
(29%67%) and L3.97 as the minor product (2%22%) (Scheme 87).105e 
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Scheme 87 
Haider et al.,106 worked on the synthesis of bis-(trifluoromethyl)pyridazine derivatives by an inverse 
electron-demand (LUMOdiene-controlled) Diels-Alder reaction. In 1994, these authors reported the 
synthesis of the tricyclic (trifluoromethyl)pyridazine derivative L3.100, starting from an indole 
derivative and tetrazine L3.73. More specifically, when indole L3.98, possessing a leaving group at the 
C3 position, reacted with tetrazine L3.73, intermediate L3.99 was formed and after aromatization by 
elimination of MeSH, bis-(trifluoromethyl)pyridazine L3.100 was isolated in 58% yield. It is interesting 
to mention that when the N-protected indole L3.101 (obtained after treatment of indole L3.98 with 
n-BuLi and mesyl chloride), was treated with tetrazine L3.73, the cycloaddition reaction failed and 
L3.102 was not formed (Scheme 88). 
                                                          
106 Haider, N.; Wanko, R. Heterocycles 1994, 38, 18051811. 
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Scheme 88 
However, when indole L3.103, possessing a N-mesyl group, without a leaving group at the C3 position, 
was treated in refluxing toluene, a ring-opening took place slowly to produce the substituted 
bis-(trifluoromethyl)pyridazine L3.105 instead of the expected aromatization compound L3.102, 
showing that, in this case the ring-opening step is more favorable than the aromatization of the indole 
as L3.102 was not formed (Scheme 89).106 
 
Scheme 89 
An unexpected double inverse electron demand Diels-Alder reaction was reported in 1999, when 
dienamine L3.106 reacted with 2.0 equiv of tetrazine L3.73, as two unexpected monocyclic 
cycloadducts, L3.107 and L3.108 were obtained in 38% and 44% yield respectively (Scheme 90).107  
                                                          
107 Kotschy, A.; Novak, Z.; Vincze, Z.; Smith, D. M.; Hajos, G. Tetrahedron Lett. 1999, 40, 63136316. 
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Scheme 90 
It is worth mentioning that 2.0 equiv of tetrazine L3.73 were necessary for the consumption of 
dienamine L3.106. Therefore, according to the authors, as one of the two double bonds of dienamine 
L3.106 is trisubstituted, tetrazine L3.73 reacted only with the disubstituted double bond to form 
intermediate L3.110, while intermediate L3.109 was not formed. Reaction of the remaining enamine 
in L3.110 with a second equivalent of tetrazine L3.73, led to the bis-dihydropyridazine intermediate 
L3.111 which after disproportionation gave pyridazine derivatives L3.107 and L3.108 (Scheme 91).107 
 
Scheme 91 
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Over the years, the Diels-Alder reaction with inverse electron demand, has found application in the 
synthesis of substituted pyridazines and derivatives, which could act as a bioisoster of other 
heteroaromatic rings. 
For example, the group of Seitz, has envisioned to replace the pyridine ring of ()-anabasine, which 
is a tobacco alkaloid with potential agonist activity towards nicotinic acetylcholine receptors, by a 
bis-(trifluoromethyl)pyridazine to access compound L3.115 and study its biological activity. 
Consequently, enol ether L3.112 was used as an electron-rich dienophile which reacted with tetrazine 
L3.73 to form the Diels-Alder intermediate L3.113. After elimination of N2 and methanol, pyridazine 
derivative L3.114 was formed and after deprotection of the amine (TFA, CH2Cl2), the desired 
enantioenriched compound L3.115 was isolated in 84% yield (Scheme 92).108 
 
Scheme 92 
Similarly, the replacement of the 1-chloropyridine substituent of epibatidine, an analgesic agent, by 
a bis-(trifluoromethyl)pyridazine moiety was envisioned, to access the pyridazine-containing 
compound L3.118. The Diels-Alder reaction between the electron-rich dienophile L3.116 and the 
electron-poor diene L3.73, gave cycloadduct L3.117 in 88% yield according to a mechanism similar to 
the one reported in Scheme 92. Deprotection of the amine using trimethylsilyl iodide and methanol, 
afforded compound L3.118 (Scheme 93).109 
                                                          
108 Stehl, A.; Seitz, G.; Schulz, K. Tetrahedron 2002, 58, 13431354. 
109 Che, D.; Wegge, T.; Stubbs, M. T.; Seitz, G.; Meier, H.; Methfessel, C. J. Med. Chem. 2001, 44, 4757. 
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Scheme 93 
Norferruginine is another potent agonist of nicotinic acetylcholine receptors which could be used 
potentially for the treatment of several central nervous system diseases. A series of compounds, 
bioisoteric of norferruginine, were therefore synthesized and studied, and the 
bis-(trifluoromethyl)pyridazine derivative L3.123 was one of them. After treatment of tropanone 
L3.119 with morpholine and p-toluenesulfonic acid, enamine L3.120 was obtained. The enamine 
L3.120 underwent a successful Diels-Alder reaction with inverse electron demand in the presence of 
tetrazine L3.73, to afford the polycyclic compound L3.121 in 93% yield. Further treatment of L3.121 
with p-toluenesulfonic acid, led to an aromatization step and to compound L3.122, which could then 
be deprotected to access bis-(trifluoromethyl)pyridazine derivative L3.123 (Scheme 94).110 
 
Scheme 94 
                                                          
110 Gündisch, D.; Kämpchen, T.; Schwarz, S.; Seitz, G.; Siegl, J.; Wegge, T. Bioorg. Med. Chem. 2002, 10, 19. 
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Furocoumarins are photoreactive molecules that can covalently link to DNA. Cross-linking problems 
are common during the furocoumarins mode of action, and could be limited and eventually 
eliminated by the insertion of nitrogen-containing rings in the furocoumarin system, that would 
improve the interactions with DNA. Therefore, the group of Uriarte,111 reported the synthesis of 
bis-(trifluoromethyl)pyridazine-containing furocoumarins, which could eventually limit cross-linking 
problems. For example L3.127 can be obtained by an inverse electron demand Diels-Alder reaction 
between tetrazine L3.73 and the enolized form of furocoumarin L3.124, L3.125. The reaction 
proceeded smoothly, to afford after elimination of H2O and N2, the desired polycyclic compound 
L3.127 in 54% yield (Scheme 95).111b 
 
Scheme 95 
Therefore, the Diels-Alder reaction with inverse electron demand of the electron-poor tetrazine L3.73 
with a variety of electron-rich dienophiles, constitutes an important method to access pyridazines 
substituted by two CF3 groups at the α position of each nitrogen.
                                                          
111 a) Gonzalez-Gomez, J. C.; Dedola, T.; Santana, L.; Uriarte, E.; Begala, M.; Copez, D.; Podda, G. J. Heterocycl. 
Chem. 2000, 37, 907910; b) Gonzalez-Gomez, J. C.; Santana, L.; Uriarte, E. Synthesis 2002, 4346; c) Gonzalez, 
J. C.; Lobo-Antunes, J.; Pérez-Lourido, P.; Santana, L.; Uriarte, E. Synthesis 2002, 475478. 
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2. Context of the study and objective 
Over the years, the pyridazine core has been present in several commercial drugs and drug candidates 
(see Section 1.2). In addition, the biological significance of pyridazines trifluoromethylated analogues 
has recently become a new trend, therefore the search for new efficient methods for the synthesis 
of (trifluoromethyl)pyridazines has become a challenge.  
Recently, a [2+1]/[3+2]-cycloaddition sequence was developed in our laboratory, involving an alkyne 
L3.128, a difluorocarbene source and a diazo compound, to access fluoropyridazines L3.132 
possessing an ester group at the C6 position. More specifically, in the presence of a difluorocarbene, 
alkynes L3.128 underwent a [2+1]-cycloaddition to form 3,3-difluorocyclopropenes L3.129. These 
cyclopropenes then underwent a [3+2]-cycloaddition in the presence of an alkyl diazoacetate to 
afford cyclopropanopyrazolines L3.130. Ring-expansion of L3.130 led to the dihydropyridazines 
L3.131, which after aromatization, afforded the desired pyridazines L3.132 (Scheme 96).112 
 
Scheme 96 
Pyridazines L3.132 were further functionalized by a nucleophilic aromatic substitution (SNAr), to 
afford a diversity of highly substituted pyridazines L3.133 (Scheme 97). 
 
Scheme 97 
                                                          
112 Tran, G.; Gomez Pardo, D.; Tsuchiya, T.; Hillebrand, S.; Vors, J. -P.; Cossy, J. Org. Lett. 2015, 17, 34143417. 
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Our goal was to replace the commercially available diazoacetate compounds by the 
non-commercially available (trifluoromethyl)diazomethane, to access 6-(trifluoromethyl)pyridazines 
O. As this method is limited to pyridazines possessing a fluorine substituent at the C4 position, the 
replacement of the fluorine atom by other nucleophiles using a nucleophilic aromatic substitution 
(SNAr) was envisaged to access 3,4,6-functionalized pyridazines P (Scheme 98).  
 
Scheme 98 
Before the presentation of our results, we will briefly describe the properties of 
(trifluoromethyl)diazomethane, along with its preparation and its use in organic chemistry. 
(Trifluoromethyl)diazomethane is a yellow gas, first reported by Gilman and Jones in 1943.113 The 
boiling point of this diazo compound is 13 °C. In addition, (trifluoromethyl)diazomethane is suspected 
to be toxic and is considered to be an explosive molecule, with 50100% of the energy released by 
the same weight of TNT.114 Two resonance structures contribute to its structure and properties 
(Scheme 99). 
 
Scheme 99 
(Trifluoromethyl)diazomethane L3.138 can be prepared by the diazotization of the commercially 
available 2,2,2-trifluoroethylamine hydrochloride L3.134 with sodium nitrite (NaNO2) in H2O, with or 
without the presence of an acid. HNO2 is the active agent formed in situ that carries out the 
diazotization. Therefore, the reaction of HNO2 with trifluoroethylamine L3.134 leads to the N-nitroso 
intermediate L3.135, which after dehydration, affords the diazonium intermediate L3.137. 
Elimination of the acidic proton leads to (trifluoromethyl)diazomethane L3.138 (Scheme 100). 
                                                          
113 Gilman, H.; Jones, R. G. J. Am. Chem. Soc. 1943, 65, 14581460. 
114 Fields, R.; Tomlinson, J. P. J. Fluorine Chem. 1979, 13, 147158. 
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Scheme 100 
Recently, Carreira et al. reported the successful formation of (trifluoromethyl)diazomethane L3.138 
from trifluoroethylamine hydrochloride L3.134 in a mixture of CH2Cl2/H2O (30:1) (Scheme 101).115  
 
Scheme 101 
Despite its toxicity and explosiveness, (trifluoromethyl)diazomethane L3.138 has emerged as a useful 
reagent as it can be involved in: 
a) the cyclopropanation and cyclopropenation of alkenes and alkynes in the presence of an 
appropriate metal to produce respectively (trifluoromethyl)cyclopropanes and 
(trifluoromethyl)cyclopropenes, 
b) a [1,3]-dipolar cycloaddition of alkynes and alkenes, to afford (trifluoromethyl)pyrazoles and 
(trifluoromethyl)pyrazolines respectively, 
c) the homologation of aliphatic aldehydes and cyclic ketones in the presence of a Lewis Acid to access 
(trifluoromethyl)ketones (Scheme 102).  
                                                          
115 Morandi, B.; Carreira, E. M. Angew. Chem. Int. Ed. 2011, 50, 90859088.  
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Scheme 102 
 
In summary, (trifluoromethyl)diazomethane L3.138 is a versatile reagent which can be considered as 
a 1,1,1-trifluoroethyl carbene unit. However, this compound has to be handled with great care.
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3. Results and discussion 
For our part, we were interested in the synthesis of pyridazines O, possessing a CF3 group at the C6 
position. We envisaged to form these pyridazines by the [2+1]-cycloaddition of difluorocarbene with 
terminal alkynes M, followed a [3+2]-cycloaddition between the formed difluorocyclopropene 
intermediates N and (trifluoromethyl)diazomethane (Scheme 103). 
 
Scheme 103 
We therefore initiated our study by synthesizing the starting materials e.g. different terminal alkynes, 
which would be used for the scope of the reaction. 
3.1. Synthesis of the starting materials 
As most of the terminal alkynes are either very expensive or not commercially available, their 
preparation is necessary. Most of these alkynes were easily accessible by a Sonogashira 
cross-coupling reaction between an aryl halide and trimethylsilylacetylene using PdCl2(PPh3)2 (510 
mol %), CuI (510 mol %) and Et3N (3.0 equiv) in THF, followed by the cleavage of the trimethylsilyl 
group by treatment with K2CO3 in MeOH. The results are summarized in Table 7. Terminal alkynes 6 
and 7, possessing an aromatic ring substituted by a nitro group or an ester at the para-position, were 
isolated in 76% and 57% yield respectively from the corresponding aryl iodides 1 and 2 (Table 7, 
entries 1 and 2). The Sonogashira cross-coupling of trimethylsilylacetylene with bromo-pyridines 3 
and 4, followed by the cleavage of the TMS group, led to the desired alkynes 8 and 9 in 61% and 53% 
yield respectively (Table 7, entries 3 and 4). Treatment of 5-bromo-2-methylbenzoxazole 5 with 
trimethylsilylacetylene under the Sonogashira cross-coupling conditions, gave the corresponding 
alkyne 10 in 87% yield (Table 7, entry 5). 
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Entry Ar-X Conditions  
1 
 
1) PdCl2(PPh3)2 (5 mol %) 
CuI (5 mol %), Et3N (3.0 equiv) 
THF, rt, 2 h 
2) K2CO3 (0.1 equiv), MeOH, rt, 2 h  
2 
 
1) PdCl2(PPh3)2 (5 mol %) 
CuI (5 mol %), Et3N (3.0 equiv) 
THF, rt, 2 h 
2) K2CO3 (3.0 equiv), MeOH, rt, 1 h  
3 
 
1) PdCl2(PPh3)2 (5 mol %) 
CuI (5 mol %), Et3N (3.0 equiv) 
THF, rt, 2 h 
2) K2CO3 (0.1 equiv), MeOH, rt, 2 h  
4 
 
1) PdCl2(PPh3)2 (5 mol %) 
CuI (5 mol %), Et3N (3.0 equiv) 
THF, 90 °C, 2 h 
2) K2CO3 (0.1 equiv), MeOH, rt, 30 min  
5 
 
1) PdCl2(PPh3)2 (10 mol %) 
CuI (10 mol %), Et3N (3.0 equiv) 
THF, rt, 2 h 
2) K2CO3 (3.0 equiv), MeOH, rt, 4 h  
Table 7 
Alkyne 12, possessing an aryl group substituted by a phosphonate at the para-position, was 
synthesized from the aryl iodide 11. The Sonogashira coupling of 11 with trimethylsilylacetylene, 
followed by a second coupling catalyzed by palladium (0) was used to introduce a diethyl phosphite 
substituent [Pd(PPh3)4 (5 mol %), PPh3 (0.5 mol %) and Et3N in toluene at 110 °C for 4 h]. After the 
cleavage of the TMS group (TBAF in THF at 0 °C for 2 h), the terminal alkyne 12 was isolated with an 
overall yield of 71% (Scheme 104). 
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Scheme 104 
Alkyne 14, possessing an aromatic ring substituted by a methyl ester at the meta-position, was easily 
obtained from 3-ethynylbenzoic acid 13. When alkyne 13 was treated with methyl iodide (1.6 equiv) 
in the presence of K2CO3 (1.5 equiv), in DMF at rt for 16 h, alkyne 14 was isolated in 90% yield (Scheme 
105). 
 
Scheme 105 
To access propargylamino derivatives, a Mitsunobu reaction was carried out. Thus, N-propargyl 
phthalimide 17 was synthesized in 87% yield from propargylic alcohol 15 and phthalimide 16, using 
PPh3 and DIAD (Scheme 106).  
 
Scheme 106 
By using the same Mitsunobu conditions (PPh3, DIAD), N-homopropargyl phthalimide 19 was isolated 
in 91% yield, starting from homopropargylic alcohol 18 and phthalimide 16. After treatment of 19 
with hydrazine (EtOH, reflux, 1 h) followed by treatment with Boc2O (2.5 equiv), DMAP (1.0 equiv) 
and Et3N (3.0 equiv), the protected homopropargylamine 20 was formed. Given that our goal was to 
obtain alkyne 21, the monoprotected alkyne 20 was not isolated but directly treated with Boc2O in 
the presence of DMAP, to afford the desired alkyne 21 in 20% yield from 19 (Scheme 107). 
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Scheme 107 
3.2. Synthesis of α-(trifluoromethyl)pyridazines 
3.2.1. Optimization of the reaction conditions  
To access α-(trifluoromethyl)pyridazines, the optimization of the reaction conditions was carried out 
with phenylacetylene 22. To form the difluorocyclopropene 23 from 22, the difluorocarbene was 
generated according to the reaction conditions reported by Hu and Prakash et al. (TMSCF3, NaI, THF, 
110 °C, 2 h).116 When the Ruppert-Prakash reagent (TMSCF3) was treated with sodium iodide, the CF3 
anion was generated, and under high temperature (110 °C), the difluorocarbene was formed along 
with a fluorine anion. A [2+1]-cycloaddition could then take place, between the difluorocarbene and 
phenylacetylene 22, to produce the difluorocyclopropene 23. This compound was not isolated, but 
was directly treated with (trifluoromethyl)diazomethane. This latter, was generated by using the 
conditions developed by Carreira et al.115 Thus, when 2,2,2-trifluoroethylamine hydrochloride (2.05 
equiv) was treated with sodium nitrite (2.4 equiv), in a mixture of 0.3 M CH2Cl2/H2O (30:1) at 0 °C for 
1 h, (trifluoromethyl)diazomethane was formed. This solution was then cooled to 78 °C and 
transferred to the difluorocyclopropene solution. After 46 h at rt, the desired 
(trifluoromethyl)pyridazine 24 was obtained in 78% yield (Scheme 108). 
                                                          
116 Wang, F.; Luo, T.; Hu, J.; Wang, Y.; Krishnan, H. S.; Jog, P. V.; Ganesh, S. K.; Prakash, G. K. S.; Olah, G. A. 
Angew. Chem. Int. Ed. 2011, 50, 71537157.  
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Scheme 108 
To optimize the reaction conditions, we first decided to carry out the [3+2]-cycloaddition at 80°C 
instead of rt in order to decrease the reaction time. However at 80 °C, the corresponding pyridazine 
24 was only obtained in 66% yield, while the reaction time remained the same (46 h) (Table 8, entry 
2 versus entry 1). As the yield in 24 was better at rt than at 80 °C, we then turned our attention to the 
influence of the concentration of the diazo compound (2.05 equiv) on the yield of 24. Instead of 0.3 
M solution, a 0.6 M solution of (trifluoromethyl)diazomethane in CH2Cl2/H2O (30:1) was used. Under 
these conditions, pyridazine 24 was still obtained in a moderate yield of 60% after 40 h (Table 8, entry 
3). When 1.5 equiv of (trifluoromethyl)diazomethane were used instead of 2.05 equiv, at a 
concentration of 0.6 M in CH2Cl2/H2O (30:1), the desired compound 24 was isolated in 87% yield after 
40 h at rt (Table 8, entry 4).  
 
Entry Equiv Concentration (M) Temperature (°C) Time (h) Yield (%) 
1 2.05 0.3 rt 46 78 
2 2.05 0.3 80 46 66 
3 2.05 0.6 rt 40 60 
4 1.5 0.6 rt 40 87 
Table 8 
Therefore, the best conditions to access pyridazine 24 from phenylacetylene 22 are 1.5 equiv of 
(trifluoromethyl)diazomethane at a concentration of 0.6 M in CH2Cl2/H2O (30:1) at rt. The desired 
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pyridazine 24 was isolated in 87% yield from phenylacetylene 22 after a [2+1]/[3+2]-cycloaddition 
sequence utilizing TMSCF3 and NaI in THF at 110 °C for 2 h, followed by the addition of 0.6 M solution 
of (trifluoromethyl)diazomethane in CH2Cl2 at rt. 
3.2.2. Scope of the reaction 
3.2.2.1. Terminal alkynes substituted by an aryl group 
To study the scope of the reaction, we first examined the reactivity of terminal alkynes possessing 
aromatic rings substituted by electron-donating groups. When alkyne 25, possessing an aromatic 
group substituted by a methyl group at the para-position, was engaged in the cycloaddition sequence, 
the corresponding compound 31 was isolated in 75% yield although the reaction time was long (6 
days) (Table 9, entry 2). The reaction time was increased to 3 weeks, when the terminal alkyne was 
substituted by an aromatic ring possessing a p-MeO or a o-MeO group, however, the cycloadducts 32 
and 33 were respectively isolated in good yields of 83% and 73% (Table 9, entries 3 and 4). When the 
alkyne possessed a trisubstituted aryl group such as in 28, this latter underwent the cycloaddition 
sequence successfully, leading to (trifluoromethyl)pyridazine 34 in 76% yield (Table 9, entry 5). It is 
worth noting that it took one month as well as 2.0 equiv of (trifluoromethyl)diazomethane to obtain 
a total conversion of the difluorocyclopropene. Nevertheless, when the same reaction was carried 
out at 55 °C, pyridazine 34 was obtained in 83% yield after 12 days (see footnote b). On the contrary, 
when 4-ethynyl-N,N-dimethylaniline 29 was engaged in the cycloaddition sequence, neither product 
35 nor the difluorocyclopropene were observed (Table 9, entry 6). A possible explanation might be 
that the nucleophilic character of the dimethylaniline (pKa=5.2), can interact with the electrophilic 
difluorocarbene leading to the deactivation of the difluorocarbene and to the degradation of the 
product. Furthermore, when alkyne 30, substituted with a methoxy naphthalene, was involved in the 
[2+1]/[3+2]-cycloaddition sequence, pyridazine 36 was formed in a good yield of 79% after 40 h (Table 
9, entry 7).  
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Entry  Time Product (%) 
1 
 
40 h 
 
2 
 
6 d 
 
3 
 
3 weeks 
 
4 
 
15 d 
 
5a,b 
 
1 month 
 
6 
 
 
 
7 
 
40 h 
 
a) 2.0 equiv of (trifluoromethyl)diazomethane were necessary for a total conversion of the cyclopropene.  
b) When the reaction was carried out at 55 °C, the reaction time decreased in 12 days and the product was obtained in 83% yield. 
Table 9 
The reactivity of terminal alkynes substituted by aryl groups possessing electron-withdrawing 
substituents was then examined. We noticed that the reaction times were in most cases shorter than 
the reaction times required for alkynes possessing aryl groups substituted with electron-donating 
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substituents. When 1-ethynyl-2-trifluoromethylbenzene 37 was treated with TMSCF3/NaI in THF at 
110 °C for 2 h, followed by the addition of (trifluoromethyl)diazomethane in CH2Cl2, pyridazine 41 
was formed in 66% yield after 48 h (Table 10, entry 1). Alkynes 14 and 7, possessing an ester group 
at the meta- and para-position of the aromatic ring respectively, were transformed to 
(trifluoromethyl)pyridazines 42 and 43 in good yields, 76% and 67% respectively (Table 10, entries 2 
and 3). A decrease in the yield of pyridazines was observed when alkynes 12 and 6, substituted by an 
aryl possessing a p-PO(OEt)2 or a p-NO2 group underwent the [2+1]/[3+2]-cycloaddition sequence, as 
the corresponding pyridazines 44 and 45 were isolated in low yields, 27% and 34% respectively (Table 
10, entries 4 and 5). It is worth noting that the presence of a weak electron-withdrawing substituent 
such as a bromine or a fluorine atom at the para-position of the aromatic ring, allowed an increase in 
the yield of pyridazines, as 46 and 47 were isolated in 85% and 57% yield respectively. However, 
longer reaction times of 5 to 7 days were necessary for the complete conversion of the 
difluorocyclopropene intermediate (Table 10, entries 6 and 7). Alkyne 40, possessing an aromatic ring 
substituted by a fluorine atom and a methyl group, afforded pyridazine 48 in a very good yield of 89% 
after 72 h of reaction (Table 10, entry 8).
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Entry  Time Product (%) 
1 
 
48 h 
 
2 
 
72 h 
 
3 
 
24 h 
 
4 
 
48 h 
 
5a 
 
24 h 
 
6 
 
7 d 
 
7 
 
5 d 
 
8 
 
72 h 
 
a) 2.0 more equiv of TMSCF3 were necessary for a total conversion of the alkyne.  
Table 10 
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In summary, terminal alkynes possessing aromatic rings substituted by electron-donating groups and 
terminal alkynes possessing aromatic rings substituted by electron-withdrawing groups, underwent 
the [2+1]/[3+2]-cycloaddition sequence successfully, to produce 6-(trifluoromethyl)pyridazines. In 
the case of alkynes possessing an aryl group substituted by electron-donating groups, long reaction 
times were required for the total conversion of difluorocyclopropenes to the corresponding 
pyridazines. In the case of alkynes possessing an aryl group substituted by an electron-withdrawing 
group, lower yields than those obtained with alkynes substituted by an aryl possessing 
electron-donating groups, were observed. The presence of electron-withdrawing substituents on the 
aryl group can be detrimental to the yields of difluorocyclopropenes, as these latter can be prone to 
a nucleophilic attack by the anions present in the reaction mixture (CF3 and I) when treated with the 
Hu and Prakash conditions. To solve this problem, another source of difluorocarbene was envisaged, 
based on the work of Chen et al.117 Thus, TMSCF3 was replaced by trimethylsilyl 
fluorosulfonyldifluoroacetate (TFDA) and NaI by a catalytic amount of NaF. After the attack of the 
fluorine to the trimethylsilyl group of TFDA, a difluorocarbene is formed, along with CO2, SO2 and 
fluorine. This fluorine can then attack another molecule of TFDA, in consequence a catalytic amount 
of NaF is necessary (Scheme 109). For the formation of the difluorocarbene using TFDA, a slow 
addition of this latter in the reaction media at high temperature is needed, therefore the reaction 
was carried out in diglyme (b.p.=162 °C) at 120 °C.  
 
Scheme 109 
As these conditions do not involve the presence of strong nucleophiles in the reaction mixture, 
terminal alkynes substituted by an aryl group possessing an electron-withdrawing substituent could 
lead to the corresponding pyridazines in higher yields than those obtained previously with 
TMSCF3/NaI (see Table 10). However, when 1-ethynyl-2-trifluoromethylbenzene 37 was treated with 
TFDA, in the presence of a catalytic amount of NaF in diglyme at 120 °C, followed by the addition of 
(trifluoromethyl)diazomethane in CH2Cl2, pyridazine 41 was obtained in a lower yield of 43% than the 
                                                          
117 a) Tian, F.; Kruger, V.; Bautista, O.; Duan, J. -X.; Li, A. -R.; Dolbier, Jr. W. R.; Chen, Q. -Y. Org. Lett. 2000, 2, 
563564; b) Xu, W.; Chen, Q. -Y. J. Org. Chem. 2002, 67, 94219427. 
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yield obtained with TMSCF3/NaI (66%) (Table 11, entry 1). Furthermore, when treated with TFDA, 
alkynes 14 and 7, led to pyridazines 42 and 43 in 76% and 68% yield, which means that no 
improvement in the yields was observed whatever the method used (Table 11, entries 2 and 3). Yields 
in 44 were similar when using TMSCF3/NaI and TFDA/NaF as alkyne 12 was transformed to pyridazine 
44 in 25% yield (versus 27% yield with TMSCF3/NaI) (Table 11, entry 4). However, when alkyne 6, 
possessing an aromatic ring substituted by a p-NO2 group, underwent the [2+1]/[3+2]-cycloaddition 
sequence using TFDA/NaF, pyridazine 45 was obtained in 56% yield which is higher than the 34% yield 
obtained with TMSCF3/NaI (Table 11, entry 5). When alkyne 49, substituted by an aromatic ring 
possessing a cyano group at the meta-position, was engaged in the cycloaddition sequence, the 
corresponding product 50 was obtained in a good yield of 60% (Table 11, entry 6). It is worth 
mentioning, that although in most cases the yields remained low, the reaction times were slightly 
improved when the TFDA/NaF procedure was used compared to the TMSCF3/NaI procedure. 
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Entry  Time Product (%) 
1 
 
16 h 
 
2 
 
16 h 
 
3a 
 
24 h 
 
4a 
 
16 h 
 
5 
 
16 h 
 
6a 
 
16 h 
 
a) 2.0 more equiv of TFDA were necessary for a total conversion of the alkyne.  
Table 11 
The same observations were made when alkyne 27, possessing an aromatic ring substituted by an 
electron-donating group, was submitted to the TFDA procedure. Although the corresponding 
pyridazine 33 was obtained in a slightly lower yield compared to the one obtained with the TMSCF3 
procedure (68% versus 73%), the reaction time was significantly improved from 15 days to 4 days 
(Scheme 110). 
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Scheme 110 
Therefore, compared to the TMSCF3/NaI procedure, although the TFDA procedure was not able to 
improve the yields in pyridazines from alkynes possessing an aryl group substituted by 
electron-withdrawing groups, it remains a useful method to access pyridazines from alkynes 
substituted by aryl groups with electron-withdrawing or electron-donating substituents, as the 
[2+1]/[3+2]-cycloaddition products were obtained in shorter reaction times compared to the reaction 
times needed for the TMSCF3 procedure. 
3.2.2.2. Terminal alkynes substituted by heterocycles 
Terminal alkynes substituted by heteroaromatic rings were also involved in the 
[2+1]/[3+2]-cycloaddition sequence. When 2-ethynylpyridine 51 was submitted to the TMSCF3 
procedure (TMSCF3/NaI, THF, 110 °C, 2 h), pyridazine 53 was obtained in a low yield of 12%, possibly 
due to the nucleophilicity of the pyridine nitrogen (pKa=5.25) which can react with the 
difluorocarbene. When the same alkyne was submitted to the TFDA procedure (TFDA/NaF, diglyme, 
120 °C, 2 h), only the degradation of the starting material was observed (Table 12, entry 1). However, 
when 2-chloro-6-ethynylpyridine 8 was treated with the system TMSCF3/NaI, the corresponding 
(trifluoromethyl)pyridazine 54 was isolated in a 25% yield, possibly due to a decrease in the 
nucleophilic character of the nitrogen of the pyridine. It is worth mentioning that treatment of 
2-chloro-6-ethynylpyridine 8 with the TFDA/NaF system, gave pyridazine 54 in 30% yield (Table 12, 
entry 2). In addition, treatment of 2-chloro-5-ethynylpyridazine 9 with TMSCF3/NaI led to the 
cycloaddition product 55 in 37% yield, while its treatment with TFDA/NaF led to the degradation of 9 
(Table 12, entry 3). The cycloaddition sequence applied to 3-ethynylthiophene 52, using the two 
procedures, led to pyridazine 56 in 76% yield when TMSCF3/NaI was used and in 52% when TFDA/NaF 
was utilized (Table 12, entry 4). Treatment of alkyne 10, substituted by a benzoxazole group, with 
TMSCF3/NaI, followed by the addition of (trifluoromethyl)diazomethane in CH2Cl2, afforded pyridazine 
57 in 75% yield (Table 12, entry 5). 
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Entry  Conditions Time Product (%) 
1a 
 
 
 
TMSCF3 
TFDA 
24 h 
 
 
2b,c 
 
 
 
TMSCF3 
TFDA 
40 h 
16 h 
 
3d 
 
 
 
TMSCF3 
TFDA 
48 h 
 
 
4 
 
 
 
TMSCF3 
TFDA 
72 h 
24 h 
 
5b 
 
 
TMSCF3 
 
48 h 
 
a) 1.0 more equiv of TMSCF3 was necessary for a total conversion of the alkyne. 
b) 2.0 more equiv of TMSCF3 were necessary for a total conversion of the alkyne. 
c) 2.0 more equiv of TFDA were necessary for a total conversion of the alkyne. 
d) 4.0 more equiv of TMSCF3 were necessary for a total conversion of the alkyne. 
Table 12 
It is worth mentioning that when 2-chloro-6-ethynylpyridine 8 was treated with TMSCF3, beside 
pyridazine 54, the presence of two more products was observed by GC/MS analysis, compounds 58 
and 59. Compound 58 could be the result of the deprotonation of alkyne 8 by the CF3 anion generated 
in the reaction media followed by a trimethylsilylation of 60. In the case of compound 59, this latter 
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could be formed either by attack of the difluorocarbene on 58, or by deprotonation of the 
difluorocyclopropene 61 followed by a trimethylsilylation (Scheme 111). 
 
Scheme 111 
3.2.2.3. Terminal alkynes substituted by alkyl groups 
To further expand the scope of the reaction, terminal alkynes substituted by alkyl groups were 
engaged in the [2+1]/[3+2]-cycloaddition sequence. Treatment of alkynes 6264 with TMSCF3/NaI, 
followed by treatment with (trifluoromethyl)diazomethane in CH2Cl2, allowed the formation of the 
corresponding pyridazines 6567, although in moderate yields. For example, alkyne 62, substituted 
by a cyclohexyl group, gave the desired pyridazine 65 in 38% yield after 12 days (Table 13, entry 1). 
Alkynes 63 and 64, substituted by a benzyl or a methoxymethyl group, were transformed to the 
corresponding cycloadducts 66 and 67 in 39% and 20% yield respectively (Table 13, entries 2 and 3). 
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Entry  Time Product (%) 
1 
 
12 d 
 
2 
 
20 d 
 
3 
 
72 h 
 
Table 13 
Alkynes substituted by alkyl chains with protected nitrogen groups, were also involved in the 
[2+1]/[3+2]-cycloaddition sequence, by using both procedures, TMSCF3/NaI and TFDA/NaF. When 
N-propargyl phthalimide 17 was treated with TMSCF3/NaI in THF, at 110 °C for 2 h, followed by the 
addition of (trifluoromethyl)diazomethane, (trifluoromethyl)pyridazine 68 was isolated in 17% yield 
after 48 h. The yield in 68, as well as the reaction time were improved, when TMSCF3/NaI was 
replaced by TFDA/NaF, as the (trifluoromethyl)pyridazine was isolated in 57% yield after 16 h (Table 
14, entry 1). Similarly, treatment of N-homopropargyl phthalimide 19 with the TMSCF3/NaI system, 
led to pyridazine 69 in 29% yield after 48 h, whereas treatment of 19 with the TFDA/NaF system 
afforded 69 in 40% yield after 16 h (Table 14, entry 2). This improvement of the reaction time when 
using the TFDA/NaF procedure, was also observed in the case of alkyne 21. However, for this 
compound, a higher yield in pyridazine 70 was obtained with the TMSCF3 procedure than with the 
TFDA procedure (Table 14, entry 3). 
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Entry  Conditions Time Product (%) 
1a,b 
 
 TMSCF3 
TFDA 
48 h 
16 h 
 
2a 
 
TMSCF3 
TFDA 
48 h 
16 h 
 
3c 
 
TMSCF3 
TFDA 
40 h 
16 h 
 
a) 2.0 more equiv of TMSCF3 were necessary for a total conversion of the alkyne.  
b) 3.0 more equiv of TFDA were necessary for a total conversion of the alkyne.  
c) 1.0 more equiv of TMSCF3 were necessary for a total conversion of the alkyne. 
Table 14 
Thus, the reaction scope could be expanded not only to alkynes substituted by aromatic rings 
possessing electron-donating and electron-withdrawing groups but also to alkynes substituted by 
heterocycles and alkyl groups. Even though problems were encountered when a basic nitrogen is 
present on the heterocyclic rings, a variety of (trifluoromethyl)pyridazines were obtained, with the 
TMSCF3/NaI and/or the TFDA/NaF procedure. 
3.2.3. Other fluorinated diazo compounds 
To increase the diversity of substituted pyridazines possessing different fluorinated groups at the C6 
position, other non-commercially available fluorinated diazo compounds were prepared and involved 
in the [2+1]/[3+2]-cycloaddition sequence.  
When 1.5 equiv of (pentafluoroethyl)diazomethane, prepared according to the literature118 from 
2,2,3,3,3-pentafluoropropanamine hydrochloride and sodium nitrite (NaNO2), reacted with 
                                                          
118 a) Mykhailiuk, P. K. Chem. Eur. J. 2014, 20, 49424947; b) Mykhailiuk, P. K. Beilstein J. Org. Chem. 2015, 11, 
1624; c) Mykhailiuk, P. K.; Ishchenko, A. Y.; Stepanenko, V.; Cossy, J. Eur. J. Org. Chem. 2016, 54855493. 
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difluorocyclopropene 23, the cycloaddition product 71 was isolated in 71% yield (Scheme 112). It 
should be mentioned that difluorocyclopropene 23 was formed after a [2+1]-cycloaddition between 
the difluorocarbene generated from TMSCF3/NaI and phenylacetylene 22. 
 
Scheme 112 
In addition, the (difluoromethyl)diazomethane was prepared according to the literature,119 starting 
from 2,2-difluoroethylamine and tert-butyl nitrite in CH2Cl2, in the presence of a catalytic amount of 
acetic acid. It is worth noting that heating the reaction mixture at 70 °C for 10 min was necessary to 
form the (difluoromethyl)diazomethane. When 2.0 equiv of this diazo compound were added to the 
difluorocyclopropene 23, the desired pyridazine 72 was obtained in a low yield of 13% and only 65% 
conversion of 23 was observed after 9 days (Scheme 113). 
 
Scheme 113 
To achieve a total conversion of 23 as well as to obtain a higher yield in 72, 4.0 equiv of 
(difluoromethyl)diazomethane were necessary to carry out the [3+2]-cycloaddition. Under these 
conditions, the corresponding pyridazine 72 was isolated with an improved yield of 44% after 8 days 
(Scheme 114). 
                                                          
119 a) Mykhailiuk, P. K. Angew. Chem. Int. 2015, 54, 65586561; b) Li, J.; Yu, X. -L.; Cossy, J.; Lv, S. -Y.; Zhang, H. 
-L.; Su, F.; Mykhailiuk, P. K.; Wu, Y. Eur. J. Org. Chem. 2017, 266270. 
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Scheme 114 
In summary, the [2+1]/[3+2]-cycloaddition sequence can be carried out not only with 
(trifluoromethyl)diazomethane, but also with other fluorinated diazo compounds, allowing the access 
to a variety of fluorinated pyridazines.  
3.3. Post-functionalization at the C4 position 
α-(Trifluoromethyl)pyridazines O’ were easily accessed by a [2+1]/[3+2]-cycloaddition sequence 
between terminal alkynes M, a difluorocarbene source and a diazo compound. Although this 
cycloaddition sequence is a convenient method to introduce a variety of substituents at the C3 and 
C6 position, the substituent at the C4 position remains always a fluorine atom. To access a diversity 
of pyridazines P’, functionalized at the C4 position, we took advantage of the presence of the fluorine 
atom to introduce other substituents. As fluoropyridazines can be ideal substrates for a nucleophilic 
aromatic substitution (SNAr), this reaction was chosen to functionalize these pyridazines at the C4 
position (Scheme 115).  
 
Scheme 115 
3.3.1. Reactivity of 4-fluoropyridazines with nucleophiles 
Pyridazine 24, substituted by a phenyl group at the C3 position, was chosen as a model substrate, to 
study the nucleophilic aromatic substitution. The fluorine atom can be easily replaced by different 
nucleophiles and the results are reported in Table 15. When pyridazine 24 reacted with a secondary 
amine such as morpholine or dibenzylamine in acetonitrile at 100 °C, the corresponding pyridazines 
73 and 74, were obtained in 85% and 83% yield respectively (Table 15, entries 1 and 2). When a 
primary amine was used as the nucleophile such as allylamine, the desired compound 75 was isolated 
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in a quantitative yield (Table 15, entry 3). Treatment of pyridazine 24 with sodium methoxide in 
acetonitrile, led to pyridazine 76 in 69% yield (Table 15, entry 4). Interestingly, pyridazine 76 was 
obtained in a higher yield of 76% when 24 was treated with methanol in the presence of DBU in DMSO 
(Table 15, entry 5). When the allyl alcohol was used as a nucleophile, the corresponding pyridazine 
77 was isolated in 71% yield (Table 15, entry 6). In addition, sulfur containing nucleophiles can be 
used such as sodium ethanethiolate, leading to pyridazine 78 in 94% yield (Table 15, entry 7). By using 
carbon nucleophiles such as a malonate anion, the corresponding product 79 was obtained with an 
excellent yield (92%) (Table 15, entry 8) however, when a nitromethane anion or a cuprate were used, 
the desired pyridazines 80 and 81 were isolated in low yields of 52% and 12% respectively (Table 15, 
entries 9 and 10).  
 
Entry Nucleophile Conditions Product (%) 
1 
 
MeCN, 100 °C, 3 h 
 
2  MeCN, 100 °C, 72 h 
 
3 
 
MeCN, 100 °C, 4 h 
 
4  MeCN, 100 °C, 48 h 
 
5  
DBU (3.0 equiv) 
DMSO, 80 °C, 3 h 
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6 
 
DBU (3.0 equiv) 
DMSO, 80 °C, 3 h 
 
7  MeCN, 100 °C, 4 h 
 
8 
 
DBU (3.0 equiv) 
DMSO, 80 °C, 3 h 
 
9  
DBU (3.0 equiv) 
DMSO, 80 °C, 3 h 
 
10 
 
Et2O, 0 °C, 48 h 
 
Table 15 
Pyridazine 24 is an excellent substrate for an SNAr reaction, allowing the introduction of different 
nucleophiles such as amines, alkoxy and sulfur derivatives as well as carbanions, to access highly 
functionalized pyridazines.  
3.3.2. Variation of the substituent at the C3 position 
The influence of the substituent at the C3 position of the (trifluoromethyl)pyridazines was 
investigated on the nucleophilic aromatic substitution, using morpholine as a nucleophile. As 
reported previously, when pyridazine 24, substituted by a simple phenyl group at the C3 position was 
treated with morpholine in acetonitrile, the SNAr product 73 was obtained in 85% yield (Table 16, 
entry 1). The replacement of the phenyl ring at C3 by 4-fluorobenzene (the fluorine atom being a 
weak electron-withdrawing group), led to the corresponding α-(trifluoromethyl)pyridazine 82 in an 
excellent yield (quant) (Table 16, entry 2). Treatment of pyridazine 43, possessing an aromatic ring 
substituted by a p-CO2Me group, led to the desired compound 83 in a good yield of 82% (Table 16, 
entry 3). In addition, when pyridazine 32, substituted by an aromatic ring possessing an 
electron-donating group at the para-position, was submitted to the same conditions, pyridazine 84 
was isolated in a quantitative yield (Table 16, entry 4). Replacement of the p-OMe by o-OMe 
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substituent, induced a slight decrease of the yield as pyridazine 85 was obtained in 78% yield instead 
of a quantitative yield (Table 16, entry 5). 
 
Entry Substrate Product (%) 
1a 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
a) The reaction was carried out at 100 °C. 
Table 16 
From the obtained results, we notice that all the products resulting from the SNAr were obtained in 
very good to excellent yields independently of the nature and the position of the substituent at the 
C3 position of the α-(trifluoromethyl)pyridazines. However, the best yields were obtained when the 
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aromatic ring is substituted by an electron-donating or a weak electron-withdrawing group at the 
para-position, indicating a small influence of the stereoelectronic effects of the substituents of the 
aromatic ring on the SNAr reaction. 
3.3.3. Variation of the substituent at the C6 position 
The SNAr was also carried out with 4-fluoro-pyridazines 71 and 72, substituted by different fluorinated 
groups at the C6 position. When pyridazine 71, substituted by a pentafluoroethyl group at the C6 
position, was treated with allylamine and sodium ethanethiolate in acetonitrile at 100 °C, pyridazines 
86 and 87 were isolated in 90% and 84% yield respectively (Scheme 116). 
 
Scheme 116 
The nucleophilic aromatic substitution applied to the 4-fluoro-pyridazine 72 also proceeded 
uneventfully when this pyridazine was treated with allylamine and sodium ethanethiolate, as the 
desired products 88 and 89 were obtained in very good yields of 92% and 87% respectively (Scheme 
117). 
 
Scheme 117
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4. Conclusion 
During this work, a variety of fluorinated pyridazines O’ were synthesized by using a 
[2+1]/[3+2]-cycloaddition sequence between a terminal alkyne M, a difluorocarbene and a diazo 
compound. Indeed, after the [2+1]-cycloaddition of the alkynes M with a difluorocarbene, the 
difluorocyclopropenes N were formed, which after a [3+2]-cycloaddition with a diazo compound 
afforded intermediates Q. After a rearrangement and an aromatization step, pyridazines O’ were 
obtained in 12%89% yield (Scheme 118).120 
 
Scheme 118 
Moreover, pyridazines O’, could be further functionalized by a nucleophilic aromatic substitution 
(SNAr), which rapidly and efficiently led to pyridazines P’ in 12%99% yield, with no significant 
influence of the substituents at the C3 and C6 positions (Scheme 119).  
 
Scheme 119 
It is worth mentioning that during my PhD, a Master student (Gregory Fredj) worked on the synthesis 
of pyridazines S, possessing a hydrogen in the place of the CF3 group. When 
(trifluoromethyl)diazomethane was replaced by (trimethylsilyl)diazomethane, fluoropyridazines S 
were obtained. These fluoropyridazines could also be functionalized at the C4 position, when treated 
with different nucleophiles, to access a variety of 3,4-substituted pyridazines T (Scheme 120).120 
                                                          
120 Feraldi-Xypolia, A.; Fredj, G.; Tran, G.; Tsuchiya, T.; Vors, J. -P.; Mykhailiuk, P.; Gomez Pardo, D.; Cossy, J. 
Asian J. Org. Chem. 2017, 6, 927935. 
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Scheme 120 
Due to this efficient approach, a diversity of substituted 6-(trifluoromethyl)pyridazines can be 
obtained and can potentially lead to interesting biologically active compounds.
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Experimental Part 
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1. General experimental methods 
All reactions were carried out under an argon atmosphere unless otherwise specified. Flasks were 
oven-dried at 120 °C and cooled down under argon prior to use. THF and Et2O were distilled over 
sodium/benzophenone. Et3N, CH2Cl2 and diglyme were distilled over CaH2. NaI and NaF were dried at 
120 °C for 24 h and cooled down under Ar atmosphere. MeCN and DMSO were bought dry from 
Aldrich and used as received. All others reagents were used as obtained from Aldrich without further 
purification unless otherwise specified.  
Purification by flash column chromatography was carried out by using silica gel (pore size 60 Å, 230 
mesh). TLC were performed on silica gel plate (Merck 60F254) and visualized either with a UV lamp 
(254 nm) or by treatment with an aqueous potassium permanganate solution (KMnO4/K2CO3/AcOH) 
and subsequent heating.  
Melting points (Mp) were recorded using a Wagner & Munz Kofler bench and a Büchi Melting Point 
M-560 apparatus with open capillaries. 
 1H NMR spectra were recorded on a Bruker AVANCE 400 at 400 MHz and data are reported as 
follows: chemical shift in ppm, with the solvent as internal standard (CDCl3, δ 7.26 ppm). The 
multiplicity and shape of signals are designated by the following abbreviations: s = singlet, d = doublet, 
t = triplet, q = quadruplet, m = multiplet, br = broad, app = apparent. Coupling constants J were 
measured in Hertz. 
13C NMR spectra were recorded on a Bruker AVANCE 400 at 100 MHz and data are reported as 
follows: chemical shift in ppm, with the solvent as internal standard (CDCl3, δ 77.16 ppm). The 
multiplicity and shape of signals are designated by the following abbreviations: s = singlet, d = doublet, 
t = triplet, q = quadruplet, br = broad, m = multiplet. Coupling constants J were measured in Hertz.  
Infrared (IR) were recorded with a Bruker TENSORTM 27 (IRFT), wave-numbers are indicated in cm–1.  
Mass spectra with electronic impact (MS-EI) were recorded from a Shimadzu GCMS-QP 2010S.  
High Resolution Mass Spectra (HRMS) were performed by the Centre Regional de Microanalyse 
(Université Pierre et Marie Curie, Paris VI, France).
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2. Synthesis and experimental data of terminal alkynes  
1-Ethynyl-4-nitrobenzene (6)121 
 
In a pressure vial were introduced the 1-iodo-4-nitrobenzene 1 (1.00 g, 4.0 mmol, 1.0 equiv), CuI 
(38.7 mg, 0.20 mmol, 5 mol %) and PdCl2(PPh3)2 (141.5 mg, 0.20 mmol, 5 mol %). The vial was flushed 
with argon and dry and degassed THF (10 mL) was added, followed by Et3N (1.7 mL, 3.1 mmol, 3.0 
equiv) and ethynyltrimethylsilane (0.7 mL, 4.89 mmol, 1.2 equiv). The mixture was then sealed with 
a teflon-lined cap and stirred at rt for 2 h. The reaction mixture was filtered over a thin bed of silica 
gel (AcOEt washings), then an aqueous saturated NaHCO3 solution was added to the filtrate and the 
aqueous phase was extracted twice with AcOEt. The combined organic phases were washed with 
brine, dried over Na2SO4 and concentrated under reduced pressure. The product was directly 
engaged without purification and MeOH (15 mL) and K2CO3 (650 mg, 0.36 mmol, 0.1 equiv) were 
added. The resulting suspension was stirred under air at rt for 2 h. The reaction mixture was then 
concentrated under reduced pressure, an aqueous saturated NaHCO3 solution was added and the 
aqueous phase was extracted three times with AcOEt. The combined organic phases were dried over 
Na2SO4 and concentrated under reduced pressure. The crude mixture was purified by flash 
chromatography (Et2O/PE=5:95) to afford 6 (304 mg, 2.21 mmol, 76%) as a beige solid. 
Mp: 148 °C. 
IR (neat): 3254, 1594, 1509, 1351, 1311, 1288, 1107 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.20 (d, J = 8.9 Hz, 2H, H5), 7.64 (d, J = 9.0 Hz, 2H, H4), 3.36 (s, 1H, H1). 
13C NMR (CDCl3, 100 MHz): δ 17.7 (C, C3), 133.1 (CH, C5), 129.1 (C, C6), 123.7 (CH, C4), 82.5 (C, C2), 81.6 
(CH, C1). 
MS m/z (relative intensity): 147 (M+•, 100), 117 (52), 101 (84), 89 (41), 75 (92), 74 (32), 63 (16), 51 
(43), 50 (18).  
 
 
 
                                                          
121 Schmidt, B.; Riemer, M.; Schilde, U. Eur. J. Org. Chem. 2015, 76027611. 
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Methyl 4-ethynylbenzoate (7)122  
 
In a pressure vial were introduced the methyl 4-iodobenzoate 2 (1.36 g, 5.19 mmol, 1.0 equiv), CuI 
(50 mg, 0.26 mmol, 5 mol %) and PdCl2(PPh3)2 (183 mg, 0.26 mmol, 5 mol %). The vial was flushed 
with argon and dry and degassed THF (13 mL) was added, followed by Et3N (1.6 g, 2.2 mL, 15.8 mmol, 
3.0 equiv) and ethynyltrimethylsilane (621 mg, 0.9 mL, 6.32 mmol, 1.2 equiv). The mixture was then 
sealed with a teflon-lined cap and stirred at rt for 2 h. The reaction mixture was filtered over a thin 
bed of silica gel (AcOEt washings), then an aqueous saturated NaHCO3 solution was added to the 
filtrate and the aqueous phase was extracted twice with AcOEt. The combined organic phases were 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The crude mixture 
was purified by flash chromatography (AcOEt/PE=2:98) to afford the desired product (1.20 g, 
5.16 mmol, quant) as a white solid. 
 
Methyl 4-[2-(trimethylsilyl)ethynyl]benzoate122 
Mp: 57 °C. 
IR (neat): 2956, 1719, 1604, 1441, 1406, 1274, 1248, 1172, 1108, 1018, 840 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.97 (d, J = 8.6 Hz, 2H, H6), 7.52 (d, J = 8.6 Hz, 2H, H5), 3.91 (s, 3H, H9), 
0.26 (s, 9H, H1). 
13C NMR (CDCl3, 100 MHz): δ 166.7 (C, C8), 132.0 (2xCH, C6), 129.8 (C, C4), 129.5 (2xCH, C5), 127.9 (C, 
C7), 104.2 (C, C2), 97.8 (C, C3), 52.4 (CH3, C9), 0.0 (3xCH3, C1). 
MS m/z (relative intensity): 232 (M+•, 20), 218 (18), 217 (100), 201 (5), 158 (5), 143 (7), 93 (9), 86 (5), 
79 (8). 
To a solution of methyl 4-[2-(trimethylsilyl)ethynyl]benzoate (1.2 g, 5.16 mmol, 1.0 equiv) in MeOH 
(10 mL) was added K2CO3 (2.1 g, 15.49 mmol, 3.0 equiv) in one portion. The resulting suspension was 
stirred under air at rt for 1 h. The reaction mixture was then concentrated under reduced pressure, 
an aqueous saturated NaHCO3 solution was added and the aqueous phase was extracted three times 
with AcOEt. The combined organic phases were dried over Na2SO4 and concentrated under reduced 
                                                          
122 Pearson, A. J.; Kim, J. B. Tetrahedron Lett. 2003, 44, 85258527. 
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pressure. The crude mixture was purified by flash chromatography (Et2O/PE=5:95) to afford the 
desired product 7 (468 mg, 2.92 mmol, 57%) as a white solid. 
 
Methyl 4-ethynylbenzoate (7) 
Mp: 94 °C. 
IR (neat): 3241, 1702, 1607, 1434, 1403, 1310, 1278, 1193, 1175, 1109, 1017, 959 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.99 (d, J = 8.7 Hz, 2H, H5), 7.55 (d, J = 8.6 Hz, 2H, H4), 3.92 (s, 3H, H8), 
3.23 (s, 1H, H1). 
13C NMR (CDCl3, 100 MHz): δ 166.5 (C, C7), 132.2 (2xCH, C5), 130.2 (C, C3), 129.6 (2xCH, C4), 126.9 (C, 
C6), 82.9 (CH, C1), 80.2 (C, C2), 52.4 (CH3, C8). 
MS m/z (relative intensity): 160 (M+•, 46), 130 (10), 129 (100), 101 (49), 75 (20), 74 (8), 51 (10), 50 
(5). 
2-Chloro-6-pyridine (8)112 
 
In a pressure vial were introduced 6-bromo-2-chloropyridine 3 (361 mg, 1.9 mmol, 1.0 equiv), CuI 
(18.1 mg, 0.09 mmol, 5 mol %) and PdCl2(PPh3)2 (66.1 mg, 0.09 mmol, 5 mol %). The vial was flushed 
with argon and dry and degassed THF (4.4 mL) was added, followed by Et3N (0.8 mL, 5.7 mmol, 3.0 
equiv) and ethynyltrimethylsilane (222 mg, 0.32 mL, 2.26 mmol, 1.2 equiv). The mixture was then 
sealed with a teflon-lined cap and stirred at rt for 2 h. The reaction mixture was filtered over a thin 
bed of silica gel (AcOEt washings), then an aqueous saturated NaHCO3 solution was added to the 
filtrate and the aqueous phase was extracted twice with AcOEt. The combined organic phases were 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The crude mixture 
was purified by flash chromatography (AcOEt/PE=2:98) to afford the desired product (355 mg, 
1.69 mmol, 90%) as a brown solid. 
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2-Chloro-6-[(trimethylsilyl)ethynyl]pyridine112 
Mp: 48 °C. 
IR (neat): 2960, 1569, 1555, 1429, 1250, 1158, 1140 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.60 (m, 1H, H6), 7.37 (dd, J = 7.6 and 0.9 Hz, 1H, H7), 7.26 (dd, J = 8.0 
and 0.9 Hz, 1H, H5), 0.26 (s, 9H, H1). 
13C NMR (CDCl3, 100 MHz): δ 151.3 (C, C8), 143.2 (C, C4), 138.7 (CH, C6), 126.0 (CH, C7), 124.1 (CH, C5), 
102.4 (C, C3), 96.8 (C, C2), 0.29 (3xCH3, C1). 
MS m/z (relative intensity): 210 (M+•, 8), 208 (M+•, 16), 196 (33), 194 (100), 166 (4), 164 (5), 97 (7), 
79 (17), 65 (8), 63 (16). 
To a solution of 2-chloro-6-[(trimethylsilyl)ethynyl]pyridine (355 mg, 1.69 mmol, 1.0 equiv) in MeOH 
(3.6 mL) was added K2CO3 (23.7 mg, 0.17 mmol, 0.1 equiv) in one portion. The resulting suspension 
was stirred under air at rt for 2 h. The reaction mixture was then concentrated under reduced 
pressure, an aqueous saturated NaHCO3 solution was added and the aqueous phase was extracted 
three times with AcOEt. The combined organic phases were dried over Na2SO4 and concentrated 
under reduced pressure. The crude mixture was purified by flash chromatography (Et2O/PE=5:95) to 
afford 8 (159 mg, 1.16 mmol, 68%) as a white solid. 
 
2-Chloro-6-pyridine (8) 
Mp: 37 °C. 
IR (neat): 3295, 1573, 1428, 1159, 1136, 987 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.64 (tapp, J = 7.6 Hz, 1H, H5), 7.41 (d, J = 7.6 Hz, 1H, H6), 7.32 (d, J = 8.0 Hz, 
1H, H4), 3.21 (s, 1H, H1). 
13C NMR (CDCl3, 100 MHz): δ 151.5 (C, C7), 142.4 (C, C3), 138.9 (CH, C5), 126.1 (CH, C6), 124.6 (CH, C4), 
81.6 (C, C2), 78.7 (CH, C1). 
MS m/z (relative intensity): 139 (M+•, 33), 137 (M+•, 100), 102 (77), 74 (10), 62(4), 51 (23), 50 (24). 
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2-Chloro-5-ethynylpyridine (9)112  
 
In a pressure vial were introduced 5-bromo-2-chloropyridine 4 (1.0 g, 5.2 mmol, 1.0 equiv), CuI 
(50 mg, 0.26 mmol, 5 mol %) and PdCl2(PPh3)2 (183 mg, 0.26 mmol, 5 mol %). The vial was flushed 
with argon and dry and degassed THF (13 mL) was added, followed by Et3N (1.6 g, 2.2 mL, 15.8 mmol, 
3.0 equiv) and ethynyltrimethylsilane (614 mg, 0.89 mL, 6.25 mmol, 1.2 equiv). The mixture was then 
sealed with a teflon-lined cap and heated in a Biotage Initiator microwave oven at 90 °C for 2 h. The 
reaction mixture was cooled down to rt, filtered over a thin bed of silica gel (AcOEt washings), then 
an aqueous saturated NaHCO3 solution was added to the filtrate and the aqueous phase was 
extracted twice with AcOEt. The combined organic phases were washed with brine, dried over Na2SO4 
and concentrated under reduced pressure. The crude mixture was purified by flash chromatography 
(PE=100% and Et2O/PE=2:98) to afford the desired product (790 mg, 3.77 mmol, 72%) as a white solid.  
 
2-Chloro-5-[(trimethylsilyl)ethynyl]pyridine123 
Mp: 58 °C. 
IR (neat): 2961, 1579, 1548, 1454, 1356, 1251, 1226, 1133, 1106, 1021 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.18 (dd, J = 2.3 and 0.7 Hz, 1H, H8), 7.41 (dd, J = 8.3 and 2.4 Hz, 1H, H5), 
6.99 (dd, J = 8.3 and 0.7 Hz, 1H, H6), 0.00 (s, 9H, H1). 
13C NMR (CDCl3, 100 MHz): δ 152.1 (CH, C8), 150.3 (C, C7), 141.0 (CH, C5), 123.5 (CH, C6), 118.9 (C, C4), 
99.9 (C, C2 or C3), 99.3 (C, C2 or C3), 0.5 (3xCH3, C1). 
MS m/z (relative intensity): 211 (M+•, 7), 209 (M+•, 19), 196 (35), 194 (100), 166 (5), 164 (5), 89 (7), 
80 (15), 63 (11). 
To a solution of 2-chloro-5-[(trimethylsilyl)ethynyl]pyridine (600 mg, 2.86 mmol, 1.0 equiv) in MeOH 
(6 mL) was added K2CO3 (39 mg, 0.29 mmol, 0.1 equiv) in one portion. The resulting suspension was 
stirred under air at rt for 30 min. The reaction mixture was then concentrated under reduced 
pressure, an aqueous saturated NaHCO3 solution was added and the aqueous phase was extracted 
three times with AcOEt. The combined organic phases were dried over Na2SO4 and concentrated 
                                                          
123 Hapuarachchige, S.; Montano, G.; Ramesh, C.; Rodriguez, D.; Henson, L. H.; Williams, C. C.; Kadavakkollu, S.; 
Johnson, D. L.; Shuster, C. B.; Arterburn, J. B. J. Am. Chem. Soc. 2011, 133, 67806790. 
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under reduced pressure. The crude mixture was purified by flash chromatography (Et2O/PE=5:95) to 
afford the desired product 9 (290 mg, 2.11 mmol, 74%) as a white solid. 
 
2-Chloro-5-ethynylpyridine (9) 
Mp: 84 °C. 
IR (neat): 3209, 1577, 1550, 1451, 1352, 1287, 1105, 1158, 1021 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.50 (br d, J = 2.3 Hz, 1H, H7), 7.72 (dd, J = 8.3 and 2.3 Hz, 1H, H4), 7.31 
(dd, J = 8.3 and 0.7 Hz, 1H, H5), 3.27 (s, 1H, H1). 
13C NMR (CDCl3, 100 MHz): δ 152.8 (CH, C7), 151.3 (C, C6), 141.6 (CH, C4), 124.0 (CH, C5), 118.3 (C, C3), 
81.9 (C, C2), 79.2 (CH, C1). 
MS m/z (relative intensity): 139 (M+•, 32), 137 (M+•, 100), 102 (62), 76 (8), 75 (28), 74 (14), 51 (10), 
50 (17). 
5-Ethynyl-2-methyl-1,3-benzoxazole (10)112  
 
In a pressure vial were introduced 5-bromo-2-methyl-1,3-benzoxazole 5 (1.0 g, 4.72 mmol, 1.0 equiv), 
CuI (89.8 mg, 0.47 mmol, 10 mol %) and PdCl2(PPh3)2 (331 mg, 0.47 mmol, 10 mol %). The vial was 
flushed with argon and dry and degassed THF (12 mL) was added, followed by Et3N (2.0 mL, 
14.2 mmol, 3.0 equiv) and trimethylsilylacetylene (2.0 mL, 13.7 mmol, 2.9 equiv). The mixture was 
then sealed with a teflon-lined cap and stirred at rt for 2 h. The reaction mixture was filtered over a 
thin bed of silica gel (AcOEt washings), then an aqueous saturated NaHCO3 solution was added to the 
filtrate and the aqueous phase was extracted twice with AcOEt. The combined organic phases were 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The product was 
directly engaged without purification and MeOH (11 mL) and K2CO3 (1.96 g, 14.15 mmol, 3.0 equiv) 
were added. The resulting suspension was stirred under air at rt for 4 h. The reaction mixture was 
then concentrated under reduced pressure, an aqueous saturated NaHCO3 solution was added and 
the aqueous phase was extracted three times with AcOEt. The combined organic phases were dried 
over Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash 
column chromatography (Et2O/PE=10:90) to give 10 (645 mg, 4.10 mmol, 87%) as a brown solid. 
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Mp: 71 °C. 
IR (neat): 3291, 2108, 1623, 1575, 1469, 1428, 1382, 1260, 1180 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.79 (s, 1H, H4), 7.457.39 (m, 2H, H9 and H10), 3.06 (s, 1H, H1), 2.64 (s, 
3H, H7). 
13C NMR (CDCl3, 100 MHz): δ 165.1 (C, C6), 151.3 (C, C8), 141.7 (C, C5), 129.0 (CH, C10), 123.5 (CH, C4), 
118.2 (C, C3), 110.4 (CH, C9), 83.5 (CH, C1), 76.6 (C, C2), 14.6 (CH3, C7). 
MS m/z (relative intensity): 157 (M+•, 100), 128 (9), 116 (8), 102 (16), 88 (38), 87 (12), 79 (6), 62 (31). 
Diethyl (4-ethynylphenyl)phosphonate (12)124  
 
1-Bromo-4-iodobenzene 11 (2.00 g, 7.07 mmol, 1.0 equiv), CuI (34 mg, 0.18 mmol, 2.5 mol %), 
PdCl2(PPh3)2 (20 mg, 0.028 mmol, 0.4 mol %), and PPh3 (28 mg, 0.11 mmol, 1.5 mol %) were 
introduced in a round bottom flask, which was then flushed with argon. Et3N (23 mL) was then added, 
the resulting solution was stirred at rt for 10 min, and trimethylsilylacetylene (1.00 mL, 7.07 mmol, 
1.0 equiv) was then added. The resulting solution was stirred at rt for 6 h, before being filtered over 
a glass frit. The filtrate was concentrated under reduced pressure to give a yellow oil, which was then 
filtered over a short pad of silica gel (PE washings). The filtrate was concentrated under reduced 
pressure to give the desired product (1.8 g, 7.1 mmol, quant) as a white solid. 
 
[(4-Bromophenyl)ethynyl]trimethylsilane125 
Mp: 58 °C. 
IR (neat): 2959, 1486, 1394, 1250, 1214, 1071, 1011 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.447.38 (m, 2H, H6), 7.337.26 (m, 2H, H5), 0.24 (s, 9H, H1). 
13C NMR (CDCl3, 100 MHz): δ 133.5 (CH, C5), 131.6 (CH, C6), 122.9 (C, C4 or C7), 122.3 (C, C4 or C7), 104.0 
(C, C3), 95.5 (C, C2), 0.0 (3xCH3, C1). 
                                                          
124 Onouchi, H.; Maeda, K.; Yashima, E. J. Am. Chem. Soc. 2001, 123, 74417442. 
125 Shigeta, M.; Watanabe, J.; Konishi, G. Tetrahedron 2013, 54, 17611764. 
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MS m/z (relative intensity): 254 (M+•, 22), 252 (M+•, 22), 239 (100), 237 (100), 220 (14), 209 (5), 207 
(6), 158 (4), 119 (9), 118 (9), 109 (3), 107 (4), 79 (10). 
In a pressure vial were weighted [(4-bromophenyl)ethynyl]trimethylsilane (1.2 g, 4.7 mmol, 1.0 
equiv), Pd(PPh3)4 (274 mg, 0.24 mmol, 5 mol %) and PPh3 (6.2 mg, 0.024 mmol, 0.5 mol %). The vial 
was flushed with argon, then dry toluene (25 mL) was added, followed by Et3N (0.72 mL, 5.2 mmol, 
1.1 equiv). The vial was sealed with a teflon-lined cap, the reaction mixture was stirred at 110 °C for 
5 min, then diethyl phosphite (0.78 mL, 5.7 mmol, 1.2 equiv) was added through the septum. The 
reaction mixture was then stirred at 110 °C for 4 h. An aqueous saturated NaHCO3 solution was added 
to the reaction mixture, and the aqueous phase was extracted 2 times with EtOAc. The combined 
organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure 
to give a black oil. The crude mixture was purified by flash chromatography (AcOEt/PE=50:50) to give 
the desired product (1.19 g, 3.80 mmol, 81%) as a pale yellow oil. 
 
Diethyl {4-[(trimethylsilyl)ethynyl]phenyl}phosphonate124 
IR (neat): 2981, 1560, 1392, 1249, 1128, 1051, 1019, 964 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.757.70 (m, 2H, H6), 7.547.51 (m, 2H, H5), 4.154.02 (m, 4H, H8), 1.30 
(t, J = 7.1 Hz, 6H, H9), 0.25 (d, J = 3.4 Hz, 9H, H1). 
13C NMR (CDCl3, 100 MHz): δ 131.9 (2xCH, d, J = 15.2 Hz, C5), 131.7 (2xCH, d, J = 10.0 Hz, C6), 128.4 (C, 
d, J = 189.0 Hz, C7), 127.4 (C, d, J = 3.4 Hz, C4), 104.0 (C, C3), 97.6 (C, C2), 62.3 (2xCH2, d, J = 5.4 Hz, C8), 
16.4 (2xCH3, d, J = 6.4 Hz, C9), 0.0 (3xCH3, C1). 
MS m/z (relative intensity): 310 (M+•, 21), 296 (19), 295 (100), 282 (18), 267 (28), 237 (8), 221 (36), 
158 (9), 120 (15). 
To a solution of diethyl {4-[(trimethylsilyl)ethynyl]phenyl}phosphonate (1.18 g, 3.8 mmol, 1.0 equiv) 
in THF (59 mL) was added TBAF (1.0 M in THF, 13.0 mL, 3.4 mmol, 3.4 equiv). The resulting solution 
was stirred at 0 °C for 2 h. This solution was then filtered over a short pad of silica gel (EtOAc 
washings), and the filtrate was concentrated under reduced pressure to give an orange oil. The crude 
mixture was purified by flash chromatography (AcOEt/PE=50:50) to afford 12 (799 mg, 3.35 mmol, 
88%) as a yellow oil. 
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Diethyl (4-ethynylphenyl)phosphonate (12)  
IR (neat): 3200, 2983, 1560, 1392, 1240, 1125, 1049, 1016, 962 cm–1. 
1H NMR (400 MHz, CDCl3): δ 7.807.74 (m, 2H, H5), 7.597.56 (m, 2H, H4), 4.194.05 (m, 4H, H7), 3.22 
(s, 1H, H1), 1.32 (td, J = 7.1 and 0.6 Hz, 6H, H8). 
13C NMR (CDCl3, 100 MHz): δ 132.1 (2xCH, d, J = 15.2 Hz, C4), 131.8 (2xCH, d, J = 10.0 Hz, C5), 129.0 (C, 
d, J = 189.1 Hz, C6), 126.4 (C, d, J = 3.5 Hz, C3), 82.7 (C, d, J = 1.5 Hz, C2), 79.9 (CH, C1), 62.4 (2xCH2, d, 
J = 5.4 Hz, C7), 16.4 (2xCH3, d, J = 6.4 Hz, C8). 
MS m/z (relative intensity): 238 (M+•, 23), 210 (19), 183 (13), 182 (100), 166 (31), 165 (39), 129 (46), 
128 (14), 118 (43), 102 (53), 101 (37), 89 (8), 75 (27), 65 (8), 51 (12). 
Methyl 3-ethynylbenzoate (14)126 
 
To a solution of 3-ethynylbenzoic acid 13 (927 mg, 6.34 mmol, 1.0 equiv) in DMF (30 mL), were added 
K2CO3 (1.3 g, 9.41 mmol, 1.5 equiv) and MeI (1.5 g, 0.64 mL, 10.2 mmol, 1.6 equiv). The solution was 
stirred at rt for 16 h. The reaction mixture was then filtrated and concentrated under reduced 
pressure and an aqueous saturated NaHCO3 solution was added. The aqueous phase was extracted 
three times with Et2O. The combined organic phases were dried over Na2SO4 and concentrated under 
reduced pressure. The crude mixture was purified by flash chromatography (Et2O/PE=20:80) to afford 
14 (910 mg, 5.68 mmol, 90%) as a yellow pale solid. 
Mp: 54 °C. 
IR (neat): 3255, 1714, 1598, 1581, 1482, 1432, 1293, 1273, 1195, 1100, 1079, 969 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.14 (tapp, J = 1.4 Hz, 1H, H8), 7.98 (dtapp, J = 7.9 and 1.4 Hz, 1H, H6), 7.64 
(dtapp, J = 7.7 and 1.4 Hz, 1H, H4), 7.37 (tapp, J = 7.8 Hz, 1H, H5), 3.90 (s, 3H, H10), 3.17 (s, 1H, H1). 
13C NMR (CDCl3, 100 MHz): δ 166.1 (C, C9), 136.1 (CH, C4), 133.1 (CH, C8), 130.4 (C, C7), 129.7 (CH, C6), 
128.4 (CH, C5), 122.5 (C, C3), 82.5 (CH, C1), 78.3 (C, C2), 52.2 (CH3, C10). 
                                                          
126 Gao, M.; Duan, L.; Luo, J.; Zhang, L.; Lu, X.; Zhang, Y.; Zhang, Z.; Tu, Z.; Xu, Y.; Ren, X.; Ding, K. J. Med. Chem. 
2013, 56, 32813295. 
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MS m/z (relative intensity): 160 (M+•, 58), 130 (10), 129 (100), 102 (6), 101 (63), 75 (25), 74 (12), 51 
(13), 50 (6). 
N-Propargyl phthalimide (17)112  
 
To a solution of PPh3 (3.27 g, 12.5 mmol, 1.0 equiv) and phthalimide 16 (1.84 g, 12.5 mmol, 1.0 equiv) 
in dry THF (63 mL) were added neat 3-propyn-1-ol 15 (0.74 mL, 12.5 mmol, 1.0 equiv), followed by 
neat diisopropyl azodicarboxylate (2.6 mL, 12.5 mmol, 1.0 equiv). The resulting solution was stirred 
at rt for 24 h. After concentration under reduced pressure, purification by flash chromatography 
(CH2Cl2/PE=50:50) led to 17 (2.0 g, 10.8 mmol, 87%) as a white solid.  
Mp: 150 °C. 
IR (neat): 3293, 2966, 1770, 1706, 1470, 1429, 1396, 1353, 1327, 1190, 1120, 950 cm–1. 
1H NMR (400 MHz, CDCl3): δ 7.907.88 (m, 2H, H6 or H7), 7.767.74 (m, 2H, H6 or H7), 4.46 (d, J = 2.5 
Hz, 2H, H3), 2.23 (t, J = 2.5 Hz, 1H, H1). 
13C NMR (CDCl3, 100 MHz): δ 167.1 (2xC, C4), 134.4 (2xCH, C6 or C7), 132.1 (2xC, C5), 123.7 (2xCH, C6 
or C7), 77.3 (C, C2), 71.6 (CH, C1), 27.1 (CH2, C3). 
MS m/z (relative intensity): 185 (M+•, 100), 157 (70), 156 (26), 129 (29), 104 (33), 102 (41), 76 (63), 
50 (32). 
N-Homopropargyl phthalimide (19)127 
 
To a solution of PPh3 (5.23 g, 20.0 mmol, 1.0 equiv) and phthalimide 16 (2.94 g, 20.0 mmol, 1.0 equiv) 
in dry THF (100 mL) were added neat 3-butyn-1-ol 18 (1.50 mL, 20.0 mmol, 1.0 equiv), followed by 
neat diisopropyl azodicarboxylate (4.0 mL, 20.2 mmol, 1.0 equiv). The resulting solution was stirred 
at rt for 40 h. After concentration under reduced pressure, purification by flash chromatography 
(CH2Cl2/PE=50:50) led to 19 (3.6 g, 18.1 mmol, 91%) as a white solid.  
                                                          
127 Iyer, S.; Liebeskind, L. S. J. Am. Chem. Soc. 1987, 109, 27592770. 
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Mp: 136 °C. 
IR (neat): 3251, 2924, 1765, 1698, 1468, 1427, 1399, 1370, 1336, 1248, 1190, 1115, 995, 868 cm–1. 
1H NMR (400 MHz, CDCl3): δ 7.877.84 (m, 2H, H7), 7.767.72 (m, 2H, H8), 3.89 (t, J = 7.1 Hz, 2H, H4), 
2.62 (td, J = 7.1 and 2.7 Hz, 2H, H3), 1.98 (t, J = 2.7 Hz, 1H, H1). 
13C NMR (CDCl3, 100 MHz): δ 168.1 (2xC, C5), 134.1 (2xCH, C7), 132.0 (2xC, C6), 123.4 (2xCH, C8), 80.4 
(C, C2), 70.4 (CH, C1), 36.6 (CH2, C4), 18.4 (CH2, C3). 
MS m/z (relative intensity): 199 (M+•, 28), 160 (100), 133 (21), 104 (12), 77 (20), 50 (9). 
N,N-Bis[(tert-butoxy)carbonyl]-N-(but-3-yn-1-yl)carbamate (21)112  
 
To a solution of N-homopropargyl phthalimide 19 (3.14 g, 15.8 mmol, 1.0 equiv) in absolute ethanol 
(70 mL) was added hydrazine hydrate (1.20 mL, 31.5 mmol, 2.0 equiv) and the solution was refluxed 
for 1 h. The resulting suspension was poured onto 20 mL of a 1 M aqueous solution of HCl, and filtered 
over a fritted glass. The filtrate was concentrated under reduced pressure to give a yellow solid. 
This solid was suspended in MeCN (7 mL), and Boc2O (8.4 mL, 39.4 mmol, 2.5 equiv) was added, 
followed by Et3N (6.60 mL, 47.3 mmol, 3.0 equiv) and DMAP (1.93 g, 15.8 mmol, 1.0 equiv). The 
resulting suspension was stirred at rt for 20 h. An aqueous saturated solution of NaHCO3 was added, 
followed by AcOEt. The aqueous phase was extracted twice with AcOEt. The combined organic phases 
were washed once with an aqueous 0.5 M HCl solution, twice with H2O, once with brine, dried over 
Na2SO4, and concentrated under reduced pressure to afford a white solid (1.9 g). GCMS analysis 
showed that the solid was not 21 but the monoprotected product 20. 
To a solution of this crude solid (1.90 g, 11.2 mmol, 1.0 equiv) in MeCN (6 mL) was added Boc2O (3.60 
g, 16.9 mmol, 1.5 equiv), followed by DMAP (1.37 g, 11.2 mmol, 1.0 equiv). The resulting solution was 
stirred at rt for 16 h. After concentration under reduced pressure, purification by flash column 
chromatography on silica gel (Et2O/PE=20:80) led to 21 (840 mg, 3.11 mmol, 20% yield) as a white 
solid. 
Mp: 57 °C. 
IR (neat): 3285, 2981, 1733, 1696, 1393, 1368, 1347, 1280, 1142, 1110. 
1H NMR (CDCl3, 400 MHz): δ 3.77 (t, J = 7.3 Hz, 2H, H4), 2.47 (td, J = 6.7 and 2.7 Hz, 2H, H3), 1.95 (td, J 
= 2.6 and 1.4 Hz, 1H, H1), 1.51 (s, 18H, H7). 
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13C NMR (CDCl3, 100 MHz): δ 152.4 (2xC, C5), 82.6 (2xC, C6), 81.2 (C, C2), 69.8 (CH, C1), 44.9 (CH2, C4), 
28.2 (6xCH3, C7), 18.9 (CH2, C3).
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3. General procedures for the [2+1]/[3+2]-cycloaddition 
sequence 
Procedure A: TMSCF3 as the carbene CF2 source. 
In an oven-dried vial were introduced NaI (2.2 equiv) and the alkyne (1.0 equiv). The vial was then 
flushed with argon, and THF (c = 0.375 M) was added, followed by the addition of neat TMSCF3 (2.0 
equiv). The vial was then immerged in a pre-heated oil bath at 110 °C. Vigorous stirring was then 
applied for 2 h and completion of the reaction was monitored by TLC or GC/MS. If necessary, 
supplementary amounts of TMSCF3 were added until complete consumption of the alkyne. The 
reaction mixture was allowed to cool down to rt and to this solution was added Et3N (1.5 equiv), 
followed by the addition of (trifluoromethyl)diazomethane (0.6 M in CH2Cl2, 1.5 equiv). The resulting 
solution was stirred at rt under argon, until complete consumption of the gem-difluorocyclopropene, 
as assessed by TLC or GC/MS. The reaction mixture was then carefully concentrated under reduced 
pressure and purified by flash column chromatography on silica gel. 
Procedure B: TFDA as the carbene CF2 source. 
In an oven-dried vial were introduced NaF (0.2 equiv) and the alkyne (1.0 equiv). The vial was then 
flushed with argon and diglyme (c = 2.0 M) was added. The reaction mixture was then heated in a 
pre-equilibrated oil bath at 120 °C and neat TFDA (3.0 equiv) was added dropwise over 1 h using a 
syringe pump. At the end of the addition, the reaction mixture was stirred for 1 h and completion of 
the reaction was assessed by TLC or GC/MS. The reaction mixture was allowed to cool down to rt and 
to this solution was added Et3N (1.5 equiv), followed by the addition of 
(trifluoromethyl)diazomethane (0.6 M in CH2Cl2, 1.5 equiv). The resulting solution was stirred, under 
argon until complete consumption of the gem-difluorocyclopropene, as assessed by TLC or GC/MS. 
The reaction mixture was then carefully concentrated under reduced pressure and purified by flash 
column chromatography on silica gel. 
Formation of (trifluoromethyl)diazomethane in CH2Cl2 
In an oven-dried vial were introduced 2,2,2-trifluoroethylamine hydrochloride (1.5 equiv compared 
to the alkyne) and NaNO2 (1.8 equiv compared to the alkyne). The vial was then flushed with argon, 
CH2Cl2 (c = 0.6 M) and H2O (CH2Cl2/H2O=30:1) were added and the solution was stirred at 0 °C for 1 h 
and at 78 °C for 10 min. The solution was then added to the difluorocyclopropene solution via a 
syringe.
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4. Synthesis and spectroscopic data of 
6-(trifluoromethyl)pyridazines 
4-Fluoro-3-phenyl-6-(trifluoromethyl)pyridazine (24) 
 
Prepared according to procedure A from phenylacetylene 22 (70 mg, 0.69 mmol, 1.0 equiv). After the 
addition of (trifluoromethyl)diazomethane, 40 h were necessary to reach complete consumption of 
the gem-difluorocyclopropene. The crude mixture was purified by flash chromatography 
(AcOEt/PE=2:98) to afford 24 (145 mg, 0.60 mmol, 87%) as a light yellow solid. 
Mp: 75 °C. 
IR (neat): 3081, 2928, 2856, 1598, 1555, 1453, 1407, 1320, 1296, 1248, 1145, 1078, 1036 942 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.088.05 (m, 2H, H7), 7.63 (d, J = 10.5 Hz, 1H, H2), 7.567.52 (m, 3H, H8 
and H9). 
13C NMR (CDCl3, 100 MHz): δ 160.4 (C, d, J = 281.5 Hz, C3), 153.6 (C, d, J = 4.7 Hz, C4), 151.9 (C, qd, J = 
35.6 and 3.3 Hz, C1), 131.4 (CH, C9), 130.9 (C, d, J = 4.7 Hz, C6), 129.4 (2xCH, d, J = 5.2 Hz, C7), 129.0 
(2xCH, C8), 120.8 (C, qd, J = 274.6 and 2.8 Hz, C5), 111.8 (CH, dq, J = 18.1 and 2.4 Hz, C2). 
19F NMR (CDCl3, 470 MHz): δ 66.7 (s, F, CF3), 113.5 (s, 1F, F). 
MS m/z (relative intensity): 242 (M+•, 100), 214 (22), 213 (17), 195 (13), 170 (10), 164 (24), 120 (34), 
102 (14). 
HRMS: calcd for C11H7F4N2 (M+H+): 243.0540. Found 243.0542. 
4-Fluoro-3-(p-tolyl)-6-(trifluoromethyl)pyridazine (31) 
 
Prepared according to procedure A from 4-ethynyltoluene 25 (60 mg, 0.52 mmol, 1.0 equiv). After 
the addition of (trifluoromethyl)diazomethane, 6 days were necessary to reach complete 
consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (AcOEt/PE=2:98) to afford 31 (99 mg, 0.39 mmol, 75%) as a light yellow solid. 
Mp: 86 °C. 
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IR (neat): 3050, 2927, 1587, 1427, 1393, 1317, 1295, 1267, 1251, 1151, 1080, 943 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.99 (dd, J = 8.3 and 1.8 Hz, 2H, H7), 7.59 (d, J = 10.7 Hz, 1H, H2), 7.35 (br 
d, J = 8.0 Hz, 2H, H8), 2.44 (s, 3H, H10). 
13C NMR (CDCl3, 100 MHz): δ 160.4 (C, d, J = 281.2 Hz, C3), 153.6 (C, d, J = 5.1 Hz, C4), 151.6 (C, qd, J = 
35.6 and 3.3 Hz, C1), 142.0 (C, C9), 129.8 (2xCH, C8), 129.3 (2xCH, d, J = 5.5 Hz, C7), 128.1 (C, d, J = 
4.8 Hz, C6), 120.8 (C, qd, J = 274.4 and 2.7 Hz, C5), 111.6 (CH, dq, J = 18.2 and 2.4 Hz, C2), 21.5 (CH3, 
C10). 
MS m/z (relative intensity): 256 (M+•, 100), 228 (14), 213 (4), 177 (4), 159 (8), 134 (13), 133 (30), 115 
(11), 107 (4). 
HRMS: calcd for C12H9F4N2 (M+H+): 257.0696. Found 257.0696. 
4-Fluoro-3-(4-methoxyphenyl)-6-(trifluoromethyl)pyridazine (32) 
 
Prepared according to procedure A from 4-ethynylanisole 26 (70 mg, 0.53 mmol, 1.0 equiv). After the 
addition of (trifluoromethyl)diazomethane, 3 weeks were necessary to reach complete consumption 
of the gem-difluorocyclopropene. The crude mixture was purified by flash chromatography 
(AcOEt/PE=5:95) to afford 32 (120 mg, 0.44 mmol, 83%) as a light yellow oil. 
IR (neat): 2847, 1656, 1592, 1511, 1463, 1433, 1397, 1315, 1253, 1172, 1149, 1078, 1030, 980, 
940 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.128.09 (m, 2H, H7), 7.58 (d, J = 10.9 Hz, 1H, H2), 7.077.03 (m, 2H, 
H8), 3.88 (s, 3H, H10). 
13C NMR (CDCl3, 100 MHz): δ 162.3 (C, C9), 160.1 (C, d, J = 280.8 Hz, C3), 153.1 (C, d, J = 4.2 Hz, C4), 
151.1 (C, qd, J = 35.5 and 3.3 Hz, C1), 131.1 (2xCH, d, J = 6.0 Hz, C7), 123.3 (C, d, J = 5.0 Hz, C6), 120.9 
(C, qd, J = 274.6 and 2.8 Hz, C5), 114.5 (2xCH, C8), 111.5 (CH, dq, J = 18.2 and 2.4 Hz, C2), 55.5 (CH3, 
C10). 
MS m/z (relative intensity): 272 (M+•, 100), 244 (26), 200 (16), 201 (15), 151 (16), 150 (22), 135 (11), 
132 (11), 107 (13). 
HRMS: calcd for C12H9F4N2O (M+H+): 273.0646. Found 273.0648. 
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4-Fluoro-3-(2-methoxyphenyl)-6-(trifluoromethyl)pyridazine (33) 
 
Prepared according to procedure A from 2-ethynylanisole 27 (70 mg, 0.53 mmol, 1.0 equiv). After the 
addition of (trifluoromethyl)diazomethane, 15 days were necessary to reach complete consumption 
of the gem-difluorocyclopropene. The crude mixture was purified by flash chromatography 
(AcOEt/PE=5:95) to afford 33 (105 mg, 0.39 mmol, 73%) as a yellow oil. 
Prepared according to procedure B from 2-ethynylanisole 27 (65 mg, 0.49 mmol, 1.0 equiv). After the 
addition of (trifluoromethyl)diazomethane, 72 h were necessary to reach complete consumption of 
the gem-difluorocyclopropene. The crude mixture was purified by flash chromatography 
(Et2O/PE=15:85) to afford 33 (91 mg, 0.33 mmol, 68%) as a yellow oil. 
IR (neat): 2944, 1604, 1496, 1464, 1438, 1408, 1261, 1238, 1146, 1075, 1047, 1024, 1010, 942 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.607.57 (m, 2H, H2 and H11), 7.53 (ddd, J = 8.4, 7.5 and 1.7 Hz, 1H, H9), 
7.13 (tdapp, J = 7.5 and 0.9 Hz, 1H, H10), 7.05 (d, J = 8.4 Hz, 1H, H8), 3.83 (s, 3H, H12). 
13C NMR (CDCl3, 100 MHz): δ 160.7 (C, d, J = 280.8 Hz, C3), 157.6 (C, C7), 154.1 (C, d, J = 10.3 Hz, C4), 
152.3 (C, qd, J = 35.5 and 3.5 Hz, C1), 132.5 (CH, C9), 131.4 (CH, C11), 121.1 (CH, C10), 120.9 (C, qd, J = 
274.7 and 2.9 Hz, C5), 120.6 (C, d, J = 3.6 Hz, C6), 111.3 (CH, C8), 110.7 (CH, dq, J = 17.5 and 2.2 Hz, C2), 
55.7 (CH3, C12). 
MS m/z (relative intensity): 272 (M+•, 99), 253 (61), 244 (53), 213 (21), 203 (100), 164 (30), 154 (32), 
151 (34), 120 (29), 107 (43). 
HRMS: calcd for C12H9F4N2O (M+H+): 273.0646. Found 273.0649. 
4-Fluoro-3-mesityl-6-(trifluoromethyl)pyridazine (34) 
 
Prepared according to procedure A from 2-ethynyl-1,3,5-trimethylbenzene 28 (70 mg, 0.49 mmol, 1.0 
equiv). After the addition of (trifluoromethyl)diazomethane (2.0 equiv), 1 month was necessary to 
reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (AcOEt/PE=2:98) to afford 34 (105 mg, 0.37 mmol, 76%) as an orange solid. 
Mp: 95 °C. 
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IR (neat): 1613, 1550, 1446, 1401, 1279, 1246, 1148, 1069, 1010, 954, 934 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.64 (d, J = 8.4 Hz, 1H, H2), 7.02 (s, 2H, H8), 2.36 (s, 3H, H11), 2.03 (s, 6H, 
H10). 
13C NMR (CDCl3, 100 MHz): δ 160.2 (C, d, J = 276.8 Hz, C3), 156.7 (C, d, J = 11.3 Hz, C4), 152.5 (C, qd, J 
= 35.6 and 3.0 Hz, C1), 140.1 (C, C9), 136.7 (2xC, C7), 128.9 (2xCH, C8), 127.2 (C, d, J = 2.7 Hz, C6), 120.8 
(C, qd, J = 274.9 and 3.0 Hz, C5), 110.9 (CH, dq, J = 17.6 and 2.3 Hz, C2), 21.2 (CH3, C11), 19.8 (2xCH3, 
C10). 
MS m/z (relative intensity): 284 (M+•, 33), 283 (10), 269 (25), 267 (16), 265 (100), 250 (11), 215 (25), 
200 (9), 171 (6), 146 (19), 133 (7), 115 (9), 77 (10). 
HRMS: calcd for C14H13F4N2 (M+H+): 285.1009. Found 285.1009. 
4-Fluoro-3-(6-methoxynaphthalene)-6-(trifluoromethyl)pyridazine (36) 
 
Prepared according to procedure A from 2-ethynyl-6-methoxynaphthalene 30 (100 mg, 0.55 mmol, 
1.0 equiv). After the addition of (trifluoromethyl)diazomethane, 40 h were necessary to reach 
complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (AcOEt/PE=4:96 and 6:94) to afford 36 (139 mg, 0.43 mmol, 79%) as a yellow solid. 
Mp: 119 °C. 
IR (neat): 1629, 1487, 1426, 1386, 1255, 1203, 1164, 1076, 904 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.48 (s, 1H, H7), 8.15 (dtapp, J = 8.7 and 1.7 Hz, 1H, H15), 7.82 (d, J = 7.2 Hz, 
1H, H9 or H14), 7.80 (d, J = 7.4 Hz, 1H, H9 or H14), 7.55 (d, J = 10.9 Hz, 1H, H2), 7.17 (dd, J = 8.9 and 
2.5 Hz, 1H, H10), 7.12 (dapp, J = 2.4 Hz, 1H, H12), 3.91 (s, 3H, H16). 
13C NMR (CDCl3, 100 MHz): δ 160.5 (C, d, J = 281.5 Hz, C3), 159.5 (C, C11), 153.4 (C, d, J = 4.3 Hz, C4), 
151.3 (C, qd, J = 35.4 and 3.3 Hz, C1), 136.1 (C, C6), 130.8 (CH, C10 or C14), 130.1 (CH, d, J = 7.3 Hz, C7), 
128.4 (C, C13), 127.6 (CH, C10 or C14), 126.0 (CH, d, J = 4.4 Hz, C15), 126.0 (C, d, J = 4.9 Hz, C8), 120.8 (C, 
qd, J = 274.4 and 2.6 Hz, C5), 119.8 (CH, C9), 111.6 (CH, dq, J = 18.3 and 2.4 Hz, C2), 105.7 (CH, C12), 
55.4 (CH3, C16). 
MS m/z (relative intensity): 322 (M+•, 100), 294 (7), 279 (16), 251 (21), 250 (11), 201 (9), 200 (11), 
157 (23), 147 (5). 
HRMS: calcd for C16H11F4N2O (M+H+): 323.0802. Found 323.0804. 
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4-Fluoro-3-[2-(trifluoromethyl)phenyl]-6-(trifluoromethyl)pyridazine (41) 
 
Prepared according to procedure A from 1-ethynyl-2-(trifluoromethyl)benzene 37 (70 mg, 
0.41 mmol, 1.0 equiv). After the addition of (trifluoromethyl)diazomethane, 48 h were necessary to 
reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (Et2O/PE=10:90) to afford 41 (84 mg, 0.27 mmol, 66%) as a yellow oil. 
Prepared according to procedure B from 1-ethynyl-2-(trifluoromethyl)benzene 37 (80 mg, 
0.47 mmol, 1.0 equiv). After the addition of (trifluoromethyl)diazomethane, 16 h were necessary to 
reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (Et2O/PE=10:90) to afford 41 (66 mg, 0.20 mmol, 43%) as a yellow oil. 
IR (neat): 1413, 1315, 1281, 1167, 1132, 1087, 1059, 1036, 942 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.88 (m, 1H, H10), 7.777.71 (m, 2H, H8 and H9), 7.68 (d, J = 8.4 Hz, 1H, 
H2), 7.51 (m, 1H, H7). 
13C NMR (CDCl3, 100 MHz): δ 160.2 (C, d, J = 279.7 Hz, C3), 154.9 (C, d, J = 10.8 Hz, C4), 153.3 (C, qd, J 
= 35.8 and 3.1 Hz, C1), 132.2 (CH, C9), 131.5 (CH, C7), 130.9 (CH, C8), 129.7 (C, q, J = 31.5 Hz, C11), 129.2 
(C, m, C6), 127.2 (CH, q, J = 4.7 Hz, C10), 123.7 (C, q, J = 273.8 Hz, C12), 120.7 (C, qd, J = 275.1 and 3.0 Hz, 
C5), 111.0 (CH, dq, J = 17.1 and 2.4 Hz, C2). 
MS m/z (relative intensity): 310 (M+•, 100), 291 (11), 263 (9), 232 (30), 213 (89), 193 (14), 187 (14), 
182 (11), 169 (24), 138 (6), 75 (12), 69 (13). 
HRMS: calcd for C12H6F7N2 (M+H+): 311.0414. Found 311.0415. 
4-Fluoro-3-(3-carbomethoxyphenyl)-6-(trifluoromethyl)pyridazine (42) 
 
Prepared according to procedure A from methyl 3-ethynylbenzoate 14 (70 mg, 0.44 mmol, 1.0 equiv). 
After the addition of (trifluoromethyl)diazomethane, 72 h were necessary to reach complete 
consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (Et2O/PE=15:85) to afford 42 (100 mg, 0.33 mmol, 76%) as a white solid. 
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Prepared according to procedure B from methyl 3-ethynylbenzoate 14 (60 mg, 0.37 mmol, 1.0 equiv). 
After the addition of (trifluoromethyl)diazomethane, 16 h were necessary to reach complete 
consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (Et2O/PE=15:85) to afford 42 (85 mg, 0.28 mmol, 76%) as a white solid. 
Mp: 130 °C. 
IR (neat): 3076, 2924, 2853, 1721, 1593, 1450, 1412, 1396, 1299, 1242, 1180, 1163, 1138, 1082, 972, 
932 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.76 (dd, J = 3.1 and 1.6 Hz, 1H, H7), 8.31 (ddd, J = 7.9, 3.0 and 1.5 Hz, 
1H, H11), 8.25 (dtapp, J = 7.8 and 1.4 Hz, 1H, H9), 7.71 (d, J = 10.5 Hz, 1H, H2), 7.67 (tdapp, J = 7.9 and 
1.4 Hz, 1H, H10), 3.97 (s, 3H, H13). 
13C NMR (CDCl3, 100 MHz): δ 166.3 (C, C12), 160.6 (C, d, J = 281.9 Hz, C3), 152.8 (C, d, J = 5.4 Hz, C4), 
152.3 (C, qd, J = 35.8 and 3.3 Hz, C1), 133.6 (CH, d, J = 4.7 Hz, C11), 132.3 (CH, C10), 131.3 (C, d, 
J = 4.7 Hz, C6), 131.2 (C, C8), 130.6 (CH, d, J = 5.9 Hz, C7), 129.3 (CH, C9), 120.7 (C, qd, J = 274.7 and 
2.7 Hz, C5), 112.0 (CH, dq, J = 17.9 and 2.4 Hz, C2), 52.5 (CH3, C13). 
MS m/z (relative intensity): 300 (M+•, 47), 270 (15), 269 (100), 242 (85), 241 (68), 193 (9), 144 (16), 
135 (8), 119 (6), 111 (8), 95 (8), 75 (6), 69 (7). 
HRMS: calcd for C13H9F4N2O2 (M+H+): 301.0595. Found 301.0596. 
4-Fluoro-3-(4-carbomethoxyphenyl)-6-(trifluoromethyl)pyridazine (43) 
 
Prepared according to procedure A from methyl 3-ethynylbenzoate 7 (70 mg, 0.44 mmol, 1.0 equiv). 
After the addition of (trifluoromethyl)diazomethane, 24 h were necessary to reach complete 
consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (Et2O/PE=15:85) to afford 43 (88 mg, 0.29 mmol, 67%) as a yellow solid. 
Prepared according to procedure B from methyl 4-ethynylbenzoate 7 (90 mg, 0.56 mmol, 1.0 equiv). 
Supplementary amounts of TFDA (0.22 mL, 2.0 equiv) were necessary to reach complete 
consumption of the alkyne. After the addition of (trifluoromethyl)diazomethane, 24 h were necessary 
to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (Et2O/PE=15:85) to afford 43 (115 mg, 0.38 mmol, 68%) as a yellow solid. 
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Mp: 121 °C. 
IR (neat): 1723, 1602, 1552, 1425, 1395, 1278, 1261, 1145, 1109, 1077, 1012, 945 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.238.16 (m, 4H, H7 and H8), 7.71 (d, J = 10.5 Hz, 1H, H2), 3.98 (s, 3H, 
H11). 
13C NMR (CDCl3, 100 MHz): δ 166.3 (C, C10), 160.7 (C, d, J = 282.3 Hz, C3), 152.7 (C, d, J = 5.1 Hz, C4), 
152.4 (C, qd, J = 35.6 and 3.4 Hz, C1), 134.9 (C, d, J = 4.8 Hz, C6), 132.6 (C, C9), 130.1 (2xCH, C8), 129.4 
(2xCH, d, J = 5.3 Hz, C7), 120.7 (C, qd, J = 274.6 and 2.7 Hz, C5), 112.0 (CH, dq, J = 18.0 and 2.4 Hz, C2), 
52.5 (CH3, C11). 
MS m/z (relative intensity): 300 (M+•, 36), 269 (100), 241 (42), 193 (9), 144 (20), 119 (11), 99 (11), 75 
(12), 69 (13). 
HRMS: calcd for C13H9F4N2O2 (M+H+): 301.0595. Found 301.0596. 
4-Fluoro-3-[4-(diethoxyphosphoryl)phenyl]-6-(trifluoromethyl)pyridazine (44) 
 
Prepared according to procedure A from diethyl (4-ethynylphenyl)phosphonate 12 (80 mg, 
0.34 mmol, 1.0 equiv). After the addition of (trifluoromethyl)diazomethane, 48 h were necessary to 
reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (MeOH/CH2Cl2=2:98) to afford 44 (34 mg, 0.09 mmol, 27%) as a colorless oil. 
Prepared according to procedure B from diethyl (4-ethynylphenyl)phosphonate 12 (90 mg, 
0.38 mmol, 1.0 equiv). Supplementary amounts of TFDA (0.15 mL, 2.0 equiv) were necessary to reach 
complete consumption of the alkyne. After the addition of (trifluoromethyl)diazomethane, 16 h were 
necessary to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was 
purified by flash chromatography (Et2O=100%) to afford 44 (36 mg, 0.10 mmol, 25%) as a colorless 
oil. 
IR (neat): 2927, 1421, 1389, 1314, 1252, 1175, 1156, 1078, 1053, 1024, 967, 943 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.238.19 (m, 2H, H8), 8.058.00 (m, 2H, H7), 7.71 (d, J = 10.4 Hz, 1H, 
H2), 4.254.12 (m, 4H, H10), 1.37 (td, J = 7.1 and 0.4 Hz, 6H, H11). 
13C NMR (CDCl3, 100 MHz): δ 160.7 (C, d, J = 282.3 Hz, C3), 152.8 (C, d, J = 6.3 Hz, C4), 152.6 (C, qd, J = 
36.0 and 3.5 Hz, C1), 134.6 (C, m, C6), 132.4 (2xCH, d, J = 10.0 Hz, C8), 131.8 (C, d, J = 187.9 Hz, C9), 
129.4 (2xCH, dd, J = 14.9 and 5.2 Hz, C7), 120.7 (C, qd, J = 274.6 and 2.9 Hz, C5), 112.1 (CH, dq, J = 17.9 
and 2.3 Hz, C2), 62.6 (2xCH2, d, J = 5.5 Hz, C10), 16.5 (2xCH3, d, J = 6.4 Hz, C11). 
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MS m/z (relative intensity): 378 (M+•, 20), 350 (14), 349 (11), 322 (100), 305 (40), 269 (51), 258 (26), 
242 (49), 193 (12), 144 (15), 136 (6), 120 (7), 99 (7), 81 (8), 65 (18). 
HRMS: calcd for C15H15F4N2O3PNa (M+Na+): 401.0649. Found 401.0649. 
4-Fluoro-3-(4-nitrophenyl)-6-(trifluoromethyl)pyridazine (45) 
 
Prepared according to procedure A from 1-ethynyl-4-nitrobenzene 6 (60 mg, 0.41 mmol, 1.0 equiv). 
Supplementary amounts of TMSCF3 (0.13 mL, 2.0 equiv) were necessary to reach complete 
consumption of the alkyne. After the addition of (trifluoromethyl)diazomethane, 24 h were necessary 
to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (Et2O/PE=15:85) to afford 45 (40 mg, 0.14 mmol, 34%) as a light yellow solid. 
Prepared according to procedure B from 1-ethynyl-4-nitrobenzene 6 (60 mg, 0.41 mmol, 1.0 equiv). 
After the addition of (trifluoromethyl)diazomethane, 16 h were necessary to reach complete 
consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (Et2O/PE=15:85) to afford 45 (66 mg, 0.23 mmol, 56%) as a light yellow solid. 
Mp: 126 °C. 
IR (neat): 2922, 1604, 1520, 1430, 1392, 1349, 1304, 1252, 1148, 1080, 943 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.448.41 (m, 2H, H8), 8.358.32 (m, 2H, H7), 7.78 (d, J = 10.5 Hz, 1H, 
H2). 
13C NMR (CDCl3, 100 MHz): δ 160.8 (C, d, J = 282.9 Hz, C3), 153.0 (C, qd, J = 36.0 and 3.6 Hz, C1), 151.6 
(C, d, J = 4.7 Hz, C4), 149.5 (C, C9), 136.7 (C, d, J = 4.9 Hz, C6), 130.6 (2xCH, d, J = 5.5 Hz, C7), 124.2 
(2xCH, C8), 120.5 (C, qd, J = 275.1 and 2.9 Hz, C5), 112.3 (CH, dq, J = 17.8 and 2.4 Hz, C2). 
MS m/z (relative intensity): 287 (M+•, 100), 257 (15), 241 (49), 229 (16), 193 (20), 151 (23), 144 (32), 
99 (12), 75 (13), 69 (15). 
HRMS: calcd for C11H6F4N3O2 (M+H+): 288.0391. Found 288.0390. 
4-Fluoro-3-(4-bromophenyl)-6-(trifluoromethyl)pyridazine (46) 
 
Prepared according to procedure A from 1-ethynyl-4-bromobenzene 38 (70 mg, 0.39 mmol, 1.0 
equiv). After the addition of (trifluoromethyl)diazomethane, 7 days were necessary to reach 
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complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (AcOEt/PE=2:98) to afford 46 (105 mg, 0.33 mmol, 85%) as a white solid. 
Mp: 106 °C. 
IR (neat): 2971, 1591, 1423, 1386, 1308, 1286, 1253, 1155, 1080, 1009, 943 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.017.98 (m, 2H, H7), 7.927.69 (m, 2H, H8), 7.65 (d, J = 10.6 Hz, 1H, 
H2). 
13C NMR (CDCl3, 100 MHz): δ 160.4 (C, d, J = 281.8 Hz, C3), 152.7 (C, d, J = 4.5 Hz, C4), 152.2 (C, qd, J = 
35.7 and 3.3 Hz, C1), 132.4 (2xCH, C8), 130.9 (2xCH, d, J = 5.6 Hz, C7), 129.8 (C, d, J = 4.9 Hz, C6), 126.5 
(C, C9), 120.7 (C, qd, J = 274.7 and 2.9 Hz, C5), 111.9 (CH, dq, J = 18.0 and 2.4 Hz, C2). 
MS m/z (relative intensity): 322 (M+•, 98), 320 (M+•, 100), 294 (17), 292 (17), 248 (9), 250 (9), 213 
(34), 144 (18), 119 (22), 99 (17), 75 (16), 69 (10). 
HRMS: calcd for C11H6BrF4N2 (M+H+): 320.9645 and 322.9625. Found 320.9646 and 322.9625. 
4-Fluoro-3-(4-flluorophenyl)-6-(trifluoromethyl)pyridazine (47) 
 
Prepared according to procedure A from 1-ethynyl-4-fluorobenzene 39 (60 mg, 0.50 mmol, 1.0 
equiv). After the addition of (trifluoromethyl)diazomethane, 5 days were necessary to reach 
complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (AcOEt/PE=5:95) to afford 47 (74 mg, 0.28 mmol, 57%) as a yellow solid. 
Mp: 102 °C. 
IR (neat): 3084, 2927, 1603, 1511, 1421, 1392, 1310, 1298, 1274, 1255, 1234, 1170, 1143, 1102, 1079, 
944 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.178.12 (m, 2H, H7), 7.65 (d, J = 10.7 Hz, 1H, H2), 7.287.23 (m, 2H, 
H8). 
13C NMR (CDCl3, 100 MHz): δ 164.8 (C, d, J = 253.8 Hz, C3 or C9), 160.4 (C, d, J = 281.3 Hz, C3 or C9), 
152.6 (C, d, J = 5.0 Hz, C4), 152.0 (C, qd, J = 35.7 and 3.3 Hz, C1), 131.7 (2xCH, dd, J = 8.8 and 5.7 Hz, 
C7), 127.1 (C, dd, J = 4.7 and 3.5 Hz, C6), 120.6 (C, qd, J = 274.6 and 2.8 Hz, C5), 116.4 (2xCH, d, 
J = 21.9 Hz, C8), 111.9 (CH, dq, J = 18.1 and 2.4 Hz, C2). 
MS m/z (relative intensity): 260 (M+•, 100), 232 (21), 213 (12), 188 (10), 182 (17), 138 (34), 120 (13), 
75 (8), 69 (7). 
HRMS: calcd for C11H6F5N2 (M+H+): 261.0446. Found 261.0444. 
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4-Fluoro-3-(4-fluoro-3-methylphenyl)-6-(trifluoromethyl)pyridazine (48) 
 
Prepared according to procedure A from 4-ethynyl-1-fluoro-2-methylbenzene 40 (60 mg, 0.45 mmol, 
1.0 equiv). After the addition of (trifluoromethyl)diazomethane, 72 h were necessary to reach 
complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (AcOEt/PE=2:98) to afford 48 (111 mg, 0.40 mmol, 89%) as a yellow oil. 
IR (neat): 1592, 1504, 1414, 1380, 1307, 1255, 1235, 1146, 1080, 1037, 949 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.99 (br d, J = 7.3 Hz, 1H, H7), 7.937.89 (m, 1H, H11), 7.63 (d, J = 10.7 Hz, 
1H, H2), 7.17 (tapp, J = 8.9 Hz, 1H, H10), 2.37 (d, J = 1.9 Hz, 3H, H12). 
13C NMR (CDCl3, 100 MHz): δ 163.4 (C, d, J = 251.6 Hz, C9), 160.3 (C, d, J = 281.2 Hz, C3), 152.8 (C, d, J 
= 4.9 Hz, C4), 151.8 (C, qd, J = 35.6 and 3.2 Hz, C1), 132.9 (CH, tapp, J = 5.3 Hz, C7), 129.0 (CH, dd, J = 8.9 
and 6.2 Hz, C11), 126.8 (C, dd, J = 4.5 and 3.9 Hz, C6), 126.1 (C, d, J = 17.8 Hz, C8), 120.8 (C, qd, J = 274.6 
and 2.8 Hz, C5),115.8 (CH, d, J = 23.0 Hz, C10), 111.8 (CH, dq, J = 18.2 and 2.4 Hz, C2), 14.7 (CH3, d, 
J = 3.4 Hz, C12). 
MS m/z (relative intensity): 274 (M+•, 100), 246 (20), 202 (10), 177 (11), 152 (17), 151 (33), 133 (15), 
134 (11), 83 (5), 57 (5). 
HRMS: calcd for C12H8F5N2 (M+H+): 275.0602. Found 275.0603. 
4-Fluoro-3-(3-benzonitrile)-6-(trifluoromethyl)pyridazine (50) 
 
Prepared according to procedure B from 3-ethynyl-benzonitrile 49 (60 mg, 0.47 mmol, 1.0 equiv). 
Supplementary amounts of TFDA (0.19 mL, 2.0 equiv) were necessary to reach complete 
consumption of the alkyne. After the addition of (trifluoromethyl)diazomethane, 16 h were necessary 
to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (Et2O/PE=30:70) to afford 50 (76 mg, 0.28 mmol, 60%) as a white solid. 
Mp: 85 °C. 
IR (neat): 2233, 1595, 1557, 1416, 1441, 1393, 1299, 1254, 1145, 1082, 948 cm–1. 
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1H NMR (CDCl3, 400 MHz): δ 8.328.28 (m, 2H, H7 and H11), 7.79 (m, 1H, H9), 7.67 (d, J = 10.5 Hz, 1H, 
H2), 7.65 (tdapp, J = 7.8 and 0.7 Hz, 1H, H10). 
13C NMR (CDCl3, 100 MHz): δ 160.7 (C, d, J = 282.3 Hz, C3), 152.9 (C, qd, J = 35.8 and 3.4 Hz, C1), 151.5 
(C, d, J = 4.7 Hz, C4), 134.7 (CH, C9), 133.5 (CH, d, J = 5.2 Hz, C7 or C11), 132.9 (CH, d, J = 5.9 Hz, C7 or 
C11), 132.3 (C, d, J = 4.8 Hz, C6), 130.2 (CH, C10), 120.6 (C, qd, J = 275.0 and 3.0 Hz, C5), 118.0 (C, C12), 
113.7 (C, C8), 112.3 (CH, dq, J = 17.9 and 2.4 Hz, C2). 
MS m/z (relative intensity): 267 (M+•, 100), 239 (20), 238 (17), 220 (14), 189 (28), 145 (23), 127 (9), 
118 (9), 75 (12), 69 (9). 
HRMS: calcd for C12H5F4N3Na (M+Na+): 290.0312. Found 290.0313. 
4-Fluoro-3-(6-pyridin-2-yl)-6-(trifluoromethyl)pyridazine (53) 
 
Prepared according to procedure A from 6-ethynylpyridine 51 (80 mg, 0.78 mmol, 1.0 equiv). 
Supplementary amounts of TMSCF3 (0.11 mL, 1.0 equiv) were necessary to reach complete 
consumption of the alkyne. After the addition of (trifluoromethyl)diazomethane, 24 h were necessary 
to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (AcOEt/PE=25:75) to afford 53 (22 mg, 0.09 mmol, 12%) as a brown oil. 
IR (neat): 3061, 2926, 2855, 1723, 1590, 1474, 1443, 1409, 1304, 1256, 1178, 1154, 1085, 946 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.83 (br d, J = 4.7 Hz, 1H, H10), 8.30 (dd, J = 7.9 and 0.6 Hz, 1H, H7), 7.97 
(tdapp, J = 7.8 and 1.8 Hz, 1H, H8), 7.71 (d, J = 10.0 Hz, 1H, H2), 7.51 (m, 1H, H9). 
13C NMR (CDCl3, 100 MHz): δ 161.2 (C, d, J = 287.5 Hz, C3), 153.0 (C, qd, J = 35.6 and 3.9 Hz, C1), 152.9 
(C, d, J = 3.8 Hz, C4), 151.2 (C, d, J = 6.4 Hz, C6), 149.9 (CH, C10), 137.4 (CH, C8), 125.4 (CH, C9), 124.7 
(CH, C7), 120.7 (C, qd, J = 274.8 and 2.7 Hz, C5), 112.6 (CH, dq, J = 17.4 and 2.4 Hz, C2). 
MS m/z (relative intensity): 243 (M+•, 100), 196 (8), 165 (20), 146 (15), 94 (9), 78 (10), 51 (11). 
HRMS: calcd for C10H5F4N3Na (M+Na+): 266.0312. Found 266.0334. 
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4-Fluoro-3-(6-chloropyridin-2-yl)-6-(trifluoromethyl)pyridazine (54) 
 
Prepared according to procedure A from 2-chloro-6-ethynylpyridine 8 (70 mg, 0.51 mmol, 1.0 equiv). 
Supplementary amounts of TMSCF3 (0.15 mL, 2.0 equiv) were necessary to reach complete 
consumption of the alkyne. After the addition of (trifluoromethyl)diazomethane, 40 h were necessary 
to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (AcOEt/PE=10:90) to afford 54 (35 mg, 0.13 mmol, 25%) as a yellow solid. 
Prepared according to procedure B from 2-chloro-6-ethynylpyridine 8 (100 mg, 0.73 mmol, 1.0 
equiv). Supplementary amounts of TFDA (0.29 mL, 2.0 equiv) were necessary to reach complete 
consumption of the alkyne. After the addition of (trifluoromethyl)diazomethane, 16 h were necessary 
to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (Et2O/PE=15:85) to afford 54 (60 mg, 0.22 mmol, 30%) as a yellow solid. 
Mp: 125 °C. 
IR (neat): 3085, 1592, 1580, 1568, 1410, 1389, 1268, 1173, 1158, 1136, 1091, 1081, 987, 950 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.25 (br d, J = 7.7 Hz, 1H, H7), 7.94 (tapp, J = 7.9 Hz, 1H, H8), 7.73 (d, J = 
9.8 Hz, 1H, H2), 7.65 (dd, J = 8.0 and 0.8 Hz, 1H, H9). 
13C NMR (CDCl3, 100 MHz): δ 161.1 (C, d, J = 288.9 Hz, C3), 153.3 (C, qd, J = 35.7 and 3.7 Hz, C1), 151.6 
(C, d, J = 2.1 Hz, C4), 151.4 (C, C10), 151.3 (C, d, J = 6.2 Hz, C6), 139.9 (CH, C8), 126.4 (CH, C9), 123.1 (CH, 
C7), 120.6 (C, qd, J = 275.0 and 2.5 Hz, C5), 112.8 (CH, dq, J = 17.1 and 2.4 Hz, C2). 
MS m/z (relative intensity): 279 (M+•, 30), 277 (M+•, 100), 242 (7), 230 (8), 214 (32), 194 (26), 164 
(8),155 (8), 145 (8), 120 (17), 112 (7), 100 (7), 76 (12), 69 (13), 50 (7). 
HRMS: calcd for C10H4ClF4N3Na (M+Na+): 299.9922 and 301.9893. Found 299.9923 and 301.9892. 
4-Fluoro-3-(6-chloropyridin-3-yl)-6-(trifluoromethyl)pyridazine (55) 
 
Prepared according to procedure A from 2-chloro-5-ethynylpyridine 9 (70 mg, 0.51 mmol, 1.0 equiv). 
Supplementary amounts of TMSCF3 (0.30 mL, 4.0 equiv) were necessary to reach complete 
consumption of the alkyne. After the addition of (trifluoromethyl)diazomethane, 48 h were necessary 
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to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (AcOEt/PE=10:90) to afford 55 (52 mg, 0.19 mmol, 37%) as an orange solid. 
Mp: 112 °C. 
IR (neat): 1586, 1546, 1468, 1423, 1411, 1367, 1281, 1259, 1238, 1174, 1142, 1110, 1081, 1005, 
942 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 9.13 (m, 1H, H10), 8.47 (ddd, J = 8.4, 2.5 and 1.1 Hz, 1H, H7), 7.74 (d, J = 
10.5 Hz, 1H, H2), 7.58 (dd, J = 8.4 and 0.7 Hz, 1H, H8). 
13C NMR (CDCl3, 100 MHz): δ 160.6 (C, d, J = 282.2 Hz, C3), 154.6 (C, d, J = 1.0 Hz, C9), 152.8 (C, qd, J = 
36.0 and 3.3 Hz, C1), 150.4 (C, d, J = 5.4 Hz, C4), 150.1 (CH, d, J = 8.4 Hz, C10), 139.1 (CH, d, J = 4.4 Hz, 
C7), 126.2 (C, d, J = 5.3 Hz, C6), 125.0 (CH, C8), 120.6 (C, qd, J = 274.8 and 2.8 Hz, C5), 112.2 (CH, dq, J = 
17.6 and 2.4 Hz, C2). 
MS m/z (relative intensity): 279 (M+•, 34), 277 (M+•, 100), 242 (9), 214 (15), 194 (14), 155 (15), 120 
(20), 93 (9), 69 (14). 
HRMS: calcd for C10H5ClF4N3 (M+H+): 278.0103 and 280.0073. Found 278.0105 and 280.0073. 
4-Fluoro-3-(2-thiophen-3-yl)-6-(trifluoromethyl)pyridazine (56) 
 
Prepared according to procedure A from 3-ethynylthiophene 52 (60 mg, 0.55 mmol, 1.0 equiv). After 
the addition of (trifluoromethyl)diazomethane, 72 h were necessary to reach complete consumption 
of the gem-difluorocyclopropene. The crude mixture was purified by flash chromatography 
(Et2O/PE=3:97) to afford 56 (104 mg, 0.42 mmol, 76%) as a yellow solid. 
Prepared according to procedure B from 3-ethynylthiophene 52 (60 mg, 0.55 mmol, 1.0 equiv). After 
the addition of (trifluoromethyl)diazomethane, 24 h were necessary to reach complete consumption 
of the gem-difluorocyclopropene. The crude mixture was purified by flash chromatography 
(Et2O/PE=3:97) to afford 56 (72 mg, 0.29 mmol, 52%) as a yellow solid. 
Mp: 76 °C.  
IR (neat): 1602, 1560, 1522, 1435, 1422, 1357, 1267, 1193, 1148, 1116, 1075, 1034, 950 cm–1.  
1H NMR (CDCl3, 400 MHz): δ 8.30 (m, 1H, H9), 8.02 (dtapp, J = 5.2 and 1.3 Hz, 1H, H7), 7.61 (d, J = 
10.9 Hz, 1H, H2), 7.50 (ddd, J = 5.2, 3.0 and 0.4 Hz, 1H, H8). 
13C NMR (CDCl3, 100 MHz): δ 159.9 (C, d, J = 281.1 Hz, C3), 151.5 (C, qd, J = 35.6 and 3.3 Hz, C1), 149.8 
(C, d J = 5.3 Hz, C4), 132.8 (C, d, J = 5.4 Hz, C6), 130.5 (CH, d, J = 10.3 Hz, C9), 127.5 (CH, d, J = 3.8 Hz, 
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C7), 126.7 (CH, d, J = 0.9 Hz, C8), 121.2 (C, qd, J = 274.5 and 3.0 Hz, C5), 111.5 (CH, dq, J = 17.7 and 
2.4 Hz, C2), 
MS m/z (relative intensity): 248 (M+•, 100), 220 (16), 201 (17), 176 (9), 170 (14), 157 (3), 126 (29), 108 
(11), 107 (8), 81 (9), 69 (17).  
HRMS: calcd for C9H5F4N2S (M+H+): 249.0104. Found 249.0103. 
4-Fluoro-3-(2-methylbenzo[d]oxazole)-6-(trifluoromethyl)pyridazine (57) 
 
Prepared according to procedure A from 5-ethynyl-2-methyl-1,3-benzoxazole 10 (70 mg, 0.45 mmol, 
1.0 equiv). Supplementary amounts of TMSCF3 (0.13 mL, 2.0 equiv) were necessary to reach complete 
consumption of the alkyne. After the addition of (trifluoromethyl)diazomethane, 48 h were necessary 
to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (CH2Cl2/Et2O=2:98) to afford 57 (99 mg, 0.33 mmol, 75%) as a light yellow solid. 
Mp: 151 °C. 
IR (neat): 2922, 1594, 1402, 1382, 1333, 1269, 1254, 1139, 1071, 947 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.37 (tapp, J = 1.5 Hz, 1H, H7), 8.11 (dtapp, J = 8.6 and 1.5 Hz, 1H, H12), 7.68 
(d, J = 10.6 Hz, 1H, H2), 7.65 (dd, J = 8.6 and 0.4 Hz, 1H, H11), 2.70 (s, 3H, H13). 
13C NMR (CDCl3, 100 MHz): δ 165.4 (C, C9), 160.4 (C, d, J = 281.3 Hz, C3), 153.4 (C, d, J = 4.7 Hz, C4), 
152.9 (C, C10), 151.8 (C, qd, J = 35.7 and 3.4 Hz, C1), 142.2 (C, C8), 127.1 (C, d, J = 4.8 Hz, C6), 126.2 (CH, 
d, J = 4.6 Hz, C12), 121.1 (CH, d, J = 6.6 Hz, C7), 120.7 (C, qd, J = 274.6 and 2.8 Hz, C5), 111.8 (CH, dq, J 
= 18.2 and 2.4 Hz, C2), 111.0 (CH, C11), 14.6 (CH3, C13). 
MS m/z (relative intensity): 297 (M+•, 100), 269 (13), 225 (12), 200 (26), 175 (18), 157 (7), 150 (7), 
106 (14), 81 (7), 63 (6). 
HRMS: calcd for C13H8F4N3O (M+H+): 298.0598. Found 298.0598. 
4-Fluoro-3-cyclohexyl-6-(trifluoromethyl)pyridazine (65) 
 
Prepared according to procedure A from cyclohexylacetylene 62 (60 mg, 0.55 mmol, 1.0 equiv). After 
the addition of (trifluoromethyl)diazomethane, 12 days were necessary to reach complete 
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consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (AcOEt/PE=2:98) to afford 65 (53 mg, 0.21 mmol, 38%) as a yellow oil. 
IR (neat): 2933, 2857, 1604, 1554, 1451, 1411, 1370, 1319, 1284, 1242, 1182, 1151, 1060, 950 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.38 (d, J = 9.4 Hz, 1H, H2), 3.18 (m, 1H, H6), 1.89–1.72 (m, 7H, H7, H8 and 
H9), 1.45–1.23 (m, 3H, H8 and H9). 
13C NMR (CDCl3, 100 MHz): δ 161.4 (C, d, J = 9.2 Hz, C4), 160.4 (C, d, J = 277.8 Hz, C3), 151.8 (C, qd, J = 
35.2 and 3.2 Hz, C1), 120.9 (C, qd, J = 274.7 and 3.1 Hz, C5), 110.3 (CH, dq, J = 17.5 and 2.4 Hz, C2), 39.2 
(C, d, J = 2.1 Hz, C6), 31.0 (2xCH2, C7), 26.4 (2xCH2, C8), 25.8 (CH2, C9). 
MS m/z (relative intensity): 248 (M+•, 6), 233 (8), 219 (20), 207 (15), 193 (100), 180 (86), 145 (9), 95 
(6), 81 (6), 67 (6). 
HRMS: calcd for C11H13F4N2 (M+H+): 249.1009. Found 249.1009. 
4-Fluoro-3-benzyl-6-(trifluoromethyl)pyridazine (66) 
 
Prepared according to procedure A from 3-phenyl-1-propyne 63 (60 mg, 0.52 mmol, 1.0 equiv). After 
the addition of (trifluoromethyl)diazomethane, 20 days were necessary to reach complete 
consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (AcOEt/PE=2:98) to afford 66 (51 mg, 0.20 mmol, 39%) as a light yellow oil. 
IR (neat): 3066, 1602, 1559, 1496, 1455, 1415, 1304, 1281, 1242, 1183, 1144, 1056, 956 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.46 (d, J = 9.0 Hz, 1H, H2), 7.36–7.22 (m, 5H, H8, H9 and H10), 4.49 (d, J = 
1.9 Hz, 2H, H6). 
13C NMR (CDCl3, 100 MHz): δ 160.8 (C, d, J = 278.9 Hz, C3), 156.9 (C, d, J = 9.5 Hz, C4), 152.5 (C, qd, J = 
35.7 and 3.2 Hz, C1), 135.8 (C, C7), 129.2 (2xCH, C8 or C9), 129.0 (2xCH, C8 or C9), 127.5 (CH, C10), 120.7 
(C, qd, J = 274.9 and 3.1 Hz, C5), 110.9 (CH, dq, J = 16.4 and 2.4 Hz, C2), 36.8 (CH2, d, J = 1.9 Hz, C6). 
MS m/z (relative intensity): 256 (M+•, 31), 255 (100), 235 (10), 215 (5), 133 (8), 118 (5), 91 (9), 65 (6), 
51 (6). 
HRMS: calcd for C12H9F4N2 (M+H+): 257.0696. Found 257.0695. 
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4-Fluoro-3-methoxymethyl-6-(trifluoromethyl)pyridazine (67) 
 
Prepared according to procedure A from methyl propargyl ether 64 (60 mg, 0.86 mmol, 1.0 equiv). 
After the addition of (trifluoromethyl)diazomethane, 72 h were necessary to reach complete 
consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (AcOEt/PE=20:80) to afford 67 (36 mg, 0.17 mmol, 20%) as a brown solid. 
Mp: 54 °C. 
IR (neat): 2931, 1608, 1561, 1423, 1306, 1252, 1172, 1144, 1101, 1061, 997, 950 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.60 (d, J = 8.9 Hz, 1H, H2), 4.95 (d, J = 1.3 Hz, 2H, H6), 3.52 (s, 3H, H7). 
13C NMR (CDCl3, 100 MHz): δ 161.6 (C, d, J = 281.4 Hz, C3), 153.5 (C, d, J = 9.5 Hz, C4), 153.7 (C, qapp, J 
= 33.8 Hz, C1), 120.6 (C, qd, J = 275.2 and 3.1 Hz, C5), 111.3 (CH, dq, J = 16.0 and 1.9 Hz, C2), 69.0 (CH2, 
br s, C6), 59.4 (CH3, C7). 
MS m/z (relative intensity):180 (M+•‒CH2O, 100), 132 (29), 101 (24), 81 (6), 75 (8), 69 (11), 63 (10), 
57 (6). 
HRMS: calcd for C7H7F4N2O (M+H+): 211.0489. Found 211.0642. 
4-Fluoro-3-[(1,3-dioxoisoindolin-2-yl)methyl]-6-(trifluoromethyl)pyridazine (68) 
 
Prepared according to procedure A from N-propargyl phthalimide 17 (100 mg, 0.54 mmol, 1.0 equiv). 
Supplementary amounts of TMSCF3 (0.16 mL, 2.0 equiv) were necessary to reach complete 
consumption of the alkyne. After the addition of (trifluoromethyl)diazomethane, 48 h were necessary 
to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (AcOEt/PE=20:80) to afford 68 (30 mg, 0.09 mmol, 17%) as a white solid. 
Prepared according to procedure B from N-propargyl phthalimide 17 (100 mg, 0.54 mmol, 1.0 equiv). 
Supplementary amounts of TFDA (0.32 mL, 3.0 equiv) were necessary to reach complete 
consumption of the alkyne. After the addition of (trifluoromethyl)diazomethane, 16 h were necessary 
to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (AcOEt/PE=20:80) to afford 68 (100 mg, 0.31 mmol, 57%) as a white solid. 
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Mp: 138 °C. 
IR (neat): 2927, 1776, 1720, 1607, 1411, 1394, 1365, 1281, 1189, 1167, 1113, 1057, 947, 905 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.917.87 (m, 2H, H9 or H10), 7.797.75 (m, 2H, H9 or H10), 7.60 (d, J = 
9.1 Hz, 1H, H2), 5.34 (s, 2H, H6). 
13C NMR (CDCl3, 100 MHz): δ 167.7 (2xC, C7), 160.5 (C, d, J = 279.9 Hz, C3), 153.4 (C, qd, J = 35.9 and 
2.9 Hz, C1), 160.0 (C, d, J = 9.8 Hz, C4), 134.4 (2xCH, C9 or C10), 132.1 (2xC, C8), 123.8 (2xCH, C9 or C10), 
120.5 (C, qd, J = 275.0 and 3.0 Hz, C5), 110.8 (CH, dq, J = 15.5 and 2.3 Hz, C2), 36.1 (CH2, C6). 
MS m/z (relative intensity): 325 (M+•, 100), 213 (12), 212 (82), 161 (81), 133 (11), 105 (13), 104 (78), 
77 (25), 76 (49), 75 (11), 50 (18). 
HRMS: calcd for C14H7F4N3NaO2 (M+Na+): 348.0367. Found 348.0366. 
4-Fluoro-3-[2-(1,3-dioxoisoindolin-2-yl)ethyl]-6-(trifluoromethyl)pyridazine (69) 
 
Prepared according to procedure A from N-homopropargyl phthalimide 19 (100 mg, 0.50 mmol, 
1.0 equiv). Supplementary amounts of TMSCF3 (0.15 mL, 2.0 equiv) were necessary to reach complete 
consumption of the alkyne. After the addition of (trifluoromethyl)diazomethane, 48 h were necessary 
to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by 
flash chromatography (AcOEt/PE=20:80) to afford 69 (50 mg, 0.15 mmol, 29%) as a pale yellow solid. 
Prepared according to procedure B from N-homopropargyl phthalimide 19 (100 mg, 0.50 mmol, 
1.0 equiv). After the addition of (trifluoromethyl)diazomethane, 16 h were necessary to reach 
complete consumption of the gem-difluorocyclopropene. The crude mixture was purified by flash 
chromatography (AcOEt/PE=20:80) to afford 69 (68 mg, 0.20 mmol, 40%) as a pale yellow solid. 
Mp: 143 °C. 
IR (neat): 2925, 2854, 1720, 1700, 1430, 1410, 1304, 1250, 1171, 1153, 1132, 1058, 997, 948 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.817.79 (m, 2H, H10 or H11), 7.747.71 (m, 2H, H10 or H11), 7.52 (d, J = 
9.0 Hz, 1H, H2), 4.25 (t, J = 6.7 Hz, 2H, H7), 3.54 (td, J = 6.7 and 1.4 Hz, 2H, H6). 
13C NMR (CDCl3, 100 MHz): δ 168.1 (2xC, C8), 161.2 (C, d, J = 278.4 Hz, C3), 155.0 (C, d, J = 10.4 Hz, C4), 
152.6 (C, qd, J = 35.4 and 3.0 Hz, C1), 134.3 (2xCH, C10 or C11), 131.9 (2xC, C9), 123.5 (2xCH, C10 or C11), 
120.7 (C, qd, J = 274.8 and 3.0 Hz, C5), 110.4 (CH, dq, J = 16.4 and 2.4 Hz, C2), 35.7 (CH2, C7), 29.5 (CH2, 
d, J = 2.0 Hz, C6). 
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MS m/z (relative intensity): 339 (M+•, 49), 252 (7), 192 (16), 175 (14), 161 (11), 160 (100), 133 (17), 
105 (16), 104 (25), 77 (26), 76 (19), 50 (7). 
HRMS: calcd for C15H9F4N3NaO2 (M+Na+): 362.0523. Found 362.0529. 
4-Fluoro-3-(2-{bis[(tert-butoxy)carbonyl]amino}ethyl)-6-(trifluoromethyl)pyridazine (70) 
 
Prepared according to procedure A from N,N-bis[(tert-butoxy)carbonyl]-N-(but-3-yn-1-yl)carbamate 
21 (106 mg, 0.39 mmol, 1.0 equiv). Supplementary amounts of TMSCF3 (0.06 mL, 1.0 equiv) were 
necessary to reach complete consumption of the alkyne. After the addition of 
(trifluoromethyl)diazomethane, 40 h were necessary to reach complete consumption of the 
gem-difluorocyclopropene. The crude mixture was purified by flash chromatography 
(AcOEt/PE=5:95) to afford 70 (102 mg, 0.25 mmol, 64%) as a yellow oil. 
Prepared according to procedure B from N,N-bis[(tert-butoxy)carbonyl]-N-(but-3-yn-1-yl)carbamate 
21 (100 mg, 0.37 mmol, 1.0 equiv). After the addition of (trifluoromethyl)diazomethane, 16 h were 
necessary to reach complete consumption of the gem-difluorocyclopropene. The crude mixture was 
purified by flash chromatography (AcOEt/PE=5:95) to afford 70 (55 mg, 0.13 mmol, 36%) as a yellow 
oil. 
IR (neat): 2982, 1790, 1731, 1692, 1415, 1398, 1367, 1346, 1316, 1232, 1129, 1106, 1059, 963 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.50 (d, J = 9.0 Hz, 1H, H2), 4.11 (t, J = 6.6 Hz, 2H, H7), 3.46 (td, J = 6.5 and 
1.6 Hz, 2H, H6), 1.44 (s, 18H, H10). 
13C NMR (CDCl3, 100 MHz): δ 161.3 (C, d, J = 278.1 Hz, C3), 155.8 (C, d, J = 10.2 Hz, C4), 152.3 (2xC, C8), 
152.3 (C, qd, J = 35.5 and 3.1 Hz, C1), 120.7 (C, qd, J = 274.6 and 3.1 Hz, C5), 110.0 (CH, dq, J = 16.6 and 
2.4 Hz, C2), 82.9 (2xC, C9), 44.2 (CH2, C7), 29.9 (CH2, d, J = 2.1 Hz, C6), 28.0 (6xCH3, C10). 
HRMS: calcd for C17H23F4N3NaO4 (M+Na+): 432.1517. Found 432.1536.
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5. Synthesis and spectroscopic data of 4-fluoro-3-phenyl-6-
(perfluoroethyl)pyridazine (71) 
4-Fluoro-3-phenyl-6-(perfluoroethyl)pyridazine (71) 
 
Formation of (pentafluoroethyl)diazomethane in situ: In an oven-dried vial were introduced 
2,2,3,3,3-pentafluoropropan-1-amine hydrochloride (1.5 equiv compared to the alkyne) and NaNO2 
(1.8 equiv compared to the alkyne). The vial was then flushed with argon, CH2Cl2 (c = 0.6 M) and H2O 
(CH2Cl2/H2O=30:1) were added. The reaction was then stirred at 0 °C for 1 h and at 78 °C for 10 min. 
The solution was then added to the difluorocyclopropene solution via a syringe. 
Prepared according to procedure A from phenylacetylene 22 (70 mg, 0.69 mmol, 1.0 equiv). After the 
addition of (pentafluoroethyl)diazomethane, 72 h were necessary to reach complete consumption of 
the gem-difluorocyclopropene. The crude mixture was purified by flash chromatography 
(AcOEt/PE=2:98) to afford 71 (142 mg, 0.48 mmol, 71%) as a light yellow solid. 
Mp: 52 °C. 
IR (neat): 1591, 1550, 1411, 1393, 1334, 1320, 1194, 1145, 1099, 1040, 1019, 906 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.138.10 (m, 2H, H8), 7.66 (d, J = 10.7 Hz, 1H, H2), 7.597.54 (m, 3H, H9 
and H10). 
13C NMR (CDCl3, 100 MHz): δ 160.5 (C, d, J = 281.8 Hz, C3), 153.6 (C, d, J = 5.2 Hz, C4), 151.7 (C, td, J = 
26.3 and 3.1 Hz, C1), 131.6 (CH, C10), 130.9 (C, d, J = 4.8 Hz, C7), 129.5 (2xCH, d, J = 5.3 Hz, C8), 129.1 
(2xCH, C9), 118.7 (C, qt, J = 286.5 and 36.5 Hz, C6), 113.0 (CH, dt, J = 18.1 and 4.1 Hz, C2), 110.7 (C, tqd, 
J = 255.0, 39.0 and 2.0 Hz, C5). 
MS m/z (relative intensity): 292 (M+•, 100), 273 (5), 245 (2), 195 (74), 175 (12), 169 (6), 151 (6), 125 
(5), 120 (22), 100 (5), 98 (6), 75 (10), 69 (5), 51 (9). 
HRMS: calcd for C12H6F6N2Na (M+Na+): 315.0327. Found 315.0328.
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6. Synthesis and spectroscopic data of 4-fluoro-3-phenyl-6-
(difluoromethyl)pyridazine (72) 
4-Fluoro-3-phenyl-6-(difluoromethyl)pyridazine (72) 
1
2
3
4
5
6
N
N
F
HF2C
7
8
9
 
Formation of (difluoromethyl)diazomethane in situ: In an oven-dried vial was introduced 
2,2-difluoroethan-1-amine (4.0 equiv compared to the alkyne) and CH2Cl2 (c = 0.6 M) was added. t-
BuONO (4.8 equiv compared to the alkyne) and AcOH (0.8 equiv compared to the alkyne) were added. 
The reaction was then stirred at 70 °C for 10 min and was then allowed to cool down to rt. The solution 
was then added to the difluorocyclopropene solution via a syringe. 
Prepared according to procedure A from phenylacetylene 22 (50 mg, 0.49 mmol, 1.0 equiv). After the 
addition of (difluoromethyl)diazomethane, 8 days were necessary to reach complete consumption of 
the gem-difluorocyclopropene. The crude mixture was purified by flash chromatography 
(AcOEt/PE=3:97) to afford 72 (48 mg, 0.21 mmol, 44%) as a yellow oil. 
IR (neat): 3065, 1601, 1551, 1399, 1350, 1166, 1087, 1051, 990, 898 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.098.06 (m, 2H, H7), 7.61 (d, J = 10.6 Hz, 1H, H2), 7.597.55 (m, 3H, H8 
and H9), 7.01 (td, J = 54.4 and 1.4 Hz, 1H, H5). 
13C NMR (CDCl3, 100 MHz): δ 160.9 (C, d, J = 280.6 Hz, C3), 156.4 (C, td, J = 27.6 and 3.2 Hz, C1), 153.4 
(C, d, J = 5.8 Hz, C4), 131.3 (C, d, J = 4.6 Hz, C6), 131.2 (CH, C9), 129.4 (2xCH, d, J = 5.0 Hz, C7), 129.0 
(2xCH, C8), 112.8 (C, td, J = 240.9 and 1.4 Hz, C5), 111.1 (CH, dt, J = 16.9 and 2.0 Hz, C2). 
MS m/z (relative intensity): 224 (M+•, 100), 195 (43), 177 (11), 175 (7), 151 (8), 146 (31), 125 (7), 120 
(22), 102 (6), 94 (7), 75 (8), 51 (16). 
HRMS: calcd for C11H7F3N2Na (M+Na+): 247.0454. Found 247.0454.
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7. Post-functionalization of 6-(trifluoromethyl) pyridazines: 
Synthesis and spectroscopic data of pyridazines 7389 
4-Morpholino-3-phenyl-6-(trifluoromethyl)pyridazine (73) 
 
To a stirred solution of 4-fluoro-3-phenyl-6-(trifluoromethyl)pyridazine 24 (50 mg, 0.21 mmol, 1.0 
equiv) in MeCN (0.2 mL) was added morpholine (0.036 mL, 0.41 mmol, 2.0 equiv) and the reaction 
mixture was stirred at 100 °C for 3 h. The reaction mixture was concentrated under reduced pressure. 
The crude mixture was purified by flash chromatography (AcOEt/PE=30:70) to afford 73 (54 mg, 
0.17 mmol, 85%) as a white solid. 
Mp: 149 °C. 
IR (neat): 2960, 2859, 1582, 1568, 1426, 1374, 1313, 1291, 1274, 1253, 1179, 1133, 1098, 1071,1055, 
1010, 968 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.887.86 (m, 2H, H9 or H10), 7.507.46 (m, 3H, H9 or H10 and H11), 7.16 
(s, 1H, H2), 3.673.70 (m, 4H, H7), 3.063.03 (m, 4H, H6). 
13C NMR (CDCl3, 100 MHz): δ 155.7 (C, C3), 150.2 (C, q, J = 33.8 Hz, C1), 149.2 (C, C4), 137.0 (C, C8), 
130.0 (CH, C11), 129.0 (2xCH, C9 or C10), 128.0 (2xCH, C9 or C10), 121.7 (C, q, J = 274.9 Hz, C5), 109.6 (CH, 
q, J = 2.2 Hz, C2), 65.9 (2xCH2, C7), 49.3 (2xCH2, C6). 
MS m/z (relative intensity): 309 (M+•, 100), 308 (50), 282 (22), 251 (41), 250 (77), 202 (18), 182 (34), 
155 (9), 126 (14), 102 (23), 86 (17), 77 (14). 
HRMS: calcd for C15H15F3N3O (M+H+): 310.1162. Found 310.1161. 
4-Dibenzylamino-3-phenyl-6-(trifluoromethyl)pyridazine (74) 
 
To a stirred solution of 4-fluoro-3-phenyl-6-(trifluoromethyl)pyridazine 24 (50 mg, 0.21 mmol, 1.0 
equiv) in MeCN (0.2 mL) was added N,N-dibenzylamine (0.080 mL, 0.41 mmol, 2.0 equiv) and the 
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reaction mixture was stirred at 100 °C for 72 h. The reaction mixture was concentrated under reduced 
pressure. The crude mixture was purified by flash chromatography (AcOEt/PE=15:85) to afford 74 
(72 mg, 0.17 mmol, 83%) as a white solid. 
Mp: 127 °C. 
IR (neat): 1564, 1495, 1452, 1418, 1358, 1288, 1176, 1140, 1102, 1028, 1011, 953 908 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.857.82 (m, 2H, H12 or H13), 7.527.44 (m, 3H, H12 or H13 and H14), 
7.327.24 (m, 6H, H9 and H10), 7.11 (s, 1H, H2), 7.037.01 (m, 4H, H8), 4.18 (s, 4H, H6). 
13C NMR (CDCl3, 100 MHz): δ 155.6 (C, C3), 149.7 (C, q, J = 33.5 Hz, C1), 148.2 (C, C4), 137.7 (C, C11), 
135.6 (2xC, C7), 129.6 (CH, C14), 129.1 (2xCH, C12 or C13), 128.9 (4xCH, C8 or C9), 128.3 (2xCH, C12 or C13), 
128.1 (2xCH, C10), 128.1 (4xCH, C8 or C9), 121.7 (C, q, J = 274.9 Hz, C5), 110.9 (CH, q, J = 2.6 Hz, C2), 54.7 
(2xCH2, C6). 
MS m/z (relative intensity): 419 (M+•, 15), 418 (8), 328 (18), 250 (6), 126 (1), 92 (9), 91 (100), 65 (11). 
HRMS: calcd for C25H21F3N3 (M+H+): 420.1682. Found 420.1681. 
4-Allylamino-3-phenyl-6-(trifluoromethyl)pyridazine (75) 
 
To a stirred solution of 4-fluoro-3-phenyl-6-(trifluoromethyl)pyridazine 24 (60 mg, 0.25 mmol, 1.0 
equiv) in MeCN (0.24 mL) was added allylamine (0.037 mL, 0.50 mmol, 2.0 equiv) and the reaction 
mixture was stirred at 100 °C for 4 h. The reaction mixture was concentrated under reduced pressure. 
The crude mixture was purified by flash chromatography (AcOEt/PE=20:80) to afford 75 (70 mg, 
0.25 mmol, quant) as a white solid. 
Mp: 132 °C. 
IR (neat): 3267, 1590, 1548, 1507, 1427, 1387, 1290, 1180, 1142, 1096, 1011, 929 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.537.51 (m, 2H, H10 or H11), 7.457.40 (m, 3H, H10 or H11 and H12), 6.73 
(s, 1H, H2), 5.74 (m, 1H, H7), 5.205.13 (m, 3H, NH and H8). 3.793.76 (m, 2H, H6). 
13C NMR (CDCl3, 100 MHz): δ 152.2 (C, C3), 150.2 (C, q, J = 33.3 Hz, C1), 144.1 (C, C4), 133.9 (C, C9), 
131.8 (CH, C7), 130.0 (CH, C12), 129.5 (2xCH, C10 or C11), 128.7 (2xCH, C10 or C11), 121.8 (C, q, J = 274.8 Hz, 
C5), 117.0 (CH2, C8), 101.8 (CH, q, J = 2.6 Hz, C2), 44.9 (CH2, C6). 
MS m/z (relative intensity): 279 (M+•, 92), 278 (100), 251 (21), 237 (13), 202 (22), 183 (37), 126 (10), 
115 (8), 102 (21), 89 (16), 77 (16), 56 (24). 
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HRMS: calcd for C14H13F3N3 (M+H+): 280.1056. Found 280.1055. 
4-Methoxy-3-phenyl-6-(trifluoromethyl)pyridazine (76) 
 
1) To a stirred solution of 4-fluoro-3-phenyl-6-(trifluoromethyl)pyridazine 24 (50 mg, 0.21 mmol, 1.0 
equiv) in MeCN (0.2 mL) was added sodium methoxide (33.5 mg, 0.62 mmol, 3.0 equiv) and the 
reaction mixture was stirred at 100 °C for 48 h. The reaction mixture was then concentrated under 
reduced pressure. The crude mixture was purified by flash chromatography (AcOEt/PE=20:80) to 
afford 76 (36 mg, 0.14 mmol, 69%) as a pale brown oil. 
2) To a stirred solution of 4-fluoro-3-phenyl-6-(trifluoromethyl)pyridazine 24 (50 mg, 0.21 mmol, 1.0 
equiv) in DMSO (0.2 mL) was added MeOH (0.025 mL, 0.62 mmol, 3.0 equiv) and DBU (0.093 mL, 
0.62 mmol, 3.0 equiv) and the reaction mixture was stirred at 80 °C for 3 h. An aqueous saturated 
NH4Cl solution was added to the mixture and the aqueous phase was extracted with AcOEt. The 
combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The 
crude mixture was purified by flash chromatography (AcOEt/PE=20:80) to afford 76 (40 mg, 
0.16 mmol, 76%) as a pale brown oil. 
IR (neat): 2927, 1586, 1571, 1468, 1388, 1321, 1297, 1265, 1178, 1139, 1091, 1021, 918 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.907.87 (m, 2H, H8 or H9), 7.427.40 (m, 3H, H8 or H9 and H10), 7.18 (s, 
1H, H2), 3.93 (s, 3H, H6). 
13C NMR (CDCl3, 100 MHz): δ 157.1 (C, C3), 154.9 (C, C4), 151.0 (C, q, J = 34.3 Hz, C1), 133.3 (C, C7), 
130.3 (CH, C10), 129.8 (2xCH, C8 or C9), 128.4 (2xCH, C8 or C9), 121.4 (C, q, J = 274.8 Hz, C5), 104.9 (CH, 
q, J = 2.4 Hz, C2), 56.1 (CH3, C6). 
MS m/z (relative intensity): 254 (M+•, 46), 253 (100), 225 (5), 205 (6), 183 (9), 133 (14), 102 (26), 89 
(23), 77 (8), 69 (8), 63 (10), 51 (7). 
HRMS: calcd for C12H10F3N2O (M+H+): 255.0740. Found 255.0738. 
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4-Allyloxy-3-phenyl-6-(trifluoromethyl)pyridazine (77) 
 
To a stirred solution of 4-fluoro-3-phenyl-6-(trifluoromethyl)pyridazine 24 (50 mg, 0.21 mmol, 1.0 
equiv) in DMSO (0.2 mL) was added allylic alcohol (0.042 mL, 0.62 mmol, 3.0 equiv) and DBU 
(0.093 mL, 0.62 mmol, 3.0 equiv) and the reaction mixture was stirred at 80 °C for 3 h. An aqueous 
saturated NH4Cl solution was added to the mixture and the aqueous phase was extracted with AcOEt. 
The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The 
crude mixture was purified by flash chromatography (AcOEt/PE=10:90) to afford 77 (41 mg, 
0.15 mmol, 71%) as a colorless oil. 
IR (neat): 1584, 1409, 1357, 1321, 1267, 1178, 1140, 1092, 1014, 988, 926 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.027.99 (m, 2H, H10 or H11), 7.527.48 (m, 3H, H10 or H11 and H12), 7.25 
(s, 1H, H2), 6.02 (m, 1H, H7), 5.475.39 (m, 2H, H8), 4.76 (dtapp, J = 5.1 and 1.5 Hz, 2H, H6). 
13C NMR (CDCl3, 100 MHz): δ 156.0 (C, C3), 155.0 (C, C4), 150.9 (C, q, J = 34.3 Hz, C1), 133.3 (C, C9), 
130.3 (CH, C7), 130.2 (CH, C12), 129.9 (2xCH, C10 or C11), 128.4 (2xCH, C10 or C11), 121.4 (C, q, J = 274.9 Hz, 
C5), 119.8 (CH2, C8), 105.9 (CH, q, J = 2.4 Hz, C2), 69.8 (CH2, C6). 
MS m/z (relative intensity): 280 (M+•, 100), 279 (90), 251 (95), 249 (63), 239 (24), 224 (35), 203 (10), 
196 (18), 170 (9), 144 (10), 142 (10), 133 (12), 128 (17), 126 (20), 115 (16), 108 (99), 102 (42), 89 (27), 
77 (36), 69 (78), 63 (33), 51 (22). 
HRMS: calcd for C14H12F3N2O (M+H+): 281.0896. Found 281.0893. 
4-Ethylthio-3-phenyl-6-(trifluoromethyl)pyridazine (78) 
 
To a stirred solution of 4-fluoro-3-phenyl-6-(trifluoromethyl)pyridazine 24 (50 mg, 0.207 mmol, 1.0 
equiv) in MeCN (0.2 mL) was added sodium ethanethiolate (28.9 mg, 0.31 mmol, 1.5 equiv) and the 
reaction mixture was stirred at 100 °C for 4 h. An aqueous saturated NaHCO3 solution was added to 
the mixture and the aqueous phase was extracted with AcOEt. The combined organic phases were 
dried over Na2SO4 and concentrated under reduced pressure. The crude mixture was purified by flash 
chromatography (AcOEt/PE=10:90) to afford 78 (55 mg, 0.19 mmol, 94%) as a yellow oil. 
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IR (neat): 3061, 2932, 1551, 1447, 1353, 1315, 1292, 1255, 1177, 1139, 1110, 1073, 1009, 1034 cm–
1. 
1H NMR (CDCl3, 400 MHz): δ 7.717.69 (m, 2H, H9 or H10), 7.537.51 (m, 4H, H2, H9 or H10 and H11), 
2.99 (q, J = 7.4 Hz, 2H, H6), 1.39 (t, J = 7.4 Hz, 3H, H7). 
13C NMR (CDCl3, 100 MHz): δ 161.0 (C, C3), 149.1 (C, q, J = 34.2 Hz, C1), 144.6 (C, C4), 135.3 (C, C8), 
130.3 (CH, C11), 129.1 (2xCH, C9 or C10), 128.6 (2xCH, C9 or C10), 121.6 (C, q, J = 274.9 Hz, C5), 117.8 (CH, 
q, J = 2.3 Hz, C2), 25.6 (CH2, C6), 12.5 (CH3, C7). 
MS m/z (relative intensity): 284 (M+•, 36), 255 (100), 207 (28), 183 (6), 158 (5), 134 (18), 126 (9), 120 
(12), 89 (9), 77 (7), 69 (7). 
HRMS: calcd for C13H12F3N2S (M+H+): 285.0668. Found 285.0671. 
4-Dimethyl malonate-3-phenyl-6-(trifluoromethyl)pyridazine (79) 
 
To a stirred solution of 4-fluoro-3-phenyl-6-(trifluoromethyl)pyridazine 24 (50 mg, 0.207 mmol, 1.0 
equiv) in DMSO (0.5 mL) was added dimethyl malonate (0.071 mL, 0.62 mmol, 3.0 equiv) and DBU 
(0.093 mL, 0.62 mmol, 3.0 equiv) and the reaction mixture was stirred at 80 °C for 3 h. An aqueous 
saturated NH4Cl solution was added to the mixture and the aqueous phase was extracted with AcOEt. 
The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The 
crude mixture was purified by flash chromatography (AcOEt/PE=20:80) to afford 79 (67 mg, 
0.19 mmol, 92%) as a white solid. 
Mp: 118 °C. 
IR (neat): 2959, 2850, 1739, 1437, 1392, 1263, 1218, 1193, 1144, 1083, 1017, 913 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.11 (s, 1H, H2), 7.49 (br s, 5H, H10, H11 and H12), 4.91 (s, 1H, H6), 3.71 (s, 
6H, H8). 
13C NMR (CDCl3, 100 MHz): δ 166.6 (2xC, C7), 163.8 (C, C4), 150.4 (C, q, J = 34.9 Hz, C1), 134.7 (C, C3 or 
C9), 132.2 (C, C3 or C9), 130.2 (CH, C12), 129.5 (2xCH, C10 or C11), 129.1 (2xCH, C10 or C11), 125.1 (CH, q, J 
= 2.4 Hz, C2), 121.5 (C, q, J = 274.6 Hz, C5), 53.9 (2xCH3, C8), 52.7 (CH, C6). 
HRMS: calcd for C16H14F3N2O4 (M+H+): 355.0900. Found 355.0900. 
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4-Nitromethyl-3-phenyl-6-(trifluoromethyl)pyridazine (80) 
 
To a stirred solution of 4-fluoro-3-phenyl-6-(trifluoromethyl)pyridazine 24 (150 mg, 0.62 mmol, 1.0 
equiv) in DMSO (1.8 mL) was added nitromethane (0.1 mL, 1.89 mmol, 3.0 equiv) and DBU (0.28 mL, 
1.89 mmol, 3.0 equiv) and the reaction mixture was stirred at 80 °C for 3 h. An aqueous saturated 
NH4Cl solution was added to the mixture and the aqueous phase was extracted with CH2Cl2. The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude mixture was 
purified by flash chromatography (MeOH/CH2Cl2=2:98) to afford 80 (91 mg, 0.32 mmol, 52%) as a 
yellow oil. 
IR (neat): 2925, 2854, 1561, 1398, 1364, 1292, 1266, 1194, 1148, 1085, 1036, 1015, 908 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.93 (br s, 1H, H2), 7.527.42 (m, 5H, H8, H9 or H10), 5.54 (s, 2H, H6). 
13C NMR (CDCl3, 100 MHz): δ 163.8 (C, C4), 150.9 (C, q, J = 35.6 Hz, C1), 134.0 (C, C3 or C7), 130.8 (CH, 
C10), 129.4 (2xCH, C8 or C9), 129.2 (2xCH, C8 or C9), 128.3 (C, C3 or C7), 125.9 (CH, q, J = 2.4 Hz, C2), 121.2 
(C, q, J = 274.7 Hz, C5), 75.3 (CH2, C6). 
MS m/z (relative intensity): 283 (M+•, 28), 237 (100), 217 (8), 188 (64), 168 (20), 159 (12), 139 (19), 
115 (18), 89 (14), 77 (15), 69 (14), 51 (12). 
HRMS: calcd for C12H8F3N3O2Na (M+Na+): 306.0461. Found 306.0462. 
4-Methyl-3-phenyl-6-(trifluoromethyl)pyridazine (81) 
 
To a stirred solution of CuI (433 mg, 2.27 mmol, 5.5 equiv) in Et2O (7.1 mL) at 30 °C was added 
dropwise MeLi (2.58 mL, 4.13 mmol, 10.0 equiv, 1.6 M in Et2O) and the reaction mixture was stirred 
at 30 °C for 5 min. A solution of 4-fluoro-3-phenyl-6-(trifluoromethyl)pyridazine 24 (100 mg, 
0.41 mmol, 1.0 equiv) in Et2O (3.6 mL) was added to the mixture and the solution was stirred at 0 °C 
for 48 h. An aqueous saturated NH4Cl solution was added to the mixture and the aqueous phase was 
extracted with Et2O. The combined organic phases were dried over Na2SO4 and concentrated under 
reduced pressure. The crude mixture was purified by flash chromatography (AcOEt/PE=5:95 and 
10:90) to afford 81 (12 mg, 0.05 mmol, 12%) as a yellow oil. 
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IR (neat): 2920, 1448, 1397, 1318, 1293, 1269, 1197, 1169, 1128, 1092, 761, 702 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.71 (q, J = 0.8 Hz, 1H, H2), 7.637.61 (m, 2H, H8 or H9), 7.557.53 (m, 
3H, H8 or H9 and H10), 2.49 (d, J = 0.7 Hz, 3H, H6). 
13C NMR (CDCl3, 100 MHz): δ 164.3 (C, C4), 150.1 (C, q, J = 34.6 Hz, C1), 137.5 (C, C3 or C7), 136.0 (C, C3 
or C7), 129.8 (CH, C10), 129.4 (2xCH, C8 or C9), 128.8 (2xCH, C8 or C9), 125.5 (CH, q, J = 2.2 Hz, C2), 121.7 
(C, q, J = 274.4 Hz, C5), 20.1 (CH3, C6). 
MS m/z (relative intensity): 238 (M+•, 35), 237 (100), 188 (8), 170 (6), 116 (30), 115 (95), 89 (8), 63 
(18), 51 (22). 
HRMS: calcd for C12H9F3N2Na (M+Na+): 261.0610. Found 261.0608. 
4-Morpholino-3-(4-fluorophenyl)-6-(trifluoromethyl)pyridazine (82) 
 
To a stirred solution of 4-fluoro-3-(4-fluoro-phenyl)-6-(trifluoromethyl)pyridazine 47 (50 mg, 
0.19 mmol, 1.0 equiv) in MeCN (0.19 mL) was added morpholine (0.034 mL, 0.38 mmol, 2.0 equiv) 
and the reaction mixture was stirred at 80 °C for 3 h. The reaction mixture was concentrated under 
reduced pressure. The crude mixture was purified by flash chromatography (Et2O/PE=20:80 and 
30:70) to afford 82 (62 mg, 0.19 mmol, quant) as a white solid. 
Mp: 166 °C. 
IR (neat): 2960, 2858, 1602, 1570, 1508, 1433, 1402, 1320, 1299, 1228, 1134, 1117, 1054, 970 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.947.90 (m, 2H, H9), 7.227.17 (m, 3H, H2 and H10), 3.733.70 (m, 4H, 
H7), 3.06–3.03 (m, 4H, H6). 
13C NMR (CDCl3, 100 MHz): δ 163.7 (C, d, J = 250.6 Hz, C11), 154.8 (C, C3), 150.3 (C, q, J = 33.8 Hz, C1), 
149.2 (C, C4), 133.0 (C, d, J = 3.4 Hz, C8), 130.1 (2xCH, d, J = 8.3 Hz, C9), 121.6 (C, q, J = 274.9 Hz, C5), 
116.1 (2xCH, d, J = 21.7 Hz, C10), 109.9 (CH, q, J = 2.4 Hz, C2), 65.9 (2xCH2, C7), 49.3 (2xCH2, C6). 
MS m/z (relative intensity): 327 (M+•, 100), 296 (81), 282 (9), 269 (35), 268 (67), 220 (12), 201 (12), 
200 (28), 162 (7), 144 (13), 120 (17), 86 (15), 75 (5), 57 (9). 
HRMS: calcd for C15H14F4N3O (M+H+): 328.1068. Found 328.1068. 
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4-Morpholino-3-(4-carbomethoxyphenyl)-6-(trifluoromethyl)pyridazine (83) 
 
To a stirred solution of 4-fluoro-3-(4-methylbenzoate)-6-(trifluoromethyl)pyridazine 43 (50 mg, 
0.17 mmol, 1.0 equiv) in MeCN (0.16 mL) was added morpholine (0.029 mL, 0.33 mmol, 2.0 equiv) 
and the reaction mixture was stirred at 80 °C for 3 h. The reaction mixture was concentrated under 
reduced pressure. The crude mixture was purified by flash chromatography (Et2O/PE=70:30) to afford 
83 (50 mg, 0.14 mmol, 82%) as a white solid. 
Mp: 186 °C. 
IR (neat): 2956, 2856, 1719, 1578, 1564, 1434, 1402, 1275, 1179, 1135, 1113, 1009, 969, 911 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 8.198.17 (m, 2H, H10), 8.007.98 (m, 2H, H9), 7.20 (s, 1H, H2), 3.97 (s, 
3H, H13), 3.713.69 (m, 4H, H7), 3.063.04 (m, 4H, H6). 
13C NMR (CDCl3, 100 MHz): δ 166.5 (C, C12), 154.7 (C, C3), 150.6 (C, q, J = 33.9 Hz, C1), 149.3 (C, C4), 
141.3 (C, C11), 131.5 (C, C8), 130.3 (2xCH, C10), 128.1 (2xCH, C9), 121.6 (C, q, J = 274.9 Hz, C5), 109.9 
(CH, q, J = 2.4 Hz, C2), 65.9 (2xCH2, C7), 52.5 (CH3, C13), 49.5 (2xCH2, C6). 
MS m/z (relative intensity): 367 (M+•, 100), 352 (14), 336 (17), 309 (37), 308 (62), 250 (31), 240 (18), 
202 (12), 139 (17), 125 (24), 86 (14), 59 (20). 
HRMS: calcd for C17H17F3N3O3 (M+H+): 368.1217. Found 368.1216. 
4-Morpholino-3-(4-methoxyphenyl)-6-(trifluoromethyl)pyridazine (84) 
 
To a stirred solution of 4-fluoro-3-(4-methoxyphenyl)-6-(trifluoromethyl)pyridazine 32 (55 mg, 
0.20 mmol, 1.0 equiv) in MeCN (0.20 mL) was added morpholine (0.036 mL, 0.40 mmol, 2.0 equiv) 
and the reaction mixture was stirred at 80 °C for 3 h. The reaction mixture was concentrated under 
reduced pressure. The crude mixture was purified by flash chromatography (AcOEt/PE=35:65) to 
afford 84 (70 mg, 0.20 mmol, quant) as a pale yellow solid. 
Mp: 119 °C. 
IR (neat): 2863, 1431, 1300, 1252, 1174, 1135, 1113, 1035, 1001, 968, 905, 724 cm–1. 
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1H NMR (CDCl3, 400 MHz): δ 7.80 (d, J = 8.9 Hz, 2H, H9), 7.05 (s, 1H, H2), 6.93 (d, J = 8.9 Hz, 2H, H10), 
3.79 (s, 3H, H12), 3.653.62 (m, 4H, H7), 2.972.94 (m, 4H, H6). 
13C NMR (CDCl3, 100 MHz): δ 161.0 (C, C11), 155.4 (C, C3), 149.8 (C, q, J = 33.6 Hz, C1), 149.1 (C, C4), 
129.5 (2xCH, C9), 129.1 (C, C8), 121.7 (C, q, J = 274.7 Hz, C5), 114.3 (2xCH, C10), 109.7 (CH, q, J = 2.2 Hz, 
C2), 66.0 (2xCH2, C7), 55.4 (CH3, C12), 49.2 (2xCH2, C6). 
MS m/z (relative intensity): 339 (M+•, 100), 338 (60), 324 (22), 308 (29), 296 (17), 281 (20), 280 (35), 
266 (10), 250 (11), 238 (11), 213 (12), 144 (9), 132 (11), 113 (6), 89 (10), 86 (24). 
HRMS: calcd for C16H16F3N3O2Na (M+Na+): 362.1087. Found 362.1086. 
4-Morpholino-3-(2-methoxyphenyl)-6-(trifluoromethyl)pyridazine (85) 
 
To a stirred solution of 4-fluoro-3-(2-methoxyphenyl)-6-(trifluoromethyl)pyridazine 33 (72 mg, 
0.26 mmol, 1.0 equiv) in MeCN (0.26 mL) was added morpholine (0.047 mL, 0.53 mmol, 2.0 equiv) 
and the reaction mixture was stirred at 80 °C for 3 h. The reaction mixture was concentrated under 
reduced pressure. The crude mixture was purified by flash chromatography (AcOEt/PE=35:65) to 
afford 85 (70 mg, 0.21 mmol, 78%) as a white mousse. 
IR (neat): 2856, 1576, 1493, 1460, 1434, 1321, 1295, 1259, 1179, 1135, 1117, 1051, 1024, 1007, 970, 
910 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.487.42 (m, 2H, H9 and H11), 7.09 (m, 1H, H10), 7.09 (br s, 1H, H2), 7.00 
(d, J = 8.3 Hz, 1H, H12), 3.80 (s, 3H, H14), 3.57 (t, J = 4.8 Hz, 4H, H7), 3.05 (br s, 4H, H6). 
13C NMR (CDCl3, 100 MHz): δ 156.5 (C, C13), 154.1 (C, C3), 150.1 (C, q, J = 33.4 Hz, C1), 149.1 (C, C4), 
131.1 (CH, C11), 130.5 (CH, C9), 126.7 (C, C8), 121.8 (C, q, J = 274.8 Hz, C5), 121.3 (CH, C10), 111.3 (CH, 
C12), 108.6 (CH, q, J = 2.5 Hz, C2), 66.2 (2xCH2, C7), 55.6 (CH3, C14), 48.5 (2xCH2, C6). 
MS m/z (relative intensity): 339 (M+•, 71), 308 (16), 280 (13), 266 (10), 253 (100), 225 (10), 219 (10), 
182 (9), 155 (8), 131 (9), 118 (12), 102 (13), 91 (18), 86 (48), 77 (10), 57 (12). 
HRMS: calcd for C16H17F3N3O2 (M+H+): 340.1267. Found 340.1266. 
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4-Allylamino-3-phenyl-6-(pentafluoroethyl)pyridazine (86) 
 
To a stirred solution of 4-fluoro-3-phenyl-6-(pentafluoroethyl)pyridazine 71 (75 mg, 0.26 mmol, 1.0 
equiv) in MeCN (0.25 mL) was added allylamine (0.038 mL, 0.51 mmol, 2.0 equiv) and the reaction 
mixture was stirred at 100 °C for 4 h. The reaction mixture was concentrated under reduced pressure. 
The crude mixture was purified by flash chromatography (AcOEt/PE=20:80) to afford product 86 
(76 mg, 0.23 mmol, 90%) as a white solid. 
Mp: 99 °C. 
IR (neat): 1586, 1507, 1450, 1417, 1385, 1333, 1203, 1149, 1103, 1075, 1008, 997, 906 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.637.61 (m, 2H, H11 or H12), 7.547.48 (m, 3H, H11 or H12 and H13), 6.83 
(s, 1H, H2), 5.82 (m, 1H, H8), 5.305.21 (m, 3H, NH and H9), 3.873.84 (m, 2H, H7). 
13C NMR (CDCl3, 100 MHz): δ 152.0 (C, C3), 149.7 (C, t, J = 24.5 Hz, C1), 143.9 (C, C4), 133.8 (C, C10), 
131.7 (CH, C8), 130.0 (CH, C13), 129.5 (2xCH, C11 or C12), 128.7 (2xCH, C11 or C12), 118.9 (C, qt, J = 286.7 
and 37.1 Hz, C6), 117.9 (CH2, C9), 111.4 (C, tq, J = 255.7 and 38.6 Hz, C5), 103.0 (CH, t, J = 4.5 Hz, C2), 
44.9 (CH2, C7). 
MS m/z (relative intensity): 329 (M+•, 87), 328 (100), 301 (22), 287 (14), 252 (27), 233 (7), 183 (30), 
141 (7), 126 (10), 102 (20), 89 (18), 77 (15), 56 (24). 
HRMS: calcd for C15H13F5N3 (M+H+): 330.1024. Found 330.1023. 
4-Ethylthio-3-phenyl-6-(pentafluoroethyl)pyridazine (87) 
 
 
To a stirred solution of 4-fluoro-3-phenyl-6-(pentafluoroethyl)pyridazine 71 (60 mg, 0.21 mmol, 1.0 
equiv) in MeCN (0.20 mL) was added sodium ethanethiolate (29 mg, 0.31 mmol, 1.5 equiv) and the 
reaction mixture was stirred at 100 °C for 4 h. The reaction mixture was concentrated under reduced 
pressure. The crude mixture was purified by flash chromatography (AcOEt/PE=5:95) to afford 87 
(58 mg, 0.17 mmol, 84%) as a yellow oil. 
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IR (neat): 2934, 1549, 1446, 1403, 1329, 1311, 1199, 1152, 1113, 1092, 1013, 993 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.667.64 (m, 2H, H10 or H11), 7.457.43 (m, 4H, H2, H10 or H11 and H12), 
2.91 (q, J = 7.4 Hz, 2H, H7), 1.31 (t, J = 7.4 Hz, 3H, H8). 
13C NMR (CDCl3, 100 MHz): δ 160.9 (C, C3), 148.8 (C, t, J = 25.3 Hz, C1), 144.4 (C, C4), 135.2 (C, C9), 
130.4 (CH, C12), 129.2 (2xCH, C10 or C11), 128.6 (2xCH, C10 or C11), 119.0 (CH, t, J = 4.1 Hz, C2), 118.8 (C, 
qt, J = 286.8 and 36.9 Hz, C6), 111.4 (C, tq, J = 256.3 and 39.1 Hz, C5), 25.6 (CH2, C7), 12.5 (CH3, C8). 
MS m/z (relative intensity): 334 (M+•, 34), 305 (100), 257 (7), 236 (5), 234 (5), 207 (9), 158 (8), 134 
(20), 126 (8), 121 (15), 89 (8). 
HRMS: calcd for C14H12F5N2S (M+H+): 335.0636. Found 335.0638. 
5-Allylamino-3-phenyl-6-(difluoromethyl)pyridazine (88) 
 
 
To a stirred solution of 4-fluoro-3-phenyl-6-(difluoromethyl)pyridazine 72 (26 mg, 0.12 mmol, 1.0 
equiv) in MeCN (0.11 mL) was added allylamine (0.017 mL, 0.23 mmol, 2.0 equiv) and the reaction 
mixture was stirred at 100 °C for 4 h. The reaction mixture was concentrated under reduced pressure. 
The crude mixture was purified by flash chromatography (AcOEt/PE=40:60) to afford 88 (28 mg, 
0.11 mmol, 92%) as a white solid. 
Mp: 127 °C. 
IR (neat): 3248, 1585, 1546, 1504, 1424, 1357, 1299, 1240, 1193, 1148, 1085, 1035, 1008, 995, 
920 cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.647.61 (m, 2H, H10 or H11), 7.567.50 (m, 3H, H10 or H11 and H12), 6.83 
(s, 1H, H2), 6.79 (t, J = 55.0 Hz, 1H, H5), 5.84 (m, 1H, H7), 5.265.22 (m, 2H, H8), 5.08 (br s, NH), 
3.873.83 (m, 2H, H6). 
13C NMR (CDCl3, 100 MHz): δ 154.3 (C, t, J = 26.0 Hz, C1), 152.2 (C, C3), 144.2 (C, C4), 134.3 (C, C9), 
132.0 (CH, C7), 129.9 (CH, C12), 129.5 (2xCH, C10 or C11), 128.7 (2xCH, C10 or C11), 117.8 (CH2, C8), 114.1 
(CH, t, J = 240.2 Hz, C5), 101.3 (CH, t, J = 2.0 Hz, C2), 44.9 (CH2, C6). 
MS m/z (relative intensity): 261 (M+•, 100), 260 (98), 233 (17), 219 (11), 184 (29), 183 (40), 165 (5), 
126 (8), 115 (10), 102 (18), 89 (15), 77 (14), 63 (6), 56 (17), 51 (11). 
HRMS: calcd for C14H14F2N3 (M+H+): 262.1150. Found 262.1148. 
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4-Ethylthio-3-phenyl-6-(difluoromethyl)pyridazine (89) 
 
To a stirred solution of 4-fluoro-3-phenyl-6-(difluoromethyl)pyridazine 72 (26 mg, 0.12 mmol, 1.0 
equiv) in MeCN (0.11 mL) was added sodium ethanethiolate (16 mg, 0.14 mmol, 2.0 equiv) and the 
reaction mixture was stirred at 100 °C for 4 h. The reaction mixture was concentrated under reduced 
pressure. The crude mixture was purified by flash chromatography (AcOEt/PE=5:95) to afford 80 
(27 mg, 0.10 mmol, 87%) as a white solid. 
Mp: 107 °C. 
IR (neat): 2932, 1553, 1520, 1493, 1443, 1364, 1344, 1262, 1145, 1106, 1070, 1021, 1010, 918, 891 
cm–1. 
1H NMR (CDCl3, 400 MHz): δ 7.717.68 (m, 2H, H9 or H10), 7.537.50 (m, 4H, H2, H9 or H10 and H11), 
6.92 (t, J = 54.7 Hz, 1H, H5), 2.99 (q, J = 7.4 Hz, 2H, H6), 1.39 (t, J = 7.4 Hz, 3H, H7). 
13C NMR (CDCl3, 100 MHz): δ 160.8 (C, C3), 153.0 (C, t, J = 26.8 Hz, C1), 144.4 (C, C4), 135.6 (C, C8), 
130.1 (CH, C11), 129.2 (2xCH, C9 or C10), 128.6 (2xCH, C9 or C10), 117.6 (CH, t, J = 1.7 Hz, C2), 113.9 (CH, 
t, J = 240.5 Hz, C5), 25.5 (CH2, C6), 12.6 (CH3, C7). 
MS m/z (relative intensity): 266 (M+•, 39), 237 (100), 189 (24), 158 (5), 134 (16), 121 (11), 89 (7), 77 
(6), 51 (7). 
HRMS: calcd for C13H13F2N2S (M+H+): 267.0762. Found 267.0760.
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The aim of this project was to access three different families of nitrogen-containing heterocycles: 
pyrrolidines, piperidines and pyridazines, all of them possessing a CF3 group at the α position to the 
nitrogen.  
During the first part of this work, the synthesis of 2-substituted, 2-(trifluoromethyl)pyrrolidines was 
achieved by the ring contraction of 3-hydroxy-3-(trifluoromethyl)piperidine. Indeed, under the right 
conditions (triflic anhydride/proton sponge/nucleophile), the hydroxy group of the 
(trifluoromethyl)piperidine can be activated, to form an aziridinium intermediate. Due to the 
presence of the CF3 group at the C2 position of the aziridinium, a nucleophile can attack 
regioselectively at the C2’ position to afford the ring contraction products, the 2-substituted, 
2-(trifluoromethyl)pyrrolidines in moderate to very good yields. 
 
This method was then applied to the 3-hydroxy-3-(trifluoromethyl)azepane, in order to access 
2-substituted, 2-(trifluoromethyl)piperidines via a similar aziridinium intermediate. The ring 
contraction products were successfully obtained in good to excellent yields. 
 
The presence of the CF3 group proved to be crucial for the success of the ring contraction, and the 
reaction proceeds with a chirality transfer. 
The second part of this work was dedicated to the synthesis of α-(trifluoromethyl)pyridazines by a 
[2+1]/[3+2]-cycloaddition sequence between a terminal alkyne, a difluorocarbene and a diazo 
compound. After reaction of the alkyne with the difluorocarbene, a difluorocyclopropene was formed 
by a [2+1]-cycloaddition. This difluorocyclopropene underwent a [3+2]-cycloaddition in the presence 
of (trifluoromethyl)diazomethane to afford a cyclopropanopyrazoline, which after a rearrangement 
and an aromatization step, led to the desired 6-(trifluoromethyl)pyridazines. 
(Trifluoromethyl)diazomethane could be replaced be other fluorinated diazo compounds to allow 
access to different fluorinated pyridazines. 
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Finally, due to the presence of fluorine at the C4 position, these pyridazines could be further 
functionalized by a nucleophilic aromatic substitution (SNAr), to afford a variety of 3,4,6-trisubstituted 
pyridazines. 
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Synthesis of trifluoromethylated 
 nitrogen-containing heterocycles 
 
 
 
L’introduction d’un atome de fluor sur un composé organique peut avoir une influence importante 
sur les propriétés chimiques et physico-chimiques de ce composé, ainsi que sur son activité 
biologique. Par ailleurs, les hétérocycles représentent une famille de composés intéressante pour 
l’industrie pharmaceutique et agrochimique avec 70% de nouvelles molécules bioactifs possédant 
un motif hétérocyclique. Ainsi, le développement des méthodes de synthèse permettant la 
formation des hétérocycles trifluorométhylés, représente un défi  en chimie organique.  
Dans le cadre de nos travaux, nous avons dans un premier temps développé une méthode afin 
d’accéder aux α-(trifluorométhyl)pyrrolidines et α-(trifluorométhyl)pipéridines substituées, par 
contraction de cycle de (trifluorométhyl)pipéridines et (trifluorométhyl)azépanes respectivement 
via un intermédiaire aziridinium. L’attaque régiosélective du nucléophile sur l’aziridinium est 
induite par le groupement CF3 présent sur cet intermédiaire.  
Dans un deuxième temps, nous avons développé une séquence de cycloadditions [2+1]/[3+2] 
entre un alcyne terminal, un difluorocarbène et le (trifluorométhyl)diazométhane, afin d’accéder 
aux α-(trifluorométhyl)pyridazines fonctionnalisées. 
Mots clés: contraction de cycle, α-(trifluorométhyl)pyrrolidines, α-(trifluorométhyl)pipéridines, 
aziridinium, cycloaddition, α-(trifluorométhyl)pyridazines. 
 
 
The introduction of a fluorine atom in an organic compound can have major impact on the 
compounds chemical and physico-chemical properties, therefore influencing its biological activity. 
Moreover, heterocycles represent an important class of compounds for the pharmaceutical and 
agrochemical industry, given that 70% of the biologically-active molecules possess a heterocyclic 
moiety. Therefore, the development of synthetic methods which allow access to 
trifluoromethylated heterocycles represent a challenge in organic chemistry. The work presented 
in this manuscript is focused on the synthesis of nitrogen containing heterocycles possessing a CF3 
group at the α position to the nitrogen. More specifically, a variety of substituted 
α-(trifluomethyl)pyrrolidines and substituted α-(trifluomethyl)piperidines were obtained by the 
ring contraction of (trifluoromethyl)piperidines and (trifluoromethyl)azepanes respectively via an 
aziridinium intermediate. The regioselective attack of the nucleophile on the aziridinium is 
induced by the CF3 group present on the intermediate. Furthermore, a diversity of functionalized 
α-(trifluoromethyl)pyridazines were obtained by a [2+1]/[3+2]-cycloaddition sequence between 
a terminal alkyne, a difluorocarbene and (trifluoromethyl)diazomethane. 
Key words: ring contraction, α-(trifluoromethyl)pyrrolidines, α-(trifluoromethyl)piperidines, 
aziridinium, cycloaddition, α-(trifluoromethyl)pyridazines. 
 
